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Addendum concerning the thesis: 
 
The corneal endothelium reflected, 
by Bart T.H. van Dooren, 
 
December 21st 2006 
 
 
Dr. Gerrit R.J. Melles has identified statements in the thesis concerning his own scientific 
work that he believes are incorrect. He was not offered to review the entire manuscript of the 
thesis before it was printed. 
 
After discussion between the Rector Magnificus Prof.dr.S.W.J. Lamberts, the promotor 
Prof.dr.G.van Rij, Dr.G.R.J. Melles, and the promovendus it was decided to add the 
following:  
 
 
• Dr. Melles’ initial work on posterior lamellar keratoplasty was by no means influenced 
by, or based on the work by Ko et al. (reference 1139, page 201 of this thesis). 
 
Errata concerning the thesis: 
 
The corneal endothelium reflected, 
by Bart T.H. van Dooren, 
 
December 21st 2006 
 
Three figures in this thesis were published previously, but unfortunately references were not 
properly made. Permission from the publishers of the original articles for the reproduction of 
these figures in the thesis was requested by the author, and has been granted for each of these 
figures.  
 
• Figure 7.1, pages 150 and 329 of the thesis, is a reproduction of Figure 1, in the 
article: Melles GRJ, De Waard PWT, Pameijer, J.H., Beekhuis W.H. Trypan blue 
capsule staining to visualize the capsulorhexis in cataract surgery. J Cataract Refract 
Surg 1999;25:7-9. (Reference number 32 in this thesis). 
• Figure 10.1, page 203 of the thesis, is a reproduction of Figure 1, in the article: Melles 
GRJ, Lander F , Rietveld FJR, Remeijer L, Beekhuis WH, Binder PS. A new surgical 
technique for deep stromal anterior lamellar keratoplasty. Br J Ophthalmol 
1999;83:327-333. (Reference number 34 in this thesis). 
• Figure 12.1, pages  235 and 330 of the thesis, is a reproduction of Figure 1, in the 
article: Van Dooren BTH, Mulder PGH, Nieuwendaal CP, Beekhuis WH, Melles GRJ. 
Endothelial cell density after posterior lamellar keratoplasty (Melles techniques); 3 
years follow-up. Am J Ophthalmol 2004;138:211-217. This article is included in this 
thesis as chapter 12. (Reference number 1223 in this thesis). 
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 The cornea, the transparent anterior structure of the eye, transmits and refracts 
light entering the eye, and forms a barrier to protect the interior of the eye 
against the outside world. It is composed of distinctive layers. In 1849, the cor-
neal endothelium was first described as the distinctly identifiable ‘delicate and 
perishable’ innermost corneal layer. (Bowman W, 1849, as referred to in Waring 
et al.1) Leber demonstrated in 1873 the necessity of an intact endothelial layer 
for the deswelling and clarification of edematous corneas, using experimental 
studies on pressure-induced corneal edema.2 In 1920, Vogt introduced a tech-
nique of visualising the human endothelium and its individual cells in vivo. He 
applied a biomicroscopic (‘slit lamp’) technique that used the direct reflection 
of light from the endothelium-to-aqueous interface to produce an image in the 
‘Spiegelbezirk’ (specular area).3 
 Interest in endothelial function renewed in the 1940s and ‘50s, when laboratory 
research led to the concept that deswelling of the cornea involved a metabolic 
pump, which was mainly located in the endothelium.4-6 An explanation for the 
opacification of the cornea in corneal swelling was proposed in a theory devel-
oped by Maurice, involving disruption of the regular organisation of the stromal 
collagen fibrils in corneal edema.7 These concepts still are the pillars on which 
current corneal hydration physiology is based. 
 In 1968, Maurice described a contact-type ‘specular microscope’ for the view-
ing and photographing of the corneal endothelium in an intact globe,8 and in 
1970 Brown showed an example of an in-vivo endothelial ‘macrophotograph’ 
obtained with a non-contact macrophotography instrument.9 Both techniques 
used the specular reflection principle described by Vogt,3 although in neither 
paper references to Vogt’s work were made. These developments coincided 
with important concepts that developed in ophthalmic surgery: the vulnerabil-
ity of the endothelium during cataract extraction and intraocular lens implanta-
tion, endothelial cell loss after keratoplasty, and hence pre-operative evaluation 
of the endothelium in donor corneas. This led to the fast adoption of these 
prototypes of specular microscopes and further improved instruments in clini-
cal practice,  research, and eye banks, generating in its turn even more interest 
in the biology of the corneal endothelium.10-27 
 Since then, many aspects of the endothelium have been investigated. Several 
of these studies are reviewed in chapter 2 of part I of this thesis. In this chapter 
a tradition of research on the corneal endothelium is described, to which 
researchers in The Netherlands have made contributions as well.28-31 
 The present thesis may be considered to be a (collection of ) new 
contribution(s) to the vast body of knowledge that already exists on the endo-
thelium. It focuses on three main issues. The first issue is about the reliability 
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of endothelial morphometric assessments, obtained with a modern specular 
microscope and semi-automated endothelial evaluation. It was evaluated in 
methodological studies on calibration, validity, and reproducibility of measure-
ments. Also, the systematic differences between specular microscopic in-vivo 
endothelial cell densities were compared with endothelial cell counts obtained 
from donor corneas, obtained with a different, in-vitro assessment technique. 
These studies are presented in part II, Chapters 3, 4, and 5, respectively. In chap-
ter 6, optical phenomena associated with non-contact specular microscopy 
are elaborated upon, as they possibly accounted for systematic differences as 
observed in the study described in chapter 5.
 In the part III of this thesis, the second issue, toxic effects on corneal endothelial 
cells caused by exposure to trypan blue, was evaluated. Trypan blue is a (supra-) 
vital stain that since long has been in use in cornea banks, for the evaluation 
of donor cornea endothelia. Interest in this dye increased significantly with the 
introduction of its application in cataract surgery for lens capsule staining.32 
Clinical and experimental studies on possible toxic effects of trypan blue are 
presented in Chapters 8 and 9, following a review of the literature relevant to 
this topic in Chapter 7.
 The third and last issue is the evaluation of endothelial cell loss after deep 
anterior lamellar keratoplasty (DALK, Part IV, chapter 11) and posterior lamellar 
keratoplasty (PLK, Part IV, chapters 12 and 13). These studies were instigated by 
the introduction of new operative techniques,33, 34 which further developed and 
popularized surgical concepts in lamellar corneal transplantation. A history of 
lamellar keratoplasty is reviewed in Part IV, Chapter 10.
 In part V, Chapter 14, the findings of the studies presented in this thesis are 
summarized, and put into the perspective of other current developments and 
future prospects. By then the reader will already have understood, that in spite 
of the vast existing body of knowledge and the present new contributions, a lot 
of questions remain unanswered about the corneal endothelium. 
 References
 See page 287.
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I.  Basic corneal and endothelial anatomy.
 
 The cornea is the transparent, avascular, anterior- and outermost structure 
of the globe. Although the precorneal tear film is not a structural part of the 
cornea, cornea and tear film can be considered to be an integrated functional 
unit. The functions of this unit are to transmit and refract the light entering the 
eye and to form a protective barrier between the globe and the outside world 
against traumatic force, entrance of pathogens, and dehydration.35-37 The hu-
man cornea is composed of three distinctive anatomical layers. These are, from 
anterior to posterior: the epithelium with its basement membrane; the stroma, 
which is subdivided into Bowman’s layer, the lamellar stroma, and Descemet’s 
membrane; and the endothelium. Part of Descemet’s membrane is in fact the 
basement membrane of the endothelium, and therefore it is sometimes also 
considered to be part of the endothelium.27 35-37 See figure 2.I.1.
 
 The endothelium, the innermost corneal layer, consists of an approximately 5µm 
thick mosaic of cells forming a tesselated monolayer. This mosaic is configured 
of the apical, most posterior surfaces of the endothelial cells, typically with 
hexagonal forms.1 27 35-40 See figure 2.I.2. Electron microscopic studies showed 
that central apical cell membranes usually are regular and flat, whereas more 
peripheral cells have cilia. In adults, towards the far periphery endothelial cells 
have been found to cover Descemet’s membrane outcroppings called Hassall-
Henle’s warts.41 The lateral cell membranes were shown to be extremely tortuous 
and interdigitating.1 27 35-38 40 The basal, anterior sides of the endothelial cells are 
primarily hexagonal as well, albeit with more ruffled cell borders compared to 
the apical hexagons, due to larger interdigitating cell processes basally.39 42 43 
Endothelial cells contain a great number of mitochondria, as well as smooth 
and rough endoplasmatic reticula and a Golgi apparatus. This reflects a high 
metabolic activity. 1 27 35-37 40 44 Descemet’s membrane, located just anterior to 
the endothelial cells, is 8-10 µm thick. It has an anterior embryonal zone that 
is mostly banded, and a thicker, unbanded, posterior layer that constitutes the 
basement membrane of the endothelial cell layer in adults.1 27 35-37 40 44 45
 Descemet’s membrane is composed of predominantly type IV collagen 
besides other types of collagen (III-VIII), and glycoproteins including laminin 
and fibronectin. The corneal stroma is composed of organized fibrils consist-
ing mainly of type I collagen and to a lesser extent type V collagen; collagen 
types III, VI, VII, XII and XIII, have been found in the extrafibrillary stroma. The 
other important stromal proteins are the proteoglycans keratan sulfate (65 %) 
and  chondroitin/dermatan sulfate (35 %), both of which can be constituted 
by several core proteins. Collagen fibrils together with microfibrils consisting 
of fibrillin are organised in flattened bundles, the corneal lamellae. The lamellar 
stroma is secreted and maintained by the stromal fibroblasts, a.k.a. keratocytes, 
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residing between the  lamellae. Bowman’s layer which lies adjacent to the epi-
thelial basement membrane, is an acellular zone consisting of collagen fibrils 
and associated proteoglycans, densely woven in a felt-like matrix. 1 35 37 45-54 
 The corneal epithelium is  5 - 7 cell layers (50 – 52 µm) thick in adults and has 
a stratified squamous organization, providing an absolutely smooth apical sur-
face, by means of microplicae filled and covered with a glycocalyx. Its basement 
membrane is thin compared to Descemet’s membrane, and also consists of 
predominantly type IV collagen. The outermost 3 or 4 cell layers consist of  flat-
tened squamous cells, resting on and resulting from 1 –3 intermediate layers of 
wing cells, and the innermost, single layer of mitotically active, columnar, basal 
cells. All epithelial cells have highly interdigitating and undulating membranes, 
with prominent desmosome junctions and gap junctions. Especially noticable 
is the band of tight junctions between the lateral membranes of the apical cells. 
The basal cells adhere to their basement membrane through extensive anchor-
ing complexes. Epithelial anatomy and function is influenced by the subbasal 
nerve plexus.37 45
Fig. 2.I.1  The layers of the cornea.
1. Epithelium
2. Bouwman’s layer
3. Stroma
4. Descemet’s membrane
5. Endothelium
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Fig. 2.I.2  Specular microscopic image of a (fairly) normal, homogeneous endothelium.  Most cells are hexagonal, 
and there is little variation in cell size. Please note the white dots indicating counted cells with the 
“centres method” (see paragraph 2.VII.a).
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II.  Embryology of the endothelium.
 
 From gestational day 24, the optic pits pouch out from the cranial neurectoderm 
towards the surface ectoderm, and subsequently become optic cups through in-
vagination and fusion. Upon adhesion with the optic cup, the surface ectoderm is 
induced to form the lens placode. The lens placode invaginates and separates on 
day 33 from the overlying surface ectoderm, which goes on to form the corneal 
epithelium and the epidermis of the eyelids. From the beginning of the sixth ges-
tational week cells migrate in at least two consecutive waves from the periphery in 
the space between the basal lamina of the lens vesicle and the corneal epithelium. 
A double row of flattened cells is formed, which starting in the eighth week thins 
to a monolayer: the corneal endothelium.1 40 44 55-57 Initially, these migrating cells 
and hence the endothelium were thought to have a mesodermal origin, in anal-
ogy to the vascular endothelium,58 but later studies have proven them to be neu-
ral crest cells.59-62 A second wave of neural crest cells immigrates soon after anterior 
to the endothelium to form the stromal mesenchymal cells, i.e. the keratocytes or 
fibroblasts. Migration posterior of the endothelium forms the iris stromal cells, as 
well as the covering of what will become the trabecular meshwork.1 40 44 57. 
 The stromal fibroblasts produce the stromal extra-cellular components pro-
teoglycans and collagen. Descemet’s membrane results as the synthesis of a 
basement membrane by the endothelial cells or arguably by the lower stromal 
cells,56 and becomes evident as a complete, identifiable layer at a gestational 
age of 16 weeks. Its anteriormost, in-utero formed part has a mostly banded 
appearance in electron microscopy, whereas the post-partum formed part of 
Descemet’s membrane is non-banded.1 35 40 44 57 63 
 The importance of the presence of a normally developing lens for the induc-
tion of the development of a normal corneal endothelium has since long 
been recognized.56 64 Cell adhesion molecules such as  N-cadherine may play a 
role.65 66 The vulnerability of this developmental sequence is demonstrated by 
the existence of a spectrum of congenital disorders called the mesenchymal 
dysgenesis disorders, including entities such as Axenfeld-Rieger syndrome and 
Peter’s anomaly. Hallmark of these disorders is an abnormal development of 
the corneal endothelium, probably cause by abnormalities in the immigration 
of neural crest cells. This is also thought to result in incomplete or abnormal 
developmental separation between anterior chamber structures.1 40 65 67 
III. Concepts for corneal transparency, corneal    
hydration, and endothelial physiology.
 
 In 1957 Maurice postulated that prerequisite for the cornea to be transparent 
was that the parallel collagen fibrils constituting the corneal stromal lamellae 
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had a hexagonal lattice arrangement. He demonstrated the necessity for such a 
regular arrangement of the fibrils through mathematical and physical calcula-
tions on the birefringent properties of the corneal lamellae and the light-scat-
tering properties of the individual collagen fibrils in each lamella.7 This theory 
basically still holds, although the development of new models and the use of 
newer experimental techniques have resulted in adjustments and refinements. 
The proteoglycans in the corneal stroma may serve as an interconnecting mesh-
work encircling the collagen fibrils to form Maurice’s hexagonal array of fibrils. 
Uniform thickness of the fibrils and a uniform distance between the fibrils (usu-
ally smaller than ½ λ (wavelength) appear to be prerequisites for optimal light 
transmittency.68-70 Maurice also postulated that swelling of the cornea would 
disrupt the regular arrangement of the fibrils, thus providing an explanation for 
the well known observation of opacification of the cornea in corneal edema.7
 Intraocular pressures (IOP) of over 40 to 50 mm Hg have since long been 
known to cause corneal swelling.71 72 In 1857 Donders showed that the cor-
nea also has an intrinsic tendency to swell, to imbibe fluid, when immersed in 
hypotonic solutions.73 Later experiments showed that a negative pressure inside 
the cornea existed, the so called Imbibition Pressure (IP). The imbibition pressure 
is an osmotic pressure developed in the charged mucopolysaccharide gel: the 
glycosaminoglycans of the interfibrillary substance in the corneal stroma.1 4 74 The 
following relation was demonstrated between IOP, IP and swelling pressure (SP):  
 
  IP = IOP – SP. 72 74 
 The amount of swelling is different between stromal compartments: posterior 
stroma can osmotically attract and hold more water than the anterior compart-
ment, in accordance with differences in stromal glycosaminoglycan content. 
Obviously it also depends on the (hypo-)tonicity of the experimentally applied 
solutions. 45 75-79 Evidence exists that in edematous corneas not only water 
intake rises, but also stromal glycosaminoglycans are lost.80
 Normal average corneal water content is 78 %. The average central corneal 
thickness is 0.52 mm, with increasing values towards the periphery.1 72 76 
Although diurnal fluctuations in corneal thickness have been observed,81 
these fairly constant figures imply that mechanisms must exist to counteract 
the swelling pressure. These mechanisms include passive barriers and active 
transports, or ‘pumps’. In the 19th century Leber thought, after he had shown 
in his experiment that the endothelium prevented corneal swelling, that the 
main counteracting mechanism was that the endothelium was an impen-
etrable barrier.2 Studies of among others Davson, Maurice and Giardini, Harris 
and Nordquist, Mishima, and Maurice, provided evidence that the extrusion of 
water depended on metabolism dependent active pumping. Also, the corneal 
bart_part1DEF.indd   25 19-11-2006   13:34:29
ch
ap
te
r 2
26
epithelium appeared to have a considerably greater resistance to water flow 
than the endothelium. The fluid pump with the greatest activity had to be lo-
cated in the endothelium, and not in the epithelium. There also is an epithelial 
pump however, which appears to provide about 15 % of total deturgescence of 
the stroma (in rabbits).4-6 72 82 83 The prevailing theory of the endothelial functions 
that resulted is sometimes called the ‘pump-leak’ theory, with the endothelium 
being a leaky barrier against the swelling pressure, but providing a powerful 
deswelling counteraction through a  metabolically active fluid pump.1 84 85
IV. Ultrastructural and molecular functional anatomy of 
the endothelium and epithelium.
 
 Studies on animal material have shown that the corneal epithelium is a relatively 
impenetrable barrier to ion flow and hence water flow. The cause for the im-
permeability was found in the presence of paracellular zonulae occludentes or 
tight junctions in the most superficial cell layer, combined with a high electrical 
resistance in the cell membranes. Nevertheless, fluid transport capacity and ion 
secretory capacity has been demonstrated in epithelial cells.83 86-89 The endotheli-
al cells also have an apical belt of tight junctions. In the endothelium these tight 
junctions are included in the so-called apical junction complex (AJC). Although 
they appear to grow during maturation, there is accumulating evidence that 
these AJCs remain discontinuous in adults. Furthermore, they appear to be of a 
different composition than the true zonulae occludentes found in the epithe-
lium. These findings support the concept that the endothelial barrier is perme-
able, “leaky”.55 88 90-94 In an experimental setting the calcium ion concentration 
influenced the permeability of the corneal endothelium. Probably, the calcium-
dependent transmembrane cadherine proteins in the adherens junctions play 
an important role in this equilibrium, as they are integral parts of the AJCs of 
endothelial cells.94 95 The cytoskeletal protein F-actin, found to be connected to 
the AJC, was shown to be involved in maintaining the predominantly hexagonal 
cell shape of the endothelial cells. Hence it  was implicated in the forming of 
polymegathism in unstable or injured endothelia. Dibutyryl-cAMP and forskolin 
induced condensation of F-actin at the cell borders and dispersion of the tight 
junction network in cultured bovine endothelial cells, resulting in decreased 
endothelial barrier function. The AJC therefore seems to play a central role in 
endothelial cell architecture and endothelial barrier physiology. The AJC appears 
furthermore to play a role in inter-cell connectivity. Contact inhibition prevent-
ing migration of endothelial cells is supposedly modulated by the AJC. Contact 
inhibition occurs under normal circumstances and provides a stable monolayer 
of endothelial cells. It also occurs during migratory and enlargement reactions 
of the endothelial cells after endothelial cell loss and wound healing.94 96 97 
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 Regarding the exact nature and location of the endothelial pump there is still no 
unequivocal answer. Both a metabolically active Na+/K+ ATPase ion-exchanger, 
located in the basolateral membrane of the endothelial cell, and HCO3-  (bicar-
bonate) efflux via the apical membrane have been indicated as the primary ion 
pump. Water transport is thought to concur through osmotic gradients provided 
by ion transport. Inhibiton of  Na+/K+ ATPase with ouabain was found to almost 
abolish corneal deswelling. Bicarbonate efflux was found to play a role in the 
establishment of a negative electric potential across the endothelium towards 
the anterior chamber aqueous.71 98-106 Later models integrated the role of both 
pumps, including a variety of mechanisms and ion-exchangers for bicarbonate 
extrusion. 1 4 40 45 79 93 107 108 Recently, integrated models for the mechanisms in wa-
ter and ion transport in and out of the endothelial cells and through the corneal 
endothelium in and out of the stroma have become even more complex. New 
bicarbonate formation and transport mechanisms have been discovered, and 
also the  presence in endothelial cells of the Na+ - K+ - 2 Cl- ion cotransporters 
and Aquaporin water channels (specifically: type AQP1) has been established.109-117 
The Na+/K+ ATPase pump appears to contribute about 80 % of the total endothe-
lial pump function. (H.F. Edelhauser, personal communication, 2005).
V.  Endothelial mitotic capacity and endothelial  wound 
healing.
 
 Proliferative ability of the corneal endothelium appears to be species-specific. 
Rodent, bovine, and porcine endothelium has evident mitotic capacity that 
plays a major role in endothelial regeneration after (experimental) wounding. 
In contrast, in feline, primate, and human endothelia hardly any spontaneous 
mitotic activity is observed. Only relatively little cell proliferation - maximally 
10 % in cats and monkeys, in contrast to up 40 % in rabbits - was observed 
after severe endothelial damage. These similarities between cat and monkey 
endothelium and human endothelium make these animals more suitable for 
experimental models for wound healing than the often used rodents.28 118-127 On 
the molecular level, human endothelial cells have been shown to be arrested 
in the G1- phase of the cell cycle, as opposed to corneal keratocytes that have 
exited the cell cycle and are in the resting (G0) phase.128-130 Contact inhibition 
of endothelial cells appears to induce an inhibitor protein, the cyclin p27KIP1, 
that arrests the cell cycle in the G1 phase. Transforming Growth Factor (TGF)-β2 
prevents endothelial cells of entering the DNA-synthesis S-phase that normally 
would follow the G1 phase. 129 130 However, human endothelial cells have not 
completely lost their proliferative capacity, as has been shown through human 
endothelial cell culturing. Especially endothelial cells from the corneal periph-
ery (“endothelial stem cells”) and cells from younger individuals and especially 
embryos have been shown to proliferate. These findings may provide prospects 
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for the future induction of endothelial regeneration by mitosis, or for a source 
of viable cells for endothelial transplantation.129 131-133
 Notwithstanding observations of mitoses and the demonstration of mitotic 
contribution to wound healing, endothelial wound healing in humans, cats, 
and monkeys is currently thought to occur mainly through other mechanisms. 
These include endothelial cell enlargement and migration of individual cells, 
also called ‘elongation and sliding’, as well as spreading of collective groups of 
cells. Larger cells may later contract, but very large, multinucleated cells, cre-
ated by amitotic cell division, may also be observed.1 28 40 118-120 127 134-148 During 
endothelial wound healing, a posterior banded layer or posterior collagenous 
layer (PCL) is often secreted and added onto Descemet’s membrane.1 145 149 In 
experimental endothelial wounding, the expression of fibronectin changed in 
and around the cells as well as in the aqueous humour during the process of 
endothelial migration/spreading and PCL deposition. Fibronectin is an extracel-
lular matrix protein that plays a role in the connection of endothelial cells to 
their basement membrane. These findings were therefore thought to reflect 
differences in the maintenance of attachment between endothelial cells and 
Descemet’s membrane during the reparative process. Similar observations and 
conclusions were made in relation to the glycosaminoglycans keratan sulfate 
and chondroitin sulfate, and the wound healing protein thrombospondin.150-154 
The type (freeze vs. scrape) and size of the wound determined whether healing 
was found to occur mainly through collective cell spreading, or through both 
spreading and migration of individual cells. In small scrape wounds mainly 
healing through spreading occurred in which cell connectivity was maintained, 
without much of actin re-arrangement or extension of actin stress fibers. In 
contrast, after freeze-injury or more extensive scrape wounding, (myo-) fibro-
blastic transformation was observed in (part of ) the endothelial cells. Both in-
dividual migration of endothelial cells with deposition of posterior collagenous 
layers, and en-block spreading of collective endothelial cells with maintenance 
of normal endothelial cell morphology were now observed. Usually, actin rear-
rangement and appearance of actin stress-fibers, as well as assembly/disassem-
bly of microtubuli could be detected.155-162 
 These experimental results might explain why large wounds close slower than 
smaller wounds and why wounds close in different rates and patterns after 
heat-, freeze-, or scrape injury. Other factors that influence the endothelial 
wound healing rate are age and inflammation. Experimental wounds in older 
animals (rabbits) closed slower than in young animals. Wound healing in the 
presence of severe inflammation was retarded. It appears that the phenotype of 
endothelial cells in culture is modulated by polymorphonuclear cells.134 163-166
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  Regarding endothelial function, in healed wound areas the barrier function of 
the endothelium was found to recover earlier than the pump function. Usu-
ally after wound healing there was no difference in Na+/K+ ATPase pump site 
density as compared to non-injured endothelia. However, the presence of very 
large multinucleated endothelial cells, more often seen after larger wounds, 
seemed to be correlated to poorer pump function.123 134 145 167-169 
 Growth factors such as Mesodermal growth factor (MGF), Epidermal growth 
factor (EGF), Platelet derived growth factor (PDGF), basic and acidic Fibroblast 
growth factor (FGF), Transforming growth factor alpha (TGFα), and Vascular en-
dothelial growth factor (VEGF) have been shown to increase endothelial wound 
healing rate, by promoting cell migration. Some of these growth factors, such 
as EGF, also promote mitosis in endothelial cells of species with more mitotic 
capacity.146 147 170-193 Hepatocyte growth factor (HGF), and Keratinocyte growth 
factor (KGF) also stimulate cultured human endothelial cell proliferation, as did 
EGF.194 195 EGF is probably the most powerful growth factor in endothelial wound 
healing. It promotes human and animal endothelial cell migration, through ac-
tions on protein-kinase-C-mediated alterations in the actin cytoskeleton. It also 
promotes endothelial cell proliferation, especially in susceptible species or cells. 
EGFs actions can be enhanced  by agents including fetal human, respectively 
bovine serum, insulin, retinoic acid, and prostaglandin E2.194 196-202 
 Indomethacine, an inhibitor of prostaglandine E2 (PGE2) synthesis, has a direct 
stimulatory effect on endothelial wound healing through the promotion of 
the confluent spreading mechanism, which is the alternative to cell migration. 
However, it has  an inhibitory effect on the individual migration of endothelial 
cells through the inhibition of PGE2, which in turn downregulates EGF.146 201-205 
Experiments have shown a detrimental effect of corticosteroids on endothelial 
wound healing, either in direct contact with the endothelium in in-vitro studies, 
or in vivo after topical or regional administration in animal experiments. This is 
interesting as topical or regional administration of corticosteroids is common-
place after keratoplasty. The mechanism of this inhibitory effect of cortico-
steroids on woundhealing is unknown.206-208 Other drugs may also influence 
endothelial wound healing. Colchicine has been shown to delay endothelial 
wound healing, both by arresting cell division in species where this is occurs 
regularly, and by inhibiting cell migration. Both effects probably result from 
inhibition of cytoskeleton microtubuli assembly.155 209 Cytochalasin is known to 
block actin filament polymerization, and has been shown to suppress endothe-
lial cell migration after wounding.155 210-212
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VI.  Endothelial biology.
a.  Natural history of endothelial cell loss, and its effect on endothelial mor-
phometry. 
 At birth, normal human endothelial cell density (ECD) is around 6000 cells/mm2, 
perhaps even higher. 213-217 As was discussed in paragraph V, the mitotic capacity 
of endothelial cells is restricted. The ECD is expected to drop rapidly in the first 
few years after birth, when the corneal surface still increases. As a result of the 
observation of apoptosis in endothelial cells, it also has to be concluded that 
these cells are subjected to ageing. Therefore a further decline in ECD during life 
is to be expected, even in the absence of major endothelial damage.40 218  
 Changes in both endothelial morphology and cell size occurring with increasing 
age had since long been documented and indicated age-related endothelial cell 
loss.41 219 After the widespread introduction of the specular microscope, cross-
sectional epidemiological studies showed that with increasing age the mean 
endothelial cell area increased, i.e. the ECD decreased.21 213 220-227 Corneas remain 
transparent with high as well as with significantly decreased ECDs. Clear corneas 
with low ECD can for instance be seen years after corneal transplantation. This 
indicates that “normal” endothelial cell densities provide for a substantial physi-
ological reserve. Furthermore, it is evident that ECD is not directly correlated to 
endothelial functional capacity.1 40 However, ultimately there is a critical ECD of 
300 – 500 cells/mm2  below which endothelial barrier and/or pump functions be-
come insufficient to maintain corneal transparency. Inversely a mean endothelial 
cell size of  2700 – 3200 µ2 is the critical level above which transparency cannot 
be maintained. Finding such a low ECD was found to predict corneal decompen-
sation. 1 22 Remarkably, even when overall ECD was still substantially above the 
critical level, the presence of giant endothelial cells has been found to be related 
to decreased overall endothelial deswelling functions.167 Anyway, until levels close 
to the critical threshold ECD are reached, it is rather the rate of endothelial cell 
loss than the ECD per sé that indicates a risk for endothelial decompensation.
 From prospective and histological studies it became clear that the estimated 
age-related, “physiological” endothelial cell loss in adults is 0.5 to 0.9 % annually. 
40 214 228 229 Regression models have been constructed to evaluate patterns of ECD 
loss with increasing age. Initially, linear models were proposed.16 220 221 Since in 
childhood ECD loss proceeds at a much higher pace than after adolescence,21 
214 229 230 a biphasic linear model,213 216 a non-linear model,27 and an exponential 
model229 have been proposed. In other fields of biology often biphasic expo-
nential decay patterns are encountered (W.J. Armitage, personal communica-
tion, 2004). Hence, recently such a biphasic exponential model for physiological 
ECD loss was proposed.231. The model is:
  
  ECDt= p * exp (-at) + q * exp (-bt)
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 In which ECDt  is the ECD at time t; p and q are constants the sum of which is 
equal to the ECD at time zero (initial ECD); and a and b are exponential rate 
constants. 
 The residual standard deviation indicating the goodness of fit was 113.9 
cells/mm2. Half times for the two components of decay (‘fast’ and ‘slow’) are 
calculated as: 0.693/(the exponential rate constant). For physiological cell loss, 
the model found half times for the fast component of 3.1 - 3.5 years, and for 
the slow component of 224 - 277 years. See figure 2.VI.1. 231 these results were 
based on the data from Möller-Pedersen and Yee et al.216 226 The half times 
illustrate the rapid ECD-loss in youth which may  partly be caused by corneal 
growth and not only by the loss of endothelial cells. Under normal circum-
stances a large physiological reserve of endothelial cells exists. The very long 
half-time of ECD loss in the ‘slow’ phase also explains why for middle-aged and 
older individuals the ECD-loss can be quite adequately described using linear 
models. 227 232
 The advent of (semi)-automated endothelial analysis techniques made it easier 
to analyse the size and shape of individual endothelial cells. The initially inter-
changeably used morphological concepts of pleomorphism and polymegath-
ism could now be quantified. 233-236 Pleomorphism means the amount of vari-
ability in shape: (increased) pleomorphism implies a decrease in predominantly 
hexagons, accompanied by an increase in pentagonal and heptagonal cells. 
See Figure 2.VI.2. Polymegathism represents variability in cell size; (increased) 
polymegathism implies the occurrence of substantial deviations from a nor-
mally fairly uniform and narrow cell size distribution. See figure 2.VI.2. A regu-
lar-sized, hexagonal pattern is considered to be the most stable and efficient 
two-dimensional array, both geometrically and thermodynamically. 39 235 237-241 
See figure 2.I.2. Increased pleomorphism and polymegathism often indicates 
endothelial repair, possibly after cell loss. At the least it is a sign of  endothelial 
mosaic instability or endothelial “stress”.123 144 219 236 241 242 At this point it should be 
pointed out that endothelial cell loss, although it may be present, is neither the 
only explanation, nor a necessary condition for polymegathism. An electron 
microscopic study demonstrated that in polymegathous corneas the lateral cell 
walls do not run orthogonal but oblique to the endothelial and Descemetal 
planes. This may provide an explanation for the occurrence of both smaller 
and larger than normal apical (and basal) cell areas, without notable changes 
in ECD. The individual endothelial cell volume remains the same in this case.233 
243 244 Both pleomorphism and polymegathism have been expressed in several 
morphometric measures. Some of these parameters that are currently more 
often used, are the coefficient of variation of cell size (CV, i.e. the standard devia-
tion divided by the mean of the cell size) as a measure for polymegathism, and 
Hexagonality (i.e. the percentage of hexagonal cells on the total of observed 
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cells) as an inverse measure for pleomorphism.233 236 241 242 245 A general finding 
was that both pleomorphism and polymegathism increased with increasing 
age.213 220 226 229 232 246-248. This might reflect a decrease in endothelial barrier func-
tion or (perhaps less likely) in pump function with age or in disease. However, 
significant functional deteriorations are probably foremost related to the preva-
lence of giant endothelial cells, especially when their number increases. 167 233 235 
243 249-252 Some authors rate the importance of pleomorphism and polymegathism 
higher than ECD. Morphometric parameters for pleomorphism and polymegath-
ism are more sensitive indicators of endothelial imbalance or endothelial distress 
and repair. They are probably also more closely related to endothelial function 
and endothelial functional reserve than ECD / cell size. 233 239 243 251 253-255
 Table 2.VI.1 shows data from four in-vivo studies concerning normal values of  
ECD, Coefficient of variation, and Hexagonality, in relation to age. Differences 
between ECD findings from these studies may reflect differences in methodol-
ogy of measurements, exclusion criteria, and group size. Rigorous exclusion 
criteria and a relative small group size in one study226 was opposed to inclusion 
of patients with diabetes and a significant number of included paired-eye ECD 
counts in a second study.232 A third study did not mention the inclusion of pa-
tients with diabetes,227, and a fourth reported on summated data from different 
groups with different but very little exclusion criteria, and used measurements 
with two different specular microscopes.223 Furthermore the subjects inves-
tigated in different studies probably have significant differences in racial and 
perhaps socio-economic demographics. ECD in a Japanese population such as 
in the study by Inoue et al. is usually higher than in other populations.232 256 The 
data of Yee et al. on CV and Hexagonality,226 and from the prospective study by 
Bourne et al.229 are much more in the same order of magnitude (CV: 0.26 – 0.29; 
Hexagonality 73 - 61 %)  compared to those found by Inoue et al.( CV: 0.63 - 0.66; 
Hexagonality 39 – 36 %);232 these differences may be explained by the same bias 
factors mentioned above for ECD.
b.  Regional distribution of ECD over the cornea and differences between con-
tralateral eyes.
 The studies in the part a. of this paragraph all described central ECD findings, i.e. 
ECD measured from the corneal centre. Early studies found no significant differ-
ence in ECD between the central corneal areas and what they called peripheral 
areas. 136 221 226 257-259. However, the investigated populations in these studies were 
either too small to detect significant differences,136 221 257 or “peripheral” endo-
thelial photographs were actually taken quite close (i.e. 2 – 4 mm) from the 
corneal centre,226 or the statistical techniques used to evaluate differences were 
inadequate.259 260 Several more thorough studies did demonstrate regional dif-
ferences. Peripheral areas, and specifically the superior corneal area (in subjects 
under 50 years of age) yielded a higher ECD.27 260 In light microscopy studies of 
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the far corneal periphery towards the limbus, significantly higher ECDs were 
found.248 261 262. A recent study comparing four different assessment methods 
confirmed that ECD increases with distance from the central cornea towards 
the periphery.263 Increasing age appeared to cause more heterogeneity in these 
regional ECD differences, probably reflecting endothelial cell redistribution after 
endothelial cell loss.264 265. Independently of age however, ECD was higher in the 
far corneal periphery, specifically superiorly. This may reflect the presence of 
endothelial stem cells.129 131 264-266
 Most studies agree that in healthy subjects with pairs of eyes with a similar 
medical history, differences in central ECDs between contralateral eyes are only 
small,27 221 222 224 226 267 although such a difference may be statistically significant 
and therefore may need to be reckoned with.222
Table 2.VI.1   ECD, CV and Hexagonality: age related findings (cross-sectional studies).
Parameters & studies
Age groups 20 – 29 years 50 – 59 yrs 80 – 89 yrs
ECD (in cells / mm2) 
Hoffer & Kraff 1980 (n = 1523)223 N/A 2355 2256
Yee et al. 1985 (n = 32)226 2942 2685 2316
Abib & Barreto 2001 (n = 784)227 2834 2344 2077
Inoue et al. 2002 (n = 1819)232 N/A 2605 2457
CV (coefficient of variation of cell size  = s.d./mean of cell size)
Yee et al. 1985 226 0.27 0.29 0.29
Inoue et al. 2002 232 N/A 0.63 0.66
Hexagonality  ( % of hexagonals,  on the total number of cells)
Yee et al. 1985226 73 % 64 % 61 %
Inoue et al. 2002 232 N/A 39 % 36 %
bart_part1DEF.indd   33 19-11-2006   13:34:32
ch
ap
te
r 2
34
Fig. 2.VI.1.  Bi-eponential regression model for physiological endothelial cell loss. 
 (From: Armitage et al, Invest Ophthalmol Vis Sci 2003;44:3326-31).
Fig. 2.VI.2.  Specular microscopic image of an endothelium with substantial polymegathism and pleomorphism.
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VII.  Endothelial morphometric assessment, in vitro and 
in vivo.
a.  Specular microscopy.
 Vogt described the principles of viewing the living endothelial cells with a 
biomicroscopy (slit lamp) technique.3 268 At the border of two structures with 
different refractive indices a small part of the incident light is directly, i.e. not 
diffusely, reflected. Thus in what Vogt called ‘das Spiegelbezirk’ (the specular 
area) of optical borders, ‘Spiegelbilder’ (mirror images) of the structures at 
such a border are produced. These can be observed when the observation 
angle equals the incident angle of the light. See figure 6.1. Vogt described and 
showed images of the corneal endothelium, bordering the corneal stroma and 
the aqueous in the anterior chamber, and of the lens epithelium, bordering the 
aqueous and the crystalline lens proteins. With regards to the endothelium, 
he discussed the influence of the dominant epithelial reflex on the image, and 
described the observation of Hassall-Henle warts, guttata, Descemet’s folds 
and other phenomena.3. It is possible to also visualise with the biomicroscope 
some of these morphological findings in or close to the endothelium using a 
technique called ‘indirect specular microscopy’, in which light reflected from the 
anterior iris surface leads through indirect, diffuse retroillumination to an image 
in the indirect specular microscopic area, and which gives a more three-dimen-
sional impression.269 Cellular phenomena on the anterior surface of the crystal-
line lens or an IOL can also be observed using a direct specular microscopic 
technique. These observations however are extensively described elsewhere 
and are further left out of consideration here.3 270 271
 In 1968 Maurice described the design of an instrument he called a ‘specular mi-
croscope’, for the viewing and photographing of the corneal endothelium in an 
intact globe which was based on specular reflection principle.8. This prototype of 
the contact-type specular microscope, equipped with a ‘dipping cone’ for appla-
nation of the cornea, was quickly adopted in clinical practice to photograph the 
endothelium in vivo. Technical improvements regarding the focusing mecha-
nism and light source were added along the way. It was also soon described as 
a method for the evaluation of donor cornea endothelium, although this caused 
restrictions on acceptable post mortem times of harvested donor corneas. Fur-
thermore, concerns for microbiological contamination of donor corneas were 
raised. Specular microscopy was not generally adopted in American eye banks 
until 2001 (E. Pels, personal communication, 2006).10 11 13-20 22-24
 In 1970 Brown showed an example of an in-vivo endothelial “macrophotograph” 
obtained with a non-contact technique that also used the specular reflec-
tion principle.9 Subsequently, several studies using non-contact endothelial 
photography were published; either with special microscopes or with ordinary 
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slit lamps at high magnification. 12 21 213 222 224 225 228 272 There are fundamental 
differences in optical properties between contact and non-contact specular 
microscopy.21 272-275 These will be discussed in detail and illustrated with some 
calculation examples in Part II, Chapter 6 of this thesis. To counteract the bright 
epithelial reflex that inevitably restricts the observable field width, (see figure 
6.1) several approaches were reported. An adjustment to the dipping cone of 
a contact specular microscope, combined with the use of a soft contact lens 
was described. This modification both artificially ‘thickened’ the cornea-tear film 
complex and gradually (instead of abruptly) increased the refractive index  from 
the tear film towards the microscope, thus allowing a much broader illuminat-
ing beam and hence a wider image.26 27 A different approach to this problem, 
called wide field specular microscopy, involved the use of an illumination beam 
(‘slit’) oscillating at high frequency and scanning the image plane. Thus an 
apparently continuous wider image was created, which in fact was composed 
of a summation of very narrow images from consecutive optical sections. This 
principle is applicable to both contact and non-contact specular microscopes.25 
27 This same scanning slit principle was later applied in confocal microscopy, see 
part b of this paragraph VII. Wide field specular microscopy might also improve 
on sampling errors in polymegathous endothelia.276
 In-vivo qualitative evaluation of the corneal endothelium became readily avail-
able with the introduction of the clinical specular microscope.277 Moreover, 
in-vivo morphometric endothelial assessment could now be performed. The 
assessment of  ECD was initially done by manual counting of the number of 
cells in an area of known dimensions on an endothelial image, after calibration 
of the magnification. This technique, called ‘fixed-frame’ assessment, should 
be performed using the strict counting rules (the so-called forbidden lines 
principle) described by Gundersen and Sperling and Gundersen. This principle 
aims at preventing the so-called edge effect; i.e. either counting cells on edges 
of the counting zone more than once or not counting them at all.278-280 If these 
rules were applied and data of more than one count were averaged,  accept-
able to good (short-term) reproducibility in time was found, as well as good 
inter-observer reproducibility.220-222 224 228 281 With the introduction of automated 
image-analysis, through automated planimetry, individual cell size measure-
ment became available. This is the so-called variable frame analysis.234 240 280 282-285 
This allowed determination of mean cell area and ECD, and also assessment of 
polymegathism, through the calculation of the Coefficient of Variation of cell 
size or the calculation of cell size distributions. With other algorithms also cell 
shape factors such as hexagonality could be calculated.234 240 285 Assessment 
options in (semi-)automated variable frame counting methods include the ‘dot’ 
or ‘centre’ method,286-288 (derived from an earlier semi-automated method using 
nearest neighbour distances289) with which the centres of individual cells in a 
contiguous group are marked. See figure 2.I.2. This method is necessarily semi-
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automated or ‘interactive, i.e. manual marking of cells by an observer is mandato-
ry. In the ‘corners’ or ‘borders’ method the borders or corners of cells are outlined. 
The borders method can be performed in a completely automated fashion with 
software that is based on the recognition of contrast differences between cells 
and cell borders.286 287 290-294 Many of the currently commercially available specular 
microscopes use a CCD video camera to obtain images for analysis and are not 
dependent on hardcopy prints anymore. Some microscopes have in-built analy-
sis software packages, whereas with other instruments commercial or custom-
built software on a personal computer is used, and images are imported with 
a frame grabber. In most variable-frame endothelial analysis software however, 
fully automated cell border recognition is still far from flawless. This necessitates 
manual correction of software-defined cell borders before morphometric cal-
culations are performed.286 287 290-296 See figure 2.VII.1. For a representative sample 
in adults over 20 years old, at least 75 cells per image, box, or target area need 
to be counted. Under 20, the endothelium is usually more homogeneous. The 
more heterogeneous (i.e. polymegathistic and pleomorphic) the endothelium 
becomes, the less reliable a single sample from a single central cornea is for 
determining any of the morphometric parameters. And not only ECD but at least 
CV or another parameter for polymegathism should be presented in this case. 
Unrepresentative samples may also occur when the number of cells per sample 
is small, due to low density. In both these cases more samples from different 
(para-)central corneal areas should be obtained. 220 246 297-299 The validity of various 
manual, semi-, and automated assessment methods is discussed in more detail 
Part II, Chapter 3 of this thesis. The reproducibility of a modern semi-automated 
morphometric measurement method is reported in Part II, Chapter 4. 
 Early comparative studies did not report significant differences in ECD measure-
ments between non-contact and contact specular microscopy, and empha-
sized the greater patient comfort and the lower risk for microbial contamination 
with the non-contact method. Therefore, non-contact specular microscopy 
seemed particularly suitable for immediate post-operative endothelial asses-
ment.275 281 Some of the more contemporary non-contact instruments, such 
as the Topcon SP-1000, the Konan Noncon Robo SP-8000, and the Topcon SP-
2000P, have additional autofocus features, making them user-friendly.286 287 291 292 
294 300 Studies with recent specular microscopes with or without the use of semi-
automated endothelial analysis did not find significant systematic differences in 
ECD measurements between contact- and non-contact specular microscopes, 
provided that the instruments all had a correct magnification calibration.287 
300 301 Landesz et al. however did find significant differences in ECD between 
several contact and non-contact types of calibrated specular microscopes with 
semi-automated analysis. Therefore, even when calibration and the application 
of correction factors for magnification have been performed adequately, it may 
still be prudent not to use instruments interchangeably.291 302
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b.  Confocal microscopy.
 The development and principles of confocal microscopy were recently 
described in excellent review articles by Jalbert et al. and by Masters, and will 
only be summarized here.268 303 The main optical principle is that the illumina-
tion (condenser) and the observation (objective) systems have common focal 
points, hence the name ‘confocal’. Thus, light reflecting of structures surround-
ing the point of observation, which provides out of focus information and 
which obscures the image, is eliminated. A very high resolution results, allowing 
for  magnification of up to 600 x. To improve the very limited field of view, the 
focal point is rapidly scanned across the sample, and a real-time on-screen im-
age sequence is reconstructed. For scanning there are two techniques available. 
Tandem scanning, using a rotating Nipkow disc technique, provides through 
multiple pinholes multiple single spot illumination and whole area scanning. 
Slit scanning has also been used in specular microscopy and was described ear-
lier in part a. of this paragraph.268 303 Water-immersion, contact-type objectives 
are used with topical anaesthetics. Confocal microscopy provides in-vivo coro-
nal optical sections through the eye. All the corneal layers from the epithelium 
to the endothelium, including the epithelial basement membrane, Bowman’s 
layer, Descemet’s membrane, and lamellar or micro-keratome wound interfaces, 
and even edema in these layers, can be imaged. Measurement of light reflectiv-
ity of different layers can provide valuable information.303-305 Several clinical 
conditions, including keratitis, dystrophies and the iridocorneal-endothelial 
(ICE) syndrome, can be superbly imaged in-vivo.304 306 307 See figures 2.IX.1-3. All 
corneal cells, including epithelial cells, corneal nerve plexus, antigen-present-
ing Langerhans’ cells, keratocytes, and endothelial cells can be investigated. 
This allows morphologic and with image-analysis systems also quantitative 
evaluation, for instance keratocyte density measurement or ECD measurement. 
Wound healing processes can also be followed in vivo.303-305 308-311 Stromal opaci-
ties or edema preventing imaging of the endothelium in specular microscopy 
need not be a problem in confocal microscopy. 303 312 It is however not yet clear 
what the reliability of confocal ECD measurement is. Studies that evaluated 
reliability and reproducibility of ECD measurements with confocal micros-
copy,313 or compared confocal ECDs with ECDs obtained with contact296 and 
non-contact specular microscopy312 did not take into account factors related to 
the calibration of magnification. Moreover, some of these studies suffered from 
inadequate statistical methods. 312 313
c.  Light microscopy of donor corneal endothelium.
 In the seminal reports of the 1970s, specular microscopy was sometimes used 
for donor cornea endothelial evaluation.10 15 19 314 315 Only since 2001 this tech-
nique is mandatory in Eye Banks in the United States for the evaluation of donor 
corneas before they are stored. In the US, almost all corneas are preserved with 
cold storage techniques. Widespread introduction of specular microscopy for 
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donor evaluation was delayed, because of the necessity for imaging of a clear 
cornea, which restricted the post-mortem time (i.e. time between donor cornea 
procurement and endothelial evaluation; E. Pels, personal communication, 
2006). Also, there was fear of microbiological contamination. Both endothelial 
cell density and morphology, and the presence of guttata can be evaluated 
with specular microscopy, comparable to in vivo.316-321 In Europe, simultane-
ously with the introduction of the organ culture preservation method for donor 
cornea storage (instead of cold storage, see also paragraph XVI section e.), 
light microscopy techniques for endothelial evaluation were developed. These 
are applied several times during the storage process. In some eye banks both 
specular microscopy and light microscopic techniques that include trypan 
blue staining are used before the donor corneas are immersed in organ culture 
medium. This combination of evaluation techniques is often found in German 
eye banks.322 However, specular microscopic techniques are of no use anymore 
after corneas have been preserved in organ culture medium because of corneal 
swelling. At that time light microscopic evaluation has to be used (E. Pels, per-
sonal communication, 2006).
 Light-microscopic examination of donor corneas is done usually at the 
beginning of the preservation period, and always after preservation prior to 
transplantation. This takes place before transfer of the donor cornea from the 
storage medium into the transport medium. The criteria that are used to assess 
whether an endothelium is suitable for transplantation are: the extent of dam-
age to endothelial cells, the endothelial cell density, and endothelial cell and 
mosaic morphology.323 Currently, in many eye banks a direct test for endothelial 
function is not used. Instead, the evaluation of endothelial morphology is used 
as an indirect assessment. As has been discussed before, morphology reflects 
stress or damage to the endothelium, and hence to some extent the functional 
reserve capacity.324 Damage can for instance be assessed by the recognition of 
reformation figures, which lead to pleomorphism and polymegathism.249 325 
 To evaluate the extent of endothelial damage, since long vital stains have been 
used. Actually, ‘supra-vital stain’ would be a more appropriate term, as not living 
but dead and severely damaged cells are stained. In 1966, Stocker et al. and 
other authors experimented with para-nitro-blue-tetrazolium. However, this 
is not a vital but irreversible stain which makes the stained corneas useless for 
transplantation. Therefore Stocker later investigated and favoured trypan blue 
for reversible evaluation of endothelial damage in donor corneas. 326-329 Trypan 
blue (TB) staining of donor corneas was later adopted by Sperling, Pels, and 
others.325 330-333 Staining with 0.1 – 0.3 % TB for 30 – 60 seconds has now become 
routine practice for endothelial damage assessment in many cornea banks. The 
properties, toxicity, and different applications of trypan blue will be described 
more extensively in Part III, Chapter 8 of this thesis. 
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 Possibly more sensitive techniques to assess endothelial cell damage and viabil-
ity have been proposed as alternative assessment methods, but most of these 
are mainly suited for research purposes. These include:
  •   Fluorescein di-acetate vital staining;322 329 
  •   Combined acridine orange and ethidimium bromide staining, to identify   
 both viable and nonviable cells. This staining however may be toxic to the   
 endothelium, especially after exposure to light;334 
  • Janus green photometry, which gives a direct (i.e. without stained cell 
   counting) quantitative assessment of endothelial cell damage;335-337 
  • Photometric MMT-assays (see also chapter 7 and chapter 9);338 
  • In-situ TUNEL, short for “TdT dUTP mediated nick end labelling”, a technique  
 that is specifically used to demonstrate apoptosis.339 
 Except the fluorescein and acridine orange/ethidimium bromide staining these 
are all irreversible techniques, which can therefore only be used for research 
purposes and not for donor cornea evaluation. 
 In contrast, confocal laser scanning microscopy assay after calcein AM and 
ethidium homodimer-1 dual vital staining, redox fluorophotometry (in combi-
nation with specular microscopy), and 31P magnetic resonance spectroscopy, all 
allow for non-invasive, non- destructive assessments of donor corneal endo-
thelial viability c.q. metabolism.338 340 341 These techniques may provide different 
and perhaps more accurate information, especially on endothelial function, 
but require extensive investments in time and instruments – in contrast to the 
extremely cheap and fast trypan blue staining (E. Pels, personal communication, 
2006).
 Another dye, lissamine green, was proposed early on by Hassard and Kirk for 
supra-vital staining of the donor cornea endothelium.342 This vital stain did not 
gain popularity, but another observation in the same study, that application of 
hypotonic solutions can visualise endothelial cell borders by provoked swelling 
of the intercellular spaces, proved to be very valuable and was further devel-
oped by Sperling.343 344 In order to be able to estimate ECD and assess endothe-
lial mosaic and cell morphology in light microscopic donor cornea evaluation, 
it is necessary to visualise the endothelial cell borders. For research purposes, 
silver staining had been an often used technique.345 In combination with TB 
staining, the dye Alizarin red S gained much popularity and is currently still in 
use for accurate light microscopic ECD-assessment and evaluation, in endothe-
lial research.346-354 Both silver and alizarin red S staining needed tissue fixation 
and were irreversible, and therefore not suitable for donor cornea evaluation. 
For this purpose now the provoked intercellular swelling principle, in which 
application of a hypotonic solution (e.g. 1.8 % sucrose, or 0.45 % NaCl) is ap-
plied.332 343 344 Exposure to the hypotonic solution is often performed directly in 
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combination with TB staining. This sequence, when performed under sterile 
conditions, allows a complete, reversible light microscopic evaluation of the 
endothelium of transplantable donor corneas. See figure 2.VII.2. Both solutions 
are easily removed by thorough rinsing in buffered saline. 323 332 333 355 The ECD 
is estimated with a calibrated graticule in the ocular of the light microscope, 
using an empirically established estimation nomogram.323 More recently, semi-
automated image analysis methods have been developed to obtain more accu-
rate endothelial cell density assessment and more quantitative morphometric 
evaluation,356-359 as had earlier been proposed for specular microscopic donor 
cornea assessment.360 However, these systems appear to be very sensitive to 
calibration errors, image quality, and surprisingly also to the composition of the 
preservation medium. 361 362 
Fig. 2.VII.2  Donor cornea endothelium after trypan blue supra-vital staining and sucrose provoked intercellular 
swelling. Note that the cellborders are clearly visible due to swelling, that damaged cells have trypan 
blue stained nuclei, and that intercellular swelling and cell mosaic morphology is poor over Descemet’s 
folds.
Fig. 2.VII.1  Example of a specular microscopic image, analysed with the “borders” variable frame endothelial as-
sessment method. See colour figure on page 327.
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VIII.  Endothelial function tests.
a.  Pachymetry.
 Changes in corneal thickness reflect alterations in both the endothelial barrier 
and the pump functions. Baseline corneal thickness is an individual characteris-
tic for each person.72 363 364 Corneal thickness measurements a.k.a. ‘pachymetry‘ 
or ‘pachometry’ (from the ancient Greek παχύς, thick, or το πάχος, thickness) are 
clinically usually performed with either optical or ultrasound measuring instru-
ments.303 363 364 The traditional optical principles used for pachymetry included: 1. 
focussing on anterior and posterior corneal surface (successively or simultane-
ously), 2. the use of specular reflections from the anterior and posterior corneal 
surfaces, and 3. the use of scattered light reflections from the anterior and pos-
terior boundaries of an optical section through the cornea.72 84 85 303 363-367 Slit lamp 
pachymeters, using principle 3., and specular microscopes with pachymetry ca-
pacity, using principle 2., have been described and are available commercially.294 
300 363-365 367 Confocal microscopes can also be used to perform pachymetry, using 
principle 1.303 Other optical pachymetry techniques include optical coherence 
interferometry and optical coherence tomography, both based on differences 
in refractive indices, causing changes in speed of light and back reflections 
at corneal boundaries,363 364 The technique of the Orbscan corneal topograph 
(Bausch and Lomb), uses instead of the conventional Placido disc images, the 
scanning slit principle described earlier combined with advanced image analysis 
techniques. In this way it can measure both the anterior and posterior corneal 
curvatures, and also the thickness of the cornea.363 364 368 Recently the Pentacam 
has been introduced, a commercially available topograph and pachymeter 
based on a rotating camera using the old Scheimpflug principle. With this 
instrument cross-sectional images through the cornea (and crystalline lens) can 
be obtained, and hence also reliable corneal thickness measurements.369 
 The other major principle currently applied for pachymetry is based on ultra-
sound. Both ‘regular’ ultrasound probes (about 20 MHz) and the higher frequency 
(50 MHz) Ultrasound Biomicroscope (UBM, Humphrey Instruments) are contact 
instruments. The thickness measurement is based on the time lag between an 
emitted ultrasound pulse and the reflected echoes from the acoustic interface at 
the corneal posterior curvature, related to the velocity of sound in the cornea.363 364
 Several studies compared many different instruments based on both ultra-
sound and optical pachymetry. Considerable differences in thickness measure-
ment and reproducibility were found and moreover, these differences appeared 
to vary between the different studies. It is therefore advisable not to use instru-
ments with different measurement principles interchangeably in prospective 
studies.288 300 303 368-370 
 Normal values of pachymetry from a larger study with one of the older optical 
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techniques showed a central thickness of 0.523 mm and a peripheral thickness of 
0.660 mm. There was a small (but not significant) difference in men having high-
er values than women, and there were also differences in different age groups, 
with significant thinning in the corneal periphery in the higher age groups.366
b.  Hypoxic stress test.  
 The function of the endothelial pump can be assessed in vivo by measur-
ing changes in corneal thickness following hypoxic stress. Corneal hypoxia is 
produced by exposing the anterior surface of the cornea to a low-oxygen/
high-nitrogen atmosphere, or by placing a thick contact lens onto the eye. The 
accumulation of lactic acid produced by anaerobic metabolism in the epithe-
lium causes stromal swelling, either through osmosis or by directly inhibiting 
the endothelial pump. After reinstating normal oxygen tensions to the anterior 
surface, deswelling occurs over the next two to four hours at a rate consistent 
with endothelial pumping. As evaporation from the anterior surface contributes 
to corneal deturgescence, ideally the relative humidity should be controlled, 
or the investigated eyes should be kept closed during the experiment. Very 
accurate and reproducible pachymetry is needed to assess corneal deswelling 
properly. A possible relation between endothelial morphology or ECD and hy-
poxic stress may be influenced by other factors, including contact lens wearing 
history.40 255 371-379 As an alternative method for inducing corneal edema, cold 
stress may also be used. Especially in eyes with subnormal corneal sensitivity 
cold stress invokes corneal swelling.380
c.  Fluorescein fluorophotometry.
 The barrier function of the endothelium can be assessed in vivo by measuring 
the permeability of the endothelial barrier to fluorescein. Fluorescein can be ad-
ministered systemically via the oral or intravenous route, and enters the anterior 
chamber via the uvea  (corpus ciliare). Alternatively, it is topically instilled into 
the conjunctival sac, and is taken up through the cornea into the aqueous, with 
or without the use of iontophoresis. Subsequently the fluorescein concentra-
tion in both the cornea and the anterior chamber is measured fluorophoto-
metrically at repeated time intervals. Using farmacokinetic formulas, from these 
concentrations, their differences, and their change over time, the permeability 
of the endothelial layer to fluorescein in the anterior chamber can be deter-
mined. The method is time-intensive and calls for a fluorophotometry instru-
ment.1 40 84 85 364 377 379 381-384
d.  Investigational  perfusion of corneae.
 From the 1970s onwards, experiments have been performed in which (donor or 
animal) corneae had been mounted in a perfusion chamber, followed by exposure 
of the endothelial side to a continuous flow of solutions with varied compositions. 
Morphologic assessment of the endothelium via light, electron, and specular 
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microscopy, as well as functional evaluation of the endothelial function by means 
of pachymetry can be performed before, during, and after the experiment. In 
this way, in many studies toxic effects of medications and other substances were 
evaluated. Another application was the determination of the optimal constitution 
of intraocular perfusion solutions and the concentration of its constituents. The 
use of this technique to test the viability of endothelial cells on donor corneas, an 
application with direct clinical implications, has also been suggested.385-396
e.  Endothelial pump site quantification.
 As was discussed in paragraph IV, the Na+/K+ ATPase is a very important ion 
pumping (and hence water transporting) mechanism in the corneal endothe-
lium. It is thought to constitute up to 80 % of total endothelial pumping capac-
ity (H. Edelhauser, personal communication, 2005). These Na+/K+ ATPase pump 
sites can be quantified in vitro with Tritium-(3H-)labeled ouabain. Ouabain binds 
selectively (and blocks) Na+/K+ ATPase, in the ratio: one molecule ouabain to 
one Na+/K+ ATPase pump site. Scintillation spectroscopy quantifies 3H-uptake, 
and hence the number of molecules of ouabain bound, by a disc of endothelial 
cells on Descemet’s membrane with known dimensions and known ECD. With 
these known parameters, the number of Na+/K+ ATPase pump sites per cell can 
be calculated.100 101 
IX.  The primary endotheliopathies.
 
 Primary endothelial disorders, also known as neurocristopathies, result from 
abnormal migration, proliferation, or differentiation of the neural crest cells, 
the embryological progenitors of the endothelial cells. Hence, most primary 
endotheliopathies are congenital. An acquired primary endothelial abnormality 
is endothelial metaplasia. This may accompany any of the congenital primary 
endothelial disorders, and implies that endothelial cells assume the phenotype 
of another, similarly differentiated tissue. Epithelioid metaplasia implies the loss 
of contact inhibition, increased keratin expression, and proliferation of surface 
microvilli (e.g. in posterior polymorphous dystrophy and in the iridocorneo-
endothelial syndrome). Fibroblastic metaplasia implies that the cuboidal cells 
become fusiform, may loose apical junctional contact and possibly become 
multi-layered; this is a non-specific reaction to stress and can be seen in many 
endothelial disorders, and after many noxious stimuli including (experimental) 
trauma. Most endotheliopathies usually are accompanied by the deposition of 
a posterior collagenous layer (PCL), formed of long-spaced collagen, posterior 
(i.e. more towards the anterior chamber) to Descemet’s membrane 40 397 398 
 Abnormal migration of neural crest cells results in the mesenchymal dysgenesis 
syndrome, including Peter’s anomaly and the Axenfeld-Rieger syndrome which 
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were briefly addressed in paragraph III (Embryology of the endothelium) earlier 
in this chapter.65 
 Abnormal differentiation of neural crest cells causes the endothelial dystro-
phies: Congenital Hereditary Endothelial Dystrophy (CHED), Posterior Polymor-
phous Dystrophy (PPD), and Fuchs’ Endothelial Dystrophy (FED). All endothelial 
dystrophies are bilateral disorders, although not always with a completely 
symmetric presentation, particularly not in PPD. 
 CHED, a rare disorder with both autosomal recessive and dominant inheri-
tance, presents at birth with a mild to severe complete corneal edema, due to 
endothelial failure. The endothelium demonstrates fibroblastic metaplasia, of 
Descemet’s membrane only the anterior banded part exists, and a disorgan-
ised PCL is present. The anterior segment is usually normal, in contrast to the 
mesenchymal dysgenesis syndromes. In severe cases penetrating keratoplasty 
is necessary.1 27 40 217 397 398
 In contrast, PPD is usually a more slowly progressive disorder. It is suggested 
that its onset is in the perinatal period, since in some affected areas (so-called 
‘pits’) only a very thin portion of the posterior non-banded part of Descemet’s 
membrane exists. PPD is usually inherited in an autosomal dominant pattern, 
but there is a variable expression. Clusters of blister-like endothelial vesicular 
lesions are seen, in groups, traumatic-break-like bands, geographic forms, or 
even over large areas of the cornea. In these lesions endothelial cells are either 
large and pleomorphic, or small with indistinct boundaries. Some endothelial 
cells show marked epithelioid metaplasia. See figure 2.IX.1. Usually a thick PCL is 
deposited. Penetrating keratoplasty is often not necessary. 1 27 40 217 397-401
 Fuchs’ endothelial dystrophy (FED) is the most common endothelial dystrophy, 
with autosomal dominant and sporadic forms. It is more common in women, 
and usually becomes apparent around the age of 40, with the biomicroscopic 
appearance of cornea guttata. Guttae are excrescences of collagen protruding 
from Descemet’s membrane into the anterior chamber. Pigment phagocy-
tosed by endothelial cells can also be observed. Over the collagen deposited 
in guttae lie abnormal, enlarged endothelial cells. Current concepts of the 
pathophysiology agree that abnormal, diseased endothelial cells produce the 
collagenous material that is accumulated in the guttae. See figure 2.IX.2. Relat-
ing to the pathophysiologic mechanism causing the dysfunctional endothelial 
cells however there are many theories, none of which is proven. The fibrinolytic 
system, hormonal influences, increased apoptosis, and mitochondrial abnor-
malities have all been proposed as mechanisms. The result is in any case that 
the affected endothelial cells progressively thin and are finally lost, and that the 
ECD progressively drops. The remaining cells also thin and spread out. Apical 
junctional complexes may be lost, preceding fibroblastic metaplasia. A PCL is de-
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posited. Barrier function is thought to be lost gradually, whereas pump function 
may initially be increased, delaying the onset of stromal edema. However, eventu-
ally the pump-function deteriorates, demonstrated by the decline in functional 
Na+/K+ ATPase. When more guttae are formed and more endothelial cells are 
lost, perhaps accelerated by intra-ocular surgery, stromal edema and even bul-
lous keratopathy may occur. Corneal dehydration by hypertonic saline drops or 
ointment or by blow-drying usually provides mostly temporary improvement of 
edema and vision. Eventually, keratoplasty is often necessary. 1 27 40 101 217 397 398 402-406
 The Irido-Corneal Endothelial (ICE) syndrome cannot easily be classified as a 
dystrophy, because of several characteristics. For one, abnormal proliferation of 
neural crest cells is thought to cause some of the typical changes. Epithelioid 
metaplasia of these cells is a common and striking feature, which gives this syn-
drome sometimes a phenotypic resemblance with PPD. Diminished numbers of 
endothelial cells have also been encountered in ICE syndrome, probably caused 
by necrosis and/or apoptosis, which indicates that degeneration plays a role as 
well. As pathophysiologic mechanism, besides neural crest cell abnormalities 
or embryonic ectopia, inflammation (iridocyclitis and endotheliitis) has been 
mentioned and observed. Viral infection (HSV, EBV) has been suggested as a 
cause, and indeed viral DNA has been detected in some but not all examined 
patients. A “two-hit” hypothesis has been proposed, with abnormal pluripotent 
neural crest cell nests or ectopic embryonal epithelial cells accounting for the 
first hit. Inflammation or infection later in life delivers the second hit, causing 
proliferation and metaplasia, and hence the late manifestation and/or progres-
sion. ICE-syndrome is usually unilateral, with no or only minimal morphological 
changes in the other eye. It occurs mostly sporadic (isolated cases of familiar 
involvement exist), and typically affects women (female to male ratio 5 : 1) with 
an onset usually in the third to fifth decade. Occasionally bilateral involvement 
is encountered, especially in men or in familiar cases. On bio- and specular 
microscopy the endothelium has a ‘beaten-metal’ appearance. The pathog-
nomonic ‘ICE-cell’ is recognized with specular microscopy. It is very irregularly 
shaped, has oval dark and light intracellular bodies, and has a ‘negative image’, 
i.e. a dark cell surface and light cell borders. (Normal endothelial cells have light 
cell surfaces and dark cell borders on specular microscopy). See figure 2.IX.3. On 
an ultrastuctural level, the “ICE-endothelium” shows characteristics of epithelial 
metaplasia. In partial corneal involvement there is a sharp demarcation line 
between affected areas and areas with normally appearing cells that have either 
higher or lower densities than in the unaffected eye. Descemet’s membrane 
under a thick PCL is normal, implicating a post-natal onset. Secondary features, 
including corneal edema, peripheral anterior synecchiae, glaucoma, and chang-
es in iris architecture and pigmentation, result from degeneration of endothelial 
cells on the cornea and paradoxical proliferation of endothelial cells onto the 
iris or trabecular meshwork. Collagen (extended basement membrane) under 
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the ectopic endothelium produces peripheral anterior synecchiae, ectopic pu-
pil, and traction tears of the iris. Along with the predominance of some of these 
(secondary) features, the ICE syndrome used to be subdivided into essential 
iris atrophy, Chandler’s syndrome, and Cogan-Reese syndrome (also known as 
iris nevus syndrome). This labeling of subtype does not seem to be very useful 
however, and eyes can progress from one phenotype to another. Glaucoma 
needs to be controlled, and sometimes keratoplasty is indicated. 1 27 40 217 398 407-409
 It has been implied that the aetiology of PPD, CHED, mesenchymal dysgenesis, 
and ICE syndrome may to some extent be related, in that common genetic 
defects may play a role. PPD and CHED have been linked to a defect on chromo-
some 20. Even in Fuchs’ (FED) a similar genetic defect may be implied; a defect 
in the COL8A2 gene coding for collagen VIII has been identified in families with 
FED and in a family with PPD. Alternatively, common observed features may 
also be attributed to a final common pathway in pathophysiologic mechanisms, 
such as non-specific secondary dysplasia, instead of to a common primary ge-
netic cause. In this respect also phenotypic similarities between ICE syndrome 
and Axenfeld-Rieger anomaly can be pointed out. PPD has further been found 
in association with Alport syndrome, a basement membrane disorder character-
ized by heriditary nephritis and sensorineural hearing loss.1 27 40 217 364 397 398 401 409
Fig. 2.IX.1  Confocal microscopic image of a localized endothelial abnormality, typical for Posterior Polymorphous 
Dystrophy.  (Courtesy of C. Weenen, MD).
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Fig. 2.IX.2  A confocal microscopic image of Fuchs’ endothelial dystrophy. De dark and the highlighted white areas 
are abnormal endothelial cells over guttata. (Courtesy of C. Weenen, MD.)
Fig. 2.IX.3  Confocal microscopic image of an endothelium affected by the irido-corneal-endothelial (ICE) 
  syndrome. Note the “negative image” of the abnormal “ice”-cells with dark cytoplasm and light nuclei. 
Also note the demarcation line between normal and abnormal endothelium. 
 (Courtesy of C. Weenen, MD.)
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X.  Secondary endogenous endotheliopathy: ocular and 
systemic disease. 
 
 In uveitis, leukocytes in the anterior chamber sometimes migrate between and 
beneath endothelial cells causing keratic precipitates. In mild cases this is usually 
reversible with no notable endothelial cell loss. However, in more severe and/or 
chronic uveitic episodes, as well as in cases of herpes simplex uveitis with or 
without endothelitis, the ECD centrally or in the area of the keratic precipitates 
may stay decreased with increased pleomorphism and polymegathism. Endo-
thelial function may be importantly diminished during uveitic episodes.1 23 40 410-415
 In acute angle-closure glaucoma, significant endothelial damage often occurs, 
related to the duration of significantly raised IOP. Hypoxia due to stagnant 
aqueous, as well as concomitant inflammation may be pathophysiologic fac-
tors.27 416 417 Corneal swelling in angle-closure glaucoma seems to occur when 
the endothelium has indeed been damaged.416 Endothelial cell loss may occur 
in pigmentary dispersion glaucoma and especially in pseudo-exfoliative glau-
coma. Pseudoexfoliation syndrome without glaucoma led to a lesser decrease 
in ECD.27 40 418-420 The endothelial cell loss observed after glaucomato-cyclitic 
crises, also known as Posner-Schlossmann syndrome, may (in part) be caused 
by the inflammation.27 40 Lower ECDs found in congenital/infantile glaucoma 
may have resulted from the IOP, from breaks in Descemet’s membrane (Haab’s 
striae), or be secondary to corneal enlargement.1 27 In primary open angle glau-
coma, affected eyes have been reported to have fewer endothelial cells and 
greater annual losses, but this remains controversial.27 40 364 421-423 In one study the 
ECDs were inversely proportional to the means of IOPs.424 Although not entirely 
excluded, a clinical detrimental effect of  topical medication has not been dem-
onstrated.27 40 364 421
 Diabetes mellitus, both the insuline-dependent and the non-insuline depen-
dent types, has been shown to affect the endothelium. Polymegathism and 
pleomorphism were observed, indicating a higher susceptibility to stress (eg. 
surgery). ECD may also be decreased in long-standing diabetics, but this is not 
an unequivocal finding. Endothelial pump and/or barrier functions may be 
affected. Descemet’s membrane is usually normal.40 253 364 377 425-428 Argon laser 
photocoagulation in diabetics has been found to induce endothelial cell loss 
that is correlated to the amount of energy delivered to the eye by the photoco-
agulation.429
 Cystic fibrosis has also been implicated in endothelial pump and barrier dys-
function, but remarkably, a higher rather than lower ECD has been observed. 
This remained unexplained.426
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XI. Ocular trauma, and effects of radiation, topical, and 
regional medication.
 
 Birth trauma to the cornea by forceps delivery is the cause of Descemet’s 
membrane ruptures which in turn may lead to localized endothelial cell loss. 
Penetrating corneal trauma causes focal, and in larger trauma also generalized, 
endohelial cell damage and loss. The amount of endothelial cell loss correlates 
with the dimensions of the wound. Blunt traumata, including airbag trauma 
and the so called annular keratopathy, cause focal endothelial cell damage. 
Irreversibly damaged endothelial cells are shed, and the bare Descemet’s mem-
brane is repopulated by the wound healing mechanisms described earlier.1 23 40 
364 400 417 430-436 Epithelial downgrowth sometimes occurs after a penetrating injury 
or intraocular surgery. The epithelial cells stemming from the conjunctiva may 
overgrow the endothelial cells, especially in case of a pre-existent endothelial 
disease, and also overgrow chamber angle, iris and ciliary body.23 27 40 437 
 UV-B radiation may induce endothelial damage. No effect by electromagnetic 
irradiation of other wavelengths has been reported.1 40
 As discussed in the previous paragraph, endothelial damage by current topical 
ocular medications was not unequivocally demonstrated in clinical trials. In ani-
mal experiments some indications for endothelial damage by the drug timoptic 
was found. Topical epinephrine and phenylephrine were found to have some 
detrimental effect, but toxicity may also have been related to the preservatives 
in the preparation. The carbonic anhydrase inhibitors may have an action on 
endothelial physiology, i.e. by blocking (part of ) the endothelial pump. It is 
however not certain whether (prolonged) administration causes irreversible 
effects.23 364 377 421 438-441 Much more substantiated is the endothelial damage that 
can be caused by preservatives in ophthalmologic topical drugs. Benzalko-
nium chloride, chlorobutanol, methylparaben, propylparaben, thimerosal, and 
sodium bisulphite are examples of these preservatives. All are associated with 
allergies, dose-dependent epitheliotoxicity, and dose-dependent endothelio-
toxity. Endotheliotoxicity occurs in a dose much lower than needed to damage 
epithelial cells. Subconjuntival injections containing these preservatives may 
also cause toxic effects.40 387 442-445 There is a report that chlorhexidine, when used 
as a preoperative antiseptic for preparation of the surgical field in (non-ocular) 
head-and neck surgery, may cause not only epithelial defects and keratitis, but 
also endothelial damage even leading to bullous keratopathy.446 
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XII.  Effects of contact lens wear.
 
 The effect of contact lens wear on the corneal endothelium became an issue 
of concern when, within minutes of placement of a contact lens, the formation 
of blebs within endothelial cells and widening of the intercellular spaces were 
observed.447 These reversible phenomena represent intra- and inter-endothelial 
cell edema, caused by stromal acidosis as a result of epithelial hypoxia. This 
mechanism was discussed  earlier in this chapter with the hypoxic stress test, in 
paragraph VIII.b..364 448 449 Induction of hypoxia differs among the various contact 
lens materials. Poly-methyl-methacrylate (PMMA), rigid gas-permeable (RGP), 
soft hydrogel, silicone, and silicone hydrogel lenses each have different oxygen 
transmissibilities. The oxygen permeability of a contact lens is usually expressed 
as Dk/L; D is the diffusion coefficient of the material; k is the solubility coef-
ficient of the material, and L is the average thickness of the lens. Furthermore, 
the pattern of wear is important, as is the individual susceptibility. 448-450 All 
corneal layers may be affected by hypoxia, 450 but in this paragraph we will only 
focus on the endothelium. Prolonged contact lens wear causes chronic hypoxia 
and hypercapnia. Almost all contact lens types, including RGPs, induce pleo-
morphism and polymegathism within a few months of the start of wear. 364 450-460 
Highly oxygen-permeable (‘high Dk’) silicone hydrogel and silicone elastomere 
soft contact lenses, as well as piggyback lenses (an RGP lens on top of a high-
water content soft lens) may be exceptions.450 461-463 The changes become more 
pronounced and are more slowly reversible with increasing duration of wear 
over time and the number of hours of wear per day.364 450 451 457-459 As discussed 
earlier, polymegathism is not necessarily related to endothelial cell loss.244 Most 
studies have been unable to confirm lower ECD in contact lens wearers,451 456 458 
459 464 although this has been observed after PMMA contact lens wear,433 465 and 
in subsets of soft contact lens wearers,450 as well as in contact lens wear after 
penetrating keratoplasty.466 Some authors believe increased pleomorphism and 
polymegathism to precede endothelial cell loss. 457 364 450 Neither endothelial 
barrier nor pump functions may suffer directly from contact lens wear, and they 
may even be increased. However, the barrier function may be decreased in case 
of deep stromal opacities – which may be related to preservatives in contact 
lens cleaning fluids. At times of stress, eg. in a hypoxic stress test as described 
in paragraph VIII.c. of this chapter, the functional reserve of the endothelium 
pump function has been shown to be reduced.364 375 377 450 458 459 467
 Corneal reshaping with nighttime contactlenses, also known as orthokeratol-
ogy and as corneal refractive therapy, is discussed in paragraph XIV.
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XIII.  Effects of cataract surgery.
a.  Developments in techniques of cataract surgery, intra-ocular lens design 
and  implantation, in relation to endothelial cell loss.
 After the introduction of the specular microscope in the 1970s it soon became 
apparent that both the performance of cataract surgery and the implantation 
of intraocular lenses (IOLs) could cause significant endothelial cell loss.14 17 18 
Substantial endothelial cell loss may result in the long term in the complication 
bullous keratopathy (either aphakic, ABK, or pseudophakic, PPBK).251 468 Factors 
that are of influence on the severity of endothelial cell loss were now identified. 
Pre-operative factors should influence decision making, whether and how to 
operate. Some of these, such as pre-existent endothelial dystrophy, pre-existent 
endothelial pleomorphism and polymegathism, or a low ECD, are identifiable 
with a specular microscope. Other factors include previous surgery, trauma, 
glaucoma, pseudo-exfoliation, and uveitis. Intra-operative factors include direct 
endothelial trauma; placement, position, and type of an intraocular lens (IOL); 
toxicity of irrigating fluids; and the surgical technique of cataract extraction. The 
development of less damaging surgical techniques and IOLs, and the applica-
tion of safe or even protective intra-operatively used solutions, substances, and 
pharmaca, has gained much interest. Prevention or early treatment of post-op-
erative factors are further possibilities for the minimization of endothelial cell 
loss. These include elevated intraocular pressure, persistent inflammation (with 
or without anterior synecchiae), vitreo-endothelial touch, IOL dislocation, and 
intermittent IOL touch.40 251 468-475
 In early studies, the effects on the endothelium of intracapsular cataract 
extraction (ICCE) and contemporary (anterior chamber and posterior cham-
ber) phacoemulsification were evaluated. IOL placement, which had not been 
commonplace before, was also subjected to investigation. IOL types used at 
that time included anterior chamber (angle-supported and iris-attached) IOLs,  
iris-attached pupillary plane IOLs, and early types of posterior chamber IOLs .14 
17 18 20 23 27 476-481 Measured a few months postoperatively, ICCE caused ECD loss of 
around 12 %; whereas anterior chamber phacoemulsification caused an ECD 
loss of 14-34 %; this latter technique was soon after these reports abandoned 
in favour of posterior chamber phacoemulsification.23 468 477 478 480 The placement 
of an IOL was found to independently cause significant ECD loss,17 23 477 482-487 
causing scrutiny of the type and position of IOL. Especially pupillary fixated 
lenses, which for a while were widely used in combination with ICCE,  appeared 
to be the cause of substantial of endothelial cell loss. This observation initi-
ated  changes in preference towards the placement of posterior chamber IOLs 
and surgical techniques that – in contrast to ICCE - left the capsular support 
for these IOLs intact. The result was that the extracapsular cataract extraction 
(ECCE) technique became more popular. By itself however, ECCE did not differ 
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much from ICCE regarding endothelial cell loss.237 468-470 472 474 478 480 486-492 Another 
consequence of the finding of increased ECD-loss associated with IOL implan-
tation stimulated attempts to protect the endothelium during implantation.  
For this purpose first air, and later viscoelastics (see part b of this paragraph) 
were used.468 493 A different approach was the search for IOL materials or coat-
ings that showed less adherence to endothelial cells.494-496
  The next step in the development of cataract extraction techniques that 
preserved the lens capsule, was improved posterior chamber phacoemulsifica-
tion. At 6 to 12 months after modern phacoemulsification with implantation of 
an IOL in the posterior chamber - either  foldable or rigid, and preferably within 
the capsular bag - central ECD-losses of between 7.5 and 16 % are commonly 
reported. Only in one study a remarkable 24 % loss was found.497-501 The amount 
of cell loss appears to be correlated with incision dimensions. It may be some-
what larger with clear-corneal incisions than with same-sized or even larger 
scleral tunnel incisions.498 501 502 Other factors that increased ECD loss included 
shorter axial length, older age, small pupil diameter, greater infusion volume, 
and the amount of phacoemulsification energy that was used. Phaco-energy 
in turn was related to the presence of a harder nucleus.499 503 504 The technique 
used during the procedure may influence the ECD loss. Several techniques 
were developed with the aim to diminish the amount of ultrasound energy 
needed during phacoemulsification, such as divide-and-conquer nucleofraxis, 
‘phaco-chop’, ‘stop-and-chop’, ‘chip-and-flip’, and ‘reversed tip and snip’. Most 
of these techniques were to some extent effective in lowering the surgically 
induced endothelial cell loss, or to result in less postoperative deterioration in 
endothelial pump and barrier functions.505-509 In contrast, prospective studies 
comparing the older ECCE with manual nuclear expression technique to phaco-
emulsification, did not find  differences in ECD-loss (10-18 %) after 1-12 months. 
Only small and temporary differences in endothelial function were observed 
(see also part c of this paragraph) . In the case of a very hard nucleus, endothe-
lial cell loss was in one study even found to be more severe after phacoemulsifi-
cation than after traditional ECCE.510-513 
 New developments in cataract surgery focus on smaller incisions, to allow the 
creation of a more closed system regarding intra-ocular fluid currents (“better 
fluidics”). This closed system diminishes intraoperative pressure changes as well 
as the intra-operative loss of viscoelastics, which both enable better mainte-
nance of anterior chamber depth. Also, surgical control of nuclear fragments 
and cortical remnants is enhanced. Additional advantages include faster wound 
healing and less astigmatism. 514-516 A second important goal in improving 
phacoemulsification techniques is the reduction of intra-ocular energy transfer, 
especially heat production. Improved fluidics, which is also aimed for by the use 
of smaller incisions, provides higher vacuum and necessitates less ultrasound 
energy. New software modulations for ultrasound energy delivery increase the 
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length of pausing intervals - the so –called “off” time - between microbursts of 
phacoemulsification energy delivery. This provides for lower intraocular energy 
transfer, and lower temperatures at the incision. This last feature may enable 
phacoemulsification without a cooling irrigation sleeve, through a very small 
incision (0.9 – 1.4 mm). 515-523 One of these techniques has already been shown 
to diminish endothelial cell loss.524 A third factor that is subject to technical 
improvement is the occurrence of many tiny air bubbles  (“cavitation”). This 
phenomenon may also be detrimental to the endothelium. Oscillatory hand-
pieces have been developed, in order to diminish cavitation and also aiming at 
decreased intra-operative heat production.525-527 Many of these developments 
converge in bimanual phacoemulsification a.k.a. microincision cataract surgery 
(MICS) techniques that currently get a lot of attention. These involve two 
small instead of one larger clear corneal incisions. Each of these incisions gives 
access to the phacoemulsification handpiece, and the other incision is used 
for simultaneous continuous irrigation with a second instrument. This second 
irrigating instrument enables enhanced lens (fragment) manipulation including 
nuclear chopping, which further decreases phaco-energy delivery.521 522 528-530 
Besides the inevitable learning curve for a new surgical technique, currently the 
most important limitation of this technique is the size of available foldable IOLs. 
Unfortunately, enlargement of a small incision or even adding a third, larger, 
incision is still necessary at the moment.515 530 The few studies reporting on 
endothelial cell loss after bimanual phacoemulsification showed at 3 months 
postoperatively a wide range of endothelial cell losses, from 4.6 % to 15.6 %. 
Again, cell loss was related to nucleus hardness grade.521 529 531 Longer experi-
ence with and improvements in the technique, as well as improved IOLs, may 
be necessary to translate enhanced intra-operative manipulation and other 
(theoretical?) advantages into reproducible reductions in endothelial cell loss.
 Besides efforts directed at improving phacoemulsification, research is also con-
ducted on alternative techniques for lens fragmentation, among which laser-, 
water jet-, and sonic-oscillation-assisted lens removal.516 520
b.  Endothelial protection during (cataract) surgery: viscoelastic materials.
 Both the use of viscoelastic substances and the insertion of an air bubble in the 
anterior chamber were attempts to protect the endothelium during IOL inser-
tion. 23 478 532-534  However, since air bubbles themselves had been found to cause 
endothelial damage after (prolonged) contact,11 535 536 the use of viscoelastics 
soon became the preferred technique. They proved to be inert and to provide 
good protection for the endothelium against endothelial trauma. Not only  IOL 
insertion but other surgical trauma, including air bubble (cavitation) trauma 
from phacoemulsification appeared to be diminished. Additional advantages 
included the creation and maintenance of space in the anterior chamber 
facilitating surgery. Viscoelastics were therefore increasingly used, during ICCE, 
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and in ECCE, both in non-automated nuclear evacuation techniques and in 
phacemulsification .450 478 526 532 533 536-547 Concern arose about intra-ocular pressure 
increase after the use of viscoelastics, especially Na-hyaluronate. Experimentally, 
increased aqueous outflow resistance was observed. Meticulous irrigation of 
the anterior chamber and aspiration of the viscoelastic material after surgery 
was advocated to prevent or diminish this phenomenon 533 534 538 542 548-550 Current 
viscoelastics are usually subdivided into two main groups: dispersive, coating 
substances that are foremost endothelial protectors, and cohesive substances 
that predominantly maintain space. However, many viscoelastics have both ca-
pacities to some extent.551 552 The materials used include Na-hyaluronate, highly 
purified (hydroxypropyl-) methylcellulose (HPMC), hypromellose, chondroitin 
sulfate, polyacrylamide, and  combinations (eg. Na-hyaluronate and Na-chon-
droitin sulfate), with Na-hyaluronate and polyacrylamide providing more 
cohesive effects, and the other substances as well as the Na-hyaluronate/Na-
chondroitin sulfate combination more dispersive effects. Most clinical studies 
demonstrated less endothelial cell loss with the more dispersive viscoelastics. 
532-534 536 542 545-547 549-557 After the introduction of their use in cataract surgery, soon 
viscoelastics were also used in other types of anterior segment eye surgery 
such as filtering procedures for glaucoma, and penetrating keratoplasty.532
c.  Endothelial function and ongoing endothelial cell loss after cataract surgery.
 After ECCE both the endothelial pump and barrier functions have been mea-
sured. Hypoxic stress testing revealed decreased pump function up to 24 weeks 
after surgery. However, corneal thickness, which was increased during the first 
postoperative month, returned to normal thereafter. Endothelial permeability 
as measured by fluorescein fluorophotometry was significantly increased at 3 
months but not at 12 months postoperatively.510 558 559 After phacoemulsifica-
tion, fluorescein permeability may or may not be increased. Corneal pachym-
etry was significantly increased one day postoperatively, but returned to normal 
at 3 months.500 510 560 Epithelial but not endothelial Na+/K+ ATPase abnormalities 
were found after cataract surgery.561
 Some older long-term studies showed stabilization of the endothelial cell 
density 3 moths postoperatively, regardless of the type of surgery or IOL.562 563 
In most studies from this period however indications were found for continued 
endothelial cell loss years after cataract surgery with several different tech-
niques, including ICCE, ECCE, and phacoemulsification, with or without IOL 
implantation (of different types). The initial ECD-loss ranged between 12 % and 
25 %.493 564-567 In one long follow-up study, the annual loss at 10 years postop-
eratively was 2.5 %, regardless whether or not an IOL was implanted, and also 
regardless of which type of IOL was used492 In contrast, other studies reported 
that ongoing ECD-loss was related to the type and position of IOL.480 568 Mecha-
nisms that were suggested for continuing, accelerated ECD loss after cataract 
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surgery include ongoing endothelial remodelling, chronic low-grade inflamma-
tion, exposure to vitreous components, breakdown of blood-aqueous barrier 
and other changes in aqueous flow. None of these supposed mechanisms have 
been proven unequivocally.136 480 486 487 492 564 
 Only one prospective study on ECD-loss after modern phacoemulsification and 
(posterior chamber) IOL implantation with a follow-up of longer than 2 years 
could be retrieved. In this study an initial loss of  8 % (corrected for physiological 
loss) 1 year post-operatively  increased to a cumulative loss of 11.5 %  (correct-
ed) after 3 years, whereafter the ECD-loss stabilized at the physiological level.569 
In line with these findings another study reported at 2 years postoperatively an 
annual endothelial cell loss of 0.9 %, only slightly higher than the physiological 
loss.570 A retrospective study confirmed that several years after phacoemulsifica-
tion no increased endothelial cell loss was observed, even when an anterior 
chamber IOL had been inserted.571. A tentative conclusion may be that the 
increased central endothelial cell loss that is observed in the first postoperative 
years after modern phacoemulsification mainly reflects endothelial mosaic re-
modelling. This serves to increase ECD in areas with the largest initial loss, such 
as for instance at the corneal end of the tunnel incision. After the first years, 
central endothelial cell loss seems to return to physiological levels. 
 The study by Armitage et al., discussed earlier in paragraph VI.a. of this chapter, 
looked into biphasic exponential regression models for ECD loss after cataract 
surgery. It reported a shortened half time (26 years) of ECD-loss in the slow 
phase after cataract surgery that correlated with higher than physiological 
ongoing cell loss. However, the data used were from a study in which older 
techniques of cataract surgery had been applied. The model needs to be up-
dated for ECD-loss after modern phacoemulsification.231 492
XIV.  Effects of refractive surgery.
 
 There are two main principles to alter the refractive status of an eye with a (sur-
gical) intervention. One principle is to change the refractive power of a cornea 
by modifying its shape. For this purpose several techniques are currently used 
or were used in the past. These include: corneal incisions; excimer laser ablation 
of corneal tissue; lamellar corneal surgery; the insertion into the cornea of (pre-
treated) donor corneal tissue or “inert” materials such as hydrogel, silicone, or 
PMMA; and altering the corneal shape mechanically with contact lenses or ther-
mally with cautery. The other principle is the implantation of intra-ocular lenses 
of a specific refractive power into the eye, either in adjunction to, or instead and 
in the position of the crystalline lens. These techniques are respectively called 
phakic IOL implantation, and refractive lens exchange.423 572 573 
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 (Epi-)Keratophakia, corneal alloplastic inlays, manual keratomileusis, and hol-
mium laser, conductive, and thermokeratoplasty,30 572 574 575 are left out of consid-
eration in the following overview of refractive surgical procedures because they 
are not widely used anymore. 
 Radial keratotomy (RK) is an incisional procedure in which 8 to 16 peripheral 
radial corneal incisions of 90 to 100 % corneal thickness are made, with the 
aim to flatten the central cornea in myopic patients. In  the 1980s and early 
1990s this procedure was very popular, especially in the USA. Since then it has 
been largely abandoned in favour of excimer laser ablation surgery. Three to 12 
months after the RK procedure, central endothelial cell loss has been reported 
to range from 0.4 to 10 %, with case reports of 25-50 % ECD loss in case of per-
forations. Prolonged endothelial cell loss after RK is questionable. Risk factors for 
ECD loss in RK include: intra-operative microperforations, increased number of 
incisions, and a smaller diameter optical zone. Possibly, inflammation also plays 
a role. Endothelial permeability is not significantly altered after RK.572 574 576-584
 The 193-nm (= ultraviolet wavelength range) argon fluoride (EXCIted di-MER 
gas) excimer laser is a powerful instrument for the ablation of corneal tissue. 
With the excimer laser predictable and stable corneal shape alterations and 
hence predictable and stable refractive results can be obtained. Because of this 
predictability and stability, its relative easiness to use, and the favourable safety 
profile, refractive surgery with this instrument replaced RK soon after its intro-
duction in the clinical practice in the early 1990s.30 572 Experimental research in 
rabbits and monkeys has shown that the deeper excimer laser stromal ablation 
was performed, the stronger the detrimental effects on endothelial cell density,  
morphology, and barrier function became. Deposition of extra material onto 
Descemet’s membrane was also observed.423 585-593 The first excimer laser refrac-
tive surgery technique that was introduced was photorefractive keratectomy 
(PRK), in which laser stromal ablation was performed after manual, mechanical 
abrasion of the epithelium.30 572 Following PRK, a wide variation of changes in 
ECD has been observed, including slightly increasing, unchanging, and slightly 
decreasing central ECDs. Slightly improving, unchanging, or slightly deteriorating 
endothelial morphology have also all been reported.594-602 Peripheral endothelial 
cell densities may be decreased more constantly.572 Many explanations and in-
fluencing factors were proposed in discussions about the different observations 
regarding endothelial cell density and morphology after PRK. The procedure may 
have caused no or only minor central endothelial damage, and observed losses 
may be attributed to remodelling or even to merely physiological cell loss. The 
discontinuation of contact lens wearing may even have caused improvement 
of the endothelium. The age of the patient may have influenced whether or not 
endothelial cell loss occurred. Magnification changes in specular microscopic im-
ages by changes in central corneal steepness and thickness after PRK may have 
influenced ECD measurements (see also chapter 6 of this thesis). 572 596-598 601 602
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 Laser in situ keratomileusis (LASIK) was developed to overcome some shortfalls 
of PRK, in particular the discomfort and pain that subjects experience before 
the epithelium has healed, and the slower visual recovery. In LASIK excimer 
laser ablation is performed on a stromal bed, after the creation of a hinged an-
terior lamellar flap using an automated microkeratome. 603 As the laser ablation 
is usually performed closer to the endothelium than in PRK, there was some 
concern for more damage to the endothelium.423 One study indeed found that 
morphometrical changes occurred within 15 minutes after LASIK, but these 
lasted only 24 hours.604 Up to 1 year after LASIK a wide variation of observa-
tions in the endothelium has been reported, very similar to the observations 
after PRK. Endothelial cell density and morphology were reported to remain 
unaltered, to have deteriorated only minimally, or to have improved slightly. 
Again, just as with PRK, many factors were mentioned as explanation for this 
variation in findings..604-610 Laser assisted subepithelial keratomileusis (LASEK) is a 
procedure that seeks to combine some advantages of PRK and LASIK. In LASEK 
a superficial epithelial flap is made, usually with help of ethanol. Hydro- and 
viscodissection techniques have also been described. Studies on endothelial 
changes after LASEK could not be retrieved. The deleterious effect of  alcohol 
on the epithelium has been extensively studied, but no reports were found of 
its effect on the endothelium in this procedure.611 
 Intrastromal corneal ring segments (ICRS) are PMMA ring segments of 150˚ 
of arc, with diameters of 6.8 (inner) to 8.1 (outer) mm, and available in several 
thicknesses (0.25-0.45 mm). They are inserted pairwise into the corneal stroma, 
for refractive purposes usually in a superior to inferior direction, in order to flat-
ten the corneal centre and steepen the corneal mid-periphery for correction of 
myopia up to 3 to 4 diopters. Follow-up studies up to 2 years post-operatively 
have shown no or only minimal (physiological) central ECD-loss, with slightly 
more loss at the 6 o’clock and 10 o’clock positions.423 612 613 A confocal micros-
copy study reported undisturbed endothelium under the ICRS.614 The predeces-
sor of the ring segments, the intrastromal corneal ring (360˚ of arc), also did not 
lead to significant decrease in central ECD.615 616
 Orthokeratology (OK) is actually not a true surgical technique, but aims at alter-
ing the corneal shape and refractive power using contact lenses. This technique 
was first introduced in the 1960s but disappeared from practice after the mid-
1980s because of lack of effectiveness and predictive results. However, from 
the mid 1990s onwards OK has regained interest. The widespread introduction 
of corneal topography, as well as the availability of new higher Dk contact lens 
materials, and the concept of ‘reverse geometry’ design, all contributed to this 
revival. The reverse geometry design entails flatter contact lens centres and 
steeper mid-peripheral back surface shapes, which provides for good centra-
tion and a central posteriorward pressure. OK has now been renamed “corneal 
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refractive therapy” (CRT) or “corneal reshaping with contact lenses”. The current 
principle implies to reversibly meld the cornea overnight with nocturnal RGP 
contact lens wear, so that lower degrees of myopia are corrected. This should 
obviate the wear of refractive correction during daytime. Night-time wear 
needs to be ongoing to prevent regression.617 618 Nighttime CRT with reverse 
geometry lenses has been shown to cause central epithelial and corneal thin-
ning, which is currently thought to be the mechanism of action; and perhaps 
also mid-peripheral stromal / epithelial thickening, of which the mechanism and 
effects are less understood. Epithelial thinning may occur by cell volume loss, 
cell loss, cell redistribution, or a combination. 618-623 Obviously, of great concern 
with nighttime CRT is that the epithelial changes seem to lead to an increasing 
incidence of epithelial complications such as punctate epithelial keratopathy 
and hence to an increased incidence of microbial infection, especially with 
Pseudomonas aeruginosa.624-626 Studies on extended wear soft contact lenses 
had already shown a manifold increased risk for bacterial corneal ulcers. The 
incidence of ulcers was 0.2 % with extended wear soft lenses, compared to 0.04 
% daily wear soft lenses, and 0.01 % with daily wear RGP lenses.627-630 In night-
time CRT, the insults to the epithelium, the effects of lower oxygen pressure, and 
the risk for microbial keratitis may be similar to, or exceed extended wear soft 
contact lenses.624 625 631 Studies showed that after CRT, Pseudomonas binding to 
the corneal epithelium was significantly increased. Even though RGP materials, 
as used in CRT lenses appeared to bind Pseudomonas much less than high-Dk 
hydrogel materials, as used in extended-wear soft contact lenses.632 633 The age 
of the patient, and the patient’s compliance with instructions on wear and care 
may be an important factor in the rate of keratitis in nighttime CRT. This stresses 
the importance of good instructions and regular check-ups. Children seem to 
be more affected by CRT-related keratitis, which is especially troubling as this 
group may have the best indications for nighttime CRT. They are not yet suitable 
for LASIK because of unstable refraction. In contrast, CRT can be adapted as the 
refraction changes with increasing age. It may be less expensive overall. Further-
more, there are hypotheses that CRT might slow down progressive myopia. 620 
634 635 In contrast,  the ECD did not change significantly in a clinical study on the 
older OK treatments. ECD nor endothelial morphometry has deteriorated in a 
recent study with 1 year follow-up, nor in recent case reports.636-638
 Refractive lens exchange, also known as “clear lens extraction” may be a valuable 
refractive surgery technique, especially for presbyope, no longer accommodat-
ing individuals. The technique and hence the consequences for the endothe-
lium are similar to regular cataract phacoemulsification surgery, except that 
usually less phaco-energy is needed as crystalline lenses are less hard in non-
cataractous eyes. This obviously causes less of a threat to the endothelium.30 In 
a retrospective study on phacoemulsification that included cases for refractive 
indications in high myopes, a 1-year ECD-loss of 2.1 % was reported, increas-
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ing to 6.8 % after 4 years.639 In a study on clear lensectomy for hyperopia (7 to 
14 Diopters) using manual ECCE and phacoemulsification techniques, mean 
endothelial cell loss at 12 months was 7.38 %. This is similar to after cataract 
extraction with phacoemulsification.640
 Phakic IOLs are usually implanted in the anterior chamber. One type of IOLs, 
the Implantable contact lens (ICL®), is positioned in the posterior chamber in 
front of the crystalline lens, in the ciliary sulcus. The endothelial cell loss after 
implantation of ICLs appeared to continue for three years (up to 8.9 –12.9 %), 
after which stabilisation of remodelling of the endothelium was observed.641 
642 In the Netherlands, the most often used type of phakic IOL is the anterior 
chamber iris fixated Artisan® Iris Claw lens. When implanted for myopia, the 
endothelial cell loss with this lens was reported to be 4.8-5.5 % at 6 months, 7.2-
8.9 % at 12 months, 9.1 % at 24 months, and 9.8-10.9 % at 36 months, implying 
a loss of only 0.7 –1.8 % in the last two years. This indicates a stabilisation of cell 
loss, at or just slightly higher than the physiological level after the first year.643-645 
The more recent United States Food and Drug Administration Ophthec clinical 
trial reported much lower, non-significant endothelial cell losses at 6, 12, and 
24 months postoperatively, of 0.09 %, 0.87 %, and 0.78 % from baseline. When 
corrected for physiological cell loss these losses were even less.646 In a study on 
toric iris claw lenses, implanted in myopes with high astigmatism, central ECD 
increased 2.9 % from baseline at 1 year, which was tentatively explained by 
endothelial remodelling after discontinuation of contact lens wear.647 Artisan® 
phakic IOLs are also implanted for hypermetropia/hyperopia. In one study, 
the 1-year ECD loss in hyperopic patients was found to be 9.4 %,648 whereas 
in another study there was a gain of 1.0 – 3.8 % in central ECD in the first year 
followed by a decrease from baseline of  8.5 % after two years and of 11.7 % 
after three years.649 In this latter study a significant negative correlation between 
ECD-loss and anterior chamber depth was observed, which had not been the 
case in an earlier study on myopic implants.643 649 
 In some studies on older types of iris-claw IOLs, including the Worst-Fechner iris 
claw type, the reported ECD loss was significantly higher. In some cases even 
bullous keratopathy requiring penetrating keratoplasty was observed. As fac-
tors causing ECD-loss were mentioned: pre-existing corneal guttata, low scleral 
rigidity in highly myopic eyes, eye rubbing, and IOL design factors like high 
“vault” and prominent optic edge, causing proximity of (parts of ) the IOL to the 
endothelium.30 572 650 However, in other studies endothelial cell loss was compa-
rable to the later Artisan® models and also appeared to approach physiologic 
levels at 3 and four years after implantation.651 652
 With a different type of phakic IOL, the anterior chamber angle-supported 
Baïkoff phakic IOL, an ECD-loss of only 1.5 % after 5.2 years follow-up was 
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reported.653 However, with older types of angle-supported phakic IOLs such as 
the Domilens®, substantial larger endothelial cell loss was reported, especially in 
the paracentral areas and along the border of the optic. This was attributed to 
lens vaulting and eye rubbing, both possibly leading to intermittent endothelial 
touch. Implantation of this type of IOL has been dicontinued.654 655 Similar obser-
vations had been made in a primate model using angle-supported  Kelman 
Multiflex® phakic IOLs.656 657
XV.  Effects of glaucoma surgery.
 
 As mentioned earlier in paragraphs X and XI of this chapter, glaucoma prob-
ably has a detrimental effect by itself on the corneal endothelium. Toxic effects 
of topical glaucoma medications have not been demonstrated unequivocally. 
Trabeculectomy used to be the mainstay in glaucoma filtration surgery. In this 
procedure, open connections between the posterior chamber, the anterior 
chamber, and the extra-ocular subconjunctival/subtenon filtration bleb area 
are created. Uncomplicated trabeculectomy has been found to result only in 
minimal central endothelial cell loss at three months postoperatively (3.7 %). 
In case of overdrainage, leading to a flat anterior chamber with iridocorneal 
touch, central endothelial cell loss increases to 7.1 % -11.6 % at 3 to 6 months 
postoperatively. When lenticulo-corneal touch occurred, a loss of  50 % or more 
has been reported.416 421 658-660 After combined cataract extraction (phacoemulsi-
fication), implantation of a posterior chamber IOL, and trabeculectomy a 1-year  
ECD loss of 10.4 % was reported, which is similar to ordinary cataract extraction 
with implantation of an IOL (see paragraph XIII. of this chapter).661  
 As a result of observed complications of overdrainage and hypotony after 
filtration surgery, in the last decades there has been great deal of interest in 
non-penetrating filtration surgery, eg. deep sclerectomy and/or viscocanalos-
tomy. Studies on endothelial cell loss after non-penetrating filtration glaucoma 
surgery could not be retrieved. As the anterior chamber is not entered in this 
procedure, and as iridocorneal or lenticulo-corneal touch is less likely to hap-
pen, endothelial damage may be expected to be less than after trabeculec-
tomy.
 Inadequate IOP reduction by or even complete failure of a trabeculectomy 
also received a great amount of attention. Adjunctive use of the antimitotica 
mitomycin C (MMC) intraoperatively, and 5-fluorouracil (5-FU) postoperatively 
aimed at impairing fibroblast and vascular endothelial proliferation. Increased 
patency of the filters with lower resulting IOPs have been observed, but also a 
higher incidence of complications such as hypotony, thinner avascular blebs 
with a higher risk of leakage and subsequent endophthalmitis. Toxic effects on 
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corneal, scleral, and conjunctival epithelial cells sometimes resulted in necrosis 
of tissue.31 Furthermore, even in eyes in which the anterior chamber had not 
yet been entered, measurable aqueous concentrations of MMC were found 
after intra-operative application. Therefore, toxic effects of the adjunctive use of 
these antimetabolites on the corneal endothelium is of great concern. Animal 
and in-vitro studies showed a dose- and exposure-time-dependent endothelial 
toxicity of MMC and 5-FU.662-664 Clinical studies showed a central ECD-loss of  7 
– 14.5 % at 3 –12 months after intraoperative MMC or postoperative 5-FU appli-
cation in trabeculectomy. Factors found to influence postoperative endothelial 
cell loss were: the occurrence of postoperative hypotony with shallow anterior 
chamber and endothelial touch; opening of the anterior chamber before the 
intra-operative application of MMC; the concentration of MMC and 5-FU that 
was used; the exposure time to MMC; and the application site of the MMC, i.e. 
episcleral/subtenon vs. under the scleral flap.660 665 666 Combined cataract surgery 
and trabeculectomy with application of MMC after wound closure resulted at 3 
months post-operatively in a non-significant slight increase in endothelial cell 
loss compared to after placebo application (7.8 % vs. 3.6 %).667
 An alternative surgical approach to obtain a more rigorous IOP control is the 
use of a glaucoma drainage implant a.k.a. aqueous drainage device/shunt/se-
ton. In this technique, a tube in the anterior chamber drains aqueous humour 
to a subtenon filtering device. Examples of aqueous drainage devices are 
Baerveldt, Molteno, and Ahmed shunts. Endothelial damage can obviously be 
caused by overdrainage and flat anterior chamber, and further by intermittent 
tube-endothelial contact. Clinical studies reporting on amount of ECD loss with 
glaucoma drainage implants could not be retrieved. The length of the tube 
has been thought to be a factor in the occurrence of endothelial damage. The 
material of the tube may also play a role. 668-671
 Surgical and laser peripheral iridectomy and laser trabeculoplasty may be 
expected to cause focal endothelial cell loss in some instances. In one study a 
significant decrease of ECD and corneal decompensation has been observed. 
Especially argon laser iridotomy has been implicated as a cause for bullous kera-
topathy. Not only direct laser damage to the endothelium but also shear-stress 
from aqueous current contributes to this adverse effect.40 416 421 433 672-675
XVI.  The endothelium after penetrating keratoplasty.
a. Introduction
 In this paragraph, the most important factors for graft survival in penetrating 
keratoplasty (PK) are discussed. The mechanisms for endothelial cell loss, before, 
during, and after PK will be addressed. A more general background on the 
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development, indications, and techniques, of both penetrating and lamellar 
keratoplasty is presented in Chapter 10. In that chapter also the literature on 
endothelial cell loss after lamellar keratoplasty (LKP) is discussed. 
b.  Transplant  failure: statistics and causes.
 Primary penetrating corneal transplants are often considered to be highly suc-
cesful.676 However, in the literature a wide range of 10-year overall graft survival 
rates is reported for primary grafts, varying from 50 – 82 %..677-683 Probably, cor-
neal transplant survival rates differ for different patient (=recipient) populations. 
But the rates definitely differ for different transplant indications, i.e. diagnoses. 
Transplants for keratoconus have reported 10-year survival rates of over 90 
%, followed by transplants for Fuchs’ endothelial dystrophy with a survival of 
77 – 90 %. Pseudophakic and aphakic bullous keratopathy transplants had a 
reported  33 – 85 % 10-year survival. These figures are further influenced by 
presence, type, location, and the removal/exchange/implantation of (second-
ary) IOLs. Transplants for Herpes Simplex Virus had a reported 56 - 87 % sur-
vival.677-683 For some other indications the graft survival rate is even substantially 
lower: especially for re-grafts long-term graft survival rates may be smaller than 
50 %.682 ‘Therapeutic’ keratoplasties are performed when corneal perforation 
is present or imminent, or in case of refractory corneal disease. Transplants for 
active infections appear to survive relatively well, but therapeutic PKs for indica-
tions such as ocular surface problems, penetrating trauma, and immunological 
melts and immunological eye diseases usually have long term survival rates of 
less than 50 %.681 683 684 Eyes may be considered to be “high risk” for graft failure 
due to allograft rejection, because of the existence of extensive deep corneal 
neovascularisation in two or more quadrants, or because of ongoing, active, 
inflammation, or previous immunological graft rejections. These grafts also have 
mid- to long-term survival rates of (considerably) lower than 50 %.680 682 683 685 
 
 In table 2.XVI.1, the main causes for graft failure are presented. The figures are 
composed from data from an editorial in the Br J Ophthalmol in 2000 that 
reviewed studies in the UK and Australia, and further from a French and two 
American studies. The two most important causes, allograft rejection and late 
endothelial decompensation, together constituted 53 % of graft failures. En-
dothelial allograft rejection causes graft failure by means of loss of endothelial 
cells. Late endothelial decompensation refers to graft opacification by ongoing, 
non-rejection loss of endothelial cells. Additionally, there is another endothelial 
cause for graft failure. Primary graft failure occurs when donor corneas stay 
opaque and do not clear in the post-transplantation period. Most often this 
is caused by insufficient donor endothelial densities or endothelial function, 
which may result from inadequate preoperative donor cornea evaluation and/
or flaws in donor cornea preservation. Thus the total percentage of graft failures 
due to endothelial reasons may even be higher than 53 %. Therefore, the con-
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clusion is justified that endothelial failure, by whatever mechanism, is the single 
most important pathophysiological factor in PK graft failure. 319 678 680-682 686
  Earlier in this section, the importance of the  preoperative diagnosis and/or 
indication for graft survival was discussed. Other risk factors were statisti-
cally identified,678 685 687 and in one study even correlated to one of three main 
causes of graft failure: allograft rejection, endothelial cell loss, or ocular surface 
disease.685 Risk factors included Herpes Simplex Virus and (deep) stromal vascu-
larisation, which were risk factors in grafts failed because of allograft rejection. 
Diabetes mellitus, peripheral anterior synecchiae, recipient race, and small 
trephination size, were risk factors for graft failure due to endothelial cell loss. 
Glaucoma and topical glaucoma medication were also found to be risk factors 
for graft failure, in all failed grafts.678 685 687 
 Notably, donor age is probably not a strong predictor of graft survival in these 
studies. An extensive meta-analysis of many different studies was not able to 
identify donor age as a strong predictor for graft survival either.688 689 This may 
be caused by opposing effects of donor age on graft survival. A higher donor 
age has been correlated to lower donor endothelial cell density which may pre-
dispose for faster graft failure (see also later this paragraph). However, younger 
donor age has been correlated to a higher risk for allograft rejection, which will 
also cause poorer survival.687-690 
 In contrast, increasing recipient age was found to be related to decreased graft 
survival. This was thought to be related to several factors. Elderly recipients 
were transplanted more often for bullous keratopathy, for which graft survival is 
poorer than for many other indications. Also, they experienced more complica-
tions and co-morbidities after transplant.687 690 691 
 Other factors that have been mentioned to increase the risk for graft failure 
include: longer operation time, less surgical experience of the operating physi-
cian, aphakia/pseudophakia, and larger diameter graft size. Studies on these 
factors however did not produce unequivocal data. 678 680 687 691 692
c.  Corneal allograft rejection and its effects on the endothelium. 
 Corneal allograft rejection has been reported to occur in as little as 2.3 % rang-
ing up to as many as 68 % of all PK cases.693 Experimental research has shown 
that immunological rejection mechanisms can occur against cells in all layers 
of the donor cornea: the epithelium, stroma, and endothelium. The distinc-
tive rejection lines described by Khodadoust and Silverstein were observed in 
both the epithelium and the endothelium. A clinical pattern of sub-epithelial 
infiltrates may occur independent from, or concurrent with both epithelial or 
endothelial rejection signs. Both epithelial and sub-epithelial rejection usually 
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represent transient immunological phenomena, which usually react well to 
immunosuppressive treatment and leave no visually disturbing scars. However, 
endothelial rejection, which may occur as the typical endothelial rejection line  
(Khodadoust line) but may also have a more diffuse appearance with vascular 
engorgement, ciliary flush, keratic precipitates, and anterior chamber cell and 
flare, is potentially much more harmful. In contrast to rejected epithelial cells, 
rejected and lost endothelial cells are for the largest part not replenished by 
mitosis, as was discussed in paragraph V of this chapter. Significant endothelial 
cell loss leads to a breakdown of endothelial barrier and pump functions, and 
hence to edematous opacification of the graft. Graft opacification may become 
irreversible when too many endothelial cells are lost.693-699 Several studies 
observed significant endothelial cell loss after corneal allograft rejection. The 
most important factor in the occurrence of more than average ECD loss was a 
delay in diagnosis and management of the rejection episode. This delay may 
be explained by the often insidious and atypical onset of clinical symptoms 
and signs. However, up to 50 % of rejections may be iatrogenically induced, 
for instance by suture removal. Although the immunological mechanisms in 
allograft rejection are potentially suppressible with medication, still up to 50 % 
of rejection episodes are irreversible. Therefore, allograft rejection remains the 
single most important cause of endothelial cell loss and hence of transplant 
failure, as was discussed earlier in this paragraph.678 679 687 698 700-706  
 Allograft rejection involves an immunological sequence or “ arc”. In the effer-
ent arm of the arc, the target cells, in casu the (endothelial) cells of the donor 
cornea, are specifically killed by the effector mechanisms. Effector cells and 
antibodies are only activated after the cells of the donor cornea have been 
recognized as alloantigenic, in the afferent arm of the arc. The recipient Lang-
erhans cells either capture at their resident site circulating corneal alloantigens 
from the aqueous, or migrate into the donor cornea to phagocytose these 
alloantigen (the so-called indirect pathway). Antigens are then processed and 
presented. Consecutive antigen recognition takes place by a recipient T cell. 
This depends on the presentation of the antigen by the Langerhans cell in con-
text with the Major Histocompatibility Complex (MHC) a.k.a. Human Leukocyte 
Antigen (HLA) Class II molecules on both cell surfaces. The effector mechanisms 
in corneal allograft rejection involve mainly cellular killing of target cells. The 
role of antibodies and B-cells in corneal rejection is probably small. An impor-
tant part of the cellular effector mechanisms is constituted by the delayed-type 
hypersensitivity reaction, in which recipient CD4-positive T helper-cells have a 
central position. CD8-positive T cells and other cytotoxic T cells have also been 
found to be involved. Furthermore, macrophages are important effector cells 
found in rejected corneas. 707-716 
 Compared to solid tissue organ transplants, corneal transplant survival without 
immunosuppressive therapy is relatively good. This is thought to result from the 
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immune privilege of the (grafted) cornea and anterior chamber, which is based 
on several factors: 1. Absence of blood and lymph vessels in the graft and its 
bed - in non-high-risk corneal transplants - impairs the influx of leukocytes into 
the target tissue, the cornea. 2. Presence of a blood-aqueous barrier, formed 
by the tight junctions between non-pigmented epithelial cells and iris vessels 
that are non-fenestrated. This does not allow entry of macromolecules or 
leukocytes into the aqueous under normal conditions. 3. Absence of MCH class 
II molecules-expressing antigen presenting cells such as Langerhans cells from 
the (donor) corneal centre. 4. Expression by donor corneal endothelial cells of 
Fas ligand, which protects them from an attack by Fas(CD95)-positive T effector 
cells. 5. Presence, both in the aqueous and on corneal cells, of immunosuppres-
sive molecules (among which interleukins, and membrane proteins that impair 
complement dependent immune effector mechanisms). 6. Active immuno-
modulation, called Anterior Chamber Associated Immune Deviation (ACAID), by 
the induction of tolerance to specific antigens, by the graft itself.712 715 717-719. 
 In the meantime, the mainstay of current clinical rejection management in-
volves suppression of the efferent arm by intensive topical or regional cortico-
steroid treatment.693 699 720 721 Topical or subconjunctival/peribulbar steroids have 
been shown to reach higher intra-ocular concentrations compared to systemic 
corticosteroids.722 In a randomized clinical trial, additional systemic corticoste-
roid treatment did not result in better rejection reversal, nor in less late recur-
rences of graft rejection, nor in better graft survival, when compared to topical 
steroids alone.723 However in some patients, especially those who are at higher 
risk for transplant rejection and whose general condition permits it, systemic 
steroids may still be valid treatment options. These can be administered either 
orally or via a single pulse intravenously. Systemic immunosuppressants and 
topical or regional cyclosporine or tacrolimus (FK-506) application have also 
been studied.446 693 699 720 724-727. 
 Alternative approaches to the problem of corneal allograft rejection deal with 
the afferent phase of the immune arc. Pre-operative Ultraviolet-B irradiation of 
donor endothelium has been shown to provide lower rejection rates in animal 
experiments, however at the cost of substantial numbers of primary graft fail-
ures. Hypothesized mechanisms for rejection prevention include suppression 
of Langerhans’ cell function, or activation of donor specific suppressor cells.728 A 
more common approach to prevent rejection is by ABO-blood group and HLA 
matching, in analogy of solid organ transplants. HLA-matching can be applied 
to class I HLA (the classical A, B, and C) antigens, and class II (DR, DQ, and DP) 
antigens. For high-risk cases, i.e. previous graft failures due to rejections or two 
or more quadrants of deep stromal vascularisation, HLA-A, -B and -DR matching 
has become standard practice in our country. Unfortunately in the literature 
the definition of high risk is not standardized, nor is there consistency in the 
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weighing of the importance of the different HLA antigens.729. Matters have 
even become more complicated. In addition to the major class I and the class 
II antigens, there are non-classical class I antigens E, F, and G; however these 
may contribute to the immune privileged status of the cornea instead of to 
allograft rejection. 730 731 HLA-A and -B can, and possibly should be typed on the 
split level (molecular typing) instead of the broad level (serological typing), with 
special attention to empirically known ‘permissible’ and ‘taboo’ mismatches, in 
order to (rapidly) identify matches with a higher chance for prolonged graft 
survival.732-735 Similarly, with more precise molecular HLA class II DR typing, DR 
mistypings and hence unintentional mismatches may diminish.736 And then 
there is the group of minor, HLA-H, antigens, which may be important targets 
of rejection in failed PKs.737 These recent refinements may provide an explana-
tion why studies on graft survival after HLA-matching, both in high-risk and in 
normal-risk keratoplasties, have contradictory results.680 734 736 738-742 Alternative 
explanations for different results involve different more or less intense steroid 
regimens post PK,740 the above discussed immune privilege factors that may 
have become increasingly active,680 or a reduced potential for allograft rejection 
in older individuals because of a diminished capacity to expand truly novel T-
cell clones due to thymic involution in older adults.741
 For the experimental study of rejection after PK, as well as for endothelial cell loss 
as described in the next section, PK in cats and monkeys provides an excellent 
model, with very comparable mechanisms and reactions. Some of the data in 
this section and in the next of this paragraph stem from such animal models.743-745
d.  Endothelial cell loss after PK, not caused by allograft rejection.
 Since long it has been observed that endothelial cell loss from corneal trans-
plants takes place at an accelerated rate, even in the absence of additional 
surgical interventions or of episodes of clinically overt allograft rejection. Endo-
thelial cell loss appeared to occur until many years after transplantation, up to 
a reported maximum of 33 years. Whereas initial endothelial cell loss was found 
to be substantial and rapid, later cell loss appeared to be slow. As discussed in 
paragraph VI, as long as the ECD remained above a critical level (300 – 500 cells/
mm2), the grafts usually stayed clear, even many years after keratoplasty.1 12 22 27 
746-750 The so-called ‘clinical reserve’ of the endothelium however is significantly 
diminished, so that after additional insult (e.g. cataract surgery, allograft rejec-
tion) the endothelium may rapidly decompensate, causing graft failure that 
necessitates re-transplantation. 1 40 364  The barrier and pump functions of the 
endothelium are also still altered long after PK, with a diminished measurable 
pump rate, which is compensated by an increased barrier function (reduced 
permeability). Epithelial metabolism of the corneal graft is also altered as com-
pared to the normal situation.40 364 377 751 752 
 Gradual decompensation and failure of corneal grafts without apparent cause, 
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unresponsive to corticosteroids, and without a history of a rejection episode 
correlated to the time of graft failure, was called ‘late endothelial failure’ (LEF) by 
Bourne and co-workers. LEF was reported to be responsible for more than 90 
% of graft failures beyond 5 years post-keratoplasty in their series. Grafts with 
LEF had a lower ECD pre-operatively, and also a significantly higher cell loss in 
the first two postoperative months; thereafter the rate of endothelial cell loss 
was not higher than in the surviving grafts. Light- and Electron Microscopical 
studies of LEF-grafts revealed irregular-shaped endothelial cells of varying size 
with many abnormal features (for instance elongated processes, approximat-
ing nuclei in adjacent cells, the presence of multinucleated cells, increased 
microvilli density), lying on abnormal, thickened Descemet’s membrane (PCL, 
see paragraph IX). Degenerating endothelial cells and bare areas of Descemet’s 
membrane were also often observed. All these phenomena can be interpreted 
as signs of an unstable and highly stressed endothelial cell population. No 
evidence of acute or chronic rejection was found at the time of graft failure, as 
had also been described  in an older study by Polack.310 364 678 753-756 
 
 The observations on accelerated loss of endothelial cells after PK gathered in 
the above mentioned cross-sectional studies have been confirmed by longitu-
dinal studies on (central) endothelial cell loss. The most important of these lon-
gitudinal studies has been conducted by the group of Bourne and co-workers. 
They reported consistently and comprehensively on a cohort of 393 patients, 
who by now have been followed for at least 15 years, and for 20 years in many 
cases. At both time points, the loss relative to the donor ECD was 72 % and 77 
%, respectively. It should be noted that in their series the number of patients 
(“n”) examined at each of the consecutive follow-up time points decreased. The 
cause of this decrease was death or unavailability of the patients, but more im-
portantly also the occurrence of graft failure in the previous interval. The mean 
endothelial cell density measured at each time point is therefore undoubtedly 
an overestimation.24 231 310 678 757-760 
 Studies from other groups provide data that do not compare easily with Bourne 
et al.’s data. Differences in results between the various studies should be inter-
preted with caution, because of significant differences in group sizes; in opera-
tive techniques; in whether or not donor corneas had been preserved, and if so, 
which preservation technique had been used (see also section e of this para-
graph); and in methods and instruments for the prospective assessment of ECD. 
Furthermore, some studies did not provide comprehensive data on endothelial 
cell loss for their entire study population, but rather gave results for subdivided 
populations. For example, subdivisions into groups were made for if and how do-
nor corneas had been preserved, for indications for PK/pre-operative diagnosis, as 
well as for technique of operation (only PK, or additional surgery such as cataract 
extraction, IOL implantation and/or exchange, and so on).24 231 310 567 678 701 748 749 757-782 
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Remarkable endothelial cell losses were found, especially in the first postopera-
tive year, in donor corneas that had been cryopreserved. In later postoperative 
years some of these corneas still had sufficiently high ECDs.761 771 774 783
 In several studies on ECD-loss after PK, attempts have been made to fit regres-
sion models to the decrease in ECD. Linear and exponential decay models have 
been described, both providing a reasonably good fit.567 678 764 767 773 778 However, 
since the initial ECD-loss appeared to occur at a substantially higher rate than 
late loss, and in analogy of other biological decay processes, Armitage recently 
introduced a bi-phasic exponential decay model (see also paragraphs VI and XII 
of this chapter, and figure 2.XVI.1): 
  ECDt= p * exp (-at) + q * exp (-bt)
 In which ECDt  is the ECD at time t; p and q are constants the sum of which is 
equal to the ECD at time zero (initial ECD); and a and b are exponential rate 
constants.231  
 He applied this model to the data provided by Bourne in 2001.310 The residual 
standard deviation demonstrating the goodness of fit was 109.6 cells/mm2. The 
co-efficient p representing the initial proportion of ECD applied to the fast phase 
was 1457.6, with a rate constant of 0.0802; q applied to the slow phase and was 
1396.6 cells/mm2 with a rate constant of 0.0027. Half times were calculated as: 
0.693/(rate constant) and amounted to 8.6 and 257 months for the fast and slow 
phases, respectively. The relatively long fast phase indicates that not only surgical 
trauma may be severe, but also that other factors such as postoperative complica-
tions, immunologic reactions, and redistribution must play a role. Armitage found 
similar half times and also similar annual cell losses (2.4 and 2.5 % respectively) for 
the slow phase after PK and cataract extraction (ICCE and ECCE); he interpreted 
this as a common mechanism for late endothelial cell loss, possibly stemming 
from an innate, non-specific immunologic response (as opposed to allograft 
rejection), for instance initiated by breakdown of the blood-ocular barrier.231
 The most recent report on Bourne’s cohort of PK patients by Patel et al. showed 
data from the 15-year’s follow-up.760 These were different from those in Bourne’s 
own report in 2001 on his cohort and on which Armitage’s study was based.231 
310 At  15 years post PK Patel found an annual loss of 0.2 %, which is at (or below) 
the physiological level.760  This contrasts with Armitage’s finding of annual cell 
losses of 2.4 % in the late phase.231 It should be noted however that Patel’s data 
were from only 67 grafts out of an original figure of 388 grafts. All graft failures 
and regrafted eyes had already been excluded, and these 67 represented 30 % 
of the available clear grafts. Patel’s  results were therefore biased towards grafts 
with low late endothelial cell losses.760
 As mentioned before, Armitage hypothesized that late endothelial cell loss 
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may be caused by an aspecific, non-rejection-like inflammation, or perhaps a 
chronic break-down of the blood aqueous barrier, but not an allograft rejec-
tion mechanism.231 More evidence that this was not a T-cell mediated immune 
response was provided by a recent study that found that chronic ECD-loss 
was not diminished by HLA class I and II matching, with current high-standard 
HLA-typing. 782 Other possible immunological mechanisms however were not 
excluded by the authors, and these may involve antibody mediated reactions, 
or minor HLA antigen incongruence.782 As discussed earlier, the pathologic 
findings in LEF did not point to allograft rejection either. Contradictory data on 
chronic endothelial cell loss result from studies on autokeratoplasty. In auto-
keratoplasty, chronic endothelial cell loss can not result from allograft rejection. 
Three studies, of which two were experimental studies in cats, found late endo-
thelial cell loss similar to after (allogenic) PK. One other study in humans, found 
endothelial cell loss of nearly physiological levels after autologous rotational PK. 
The authors of the latter study concluded that after allogenic PK, immunologi-
cal factors are responsible for chronic endothelial cell loss.743 784-786
 
 Factors possibly influencing intra-operative and short-term post-operative ECD 
loss include, besides allograft rejection, the indication (original diagnosis) for 
PK, as discussed before. The pre-operative lens status (phakia/aphakia/pseu-
dophakia), has been mentioned as an important factor and the simultaneous 
placement or exchange of different types of IOLs in different positions has also 
been implicated. However, several other studies found no clear effect of aphakia 
or pseudophakia, or placement or exchange of IOLs.757 787-790 Lens status however 
probably has some correlation with the indication for PK (i.e. aphakic or pseudo-
phakic bullous keratopathy) and may hence not be an independent risk factor. 
The triple procedure, i.e. simultaneous PK, “open sky” ECCE, and IOL placement, 
resulted at a mean follow-up of 10.5 months postoperatively in postoperative 
ECDs that were comparable to after PK alone.791 Other factors that do affect 
postoperative endothelial cell loss are the occurrence of early postoperative 
(technical) complications,701 and the amount of surgical trauma. Surgical trauma 
may be related to several aspects. The trephination technique that is used has 
been found to influence surgical damage to the endothelium.792-800 Also tech-
nique of and proficiency in suturing influenced graft survival rates and endo-
thelial cell loss.680 796 The use of intraoperative viscoelastics probably preserves 
endothelial cells to some extent, although results are not unequivocal. Possible 
advantageous effects of viscoelastics do not seem to be caused by a protec-
tion against immune rejection.784 801 802 The indication/original diagnosis for PK 
determines the preoperative state of the recipient endothelium, i.e. the preop-
erative recipient ECD. Redistribution of donor endothelial cells on to recipient 
corneas with poor endothelium, a phenomenon that has been demonstrated 
experimentally,803 804 may contribute to a more rapid drop in central (donor) ECD 
in patients with poor recipient ECD. Conversely, endothelial redistribution phe-
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nomena from the recipient onto the graft have been observed in patients with 
PK for keratoconus, for a scrofulous corneal scar, and in patients with primary 
graft failure or after total graft rejection who experienced spontaneous graft 
clearing. It was also shown experimentally in damaged grafts transplanted into 
a host animal with normal endothelium.805-808 Hence, redistribution phenomena 
may explain some of  the differences in ECD-loss that were observed in prospec-
tive studies on ECD-loss after PK in patients with keratoconus (good recipient 
endothelium), Fuchs’ endothelial dystrophy (centrally more than peripherally 
deteriorated recipient endothelium), and pseudophakic or aphakic bullous 
keratopathy (overall bad recipient endothelium).776 777 780 In bullous keratopathy 
cases, relatively less post-operative ECD loss was found in larger-diameter PKs, in 
which a larger absolute number of donor endothelial cells had been transplant-
ed and in which the area of the recipient cornea that needed to be repopulated 
with donor endothelial cells was smaller.781 The observation that postoperative 
endothelial cell loss increases in older recipients may similarly be based on 
the fact that the (peripheral) recipient ECD usually is lower in older recipients. 
Furthermore, older recipients are less likely keratoconus patients, but more likely 
patients with Fuchs’ endothelial dystrophy or bullous keratopathy.776 809 810
e.  The influence of the donor cornea: donor ECD, influencing factors including 
age and post-mortem time, and storage techniques.
 As discussed earlier in this paragraph, PK graft survival related to late ECD loss 
depends mostly on initial (donor) ECD and perioperative ECD-loss. The rate of 
ECD loss in the late, slow phase, is less important, as this is relatively constant.231 
310 811 See figure 2.XVI.1. Applying a minimum donor ECD in eye banks, as for 
instance recommended by the European Eye Bank Association,812 is therefore 
justified.231 310 Most, but not all studies investigating the influence of donor 
age on endothelial cell density after transplantation, found that ECD after PK 
was higher with younger donors.767 776 779 809 811 Younger donors generally had a 
slightly higher ECD than older donors. The variation in ECD in corneas of older 
donors was much larger than those in younger donors. Therefore corneas 
of younger donors were more often suitable for transplantation, but still a 
significant proportion of older donors had suitable ECDs.762 813 814 However, a cor-
relation between donor age and the amount of (chronic) endothelial cell loss 
after PK was inconsistently found.678 762 765 776 781 810 815 Donor age per sé therefore 
does not have to be a restrictive factor for accepting donor tissue; (costs of ) a 
higher discard rate when permitting older donors should be weighed against 
shortage of donor tissue.320 321 323 324 762 765 813 815-817 Similarly, even donor corneas 
from pseudophakic eyes might be considered after thorough pre-operative 
examination.818 The cause of death of the donors, especially trauma, and also 
cancer and sepsis, has been shown to strongly affect endothelial cell loss and/
or metabolism during organ culture. Renal failure did so to a lesser extent, and 
cardiovascular causes affected the endothelial cells the least. 815 819 820 However, 
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donor corneas surviving the organ culture period after any of these causes 
of death may do equally well after transplantation. In contrast, other authors 
found that corneas from donors that had died from injury had less risk of graft 
failure compared to other causes of death.821 
 It is common knowledge that “fresh donor” eyes cannot be kept and used indef-
initely, as there is time-dependent endothelial cell death. This was the reason 
that several different methods of donor cornea preservation have been devel-
oped.767 The so-called post-mortem time, i.e. the time interval between excision 
of the corneoscleral button from the donor globe and the storage of the tissue 
seems to have only a small influence on the suitability of the cornea for PK and 
on endothelial cell loss after keratoplasty.779 781 813 Besides donor endothelial cell 
density, an important factor to consider is the viability of the donor endothelial 
cells, which is reflected in their morphology. In this regard not only the ECD 
but also the morphology of the donor endothelium is relevant when assess-
ing suitability of a donor cornea for transplantation.319 323 324 In paragraph VIII c 
morphologic and morphometric assessment of donor corneal endothelium is 
described. Comparable preoperative ECDs in “fresh donors” and after different 
methods for donor corneal preservation may, due to differences in endothelial 
cell viability, result in different postoperative ECD losses.747 761 
 For instance in cryopreservation endothelial cells are not lost during preserva-
tion but instead in the freezing, and especially the thawing processes. When 
combined with organ culture preservation, additional endothelial cell loss 
occurs during organ culture after thawing, possibly due to wound healing pro-
cesses. The amount of cell loss is such, even with current freezing and thawing 
techniques and the application of extracellular or intracellular cryoprotectants, 
that it prevents cryopreservation from being in large-scale use in eye banks. 
Nevertheless, there are reports of patients with long-term clear grafts after 
cryopreservation.747 761 771 774 822-830 
 All other techniques of corneal storage: cold storage (4 ºC), in moist chambers 
or in media such as MK (McCarey-Kaufman) and Optisol, and the organ cul-
ture-derived techniques (at 31 –37 ºC), show time-dependent loss of endo-
thelial cells during the preservation period.332 364 761 813 MK and Optisol are both 
examples of preservation media used to prolong endothelial viability com-
pared to moist chamber storage under cold (4 ºC) conditions. MK medium is a 
modification of tissue culture medium 199 (TC 199) and includes Hepes buffer 
and sodium bicarbonate with added dextran and antibiotics (currently gen-
tamicin); it is still in use in eye banks all over the world. After much research it 
became apparent that chondroitin sulfate in preservation media provided even 
better endothelial protection, and thus prolonged preservation time. Optisol, 
developed from predecessors K-Sol and DexSol, has both Minimal Essential 
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Medium and TC 199 as base medium and contains chondroitin sulfate, dextran, 
bicarbonate, pyruvate, antioxidants and adenosine triphosphate  precursors. All 
cold-storage type preservation media contain antibiotics, most often gentami-
cin alone or in combination with vancomycin. Optisol allows preservation for 
up to 14 days, and is currently the most often used storage medium for donor 
corneas in the US.769 831-847 Cold storage is not routinely used in The Netherlands. 
 The principle of ‘Organ culture’ donor cornea preservation is based on main-
taining endothelial cell metabolism and allowing repair of damaged cells, by 
incubation at body temperature or slightly below (31-37 ºC), in media provid-
ing nutrients and growth factors. The technique was introduced in the United 
States by Doughman and co-workers in the 1970s, then introduced in Europe 
and further developed by Sperling and co-workers, and introduced in The 
Netherlands and further developed and popularized by Pels, Völker-Dieben, and 
co-workers.323 332 762 848 849 Different approaches to organ culture have also been 
investigated.850 The exact composition of the incubation medium may vary but 
usually includes Minimal Essential Medium (MEM) or a variant (with Earle’s salts 
it is called Eagle’s MEM (EMEM)), supplemented with Hepes buffer, with extra 
L-glutamine, fetal calf serum, and sodium bicarbonate in appropriate concen-
trations. Chondroitin sulfate may or may not be administered. Antibiotics and 
antifungal medications are added. T500 (high molecular weight) dextran was 
either added to the culture medium (Sperling), and later, when it was seen to 
accumulate in the endothelial cells after long exposure, only to the transport 
medium (Pels), to ensure thinning of the donor cornea prior to transplanta-
tion.323 330 332 333 848 849 851-857 An incubation  temperature of 31 –34 ºC was found to 
result in less endothelial cell loss during incubation than incubation at 37 ºC.323 
330 332 333 813 849 This method allows for longer storage times than with the cold 
storage techniques. Storage longer than 28 days is possible but often results in 
substantial endothelial cell loss. However, occasionally storage up to even 48 
days still provided transplantable corneas.323 324 813 849 858 
 
 As cells are lost in a time-dependent way during the preservation period organ 
cultured corneas may lose more endothelial cells during the preservation pe-
riod. However, the viability of the remaining endothelial cells on organ cultured 
corneas may be higher.848 859 Endothelial cell metabolism is not arrested by low 
temperatures and the culture medium provides nutrients and growth factors. 
Therefore, the culture period allows for irreversibly injured cells to be shed, 
reversibly injured cells to heal, and corneal wounds to be repaired. This is dem-
onstrated by endothelial repair figures that were observed during endothelial 
assessment. Whether or not it is through apoptosis that donor corneas lose 
some of their endothelial cells during organ culture is controversial; differences 
in techniques for establishing the presence of apoptosis may be responsible for 
incongruous data on this matter.135 325 330 848 860 861 Anyhow, endothelia of donor 
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corneas that are suitable for transplantation after a (prolonged) organ culture 
preservation period may be considered to have passed a ‘stress test’ for viability 
of the endothelial cells.323 324 333 862 863 Additional advantages of organ culture in-
clude identification during the storage period of remaining bacterial and fungal 
contamination. Hence transplantation of contaminated donor corneas may 
be prevented.813 864 Longer storage times enable a more elective scheduling of 
corneal transplantation.762 848 862 863 In Europe many eye banks currently use the 
organ culture technique,812 and the method is also used in Australia and New 
Zealand.333 
 Clinical studies usually failed to find significant differences in post-transplant 
endothelial cell losses or graft failure rates between organ-cultured corneas and 
cold-stored corneas.762 770 775 862 863 865 866
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XVII.  Effects of intra-operatively used intra-ocular  
 substances, solutions, tamponades, and drugs.
 
 Possible effects of topical drugs on the corneal endothelium were discussed in 
paragraph XI of this chapter. Intra-operatively used viscoelastics were discussed 
in paragraph XIII. Anti-proliferative adjunctive drugs in glaucoma filtering 
surgery were discussed in paragraph XV. Other substances, solutions, and drugs 
are discussed in the present paragraph. These include substances such as 
sterilization agents and preservatives that are normally not purposefully applied 
in the anterior chamber. However, in inadvertent intracameral introdcution they 
can have devastating effects on the endothelium. Furthermore irrigating solu-
tions; intraocular/intracameral medications including antibiotics, anaesthetics, 
miotics and mydriatics; and surgical adjunctives and retinal tamponade materi-
als in vitreoretinal surgery will be reviewed briefly.
 In 1990 the toxic endothelial cell destruction (TECD) syndrome after routine 
ECCE was described. Its main feature was corneal decompensation, illustrated 
by Descemets folds and increased corneal thickness. Pathophysiologically, an 
endothelial cell loss of 72 % was observed, resulting in a breakdown of endo-
Fig. 2.XVI.1  Bi-exponential endothelial decay after PK.
 (from: Armitage et al., Invest Ophthalmol Vis Sci 2003;43:3326-31.)
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thelial barrier function. The cause was (unintentional) intracameral injection of a 
toxic detergent residue, which had been stuck with residual viscoelastic mate-
rial inside reusable irrigating cannulas. Some enzymatic sterilization detergents 
have been shown to contain the exotoxin subtilisin and  α-amylase, which in 
animal and in-vitro experiments had endotheliotoxic capacity 31 445 867-871 A vari-
ant of TECD is the toxic anterior segment syndrome (TASS) in which even more 
extensive damage to the anterior segment (iris, trabecular meshwork, lens) is 
caused. This is often accompanied by substantial anterior segment inflamma-
tion early i.e.within 24 hours after surgery, and it needs to be differentiated from 
bacterial endophthalmitis.872 The variety of possible causes of TECD and TASS is 
large. For instance, gas sterilization has also been demonstrated to be the cause 
of TECD and TASS, by producing copper and zinc residues from brass oxida-
tion and degradation. The copper and zinc could be experimentally shown to 
damage the corneal endothelium.872-874 Probably, no single sterilisation agent 
that adheres to residual material on or in instruments, which thus may enter the 
anterior chamber, can be considered to be safe for the endothelium and the 
anterior segment. Up to now the safest approach for the endothelium is not to 
use reusable hollow cannulas, and to clean other instruments meticulously be-
fore sterilisation..445 871 872 874 875 Even ophthalmic ointment inadvertently entering 
the anterior chamber has been shown to cause TASS. 872 876
 TECD-like keratopathy has further been observed after inadvertent intraocular 
irrigation with chlorhexidine, cetrimide, and cialit.877 Tissue glues used to repair 
corneal perforations, such as cyanoacrylate, are not intended to be used intra-
ocularly but will obviously sometimes enter the anterior chamber. These cya-
noacrylates do not seem to destroy endothelial cells directly, but do provoke a 
severe inflammatory response in the anterior chamber.124
 To maintain endothelial barrier and pump functions the composition of 
intraoperatively used intraocular irrigating solutions should be similar to aque-
ous humour. Their buffer, ionic balance, and pH must be correct (around  300 
mOsm and around 7.4, respectively.) Furthermore, their constituents must in-
clude contain calcium (barrier function) and a buffer, should include an energy 
source, and may include an anti-oxidant (e.g. glutathione).40 385 386 388 392 423 443 854 
878. Examples of well tolerated irrigating solutions are enriched balanced salt 
solutions as BSS Plus® (glucose glutathione bicarbonate solution), Opeguard 
MA, and glutathione bicarbonate Ringer’s solution. Lactated Ringer’s solution 
has been shown to induce endothelial damage, whereas Dextrose bicarbonate 
Lactated Ringer’s has shown some good results.388 878-880 The necessity of bicar-
bonate in intraocular irrigating solutions has been questioned. It does not seem 
to be a necessary prerequisite for adequate endothelial pump function after 
surgery. The endothelial pump has been hypothesized to ‘hibernate’, temporar-
ily shut down, in the absence of bicarbonate.391 393 394
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 Intracamerally used anesthestics such as lidocaine, mydriatics including cyclo-
pentolate phenylephrine and epinephrine, and miotics including acetylcholine, 
pilocarpine, and carbachol, all have demonstrated dose-dependent endothe-
liotoxic effects. However, in the currently used doses and concentrations of 
intracameral drugs such as adrenaline 1:10000, preservative-free  cylopentolate 
0.1 %, phenylephrine 1.5 %, and lidocaine hydrochloride 1 %, however, no (ad-
ditional) clinical endothelial cell loss has been observed 396 423 443 881-885 For many 
common antibiotics including gentamicin, amikacin, cephalotin, cefazolin, 
ceftazidime, ofloxacin, amfotericine-B, and tobramycin, dose-and /concentration-
related endothelial toxicity has been observed. Dosage needs to be low as dose-
related retinotoxicity is even a greater concern than endotheliotoxicty.31 40 395 408 445 
886-895 Povidone-iodine in the infusion solution, as an alternative to intracameral 
antibiotics, needs to be diluted, because of concentration-related endothelial 
toxicity.896 Preservatives used in topical medication, should not be used intraocu-
larly, neither should topical or regional drugs containing preservatives be applied 
when an open connection to the anterior chamber exists. 40 387 442-445
 Pars-plana vitrectomy may have direct detrimental effects on the endothelium, 
which may be enhanced in the case of aphakia. A contributing factor to endo-
thelial damage in pars-plana vitrectomy may be increased hydrostatic pressure 
of the infusion fluid during parts of the operation.897 898 Gases and fluids used as 
surgical adjunctives or tamponades in vitreoretinal surgery, including air (see 
also paragraph XIII.), SF6, C3F8, perfluorocarbon, and silicone oil, have all been 
correlated to endothelial cell dysfunction and death when these substances 
are in direct proximity to the endothelium. Damage appears to occur mainly 
through impaired endothelial metabolism due to decreased aqueous imbibi-
tion, rather than through direct toxicity, and increases when exposure times are 
longer.11 40 535 899-908
 References
 See page 287.
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Abstract
 Purpose 
To report on the calibration of the Topcon SP-2000P specular microscope and the Endo-
thelial Cell Analysis Module of the IMAGEnet2000 software, and to establish the validity 
of the different endothelial cell density (ECD) assessment methods available in these 
instruments.
 Methods
Using an external microgrid, we calibrated the magnification of the SP-2000P and the 
IMAGEnet software. In both eyes of 36 volunteers, we validated four ECD assessment 
methods  by comparing these methods to the gold standard Manual ECD, manual 
counting of cells on a video print. These methods were: the Estimated ECD, estimation 
of ECD with a reference grid on the camera screen; the SP-2000P ECD, pointing out 
whole contiguous cells  on the camera screen; the Uncorrected IMAGEnet ECD, using 
automatically drawn cell borders, and the Corrected IMAGEnet ECD, with manual cor-
rection of incorrectly drawn cell borders in the automated analysis. Validity of each 
method was evaluated by calculating both the mean difference with the Manual ECD 
and Bland and Altman’s Limits-of-Agreement.
 Results
Preset factory values of magnification were incorrect, resulting in errors in ECD of up 
to 9 %. All assessments except one of the Estimated ECDs differed significantly from 
Manual ECDs, with most differences being similar, (< 6.5%), except for Uncorrected IMA-
GEnet ECD: 30.2 %. Corrected IMAGEnet ECD showed the narrowest limits of agreement 
(-4.9 to +19.3 %). 
 Conclusions
We advise to check the calibration of magnification in any specular microscope or en-
dothelial analysis software as it may be erroneous. Corrected IMAGEnet ECD is the most 
valid of the investigated methods  in the Topcon SP2000P/IMAGEnet 2000 combination. 
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  Introduction
 
 The endothelial cell density (ECD) of a cornea may be important in the planning 
of intra-ocular surgery, notably in assessing the risk of corneal decompensation. 
Postoperatively, the ECD can assist in evaluating a surgical technique. 
 
 The Topcon SP-2000P is an easy-to-use, auto-focus specular microscope that 
combined with the Endothelial Cell Analysis Module in the IMAGEnet 2000 
software package (both Topcon Corp., Tokyo,  Japan) provides several methods 
for obtaining ECD measurements in vivo. As the SP-2000P is a non-contact 
instrument, endothelial imaging with it carries no risk of epithelial damage or 
microbiological contamination and is easily tolerated by subjects. Therefore this 
instrument seems particularly suitable for obtaining ECD measurements before 
and after intra-ocular surgery.  
 However, whether the combination of SP-2000P with any of the available as-
sessment methods yielded reliable ECD measurements was yet to be confirmed. 
In the present study, we checked the magnification calibration of the SP2000P 
camera and the IMAGEnet software. We investigated the validity of the available 
ECD assessment methods, in particular of the (semi-) automated methods com-
pared to basic manual counting. The general principles of our methods may 
also apply to other specular microscopes and endothelial analysis methods.
 Methods
 
 Calibration
 Figure 3.1a  presents a screen print obtained with our SP-2000P camera; the 
double-headed arrow indicates the mask slit width. Each individual camera has 
its own specific mask slit, an aperture that is approximately, but not exactly, 0.2 
mm. (In the camera we used we found it to be 0.1914 mm). This mask slit width 
is a central referential parameter in the calibration of the magnification of a 
SP-2000P. For proper calibration of the magnification, one should first measure 
and store the mask slit width of a particular camera, and then use this value to 
adjust the magnification value in the appropriate menu of the IMAGEnet2000 
software according to the formula: 
 New magnification value =
  .
trueMaskSlitInsideDimension
0,2(               ) x 0,00115
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 (0.00115 is the standard, pre-programmed magnification value in the IMAGE-
net2000 software; it uses 0.2 as a standard for the mask slit width.)
 The true mask slit width was obtained with an external, micro-grid calibration 
device manufactured by Topcon for calibration of their specular microscopes. 
This device was snugly fixed onto the optical emitting/receiving head of the 
specular microscope. To obtain clear images of the micro-grid on the camera 
screen without using the SP-2000P’s internal flash, an external continuous light 
source was applied behind the translucent micro-grid. Images of the microgrid 
were captured and displayed on the camera screen. Suitable images were 
similar to the diagram shown in figure 1B. With the camera’s software, the mask 
slit and the standard distance between the reference microgrid lines A and B 
(see fig. 3.1b) were measured and related, resulting in a new slit width. In order 
to eliminate both observer bias and distortion caused by the position of the 
microgrid, this procedure was repeated in ten different images each obtained 
after a slight change in position of light source and grid, and three observers 
took turns in making the measurements. The mean value of ten measurements 
was stored in the camera’s memory as the true mask slit width.
 Validity Study
 Seventy-two eyes of 36 volunteers, aged between 23 and 80 years and with no 
known ocular or systemic disease were included in the study. From each eye 3 
consecutive endothelial images of the central cornea were obtained with the 
SP-2000P. These were printed in hardcopy (Fig. 3.1.a) using a video printer, and 
then evaluated on the SP-2000P using the so-called Simplified Cell Analysis (see 
below). Finally the images were captured and saved on the hard disk of a perso-
nal computer with IMAGEnet2000 frame-grabbing and Endothelial Cell Analysis 
Module software. The combination of SP-2000P and IMAGEnet2000 endothelial 
cell analysis software provided us with four different ECD assessment methods, 
as did its predecessor, the SP1000 with contemporary versions of the IMAGE-
net.292 Each of these analysis methods was investigated. 
 First, from one randomly chosen printed image the ECD was estimated by three 
different observers, using estimation grids displayed on the SP-2000P screen 
next to the image of the endothelium. These grids consisted of examples of 
cell densities of  1000, 1500, 2000, 2500 and 3000 cells per mm2 (Fig. 3.1.a). We 
estimated ECD in steps of 250 cells/mm2 in order to enhance the accuracy of 
this Estimated ECD; we did not consider smaller steps in accuracy to be feasible. 
Each image contained at least 100-150 endothelial cells. Per eye an Estimated 
ECD was obtained by each observer. Observer 1 was an experienced corneal 
surgeon, whereas observers 2 and 3 were Ophthalmology residents.
 Second, all three captured images of each cornea were analysed by one of us 
(W.v.S.). using the Simplified Cell Analysis method in the SP-2000P itself, which 
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basically is a “centre” or “dot”  technique.286 287 In the SP-2000P, this assessment 
method requires the identification of the centres of ten or more contiguous 
cells in an endothelial image by pointing them out on the camera screen 
(clicking them with the camera mouse). Only whole cells that did not sit on any 
edge of an image were included. As instructed by the Topcon SP-2000P user 
manual, we identified the centres of on average  15 (10 –20)  cells per image. 
The software in the SP-2000P measures the distances between individual cell 
centres, then computes the mean endothelial cell area, and hence the endo-
thelial cell density. For each eye, the results of these three ECDs were averaged 
and called the SP-2000P ECD.
 Third, all images saved on the hard-disk of the personal computer were subjec-
ted to a fully automated analysis by the IMAGEnet2000 Endothelial Cell Analysis 
Module. This method is based on a planimetric variable frame technique as 
described by Waring et al.282 The software determines the borders of at least 100 
endothelial cells per image by the detection of contrast differences between 
cells and intercellular borders in a black-and-white image. Individual endothelial 
cell area is measured by the software, which then calculates the mean cell area 
and other morphometric parameters including the ECD. A standard setting of 
contrast and gain in the analysis software was used after preliminary results 
(not shown) had demonstrated that altering the settings of contrast and gain 
did not result in a better performance in the recognition of cell borders by the 
software. The mean of three analyses from each eye was called Uncorrected 
IMAGEnet ECD. 
 Finally, one of the authors (W.v.S.) corrected software-defined cell borders in 
all analysed images in IMAGEnet. This correction entailed erasing any incor-
rectly drawn or incomplete cell boundaries and redrawing them as they were 
deemed true. Then the software reperformed the planimetric endothelial cell 
analysis, and the mean of three analyses of each eye resulted in the Corrected 
IMAGEnet ECD. 
 As in the SP-2000P ECD, only whole cells with continuous cell borders were  
accepted by the IMAGEnet analysis software in the Uncorrected and Correc-
ted IMAGEnet ECDs. Edge-effects, dealing with incomplete cells on edges of 
images to be analysed, therefore did not have to be taken into account in any 
of these methods; in Estimated ECD edge-effects obviously were irrelevant.  
 All of these four differently measured ECDs of each eye were compared to what 
we adopted as our gold standard ECD: the Manual ECD, a basic fixed-frame 
counting method.241 282 We chose this method as gold standard because it was 
a completely non-automated assessment method, and we were particularly 
interested in the validity of (semi-)automated methods in comparison to a 
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non-automated method. The Manual ECD was obtained as follows: a counting 
box of 2.0 by 5.0 centimetres was placed over a hardcopy videoprint of the 
photographed endothelium. All complete cells within this box were counted, 
as well as any incomplete cells on the left and upper borders and on the left 
hand corners. A count was thus obtained according to the counting rules 
described by Gundersen, and by Sperling and Gundersen, to reduce counting 
bias caused by edge effects.278 279 Each box contained on average about 75 cells 
(range: 50 - 100). The number of cells we counted in the box was multiplied 
by a magnification factor to obtain to obtain an ECD (per square millimeter). 
The ECDs of three images of one eye were averaged to obtain the Manual ECD 
for that eye. For the calculation of the magnification factor in this method, we 
micrometrically measured the mask slit width on several hardcopy videoprints 
(Fig 3.1a, double-headed arrow). The ratio between the printed mask slit width 
and the true mask slit width, described earlier in the Calibration paragraph of 
this Methods Section, was calculated to be the linear magnification. This linear 
magnification was squared to obtain the two-dimensional magnification. The 
two-dimensional magnification factor for our box was found to be 31.56 x the 
number of counted cells.  
 Data analysis in the validity study:
 Results of both eyes of our 36 subjects were pooled, which was justified 
because we studied differences between assessment methods rather than bet-
ween eyes. Both eyes of each subject contribute independently to a possible 
difference between assessment methods. All the various ECDs were scatter-
plotted against the Manual ECD. Using Pitman’s test, we determined whether 
paired variances were significantly different between ECDs obtained by the 
several assessment methods and the Manual ECD.909 A significant difference in 
variances would indicate a difference in variability due to “noise”, i.e. a difference 
in coincidental, non-systematic variability, as opposed to a systematic difference 
between the assessment methods. 
 The comparability of the two assessment methods was evaluated by calcu-
lating the 95 % limits-of-agreement according to Bland and Altman.910 These 
Limits-of-agreement were calculated as mean difference ± 1.96 x standard devi-
ation of the difference. The absolute differences between the ECDs obtained by 
each assessment method and the manual ECDs were plotted against the aver-
ages of both ECD measurements. In these so-called Bland Altman plots, three 
horizontal lines are drawn, the middle one representing the mean difference, 
and the upper and lower lines representing the respective Limits-of-agreement. 
Ideally, the mean difference between assessment methods is near zero and the 
Limits-of-agreement remain constant throughout the whole range of measu-
rement values. However, we anticipated the possibility that the scatter of the 
differences might increase with an increasing absolute value of the ECD, i.e. that 
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the differences might be proportional to the average level. Therefore, we also 
performed a logarithmic transformation on the observed ECDs, and repeated 
the calculation of the Limits-of-agreement and of the mean differences, in order 
to assess any possible relative differences between the measurement methods.  
 Results
 
 Calibration
 In the camera and software combination we examined, we found that preset 
factory values of camera calibration, i.e. the mask slit width, was incorrect, and 
furthermore that the magnification value had been entered in an incorrect field 
in the IMAGEnet software. As a result, the IMAGEnet software computed an as-
sumed ECD that was incorrect. 
 We calculated a correction factor to compensate for the incorrect assumed 
mask slit width in images that had already been stored. The mask slit width is 
the linear reference measure for the magnification. The true observed mean 
endothelial cell area is related to the assumed mean endothelial cell area as 
the ratio of the squared true mask slit width to the squared assumed mask slit 
width. The true ECD is the inverse of the true mean endothelial cell area. This 
resulted in the following formula to obtain the true ECD: 
.
 If the magnification value had been put in an incorrect field in the IMAGEnet 
software this usually resulted in an overestimation of the observed area, for the 
ECD would then be calculated using the standard 0.2 mm for mask slit width 
instead of the – in our experience invariably - smaller true mask slit width. This 
leads to an underestimation of the ECD. In this case, the correction factor to 
multiply the assumed ECD with to obtain the true ECD in already stored images 
could be calculated by:
 .
 When considered separately, each calibration error resulted in a different error 
in ECD, up to 9 %. Because in our example the errors occurred simultaneously, 
we multiplied both correction factors to obtain the true ECD, which resulted in 
a smaller error in ECD of 6,9 %. The effects of the two simultaneously occurring 
assumedMaskSlitInsideDimension
trueMaskSlitInsideDimension(               )
2
0,2
trueMaskSlitInsideDimension(               )
2
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errors opposed each other. Two other important endothelial morphometric 
parameters provided by the IMAGEnet2000 endothelial cell analysis module 
obviously did not suffer from these calibration errors. The Coefficient of Varia-
tion of cell size (CV = standard deviation of cell size divided by mean cell size) 
was unaffected because it is a dimensionless parameter in which errors in cell 
size are divided away, and Hexagonality did not change because it does not 
depend on cell size but on the ratio of cells with 6 corners to the total number 
of cells identified.
 Validity Study
 Figures 3.2a-c, 3.3, and 3.4a-b represent scatter plots of the different ECD assess-
ment methods, plotted against Manual ECD for each eye. The Estimated ECDs 
(figs. 3.2a-c, a separate plot for each of the observers) and the SP-2000P ECDs 
(fig. 3.3) were spread symmetrically but substantially on both sides of the iden-
tity line. The Uncorrected IMAGEnet ECDs were almost invariably higher than 
the manual ECDs, and were widely spread (fig. 3.4a). The corrected IMAGEnet 
ECDs showed less variation than all the other assessment methods; however, 
they were higher than the manual ECDs (fig. 3.4b).
 With Pitman’s test, no significantly different variances were found among the 
measurement methods, except in one of three Estimated ECDs (p=0.015). 
Limits-of-agreement were calculated. Figures 3.5a-c show for each observer 
the Bland Altman plot of the difference between the Estimated ECD and the 
Manual ECD. Differences between the SP-2000P ECD, Uncorrected, and Cor-
rected IMAGEnet ECD vs. the Manual ECD are shown in  figures 3.6 and 3.7a-b. 
The mean differences and standard deviations, and their statistical significance, 
with the limits-of-agreement, as well as the mean relative differences after 
logarithmic transformation and their statistical significance, have been summa-
rized in Table 3.1. The only statistically non-significant mean relative difference 
was the Estimated ECD of Observer 1 (1.5 %, p = 0.316). The other statistically 
significant mean relative differences were found to be between – 6.3 % and 
6.5 %, with the exception of the difference of Uncorrected IMAGEnet ECD with 
Manual ECD, which was 30.2 %.
 Discussion
 
 The basic principle of (re-)checking the calibration of any measuring instrument 
was demonstrated by our findings. Ohno et al. and Modis et al. already showed 
this in specular microscopy.287 300 In our study, unchecked preset factory values 
were found to result in substantial errors, up to 9 %. 
 We focused on the SP-2000P and the IMAGEnet 2000 endothelial cell analysis 
software, since this combination is being used for preoperative planning and 
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post-operative follow-up in several ophthalmic departments in our country. 
The details of the methods we used are therefore specific to the SP-2000P and 
the IMAGEnet 2000 analysis software. However, we believe that the underlying 
principles, such as the formulas we used for the calculation of the true ECDs or 
the methods applied in the investigation of the validity of assessment methods, 
may be applicable to other combinations of specular microscopes and endo-
thelial analysis software.
 In the study on the validity of endothelial assessment methods we adopted as 
gold standard assessment method the Manual ECD, a fixed-frame method.241 
282 Although variable-frame methods may give more accurate ECD estimates 
and more information on other morphometric characterisctics,241 we chose the 
Manual ECD because this is a very basic non-automated assessment method 
to which we wanted to compare the available (semi-) automated assessment 
methods. The counting rules in fixed-frame methods in order to obtain unbi-
ased counts when dealing with edge effects, were extensively described by 
Gundersen278 and by Sperling and Gundersen279. Additionally, random aberra-
tions possibly introduced by the counting rules were diminished by averaging 
counts from three images.
 We investigated as factors contributing to validity: 1. Magnitude of any systema-
tic difference with the gold standard, i.e. a systematic error in the measurement 
method, and 2. The amount of spread in the differences from the gold standard, 
reflecting the size of individual measurement errors.
 The Estimated ECD, when performed by an experienced observer, provides a 
fast method of ECD assessment, albeit with wide limits-of-agreement (see table 
3.1). This implies that this assessment method may be considered as less valid 
when very accurate ECDs are needed, for instance in the evaluation of endothe-
lial cell loss caused by a surgical technique. It may however be a valid method 
when a fast, semi-quantitative endothelial evaluation suffices, such as in the 
preoperative assessment of the risk of a decompensation of a cornea.
 The SP-2000P ECD showed similar systematic differences with Manual ECD 
compared to Corrected IMAGEnet ECD and most Estimated ECDs. The SP-2000P 
ECD also suffered from wide limits-of-agreement (see table 3.1), indicating a 
low level of accuracy in individual measurements. Therefore, in this study the 
validity of SP2000P assessment is less than that of Corrected IMAGEnet ECD, 
and does not offer any real advantage over the Estimated ECD, because it gives 
a false impression of accuracy. It should be noted that with this method we 
counted only 10 to 20 cells per image, as was indicated in the User Manual. This 
is considerably lower than the number of cells that was counted with each of 
the other assessment methods: 75 cells or more. Doughty et al. have shown 
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that for accurate estimates, samples of at least 75 cells are needed.299 With larger 
samples one might obtain  narrower limits-of-agreement with the SP-2000P 
ECD assessment method; however we still found considerable inaccuracies 
with some larger samples (unpublished results). 
 Fully automated recognition of endothelial cell borders by the IMAGEnet en-
dothelial cell analysis software was still far from flawless, as was demonstrated 
by the results of the Uncorrected IMAGEnet ECD. Both the limits-of-agreement 
and the systematic difference with the Manual ECD were of such a magnitude 
that this method should be considered the least valid and thus the least useful 
of all, despite of its theoretical advantage in objectivity and its short analysis 
time. So the ultimate goal of having an endothelial cell analysis method that is 
both completely objective and valid was not reached with the IMAGEnet 2000 
Endothelial Cell Analysis Module.
 It is remarkable that both Uncorrected and Corrected IMAGEnet ECDs are syste-
matically higher than Manual ECDs. The reason for this remains unclear. The fact 
that variable-frame counting methods are compared to a fixed-frame counting 
method may have introduced a systematic difference. However, by adopting 
the counting rules discussed before, edge-effects are most likely avoided. Per-
haps the difference is due to some other, unknown factor in the IMAGEnet-soft-
ware data processing or calculation. In contrast to the Uncorrected IMAGEnet 
ECD, the Corrected IMAGEnet ECD is more laborious and required subjective in-
tervention. However, the Limits-of-agreement (table 3.1), which are comparable 
to those found by other authors292 indicated that the Corrected ECD is the most 
accurate of all assessment methods, with the least individual measurement er-
rors. The systematic difference of the Corrected ECD with the Manual ECD is on 
the same order of magnitude as for the other assessment methods in this study 
except the Uncorrected ECD. Most other studies on endothelial assessment 
methods report a slight systematic difference in ECD when compared to either 
manual counts or other analysis methods286 287 291-293 302
 In conclusion, when comparing Corrected IMAGEnet ECDs to the Manual ECDs 
or ECDs obtained with other assessment methods, a correction factor has to be 
taken into account. However, the Corrected IMAGEnet ECD has a high validity 
when very accurate ECD measurements are needed, as for instance in follow-up 
studies. For purposes where less accurate ECD measurements may be satisfac-
tory, such as in preoperative assessment of the risk of corneal edema, estima-
tion of  ECD by a trained observer may suffice.
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Mean difference  
with manual  ECD  
in cells / mm2
Standard
deviation
Significance 
(p-value)
Limits of  
Agreement 
(absolute)
Mean relative  
Difference 
ECD (%)
Limits of   
Agreement 
(relative)
  Estimated ECD
  Observer 1 32.7 296.1 0.352 -547.7 , 613.1 1.5 %* - 20.6 % , 29.8 %
  Observer 2 126.4 324.6 < 0.0001 -309.5 , 562.3 5.6 % - 12.2 % , 26.9 %
  Observer 3 - 147.9 222.4 < 0.0001 -783.3 , 487.5 - 6.3 % - 29.3 % , 41.4 %
  SP-2000P 126.1 324.6 0.002 -510.1 , 762.3  5.6 % - 18.8 % , 37.2 %
  IMAGEnet
  Uncorrected 725.5 349.0 < 0.0001 41.5 ,1409.5 30.2 % 0.2 % , 69.1 %
  Corrected 156.4 143.8 < 0.0001 -125.4 , 438.3 6.5 % - 4.9 % , 19.3 %
Table 3.1 Parameters of the endothelial assessment methods.
  *: The only non-significant mean relative difference ECD  (p= 0.316); all other mean relative difference ECDs had
       p = 0.001 or less.
   References
   See page 287.
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Figure 3.1a Example of a video print of the endothelial image obtained by the SP2000P. The double-headed arrow 
indicates the mask slit width that is essential in the calibration. Just right of the endothelial image are 
the reference grids for the estimation of ECD (in cells/mm2).
Figure 3.1b Picture of  external microgrid used with calibration device as it appears on the SP-2000P screen. The 
double headed arrow indicates the mask slit width. The distance between lines A and B is a standard 
distance used to calculate the mask slit width.
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Figure 3.2 Scatter plots of the Estimated ECDs, each by one of three observers (fig. 2a-2c, respectively), against the
    Manual ECD.
 Figure 3.3 Scatter plot of the SP-2000P ECD (“Simplified Cell Analysis”) against the Manual ECD.
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Figure 3.4 Scatter plot of the Uncorrected (fig.3.4a) and the Corrected (fig. 3.4b) IMAGEnet ECDs against the 
Manual ECD.
Figure 3.5 Bland Altman plots of the difference between the Estimated ECD and the Manual ECD, against the mean 
of the Estimated ECD and the Manual ECD, for each of the three observers (figs. 3.5a – c, respectively).
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Figure 3.6 Bland Altman plot of the SP-2000P ECD and the Manual ECD.
Figure 3.7 Bland Altman plots of the Uncorrected IMAGEnet ECD and the Manual ECD (fig. 3.7a),  and of the Cor-
rected IMAGEnet ECD and the Manual ECD (fig. 3.7b).
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Abstract
 Purpose
To evaluate reproducibility and biological variability in the morphometric  corneal 
endothelial parameters cell density (ECD), coefficient of variation of cell size (CV), and 
hexagonality; as well as in (optical) pachymetry. 
 Methods
From the target eye of 25 “normal”  volunteers, 17 bilateral contact-lens wearing volun-
teers, and 15 patients one year after bilateral phacoemulsification,  endothelial images 
were obtained using a Topcon SP-2000P non-contact specular microscope. Nine central 
corneal images images were obtained in two same-day sessions and a third session 3 
weeks later. Additional images were obtained from the paracentral target cornea, and 
from the central fellow eye. All images were analyzed using IMAGEnet 2000 semi-auto-
mated analysis, by one observer. Reproducibility of all parameters was evaluated using 
mixed-model ANOVA. Two additional observers analyzed 38 random images, and inter-
observer reproducibility was calculated.
 Results
Time-related reproducibility was of much less importance than sampling error, which 
was low in pachymetry and in ECD, moderately low in CV, and high in hexagonality 
measurements. Inter-observer reproducibility was high. None of the parameters sho-
wed significant systematic differences between fellow and target eyes. ECDs and CVs 
from nasal and inferior paracentral areas were not significantly different from central 
corneal values.
 Conclusions
Although pachymetry, ECD, and CV measurements are reproducible, sampling error 
may influence the reliability of all endothelial measurements. This can be improved 
by calculating the mean from several replicate measurements. Values of contralateral 
eyes may substitute for one another. Nasal and inferior ECD and CV may substitute for 
central values. 
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 Introduction
 
 Endothelial morphometric parameters such as the endothelial cell density (ECD), 
coefficient of variation of cell size (CV) as a measure for polymegathism, and the 
hexagonality of endothelial cells as a measure for pleomorphism, have been 
investigated extensively.241 The measurement of the thickness of a cornea, the 
pachymetry, is one of the most important methods to evaluate corneal endothelial 
function in vivo.84 All these parameters may be important in the planning of intra-
ocular surgery, notably in assessing the risk for corneal decompensation. They can 
also be used to evaluate endothelial damage caused by surgery. 
 The Topcon SP-2000P is an easy-to-use, auto-focus specular microscope that 
combined with the Endothelial Cell Analysis Module in the IMAGEnet 2000 
software package (both Topcon Corp., Tokyo,  Japan) enables one to obtain 
ECD, CV, hexagonality, and optical pachymetry measurements in vivo. As the 
SP-2000P is a non-contact instrument, there is no risk of epithelial damage or 
microbiological (cross-)contamination, and examinations are easily tolerated. 
Therefore, this instrument seems very suitable for obtaining measurements 
before and after intra-ocular surgery.  
 In order to correctly interpret observed changes within patients and differences 
between patients in endothelial parameters, insight in the reliability of these 
measurements is essential. In a previous study the calibration of magnification 
of the SP-2000P and the IMAGEnet2000 software, and the validity of the 
available endothelial assessment methods were described. The semi-automated 
assessment method, in which software-defined cell borders are interactively 
corrected, was found to be the most valid method for obtaining ECD.911 
 In the present study other aspects of the reliability of measurements obtained 
with this instrument were investigated. We looked into the reproducibility 
of measurements in ‘normal’ and contact-lens wearing volunteers, as well 
as in patients one year after bilateral cataract surgery. In addition, the 
“biological variability”, i.e. the reliability of paracentral or contralateral values 
of morphometric parameters as substitutes for central values, was studied. 
The methods we used are not restricted to the Topcon SP-2000P, but are also 
relevant to investigators using other specular or confocal microscopes, and 
other analysis software packages.
 Methods
 
 Three groups of subjects were studied. In all subjects one eye was randomly 
designated ‘target eye’, the other eye ‘fellow eye’. The first group consisted of 
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healthy volunteers (n = 25, mean age ± standard deviation: 38.2 ± 8.6 years; 14 
females, 11 males), not wearing contact-lenses and without any known ocular 
disease. A second  group of volunteers (n = 17, age: 32.4 ± 8.4 years, 11 females, 
6 males) included long-term, i.e. longer than two years, bilateral contact-lens 
wearers (either rigid gas permeable or soft contact lenses) without any known 
ocular disease. The third and final group consisted of patients one year after 
uncomplicated bilateral phacoemulsification with implantation of an IOL (n = 
15,  age: 72.4 ± 10.0 years, 10 females, 5males). Both eyes of one patient were 
operated within 2 months by the same surgeon, using 5mm corneoscleral tunnel 
incisions, the same divide-and-conquer technique after continuous curvilinear 
capsulorhexis, and in-the-bag implantation of the same type of  PMMA IOL. 
Phaco-times and –energies did not differ significantly between the eyes.
 
 Endothelial images were obtained using a Topcon SP-2000P auto-focus non-
contact specular microscope. Optical Pachymetry readings were directly 
provided on the microscope screen. The images were then imported into a 
personal computer and analysed with the Endothelial Cell Analysis Module of 
the  IMAGEnet2000 software. Cell borders were interactively corrected by one 
of the authors (BTHvD). The images were masked for time-point and patient 
group. After the correction of cell borders a final analysis resulted in ECD, CV, 
and Hexagonality measurements. A more detailed description of this analysis 
method has been described previously.911
 Reproducibility
 From the target eye, in a first session three successive endothelial images 
were obtained from the central cornea. In a second session a few minutes 
later, three more central endothelial images were taken. In groups 1 and 2, in 
a third session 3 weeks (mean ± SD: 23.7 ± 24.0 days) later three final central 
images were taken from the target eye. Statistical analyses were performed 
with the SAS Statistical Package (SAS Inc, Cary, Indiana). Using a mixed model 
Analysis of variance (ANOVA), total variance of all parameters was decomposed 
into a between-subjects and a within-subjects component. The latter 
component was further decomposed into three time-related within-subject 
components: within-session (three successive images), between-session same 
day, and between-session long term (three weeks). After expressing these 
components as percentages of total variance, we calculated various reliability 
indices as follows. The repeatability index was calculated as the sum of the 
between-subjects component, the within-subject between-session same day 
component, and the within-subject between-session long-term component. 
The short-term reproducibility index was calculated as the sum of the between-
subjects component and the within-subject between-session long-term 
component. The long-term reproducibility index equalled the between-
subjects component. 
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 For the calculation of inter-observer variability, 38 randomly chosen images 
from the total pool of endothelial images were once more semi-automatically  
analyzed by two additional observers (AML,WvS). For 3 observers, inter-
subject, inter-observer, and intra-observer variabilities were calculated using 
Components of Variance analysis with the software package SPSS, release 11.0 
(SPSS Inc., Chicago, Ill., USA). The inter-observer reproducibility was expressed 
as the Intra-Class-Correlation-coefficient (ICC), which is defined as the inter-
subject variance as proportion of the total variance.
 Biological variability
 In the first session, 3 central images were obtained in both paired eyes in all 
groups. Endothelial measurements from target and fellow eyes were compared. 
Also,  in groups 1 and 2 (n = 38) in the target eye endothelial images were taken 
from the other four paracentral “windows” in the SP2000P: superior, temporal, 
nasal, and inferior. These paracentral windows were located at a radius of  3 mm 
from the central axis at the 12, 10, 2, and 6 o’clock positions, as documented 
in the Topcon SP2000P manual. Paracentral measurements in group 3 (post-
phacoemulsification patients) were not included in this study.  Particularly 
measurements in the temporal and superior paracentral windows would be 
influenced by local effects of surgery on the endothelium (e.g. the sclerocorneal 
wound). This would have confounded the comparison to central measurements. 
 Differences between target and fellow eyes were statistically evaluated with a 
paired Student’s t-test and Wilcoxon Rank Sign Test, using the software package 
SPSS, release 11.0 (SPSS Inc., Chicago, Ill., USA). A probability level of 0.01 was 
adopted for statistical significance because of the large number of tests that had 
to be performed. For the comparison of endothelial parameters in paracentral 
and in central corneal areas mean differences and limits-of-agreement according 
to Bland  and Altman were calculated, 910 and Student’s t-test was performed. 
 Results
 
 Reproducibility
 Table 4.1 shows for the four parameters ECD, CV, Hexagonality, and Pachymetry 
the various reliability indices (repeatability, short-term reproducibility and long-
term reproducibility indices). Results are given for the aggregated group of 
subjects as well as separately per study group. For group 3, only the short-term 
reproducibility could be calculated, as there had been no third session.
 
 Table 4.2 shows the inter-patient, intra-observer and inter-observer variabilities 
as obtained with Components of Variance analysis for the observer-influenced 
parameters ECD, CV, and hexagonality.
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 Biological variability 
 Table 4.3 shows the mean differences between the target eye and the fellow-
eye for all 4 dependent parameters. 
 Table 4.4 shows the values of all four parameters in the 4 paracentral windows, 
separate as well as aggregate, together with the p-values obtained when 
comparing with the values in the central window. Also the mean differences 
between the values in these paracentral windows compared to in the central 
window, as well as the Limits-of-Agreement are presented in this table. 
 Discussion
 
 Reproducibility
 The first part of the present study investigated the reliability of endothelial 
morphometric parameters and pachymetry, obtained with Topcon SP2000P 
specular microscopy and semi-automated endothelial analysis. The results in 
Table 4.1 show that for all endothelial parameters the reproducibility index is 
hardly worse than the repeatability index, and the long-term reproducibility 
index is hardly worse than the short-term reproducibility index. This implies 
that there is hardly any within-subjects, time-related, biological variability 
in any of these parameters. Furthermore, the within-subject variability is 
mainly caused by sampling error of the measurement process itself, rather 
than by within-subject variability of the parameter. The component of this 
sampling error in the total variance equals 100 minus the repeatability indices 
expressed in Table 4.1. By calculating the mean of a number of replicate 
measurements, the sampling error decreases inversely proportional to the 
number of measurements. This procedure may be advisable when very precise 
measurements are needed.
 The very high repeatability index of pachymetry readings confirmed the 
capacity of the SP-2000P for discerning true intra- and inter-subject differences 
in pachymetry. Furthermore, true circadian and day-to-day biological 
fluctuations in corneal thickness may be expected to induce some variability in 
follow-up measurements and therefore accounted for most of the additional 
variability in the long- and short-term reproducibility indices. Our conclusion 
that SP2000P pachymetry readings are very reproducible confirmed the 
findings of Bovelle et al..370 Our results were slightly better than those of Nichols 
et al. who used a different specular microscope (Konan SP-9000 LC).288
 The capacity of the semi-automated assessment method to discern within- and 
between-subject ECD differences can be considered to be very good in normals 
and in post-cataract patients, and good in contact-lens wearers. Corneas of 
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contact-lens wearers usually demonstrate higher endothelial polymegathism, 
pleomorphism, and a more inhomogeneous ECD-distribution.450 This may 
result in larger sampling errors in specular microscopy and more interpretation 
difficulties in (semi-) automated ECD-assessment. Hence a slightly lower 
repeatability index in this group of subjects may be explained.
 Long- and short term reproducibility indices of the CV were only slightly less 
than the repeatability index in all the groups, indicating little or no time-
related biological variability in this parameter. The repeatability in group 1 was 
remarkably low compared to the other two groups (and the aggregate group). 
This may be explained by the fact that in group 1 the CV itself and also the total 
variance of CV was lower than in the other groups. This allowed sampling errors 
in CV to be revealed more easily in group 1. In any case, for future reference 
a margin of error should be kept in mind when investigating within- and 
between-subject differences in CV.
 At best, the repeatability index of Hexagonality was only moderate. In 
general it was much worse than for the other parameters. Therefore, the 
capacity to discern intra-subject differences in Hexagonality (e.g. in follow-up 
measurements) should be considered to be poor.
 Inter-observer reproducibility was good to excellent for ECD and CV. For ECD 
an inter-patient component of variance of 98.5 % corresponding with an Intra-
class Correlation Coefficient (ICC) of 0.985 was found. For CV, similarly high 
inter-patient and low inter-observer variances were found (ICC = 0.93). For 
Hexagonality there is a much higher intra-observer variability (30.6 %, ICC = 
69.4). 
 With regards to ECD, CV, and Hexagonality, our findings on repeatability and 
reproducibility are slightly better than those reported by Cheung et al. who 
used the same instrument and comparable statistical methods. The same 
applies to the inter-observer reproducibility.294 Other authors investigated 
other instruments and different endothelial assessment techniques, and used 
different statistical methods. Compared to their reports, sampling variances 
were relatively low and reproducibility indices were relatively high in our 
study.286 288 293 301
 Biological variability
 For all parameters the mean differences between Target Eyes and Fellow Eyes 
were minute, and none of them were statistically significant. Differences in ECD 
between fellow eyes in our study, 0.7 %, were less than in Sperling’s study on 
donor corneas, 4.0 – 4.5 %.267
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 Superior, temporal, and aggregate peripheral ECDs were significantly higher 
than central ECDs. For CV, superior and aggregate peripheral means were 
significantly higher than central. For Hexagonality no means were significantly 
different from central. As expected, all peripheral Pachymetries were significantly 
higher than central. The Bland-Altman calculations showed that the nasal ECD, 
and with a wider margin of error also the inferior ECD are similar to central ECD 
of the same cornea. In individual cases however the difference between nasal 
(or inferior) and central ECD may be considerable (wide Limits-of-Agreement). 
Our findings on paracentral differences in ECD compared to central ECD, 4.4%, 
were comparable to the 5.8 % reported in the study by Amann et al.. Differences 
between superior and central ECDs (9.9%) in our study was somewhat lower 
than their 15.9 %.263 We found that CV follows ECD in this pattern. Both Amann 
et al. and Schimmelpfennig262 263 report even larger differences in ECD when 
more peripheral corneal areas were compared to the central values. Far 
peripheral ECDs are therefore probably not representative for central ECDs.
 Conclusions
 Semi-automated IMAGEnet 2000 endothelial cell analysis on SP2000P specular 
microscopic images was shown to have a very good capability for discerning 
true inter- and intra-subject differences in ECD. CV measurements were also 
reliable, whereas reliability of hexagonality measurements was much less. 
SP2000P pachymetry readings were very reliable. The capability for discerning 
between-subject and intra-subject differences in any parameter was not 
influenced by lack or reproducibility but mostly by sampling error. This may 
be reduced by obtaining the mean of several replicate measurements. Inter-
observer variability of ECD and CV was proven to be small for trained  observers.
 Nasal (and inferior) paracentral ECD and CV may substitute for central values 
when the latter cannot be obtained. When the medical history of both eyes is 
identical, all parameters in the fellow eye may substitute for the target eye. 
 When using specular or confocal microscopes and endothelial analysis systems, 
reliability of measurements should be investigated in order to interpret intra- 
and inter-subject differences in endothelial parameters correctly. Our methods 
for reliability investigations are not restricted to our instruments, and can be 
used universally.  
 References
 See page 287.
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Reliability index (between-subjects 
component in % of total variance) 
ECD CV Hexagonality Pachymetry
All subjects (n = 57)
(1) Repeatibility index 96.9 92.0 60.8 98.0
(2) Reproducibility short-term index 96.9 92.0 60.8 97.2
(3) Reproducibility long-term index 96.8 90.6 57.2 97.0
Total variance = SD2 (= 100%) 3862 6.712 8.932 0.0402
Group 1 (n = 25)
(1) Repeatibility index 96.0 76.4 57.2 97.6
(2) Reproducibility short-term index 95.7 75.3 57.2 97.4
(3) Reproducibility long-term index 95.6 68.2 45.4 96.7
Total variance = SD2 (= 100%) 3142 3.452 8.112 0.0342
Group 2 (n = 17)
(1) Repeatibility index 92.4 90.7 74.2 97.7
(2) Reproducibility short-term index 92.4 90.7 74.2 97.4
(3) Reproducibility long-term index 92.3 90.6 74.2 96.1
Total variance = SD2 (= 100%) 2702 6.102 9.642 0.0352
Group 3 (n  = 15)
(1) Repeatibility index 97.9 93.9 47.8 98.5
(2) Reproducibility short-term index 97.9 93.9 47.8 97.0
Total variance = SD2 (= 100%) 4622 10.142 9.652 0.0522 
Table 4.1 Reliability indices and total variance in endothelial parameters.
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(1) within-session
(2) between-sessions same day
(3) between-sessions long term (3 weeks)
Total variances are in the units of the investigated parameters (cells/mm2, %, and %, for ECD, CV, and Hexagonality, 
respectively), squared. Reliability indices in %.
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ECD CV Hexagonality
Total variance = SD2 (= 100%) 450.42 7.282 9.612
Inter-subject variance = ICC
(intra-class correlation coefficient)
98.5 % 93.0 % 69.4 %
Intra-observer variance 1.3 % 4.1 % 30.6 %
Inter-observer variance 0.2 % 2.9 % 0.0 %
ECD 
(cells/mm2)
Relative ECD 
(%)
CV
(%)
Hexagonality
(%)
Pachymetry
(mm)
Mean Difference - 20.6* - 0.7* 0.55 0.04 0.003
Standard Deviation 175.5 7.0 3.14 6.00 0.016
P-values 0.379 0.446 0.193 0.959 0.172
Table 4.2 Inter-subject, Intra-observer, and inter-observer variances, expressed as components of the total variance.
Table 4.3 Mean differences between target- and fellow eyes in endothelial parameters.
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*: Each mean difference is obtained by subtracting the values in the fellow eye from the values in the target eye. Negative mean   
differences therefore indicate that the values in the fellow eyes were higher than the values in the target eyes.
Total variances are in the units of the investigated parameters (cells/mm2, %, and %, for ECD, CV, and Hexagonality, respectively),  
squared. Standard deviations, i.e. the square root of the variances, are in the same unit as the parameters investigated. 
Components of variance are in %.
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Parameter/
Window
Mean ± s.d.
Mean Difference 
(± s.d, comp. to Central)
P-value
Limits-of-
Agreement
ECD
Superior 3140 ± 442 - 301 ± 367 0.000 -1021 , 419
Temporal 3023 ± 317 - 183 ± 143 0.000 - 463 , 96
Nasal 2865 ± 337 - 25 ± 197 0.440 - 412 , 361
Inferior 2905 ± 303 - 67 ± 202 0.050 - 463 , 329
Peripheral 2984 ± 312 - 144 ± 178 0.000 - 492 , 204
Central 2858 ± 299 n/a N/a N/a
CV
Superior 34.9 ± 8.5 - 5.1 ± 6.4 0.000 -17.6 , 7.5
Temporal 31.8 ± 7.7 - 2.0 ± 5.8 0.042 -13.3 , 9.4
Nasal 31.5 ± 8.0 - 1.8 ± 5.7 0.061 - 13.1 , 9.4
Inferior 30.5 ± 5.4 - 0.9 ± 3.3 0.103 - 7.4 , 5.6
Peripheral 32.4 ± 7.1 - 2.6 ± 4.7 0.002 - 11.8 , 6.7
Central 30.1 ± 4.6 n/a N/a n/a
Hexagonality
Superior 56.5 ± 8.8 2.3 ± 8.4 0.096 - 14.1 , 18.8
Temporal 58.5 ± 9.8 0.4 ± 9.6 0.808 - 18.4 , 19.2 
Nasal 61.7 ± 9.3 - 2.6 ± 8.9 0.080 - 20.0 , 14.7
Inferior 60.2 ± 8.5 - 1.2 ± 8.5 0.415 - 17.9 , 15.6
Peripheral 59.1 ± 6.9 - 0.2 ± 6.4 0.844 - 12.8 , 12.4
Central 58.3 ± 7.3 n/a N/a n/a
Pachymetry
Superior 0.616 ± 0.054 - 0.087 ± 0.037 0.000 - 0.159, 0.015
Temporal 0.583 ± 0.043 - 0.054 ± 0.023 0.000 - 0.100 , - 0.008
Nasal 0.616 ± 0.052 - 0.087 ± 0.036 0.000 - 0.157 , - 0.018
Inferior 0.565 ± 0.043 - 0.037 ± 0.020 0.000 - 0.076 , 0.001
Peripheral 0.594 ± 0.046 -0.065 ± 0.027 0.000 - 0.118 , - 0.013 
Central 0.531 ± 0.034 n/a N/a n/a
Table 4.4 Endothelial parameters in peripheral vs central windows.
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ECDs are given in cells/mm2, CVs and Hexagonalities in %, Pachymetries in mm.
All (mean) differences are calculated by subtracting the value at hand from the central value. Negative differences therefore 
indicate that the value in the specific window was higher than the central value. Limits-of-Agreement according to Bland and   
 Altman are calculated by adding or subtracting 1.96 * standard deviation to/from the mean difference910 and are presented as: 
lowest, highest Limit-of-agreement.
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Abstract
 Aim
To investigate whether in-vivo specular microscopic endothelial cell densities (ECDs) 
systematically differ from ECDs obtained from the same corneas with an in-vitro 
technique in use in cornea banks. 
 Methods 
From 36 eyes planned to undergo penetrating keratoplasty, pre-operative in-vivo ECDs 
were obtained with a Topcon SP-2000P specular microscope and IMAGEnet 2000 semi-
automated analysis. Pachymetries and corneal topographies were also measured. Post-
operative in-vitro ECDs were obtained from the recipient buttons using endothelial-side 
light microscopy, after provoked intercellular swelling. Differences between in-vivo and 
in-vitro ECDs, and limits-of-agreement were calculated.
 Results
The mean difference between in-vivo and in-vitro ECDs was constant, 140 ± 219 cells/
mm2, and statistically significant (p= 0.004). Wide limits-of-agreement indicated that 
in individual cases differences were much larger. Compared to other eyes the mean 
difference in ECD was not significantly higher in keratoconic eyes, and there was no 
significant correlation between the mean ECD-difference, and pachymetries, mean sim-
K values, or the time-interval between operation and in-vitro ECD counts. 
 Conclusion
When comparing donor ECDs from the cornea bank to specular microscopic ECDs 
in grafted eyes, the possibility of a systematic difference between different ECD 
measurement methods should be considered. Due to its constant nature in our study, 
this difference could not be explained by optical factors alone.   
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 Introduction
 
 Endothelial cell density (ECD) is the most frequently used quantitative 
parameter in the evaluation of the status of the endothelial cell layer. Clinically, 
ECD is paramount in the assessment of endothelial damage after surgery, 
especially after keratoplasty.310 770 In the Cornea Bank Amsterdam, Amnitrans 
EyeBank, Rotterdam (both the Netherlands), and in other eye banks in Europe, 
a minimum ECD of between 2000 and 2500 cells/mm2  is a major criterion for 
acceptance of a donor cornea for transplantation.324 812 
 In several eye banks in Europe light microscopy is used to determine the 
endothelial cell density on donor corneas in vitro. Images are taken from the 
endothelial side following vital staining with trypan blue and provoked swelling 
of the intercellular space.324 332 This technique, also in use at the Cornea Bank 
Amsterdam, differs substantially from specular microscopy. In contrast,  when 
using the specular microscopy principle,3 an image of the endothelium is 
obtained from the external, epithelial side. Image analysis- and endothelial 
assessment methods for both techniques may differ substantially as well.361   
 In clinical follow-up studies on endothelial cell loss after keratoplasty, donor 
ECDs will be compared to post-operative in-vivo ECDs. In order to evaluate 
whether there was a systematic difference between ECD obtained by specular 
microscopy and light microscopy, in the present study we compared in-vivo 
ECDs from patients planned for penetrating keratoplasty (PK), to in-vitro ECDs 
obtained from these patients’ recipient corneal buttons.
 Methods
 
 Clinical material
 Thirty-six eyes of 36 patients planned for PK were included. In 24 patients, 
the diagnosis was keratoconus. Four corneas were transplanted for a corneal 
dystrophy, 3 had corneal scars after perforating trauma, 2 herpetic maculae, 1 
had a leucoma of unknown aetiology, 1 a pseudophakic bullous keratopathy, 
and 1 operation was a re-PK. 
 In-vivo endothelial cell densities
 Specular microscopy was performed preoperatively using a non-contact 
autofocus SP-2000P specular microscope (Topcon Corporation, Tokyo, Japan) in 
the Rotterdam Eye Hospital, Rotterdam, and the Department of Ophthalmology 
of the Vrije Universiteit Medical Centre, Amsterdam, both The Netherlands. 
The magnification of both instruments had been calibrated as described 
previously.911 
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 Primarily, endothelial images were obtained from the central cornea. When 
no good central images could be obtained, images were acquired from a 
paracentral area that was located within the dimensions of the future recipient 
corneal button (trephines used were all over 7.0 mm in diameter), by having the 
patient fixate slightly off-centre. When more images of one eye were available, 
one with acceptable quality was randomly chosen for analysis. All images 
were analysed using IMAGEnet2000 software (Topcon) with semi-automated 
correction of cell borders by one of the authors (BvD). 
 Whenever possible mean simulated keratometry readings (mean sim-K values, 
using an Alcon EH-290 Eyemap Corneal Topograph, Alcon Corp., Fort Worth, Tx.) 
and optical pachymetries (with the SP2000P) were obtained. 
 In-vitro endothelial cell densities
 PK was performed in the Rotterdam Eye Hospital, in the Department 
of Ophthalmology of the Erasmus Medical Centre, Rotterdam, and the 
Department of Ophthalmology of the Vrije Universiteit Medical Centre, 
Amsterdam. No intra-operative complications occurred. Recipient corneal 
buttons were trephinated and excised, and under sterile conditions placed in 
Eagle’s Minimal Essential Medium with 2 % Fetal Bovine Serum and 5 % Dextran 
T500, the transport medium for corneas preserved by organ culture (The 
Cornea Bank Amsterdam, The Netherlands).324 332 
 The buttons were transported to the Cornea Bank Amsterdam for in-vitro 
analysis. The mean time between PK and analysis was 2 ± 1.5 days (min. 0.5, 
max. 8 days). ECD assessment of the recipient buttons was performed using 
the technique for evaluation of donor corneas described previously.324 332 In 
summary, the buttons were stained with trypan blue (0.12 % in buffered saline), 
and swelling of the intercellular space was provoked with hypotonic sucrose in 
water (1.8%). Consecutively, with a light microscope at a magnification of 125 
x and a calibrated graticule in the ocular, the number of cells was estimated 
in five different areas of the corneal button. The mean of these five estimates 
resulted in one in-vitro ECD. 
 Cell counts were performed in areas outside the trephination area. Dead or 
dying cells as indicated by trypan blue staining were included in the cell count. 
Indications for recent cell loss or restoration of damage to the cell mosaic, such 
as polygonal cells with sharp edges,135 249 were not observed. 
 Statistical evaluation
 According to the method of Bland and Altman,910 differences between in-
vitro and in-vivo ECDs were calculated for each button and plotted against 
their mean. After establishing that the differences demonstrated a normal 
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distribution, the significance of the difference between the two ECDs was 
tested with a paired Student’s t-test. The variability of the differences was 
evaluated by calculation of the limits of agreement, mean ± 1.96 standard 
deviations of the mean difference. 
 Possible influence of pachymetries, mean sim-K values, or the time between 
PK and in-vitro ECD assessment on the size of the difference was evaluated by 
calculating Pearson’s correlation coefficients. For all analyses, SPSS software 
release 11.0 (SPSS Inc., Chicago, Ill., USA) was used.
 Results
 
 In figure 5.1 in-vivo ECDs are plotted against the correspondent in-vitro 
densities. The identity line represents a hypothetical zero difference between 
the two ECDs. A relation between the difference and the absolute value of ECD 
was not demonstrated.
 The mean (± standard deviation) in-vivo ECD was 2626 (± 730) cells/mm2, 
and the mean in-vitro ECD was  2486 (± 716) cells/mm2. The mean difference 
between in-vivo and in-vitro ECDs was 140 (± 219) cells/mm2, which was 
statistically significant,  p= 0.004. The difference between in-vivo and in-vitro 
ECD in patients with keratoconus (175 ± 280 cells/mm2) was not significantly (p 
= 0.390)  higher than the difference in ECD of patients with other indications for 
PKP (68 ± 238 cells/mm2). There was no significant correlation of pachymetry, 
mean sim-K, both possible optical confounders, or the time interval between 
PK and in-vitro ECD assessment, with the mean difference (table 5.1).
 The differences between the in-vivo- and in-vitro ECDs were plotted against 
the mean of in-vivo and in-vitro ECDs (figure 5.2). The observed mean 
difference (140 cells/mm2) was shown as the middle horizontal line. The limits 
of agreement, represented by the upper and lower horizontal lines, were 644 
(upper) and – 385 (lower) cells/mm2, which indicated a considerable variability 
in individual measurements.
 Discussion
 
 In our study a constant systematic difference of 140 cells/mm2 that was not 
related to the absolute value of the ECD was observed between in-vitro and 
in-vivo ECDs. This absolute, constant systematic difference is remarkable. Several 
explanations, some of which optical, for possible systematic differences may be 
considered.
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1.  The oblique angle of observation in non-contact specular microscopy may  
lead to an underestimation in the horizontal (but not the vertical) dimension 
of the observed endothelial area, and hence an overestimation of the ECD.274 287 
However, this effect is corrected by a combination of adjustments in SP-2000P 
optics and in the ECD calculation software (P. Gelissen, Topcon Europe, personal 
communication). 
2.  Underestimation of observed area may be introduced by observing a curved 
surface instead of an assumed flat surface.274 Aberrant corneal curvature and 
thickness such as in keratoconic eyes, which constituted the majority of our 
clinical material, may further influence ECD measurements.311 For instance the 
difference between observed (real) curved area and assumed flat area may 
be increased. However, calculations using Olsen’s formulas274 with different 
measures for corneal thickness and radius demonstrated that only small 
additional errors were introduced (manuscript in preparation). In the present 
study the difference between in-vivo and in-vitro ECD was slightly, but not 
significantly, larger in conic corneas. No significant correlation between either 
pachymetry or mean sim-K values, and the mean difference between in-vivo 
and in-vitro ECD was found. Laing et al. confirmed that ECDs in conic corneas 
did not differ significantly from ECDs in normal corneas, although endothelial 
morphology sometimes differed substantially.912 
3.  When observing the endothelium from the epithelial side, a magnification913 914 
of the endothelial image is introduced at the anterior corneal curvature. This 
causes the observed area to be overestimated and the ECD underestimated. 
Recently, formulas were presented for the calculation of the change in the 
magnification of the endothelium after excimer laser refractive surgery.913 914 
When we applied these formulas in theoretical calculations (manuscript in 
preparation) with changes in corneal thickness, power, or radius as may occur 
in keratoconus, the induced change in two-dimensional magnification was only 
small. 
4.  When we had to resort to specular microscopic imaging of paracentral 
areas of the cornea in order to obtain a clear endothelial image, we may 
have introduced a sampling error. Amman et al. recently demonstrated that 
paracentral areas may have ECDs that are about 9 % higher than the central 
ECD.263 In our study paracentral images were actually from areas much closer 
(i.e. within 1 mm)  than Amann’s paracentral areas of the corneal centre. The 
expected error would therefore be much smaller than 9 %.
 Differences between in-vivo and in-vitro ECDs may also have been influenced 
by characteristics related to the in-vitro light microscopic technique.
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5.  Effects on ECD of swelling of the intercellular spaces just prior to in-vitro 
ECD-assessment might be supposed to influence ECD counts, but are not 
likely to occur. Cell counting was performed with the centre of the cells. 
In addition, regular comparison of the ECD obtained after swelling of the 
intercellular spaces and after staining the cell borders with Alizarine Red has 
not shown significant differences; the performance of the technicians and the 
interobserver variability is being monitored at set time intervals as prescribed 
by a quality management system (ISO 9001:2000). In porcine corneas Sperling 
found only very small differences in ECD attributable to osmotic intercellular 
swelling, compared to other ECD measurement techniques.343 
6.  To prevent interference of trephination or transport of the recipient button 
with the cell counting,  precautions were taken during the assessment of 
the cell density as described in Materials and Methods. Mitosis of endothelial 
cells seldomly occurs in humans. Restoration of the wound area by sliding 
and stretching of the neighbouring cells, occurring in vivo, will hardly occur 
during transport of the disc at ambient temperature in vitro. In addition this 
phenomenon can be recognized by the presence of reformation figures in the 
cell mosaic.249 In our study however, these morphologic characteristics were not 
observed.
7.  When the endothelium is studied from the endothelial side in corneal 
buttons resting on their epithelium, gravity and the lack of normal biological 
support structures may cause the discs to flatten. As the observed area now 
better corresponds to a flat surface, the pre-existent overestimation of ECD 
by observation of a curved area diminishes. However, flattening may also 
increase the ECD artificially, as endothelial cells are squeezed together to fit on 
a smaller area. Hence, the net effect may still be overestimation in in-vitro ECD 
measurements.
8.  The graticule used for the estimation of the in-vitro ECD is calibrated with the 
help of a nomogram: the number of cells counted on the lines of the graticule 
plotted against the cell density assessed with Gundersen’s method.279 In normal 
corneas and with ECDs ranging between 2000 and 3000, the used linear fit is 
reliable; however the best fitted line for the nomogram is exponential. See figure 
5.3a. In the higher ranges up to 4000 cells/mm2 the in-vitro ECD is underestimated, 
whereas in the lower ranges the in-vitro ECD is overestimated. This implicates that 
in the higher ECD ranges the observed difference between in-vivo and in-vitro 
ECDs was observed to be larger than it actually was, whereas in the lower ECD 
ranges the difference was observed to be smaller than it actually was (fig 5.3b) The 
data points in graphs 5.3a. and 5.3b. represent a sample from the database of  the 
Cornea Bank Amsterdam. These were used for linear and exponential regression 
modelling, and with the linear model the counting nomogram was constructed.
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9.  A systematic difference between a fixed-frame manual ECD counting technique 
and a variable-frame semi-automated ECD assessment technique has been 
described before. In a previous study, we found a relative difference of 6.5 % 
between these two ECD assessment methods when we evaluated the validity 
of the semi-automated method.911 An overestimation of ECD by variable-frame 
methods compared to a fixed-frame method was also reported by Olsen.280 
 The specular microscopic optical sources for a difference between in-vivo and 
in-vitro ECDs that are relevant in our study (2. and 3. above) were relatively small 
and opposed each other. Furthermore, a resulting error may explain a relative 
but not an absolute difference. The importance of the error introduced by 
biological variation (4. above) is difficult to estimate, as it was both inconstantly 
present and of undetermined magnitude. However, it would probably lead to 
a slight overestimation of in-vivo ECD, causing either a relative or an absolute 
difference. Overestimation of ECD in light microscopy (7. above) does not help 
in explaining a lower in-vitro ECD compared to in vivo. The most important 
possible source of error from light microscopy, (8. above) implied that the 
absolute, constant difference that we found between in-vivo and in in-vitro ECD 
actually was an inverse relative difference, i.e. a difference that becomes smaller 
with increasing ECD (fig. 5.3b). The systematic difference between manual 
fixed-frame counting and semi-automated variable-frame ECD assessment (9. 
above) that was found in our previous study, was a relative and not an absolute 
difference. These considerations impair an unequivocal explanation of our 
findings. Probably, our findings are the sum of several of the described factors. 
 To our knowledge no other study compared in-vivo non-contact specular 
microscopy to the in-vitro technique described in this study, which,  with 
variations,  is currently in use at the Cornea Bank Amsterdam, Amnitrans 
EyeBank Rotterdam (both The Netherlands), and other eye banks in Europe.812 
Binder et al. compared contact specular microscopy, both in vitro and in 
vivo, to scanning electron microscopy (SEM).915 In some cases, significant 
differences were found between both in-vitro and in-vivo specular microscopy 
endothelial cell densities and SEM  densities, even when taking into account 
tissue shrinkage due to preparation for SEM. In contrast, Williams et al. found 
a strong correlation between the in-vitro contact specular-microscopic ECDs 
and histological cell counts in human donor corneas.916 However, calculating a 
correlation coefficient is not an adequate method for comparing two different 
assessment methods as Bland and Altman demonstrated. In spite of a strong 
correlation there may still be a significant systematic difference.910 Geroski 
and Edelhauser found in 8 human donor corneas no significant difference 
in mean endothelial cell area between (contact) specular microscopic ECD 
measurements and light microscopic cell counts after alizarin red S-staining.353 
Wiffen et al. found no significant differences between specular microscopy pre-
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enucleation (from the epithelial side) and in-vitro specular microscopy (from 
the endothelial side) post-enucleation in enucleated eyes. They used a diversity 
of specular microscopes.917 
 In conclusion, when comparing in-vitro donor endothelial cell densities 
obtained with light microscopic techniques such as used in many eye banks, to 
in-vivo ECDs, especially when obtained with non-contact specular microscopy, 
one should be aware of a possible difference. There is systematic variation 
related to the technique per se and intra-individual variation to consider. 
 References
 See page 287.
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Table 5.1 Correlation coefficients of possible optical factors with the difference between In-vivo and In-vitro ECDs.
  Possible optical factors Pearson Correlation Coefficient p = (2-tailed)
    Pachymetries - 0.067 0.699
    Mean K-values 0.341 0.167
    Time Interval 0.174 0.376
Mean sim-K-values were obtained by averaging the sim-K values obtained with an Alcon EH-290 Eyemap corneal topograph. Time 
Interval means the interval between surgery and the in-vitro ECD assessment.
Figure 5.1 Scatterplot of the in-vivo ECDs obtained by specular microscopy (y-axis) against the in-vitro ECDs 
 obtained by light microscopy (x-axis).
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Figure 5.2 Bland-Altman plot: the difference between In-vivo ECDs and In-vitro ECDs (y-axis) is plotted against the  
 average of In-vivo and In-vitro ECDs. The middle horizontal line represents the mean difference between  
 In-vivo and In-vitro ECDs; the upper and lower horizontal lines represent the respective Limits-of-  
 Agreement (mean difference ± 1.96 * standard deviation).
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Figure 5.3 The data points in graphs 5.3a. and 5.3b. represent a sample from the database of  the Cornea Bank   
 Amsterdam and were used for linear and exponential regression.
 a. Example of the fitted linear and exponential nomograms when assessing the in-vitro ECD using a
  graticule. The exponential nomogram has a better fit, which becomes more apparent in the in the lower 
 and higher ECD regions.
 b. The upper (dashed) straight line represents the observed systematic difference between the in-vivo
 ECD and the linear nomogram. In the lower ECD regions the difference is underestimated, whereas in  
 the higher ECD regions up to 4000 cells/mm2 the difference is overestimated. This implies an inverse   
 relative difference instead of a constant difference.
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Abstract
 Purpose
In non-contact specular microscopy, optical factors cause distortions that affect 
endothelial cell density (ECD) measurements. The purpose of this study was to review 
the existing theoretical formulas for each of these factors, and to calculate the amount 
of error in ECD they introduced, in relation to changes in corneal thickness and 
curvature. 
 Methods
Optical distortions were caused by: oblique (horizontal) angle of observation, and 
observation of a curved area, both causing ECD overestimation; and magnification of 
the endothelial image by the anterior corneal curvature, causing ECD underestimation. 
Formulas were reviewed with which the amount of distortion in average corneas was 
calculated. Consecutively, the effect of different values of central corneal thickness, 
and corneal radius or power was calculated. The angle of observation of the Topcon 
SP2000P specular microscope (22.5°) was used.
 Results
 The more oblique the angle of observation, the more substantial the overestimation 
of ECD, in this study 8.9 %. When this is corrected, as in the SP2000P, in most corneas 
the other optically induced errors are substantially smaller, except in thick and steep 
corneas where the underestimation of ECD due to anterior corneal magnification 
increases, in our examples up to 6.9 %. 
 Discussion
Optical distortion needs to be taken into account in non-contact specular microscopic 
morphometry. Differences in the comparison of ECDs from non-contact specular 
microscopy with data obtained with contact-specular microscopy, confocal microscopy, 
or light microscopy, may in part be explained by differences in optical distortion.
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 Introduction
 
 Non-contact specular microscopy is an often used method for the evaluation 
of the corneal endothelium in patients. Both qualitative (morphologic) 
and quantitative (morphometric) aspects of the endothelium, such as the 
endothelial cell density (ECD) can be evaluated with this technique. Non-
contact specular microscopy carries risk for neither epithelial damage nor 
microbiological contamination. Furthermore, non-contact examinations are 
well tolerated by the patient. Therefore, this method seems particularly suitable 
for follow-up of the corneal endothelium after surgical procedures. 
 The optical principles used in specular microscopy were first described by Vogt, 
who called this technique: “Spaltlampenuntersuchung im Spiegelbezirk” (i.e. 
slitlamp biomicroscopy in the specular plane)3 In summary, specular reflection 
of light occurs from an interface between two materials with a difference in 
refractive index, such as the boundary between the corneal endothelium and 
the aqueous. Details from this interface can be observed at high magnification 
when it is sufficiently regular and when the incident angle of the illuminating 
light equals the angle of observation.3 21 The first “clinical specular microscopes” 
that were developed from a prototype described by Maurice in 19688 were 
contact types,13 14 although from early on also non-contact techniques were 
propagated.12 21
 The optics of specular microscopy impose specific imaging characteristics and 
specific  requirements regarding instrument settings. Both in non-contact and 
contact specular microscopy of the endothelium the incident (illumination) 
and observation angles with the normal onto the anterior cornea must be 
larger than zero, i.e. oblique, to avoid the dominant epithelial reflection in the 
endothelial image. See also figure 6.1. Furthermore, in non-contact specular 
microscopy the image is obtained through air and through a curved anterior 
cornea, from a curved instead of a flat plane. As the anterior cornea has a 
refractive index different from air, it acts as magnifying lens of the endothelium. 
See also figure 6.1. McCarey stated that in non-contact specular microscopy, 
the size of the image that is obtained is restricted.21 Olsen showed that due 
to the dominant epithelial reflection, in non-contact specular microscopy the 
restriction of endothelial image size is governed by the angle of observation 
and the corneal thickness,274 but not by the width of the illumination slit. 
In contrast, in contact specular microscopy the size of an image of the 
endothelium is for a large part determined by the width of the illumination 
slit. A wider slit allows acquisition of larger images with more endothelial 
cells. Unfortunately, wider slits also cause more scattering of light within the 
corneal stroma, and increased scatter in turn causes loss of contrast, rendering 
less useful images. 918 In both non-contact and contact specular microscopy 
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the incident (illumination) and observation angles with the normal may be 
increased, respectively to increase image size or to diminish scatter with wider 
slits. However, oblique angles of observation cause perspectivistic distortion, 
and the larger the angles are, the greater the distortion becomes. This is 
described in more detail below. Therefore, in any case a trade-off between 
image size, image contrast, and image distortion has to be found.918 
 
 In the current (semi-)automated autofocus contact and non-contact specular 
microscopes, fixed settings for the incident-and observation angles287 and slit 
width are usually applied. The Topcon SP2000P (Topcon Corp, Tokyo, Japan) 
is such an often-used non-contact specular microscope. It has been shown 
to provide valid and reproducible ECDs when used with semi-automated 
endothelial analysis.911, (Van Dooren et al, submitted for publication) In the SP2000P, the slit 
width is around 0.2 mm - the exact value is fixed but differs in each individual 
instrument - and the incident and observation angles are 22.5°.919 It is important 
to realise that in modern instruments such as the SP2000P, the requirements 
and restrictions of non-contact specular microscopy  cause distortion 
of endothelial images as well. In turn, distortion introduces errors in the 
measurement of the ECD. Three factors can be discerned.
 First, as mentioned before, the endothelium is observed from an oblique 
angle that cannot be negligibly small.274 287 See figure 6.1a. Due to this oblique 
observation angle, an image of an endothelial area is perspectivistically 
distorted: the image actually depicts a larger area of the endothelium than it 
is assumed to do. Thus, perspectivistic distortion leads to an underestimation 
of the observed endothelial area. This in turn leads to overestimation of the 
measured ECD. 
 Second, the area that is imaged, the endothelium, is a curved rather than a flat 
plane. See figure 6.1b. A curved length is longer than the straight (dissective) 
length which is supposed to represent it. This fact also leads to underestimation 
of the observed area, and hence to overestimation of the ECD. Bron and Brown 
already mentioned this phenomenon but did not elaborate.12 Olsen described 
it in more detail, with special attention to its relation to distortion caused by 
the oblique angle of observation.274 The formulas deduced by Olsen for the 
combined distortions by oblique observation angle of a curved area will be 
reviewed in the “Methods” section. 
 Third, the observed endothelial area is magnified by the anterior corneal 
curvature. See figure 6.1c. Magnification of an image leads to overestimation of 
the observed area, which in turn causes underestimation of the ECD. Stefansson 
et al. reported in a normal eye a 2.5 % increase in the lateral image scale caused 
by this effect, but provided no calculations to substantiate this figure.225 Bourne 
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and Enoch deduced formulas for the magnification effect in contact specular 
microscopy. Isager et al. and Nawa et al. published on altered magnification of 
the endothelium in non-contact specular microscopy after corneal refractive 
surgery.913 914 Their fomulas will be reviewed in the “Methods” section.
 In clinical practice often eyes are imaged in which the corneal curvature and 
thickness are substantially different from average, such as in keratoconus or after 
corneal transplantation. The formulas presented by Bourne and Enoch, Isager et 
al., Nawa et al., and Olsen, indicated that corneal curvature and corneal thickness 
affect all the effects of optical distortion mentioned above.273 274 913 914 Hence, 
additional under- or overestimation of ECD may occur when non-contact specular 
microscopy is applied to corneas with non-average thickness and curvature.
 The aim of the present study was to review the three errors that are caused by 
optical distortion in non-contact specular microscopic ECD measurements in 
general, and in Topcon SP2000P non-contact specular microscopy in particular. 
Furthermore, we wanted to investigate the effect of different values of corneal 
thickness and curvature on these errors. For this purpose we calculated the 
magnitude of the error that was introduced by each of the effects, for several 
different values of corneal thickness and curvature. We used the appropriate 
formulas, and took the SP2000P settings for observation angle and slit width as 
a starting point. The combined effect of these errors was also evaluated.
 Furthermore, we compared whether these optical factors are applicable in 
other currently available imaging techniques of the endothelium. These include 
in-vivo techniques such as contact specular microscopy and in-vivo confocal 
microscopy. But also an in-vitro technique using light microscopy for evaluation 
of the endothelium of donor corneas from the endothelial side, which is 
performed in many eye banks,812 is discussed.
 Methods
1.  Oblique horizontal angle of observation.
 As stated before, an oblique angle of observation is necessary in specular 
microscopy, to avoid the dominant epithelial reflex.274 287 918 This applies only to 
the horizontal dimension. In the vertical dimension the eye is aligned with the 
specular microscope, and so there is no vertical angle of observation dictated 
by the technique.274 
 See figure 6.1.a. The magnitude of the error introduced by an oblique angle of 
observation is: 
  
  Lassumed = cos β * Lmax 
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 with β as the (horizontal) incident angle to the orthogonal on the cornea, 
Lmax  is the truly observed (maximal) horizontal area length, and Lassumed  is the 
resulting, underestimated horizontal length. In the settings of the Topcon 
SP2000P, the incident angle onto the anterior cornea is 22.5˚.919 Lassumed would 
therefore represent an underestimation of Lmax and also of the observed area, 
of cos(22.5˚ ) = 0.924. Hence an overestimation of the ECD of 8.2 % would be 
present. 
 
 It should be noted, that we used the angle β  which is the angle with the 
normal on to the anterior corneal curvature for the incident and observation 
angles. In his paper, Olsen used as incident and observation angles the angle 
on to the endothelium after anterior corneal deflection.274. In figure 6.1.a. this 
latter angle is the angle α. However, Olsen appears to have made a mistake 
here, since the perspectivistic distortion of an image is not altered by deflection 
of the light. In the discussion section this issue is elaborated upon in more 
detail. 
 
2.  Observation of a curved area.
 As discussed earlier, the area of the endothelium that can maximally be 
observed in non-contact specular microscopy, is restricted. See figure 6.1b. 
Olsen deduced formulas for this phenomenon and for the additional distortion 
by observation of a curved area in its relation to the distortion caused by the 
oblique angle of observation, in the horizontal dimension:274 
 
 1.  Lmax = 2 * CT * tan α ,
 in which Lmax  is the maximally observed curve length of the endothelial 
reflection, CT = corneal thickness, and tan α is the tangent of the incident 
angle to the normal after anterior deflection of the incident light by the 
anterior cornea. See figure 6.1. Please note that for this calculation the angle after 
deflection α must be used! 
 If α = 16.1˚, and CT = 0.500mm (assumed average corneal thickness), then: 
 Lmax = 0.289 mm.
 The maximal curve length Lmax can also be expressed as an angle of arc φ (in 
radians), using the corneal radius r: 
 
 2.  φ = Lmax / r .
 
 If CT =  0.500 mm, and r = 8.00 mm (assumed average corneal radius), then φ  = 
0.0361 rad.
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 The relation between the observed curve length Lobserved and φ was derived by 
Olsen to be:
 
 3.   Lobserved = cos(½ φ + β) * { (r
2) * ( sin2 φ + (1 - cos φ)2 ) }½  .
 
 Substituting φ  = 0.0361 rad and r = 8.0 mm results in:
 Lobserved = cos(0.0180 rad + β) * 0.289, which can be replaced by: 
 Lobserved = cos(0.0180 rad + β) * Lmax  . 
 Substituting β = 22.5˚ = 0.393 rad results in: 
 Lobserved = cos(0.411 rad) * Lmax = 0.917 * Lmax
 Please note that in formula 3. the undeflected angle β must be used!
  Thus, observing a curved plane causes an additional underestimation of  0.7 
% of  observed area, resulting in a 0.84 % additional overestimation of ECD 
compared to the error introduced by only the oblique observation angle. This 
therefore is only a relatively small additional error. 
 The source of error caused by the curvature in the vertical dimension was 
calculated by Olsen as well.274 This error would be greatest at the uppermost 
and lowermost border of the image, because at these vertical image borders 
a slight   vertical observation angle is present - at the horizontal plane the 
observation angle = 0. In slits of 1 mm high, the underestimation of the 
observed area at the upper- and lowermost borders (0.5 mm from the 
horizontal plane) would be according to the formula in part 1 and formula 2 in 
part 2 of this Methods section: 
  Lassumed = cos(0.5/8 rad) * Lmax = 0.998 * the vertical dimension. 
 Thus, an 0.2 % overestimation of ECD at the vertical borders of the image would 
result if the vertical slit length was 1mm. The SP2000P uses a slit illumination 
with a vertical dimension significantly shorter than 1 mm.919 The distortion in 
the vertical dimension is therefore negligible.
c.  Magnification by the anterior corneal curvature.
 The following formulas were adapted from general optical formulas presented 
by Katz and Kruger in the handbook Duane’s Clinical Ophthalmology, 920 
and formulas by Bourne and Enoch,273 who calculated this effect for contact 
specular microscopes. Especially valuable were the formulas by Isager et al.913 
and Nawa et al914, who calculated changes in magnification after changes in 
corneal thickness and power/curvature had been induced by excimer corneal 
ablation. See figure 6.3.
 If  CT = corneal thickness (mm), r = anterior corneal radius (mm), and P = 
anterior corneal refractive power (D), ncornea  = the refractive index of the 
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cornea, assumed 1.376, and nair  =  the refractive index of air = 1.0, the following 
formulas apply for magnification:
 
 4.  M = magnification = U / V  
 
 5.  U = reduced object vergence power 
   = (ncornea /object distance at the anterior corneal surface) = ncornea / CT, 
  with because of divergence, the object distance (CT) defined as   
 negative;
 
 6.  V = reduced image vergence power, and the relation between U, V, and P is: 
   U + P =V;
 
 7.   P  = (ncornea  - nair)/ r ;
  Then: 
  M = (ncornea / CT) / {(ncornea / CT) + P}
   = (ncornea / CT) / {(ncornea / CT) + (ncornea  - nair) / r} or  = 1 / {1 + (P * CT )/ ncornea }
   = (1.376/ CT) / {(1.376 / CT) + (0.376 / r)}      or  = 1 / {1 + (P * CT )/1.376}
 Remember to fill in a negative value for CT when calculating the magnification, 
and to enter CT in meters instead of millimetres when calculating with P in 
dioptres.
 
 8.  This applies for one dimension; M2 = U2 / V2  etc. for 2 dimensions. 
 
 9.  The normalized magnification (NM) is the magnification M2 in a 
situation with a specific corneal thickness and radius c.q. power, divided by 
the magnification for the assumed average values (M2avg). In our case these 
assumed average values are CT =  0.500 mm, and respectively r = 8.0 or P = 43.0 
D. In the settings of the Topcon SP2000P these also are the standard settings.913 
An increased (i.e. higher than 1.0) normalized magnification means that the 
observed endothelial area is additionally enlarged due to altered circumstances, 
whereas a normalized magnification lower than 1.0 implies less than normal 
magnification. 
 Results
 
1 & 2.  Olsen’s formulas for observation of a curved area under an oblique angle.
 In Table 6.1, the effects of optical distortion on the observed horizontal curve 
length in relation to the maximal curve length are presented for different 
values for corneal radius and thickness. For the calculations, Olsen’s formulas for 
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oblique angle of observation and observation of curved areas were used, with 
a value of 22.5˚ for the observation angle, and assuming 0.500 mm as average 
corneal thickness, and 8.00 mm as average corneal radius.
 From section 1 and 2 of Methods & formulas it was clear that the effect of an 
oblique angle of observation amounted to an overestimation error of ECD of 
8.2 %, to which an error of 0.84 % was added due to observation of  a curved 
area. From the calculations in Table 6.1 it follows that the effect of different 
values of corneal thickness and radius on these first two errors was relatively 
small. The largest effects were found in thick, steep corneae (e.g. r = 7.00 mm, 
CT = 0.600 mm), which caused in our example an extra overestimation of ECD 
of  0.3 %, or in thin, flat corneae (e.g. r = 9.00 mm, CT = 0.400 mm) in which the 
overestimation in ECD in an averagely curved cornea was diminished with 0.2 
%. In clinically more common thin, steep corneae (such as in keratoconus, e.g. 
r = 7.00 mm and CT = 0.400 mm) the overestimation of ECD was not different 
than in the average cornea. For other combinations of radius and thickness, 
please see Table 6.1.
3.  Anterior corneal magnification.
 In Table 6.2, calculation examples for magnification (M2) and normalized 
magnification (NM) are given for several values of CT, r, and P. Some of these 
examples can also be found in the study by Isager et al. in their table 1.913. From 
Table 6.2 it appears that for the range of values provided for CT, r, and P (CT 
from 0.350 mm to 0.650 mm, r from 6.00 to 10.0 mm, P from 38 to 60 D), the 
image magnification ranges from 1.9 to 6.2 %. This causes an underestimation 
of ECD of 1.9 to 5,8 %. Thinner flatter corneas have the least magnification 
whereas thick steep corneas have the highest magnification. Thin steep 
corneas, such as often encountered in keratoconus patients, appear to have 
magnifications that are actually very close to those of normal corneas. (I.e. 
tenths of a percent point lower). 
 
 It should be noted that the assumed averages for corneal thickness (0.500 
mm), radius (8.00 mm) and corneal Power (43.0 D) were chosen for convenient 
calculation in these examples, and do not represent the actual population 
average. This also explains why in our examples the assumed average corneal 
radius does not entirely correspond with the assumed average corneal power, 
although it physically should (P = (ncornea  - nair)/ r). 
4.  Combined effects of optical distortions.
 In the preceding sections it was shown that the contribution of the oblique 
angle of observation to this overestimation of ECD is much more important in 
this overestimation than the effect of observing a curved area. In the SP2000P, 
for average values of CT and r these are 8.2 and 1.2 %, respectively. The third 
factor, the magnification of the image by the anterior  corneal curvature leads 
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to an overestimation of the observed area and hence to an underestimation of 
the ECD. For average values of  CT and r (P) this underestimation of ECD is 3.4 
(3.1) %. 
 All these factors considered together result in an overestimation of ECD of 
1.094 * 0.966 = 1.060, i.e. 6 %. However, the error introduced by the oblique 
angle of observation is supposedly corrected in the SP2000P, by a combination 
of adjustments in the camera optics and software. (P. Gelissen, Topcon 
Europe, personal communication). Hence, in an average cornea a remaining 
underestimation of ECD of 2.2 % would result from the effects of observing a 
curved area and the anterior corneal magnification (1.2 % overestimation vs. 3.4 
% underestimation; 1.012 * 0.966 = 0.978).
  
 
 Discussion
 
 In non-contact specular microscopy, three optical factors cause distortion 
and hence an error in ECD measurement. These are: an oblique angle of 
observation, observing a curved area, and magnification of the image by 
the anterior corneal curvature. Of the first two factors, the error caused by 
a horizontal oblique angle of observation is by far the more substantial. In 
the SP2000P this error is corrected (P. Gelissen, Topcon Europe, personal 
communication, 2004). In average corneas, the remaining two factors cause a 
slight underestimation of ECDs measured with the SP2000P, of 2 to 2.5 %.
 Corneal factors such as corneal thickness and radius or power influenced 
these optically induced errors. Even with substantial alterations in these 
corneal characteristics, the overestimation of the ECD by observing a curved 
area from an oblique angle did hardly change (0.3 % or less). In contrast, the 
underestimation of the ECD by the anterior corneal curvature magnification 
ranged from 1.9 to 5.8 % with different values for corneal thickness and radius 
or power. The largest variation was caused by a substantially increased corneal 
thickness. Obviously, an altered corneal refractive index would also have an 
impact on the described optical factors. Both an altered refractive index and 
a severe thickening of the cornea may be present in corneal edema or other 
diseased states. However, in these circumstances it would be difficult, if not 
impossible, to obtain any specular microscopic images at all. 
 An essential point needs to be made regarding the literature on the effect of an 
oblique angle of observation in specular microscopy. Olsen used in his study 
not the incident angle onto the anterior cornea, but the angle that results 
after anterior corneal deflection (i.e. not 22.5˚, but 16.1˚). However, Olsen made 
a  mistake here, since basic physics indicates that perspectivistic distortion 
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of an image is not altered by deflection of the incident and reflected light. A 
simple physical experiment in which a ruler attached to an glass surface is 
photographed under an oblique angle may demonstrate this. In the study 
by Ohno et al., also the incident angle onto the anterior corneal surface and 
not the angle after anterior corneal deflection is used.287 Even Olsen’s own 
experimental data indicate that he should have used the incident angle onto 
the anterior corneal surface (in his case 23°) instead of the angle after anterior 
corneal deflection (16.5°) in his calculations.274 
 
 Modern contact specular microscopes usually have smaller observation angles 
than non-contact specular microscopes.287 Hence, in most contact specular 
microscopes, distortion by an oblique observation angle will be much less 
than in most non-contact instruments. So called “wide-field” contact specular 
microscopes use additional methods for image acquisition, and are left out of 
consideration.25-27 In confocal microscopy a substantial angle of observation is 
not required, as the common focal point principle eliminates strong reflections 
from surrounding tissue. Furthermore, several images are sampled in three 
dimensions.303 Hence, it may be assumed that there is not a significant effect 
of an oblique angle of observation. The distortion of an oblique angle of 
observation can also be neglected in eye banking endothelial light microscopy, 
where areas of the endothelium are observed from the endothelial side, under 
(close to) orthogonal angles.  
 
 The additional error in the overestimation of ECD introduced by observing a 
curved area instead of a flat area, was relatively small in non-contact specular 
microscopy. In contact specular microscopy, most instruments use a “dipping” 
applanation cone and a coupling medium to minimize corneal curvature 
deformation.14 15 918 Yet some applanation of the cornea may still occur, which will 
diminish the curvature of the observed endothelial area. This in turn diminishes 
the difference between the truly observed and the assumedly observed area, 
causing less underestimation of the observed area, and hence less overestimation 
of the ECD. Similarly, in confocal microscopy applanatory effects may also occur. 
The sampling technique with which images in different dimensions are obtained 
will further diminish curvatural distortion.303 In light microscopy curvatural 
distortion may be diminished by gravity. Excised donor corneoscleral buttons lying 
on their epithelial side in a petri-dish will become somewhat flattened. This again 
may diminish the overestimation of ECD. However, simultaneously the ECD may 
be increased by the flattening as the same amount of cells now have a smaller 
area on which they rest. Both effects may neutralize each other.                                  
                                            
 In contact specular microscopy and confocal microscopy, lack of a cornea-air 
interface due to a coupling medium, together with some applanation of the 
cornea, will diminish the effect of anterior corneal magnification.273 303 When 
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observing the endothelium from the endothelial side, as in light microscopy, 
this factor is not relevant.
 In conclusion, in the present study we have reviewed the optical distortions 
that may affect ECD counts in non-contact specular microscopy. An oblique 
(horizontal) angle of observation, and the observation of a curved area both 
cause ECD overestimation. Magnification of the endothelial image by the 
anterior corneal curvature causes ECD underestimation. Corneal thickness, and 
corneal radius or power affect the amount of distortion. The more oblique the 
angle of observation, the more substantial the overestimation of ECD. When 
this is corrected as in the SP2000P, in most corneas the other optically induced 
errors are rather small, and a slight underestimation of ECD remains. However, 
in thicker, steeper corneas, ECD underestimation due to anterior corneal 
magnification becomes more important. Differences that are found in the 
comparison of ECDs from non-contact specular microscopy to data obtained 
with contact-specular microscopy, confocal microscopy, or light-microscopy, 
may in part be explained by differences in optical distortion.
 References
 See page 287.
Figure 6.1 Diagrammatic representation of the optic distortions in non-contact specular microscopy. 
 See colour figure on page 328.
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I.  Introduction to vital stains in ophthalmology.
 
 Early in the twentieth century the principle of vital staining was introduced 
in medicine. In this diagnostic technique, dyes are injected into the body 
of living animals or humans, or applied onto living cells. Non-vital staining 
techniques are more often applied and better known, e.g. histologic staining. 
In this technique dyes are mostly applied onto dead tissue, and furthermore, 
fixation (and sectioning) of the tissue is usually necessary before the staining 
itself is done, killing any cell that may still have been alive. Whether the dyes 
themselves in non-vital staining are or are not toxic is not really important, as 
the investigated tissues do not need to survive. In contrast, vital stains must 
not be lethal to the living cells, nor damage the organs, nor be harmful to the 
organisms, to respectively in which they are applied. Therefore, possible toxicity 
of vital stains is of great concern.921-925 
 The best known diagnostic vital stain used in ophthalmology is fluorescein, a 
yellow macromolecular hydroxyxanthene dye (C20H10O5Na2,
926). It has seen a 
long and very frequent use and has a good safety record. Topical application of 
fluorescein aids in the detection of corneal epithelial lesions (“positive staining”). 
Coloration of the tear film aids in applanation tonometry, in evaluating tear 
film stability and lacrimal drainage, in contact lens fitting, and in testing of 
leakage of aqueous from corneal wounds (Seidel test). A so-called negative 
staining pattern refers to the highlighting of non-staining elevated lesions as 
they project through the stained tear film.927-930 Systemic (intravenous or oral) 
application allows its use as a contrast dye in retinal angiography. Fluorescein 
can also be applied in a test of the endothelial barrier, as discussed in paragraph 
VIII c. Here, fluorescein concentration is quantitated with fluorophotometry.1 
40 84 85 364 377 379 381-384 Using the dye’s fluorescence property enhances all of these 
tests, and in the case of fluorescein angiography fluorescence it is essential. 
To cause fluorescence, fluorescein molecules are excitated with light from 
the blue wavelength part of the spectrum. In biomicroscopy for instance a 
cobalt blue filter is applied. In fluorescein’s use as a tool to detect epithelial 
defects it stains areas where epithelial cells are completely absent or where 
their intercellular junctions are disrupted. It may stain living cells but less 
effectively than its alternatives, lissamine green and rose bengal. Rose bengal 
also is a halide derivate of the hydroxyxanthene dye family, akin to fluorescein.  
It stains devitalized corneal and conjunctival cells or cells that have lost their 
mucin surface, but is blocked by a healthy tear film. It is intrinsically toxic to the 
epithelium.927-930  
 Concern about toxicity of vital stains became more urgent when some of them 
were beginning to be used not only diagnostically but also during ophthalmic 
surgery. Currently, the most often used surgical applications of vital stains are 
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lens capsule staining in cataract surgery and membrane staining in vitreoretinal 
surgery. See figure 7.1. The most often used vital stains for both purposes are 
trypan blue (TB) and indocyanine green (ICG). The surgical use of both dyes 
implied a substantial increase in the scope their application. Furthermore, 
the staining was applied in the vicinity of very delicate living cells with critical 
functions, and without regenerative capacity: the corneal endothelium, the 
retinal photoreceptors and nerve cells, and the retinal pigment epithelium. 
Hence it is understandable that a lot of research on the toxicity of TB and ICG 
was stimulated by the fear for possibly widespread iatrogenic damage. 
 In the following paragraphs, a systematic review is presented of the literature 
on trypan blue and its counterpart indocyanine green, describing their history, 
characteristics, and toxicity; regarding both surgical and other applications. 
Other vital stains are touched upon only briefly, in the context of their use as 
an alternative adjunct for a specific surgical application. This review serves as a 
background to the studies described in Chapters 8 and 9. These studies present 
data on toxicity and safety regarding the corneal endothelium, concerning the 
use of trypan blue lens capsule staining in cataract surgery.
Fig. 7.1 Trypan blue capsule staining to aid visualisation of the anterior lens capsule in mature cataract 
  phacoemulsification.
  See colour figure on page 329. 
II.  History, characteristics, and applications of trypan 
blue and indocyanine green.
a.  Trypan Blue (TB). 
 In 1914, Evans and Schulemann reviewed a category of vital stains that did 
not undergo chemical transformation (e.g., oxidation or reduction) inside the 
human body. An important characteristic of these stains was that they were not 
perceptibly toxic when injected into the bloodstream of living animals. These 
dyes were stored inside living cells, especially leukocytes (reticuloendothelial cells) 
by means of phagocytosis. Stain granules within cells could easily be detected 
with light microscopy. All dyes in this group contained benzidine-groups, and one 
of the foremost categories on which Evans and Schulemann reported was that of 
the di-azo dyes. Di-azo refers to the two N = N bonds between the three double 
hexagons (i.e. benzidine rings) that constitute the chemical backbone of the dyes 
in this group. The capacity of being a good vital stain was thought to depend on 
the presence, number, and/or position of sulphonic acid (radicle) groups, NaSO3, 
attached to the benzidine rings. Monosulphonic benzidine rings appeared to have 
lesser vital staining capacity than disulphonic benzidine rings.921 Trypan blue was 
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one of the di-azo dyes and has the formula (C34H24N6O14S4Na4,
926), with 4 sulphonic 
acid groups. 921 See figure 7.2.
 
 Besides being phagocytized, diffusion of TB into dead or severely damaged 
cells is another way in which it stained cells. This type of staining is more 
uniform and diffuse than the granular staining after phagocytosis. 921 922 924 
In Pappenheimer’s study of 1917, experimentally damaged lymphocytes in 
animal thymus tissue were stained in this way.922 Strictly speaking, this latter 
mechanism of TB staining should be not be called vital staining but supra-vital 
staining, as the dye does not stain living cells but dead or irreversibly damaged 
cells. For this type of staining substantial cell (or nuclear) membrane damage 
appears to be a prerequisite, and the nucleus more than the cytoplasm of the 
damaged cell is stained.931 
 Later a third way of staining with TB was discovered, when it was noted that TB 
stained basement membranes such as Descemet’s membrane that had been 
denuded from their (endothelial) cells. (E. Pels, personal communication, 1998).
 The first ophthalmic use of TB was described by Stocker et al., who, using the 
supra-vital staining principle, applied TB (0.25 %) to assess endothelial cell 
damage in donor corneas.326-328 The technique of TB (supra-) vital staining of 
donor corneal endothelia has since then stayed in use in eye banks using the 
organ culture preservation method. Currently, usually TB in a concentration of 
0.1 to 0.3 % is applied.812 See Chapter 2 of this thesis, paragraph VIII c., for an 
extensive description of the development and the technique of TB staining of 
donor corneas; and paragraph XVI e. for an extensive discussion of the organ 
culture preservation method for donor corneas.
 In 1967 Norn instilled TB in the conjunctival sac of patients to specifically 
stain pathological cornea processes. He judged a mixture of rose bengal and 
fluorescein to be more useful than TB.931 In 1979, Norn described “postmortal 
vital staining” of the cornea and conjunctiva, in order to determine the nature 
of the processes that give dead eyes the “glazed” look.932 As early as 1971, he 
reported on intra-operative endothelial staining of the endothelium with 
TB. He instilled TB 0.1 %- 0.25 % into the anterior chamber of 80 eyes during 
intra-capsular cataract extraction (ICCE). In this series he observed stained 
lines where the cornea had been bended, larger stained areas in cases of 
corneo-vitreous touch, and irregularly stained figures after alpha-chymotrypsin 
injection. He observed no postoperative complications related to the use of 
TB. In this paper he reported the observation that the lens capsule was also 
stained by TB.933 In a follow-up study, he reported on 47 patients 6-12 months 
after ICCE with intraoperative TB instillation in the anterior chamber. They were 
compared to randomized control patients that had undergone ICCE without TB 
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staining. No significant differences in pachymetry or clinical outcomes such as 
visual acuity were found.934 A second follow-up study, 8 years post-operatively, 
reported on 24 remaining patients from his cohort. In 15 patients from this 
group, the eye in which TB had been applied was compared with the operated 
but non-stained contralateral eye. No differences between stained and non-
stained eyes were observed regarding endothelial cell density, pachymetry or 
clinical outcomes.935 In both follow-up studies Norn concluded that the intra-
operative use of TB was not (additionally) harmful for the corneal endothelium.
 Completely different effects of TB have also since long been known. Among 
the earliest reports on the use of trypan blue was that it was the first agent 
used to treat bovine babesia, an intraerythrocytic parasite similar to malaria, in 
1909.936 Since 1948 it has been known that it can be used to create congenital 
malformations in animal models. Several animal species have been used for 
this purpose, including rabbits, chickens, rats and mice. Usually, TB was injected 
intraperitoneally in pregnant animals, in a species-specific teratogenic “window” 
early in gestation, in a species-specific teratogenic dose. (See also paragraph 
IV of this chapter). Especially closure defects of the neural tube, foremost spina 
bifida, have been encountered. There has been some discussion whether the 
abnormalities resulted from arrested embryological development, or from 
degeneration and necrosis from already formed “anlagen”.937 938 Schmidt et 
al. have demonstrated in a rat model that the development of virtually all 
important structures of the embryological eye can also be halted, directly or 
indirectly, by intraperitoneal TB injections in the mother animal.939 940.
 Besides teratogenic properties, TB also may have some carcinogenic capacities 
in animal experiments. In specific inbred strains of rats, reticuloendothelial 
tumours have been induced in the liver after regimens of repeated 
subcutaneous injections of small doses of a 1% TB solution. (For exact doses 
and regimens, see paragraph IV of this chapter). The tumours probably stem 
from macrophages (in the liver: Kupfer cells), which are indeed the cells 
expected to actively phagocytose TB.941
b.  Indocyanine Green (ICG).
 Indocyanine green is a tricarbonate green dye (C43H47N 2 NaO6 S2, 
926) with a 
molecular weight of 775 D. See figure 7.3. After intravenous injection, this dye is 
for more than 95 % bound to plasma albumin and it is completely excreted via 
the hepatic pathway. Since 1956 it has been used intravenously to determine 
cardiac output, hepatic function, and in liver blood flow studies.923 925 In 1970 
this dye was introduced in ophthalmology. It enabled choroidal angiography 
after intravenous injection. ICG angiography appears to be especially 
useful for evaluating retinal pigment epithelial detachments and choroidal 
neovascularisations.942-944 These applications have seen a long and apparently 
safe use since.945
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 Similarly to trypan blue ICG has also been applied as a supra-vital stain in the 
evaluation of donor corneas, and also similarly did not appear to be harmful 
to living corneal cells. However, in contrast to trypan blue ICG has not seen 
widespread use in eye banks after the first publication.946 To our knowledge, ICG 
was not used in intra-ocular surgery before 1998.947
Fig. 7.2 Structure formula of trypan blue. Note the two N = N (azo-)bonds, each
  connecting two double hexagonal rings. (Trypan blue is a di-azo dye).
Fig. 7.3 Structure formula of indocyanine green.
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III.  Intra-operative applications of TB and ICG: cataract 
surgery, vitreoretinal surgery, and  keratoplasty. 
a.  Lens capsule staining in cataract surgery.
 An important objective of the extracapsular types of cataract surgery, which 
include the phacoemulsification techniques, is to preserve the lens capsule. 
The preservation of the capsule serves to ensure the stability of the eye, 
and to facilitate effective cataract extraction and placement of an IOL in 
its natural and logical position. An essential step was the development of 
a technique for providing an opening in the anterior lens capsule which 
simultaneously preserved the integrity of the remainder of the capsule. 
For this purpose, from the early 1980s onwards, the continuous circular 
(a.k.a. curvilinear) capsulorhexis or CCC was developed concurrently and 
independently by Gimbel in North America, Neuhann in Europe, and Shimizu 
in Japan.948 However, in case of low contrast, e.g. in the absence of a red 
fundus reflex, performing an uncomplicated CCC may suffer from poor 
visualisation. This is often the case in eyes with a white, mature, hypermature, or 
intumescent cataract, and/or a heavily pigmented fundus, e.g. after panretinal 
lasercoagulation. 
 To overcome this problem, Gimbel proposed a two-stage CCC, in which first 
a small-diameter CCC is performed to allow for phacoemulsification, followed 
by a second, larger diameter CCC to facilitate IOL implantation.949 950 Variations 
on this technique are currently still in use. Drawbacks are a longer procedure, 
incomplete CCC with or without anterior capsule tears or even posterior 
capsule tears (up to 28 % of cases), and the technically more demanding 
performance of phacoemulsification of a hard nucleus through a small 
capsulorhexis. Because of these drawbacks, sometimes conversion to ECCE with 
manual nuclear expression is necessary.951 952 Instrumental approaches to the 
problem of poor visualisation of the capsulorhexis included anterior capsule 
diathermy using a straight, high-frequency bipolar diathermy probe,953-955 and 
side illumination using a fiberoptic endoilluminator.956 
 Staining the anterior capsule was a third approach. Initially intracapsular 
injection of a Na-fluorescein solution, possibly combined with blue light,957 958 
and hemocoloration of the capsule with autologous blood were reported.959 
From 1998 onwards, the use of several other staining methods and dyes were 
reported. 
 Gentian violet (a.k.a. crystal violet; C25H30CIN3,
926) was among the first dyes to 
be investigated. Gentian violet in concentrations as low as 0.001 % (alone 
or in combination with methylene blue 1 %),  provided adequate staining 
of the capsule. However it also resulted in temporary corneal edema, and 
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also in anterior chamber reaction.960 961 Increased pachymetry, from 543.6 
μm preoperatively to 578.1 μm 1 month postoperatively, which was not 
statistically significant, was measured after its use.962 In rabbit experiments, all 
crystal violet concentrations were useful for staining purposes, but there was a 
concentration dependent toxicity. Concentrations of 0.25 % and lower did not 
result in (persistent) gross abnormalities on light or electron microscopy, and 
0.05 % did not seem to  result in any abnormalities.963
 Horiguchi et al. reported on successful capsular staining with one or two drops 
of indocyanine green (ICG) in a concentration of 0.5 %. Furthermore, no toxic 
effects of ICG were seen with biomicroscopic, applanation tonometric, specular 
microscopic, and laser flare-cell photometric investigation in this study of 10 
cases.947 More reports on the successful use of ICG for capsule staining in several 
clinical and experimental settings followed. The dye, which is usually dissolved 
from the dry form into a 0.5 % solution in the operating room, is currently a 
popular choice for anterior capsule staining. 964-971 Studies on possible ocular 
toxicity of ICG are described more extensively in section IV of this chapter.
 In 1999, Melles introduced the use of trypan blue 0.1 %, applied onto the 
anterior lens capsule under an air bubble. His results showed good capsule 
staining ability and no apparent toxic effects, in a series of 30 patients with 
mature cataracts. In this study Melles reported that he had studied staining 
properties in eye-bank globes of a great number of other dyes. However, 
except for TB the dyes either did not have good staining ability, or were 
suspected to be toxic, or had never been applied for intra-ocular use before.32 
TB, both generically made solutions and commercially available preparations 
(Vision Blue®, 0.1 % and 0.06 %, DORC, Zuidland, The Netherlands), is more 
economic in use than for instance ICG. This, added to its effective staining 
capacity and apparent safety, is probably what helped TB capsule staining to 
gain wide-spread popularity. TB has now become an often used tool in Europe, 
and Vision Blue® has recently been approved by the FDA for use in the United 
States as well. Especially in countries where white cataracts are still much more 
common, such as India and Turkey, it is used often. It were Indian and Turkish 
authors who were able to constitute reasonably large clinical series. These 
confirmed the effectivity and clinical safety of the use of TB.962 972 973 Multiple 
minor modifications in the technique of application of the dye were reported. 
Modifications ranged from the shape of the cannula and the use of  side to 
side movements during injection, to applying TB under a viscoelastic material 
instead of under an air bubble, to even mixing the dye with the viscoelastic Na-
hyaluronate. Apparently all of these provided satisfactory capsule staining. 973-976 
The effective concentration of TB for capsule staining under viscoelastics may 
be as low as 0.0125 %. 975 There are indications that TB does not only facilitate 
CCC by improved visualisation, but also by increasing the capsule stiffness due 
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to light-induced collagen cross-linking.977 TB capsule staining may furthermore 
be useful for improved visualisation of the lens capsule during cataract 
extraction in patients with corneal opacities.978 It has further been shown to be 
useful when applied to find the lost leading edge of a capsulorhexis that had 
already been started before staining.979 Trypan blue has also been shown to 
be a useful aid to visualise inadvertently prolapsing vitreous into the anterior 
chamber.980 Both ICG and TB were found to be useful for trainee surgeons 
in the performance of critical or additional steps in the phacoemulsification 
procedure, in experimental as well as clinical settings. 962 964 966-968 
 In comparative experimental and clinical studies, both 0.5 % ICG and 0.1 % 
TB solutions were found to provide effective capsule staining, as did gentian 
violet 0.001 %. In contrast, autologous blood and subcapsular fluorescein 
2 % were less effective stains, although digitally analysed colour saturation 
was comparable for fluorescein- and TB-stained capsular material. Moreover, 
subcapsular fluorescein was in some cases been found to inadvertently stain 
lenticular substance, or to leak into the vitreous. Both may decrease intra-
operative CCC visualisation.962 964 966-968 981 982 After long exposure (180 minutes) 
under experimental conditions, both TB 0.1% and fluorescein 2 % stained 
PMMA and especially hydrophilic acrylic IOLs.982
b.  ICG and TB in vitreoretinal surgical membrane staining.
1.	 	 Indocyanine	Green	for	internal	limiting	membrane	staining.
  An important goal in current vitreoretinal surgery for vitreomacular traction 
syndromes including macular holes, and for diabetic macular edema, is 
the removal of the internal limiting membrane (ILM) of the macular retina. 
Complete macular ILM removal has been shown to result in an improved 
macular hole closure rate and to support resolution of macular edema.983-988 
The ILM however is a poorly visible membrane, which makes complete removal 
difficult to perform and increases the risk on incomplete or inappropriate 
removal, leading to retinal damage, retinal edema, or pigment epithelium 
alterations.985-987 Favourable reports on the intra-operative application of vital 
stains in cataract surgery (as discussed in the last section) encouraged intra-
operative vital staining in macular surgery. From 2000 onwards experimental 
and clinical studies reported on effective and selective staining of the internal 
limiting membrane by ICG, resulting in anatomically and functionally successful 
macular hole surgery. Solvents to dilute the ICG solution included BSS  and 
viscoelastic material. Usually applied concentrations of ICG ranged from 
0.025 % to 0.5 %.989-994 The first reported adverse finding after ICG-assisted ILM 
peeling was the case of a patient who showed persisting fluorescence at 795 
nm, six weeks after macular hole surgery, however with good anatomical and 
functional improvement.995 Soon thereafter more clinical and experimental 
studies reported a link between other troubling phenomena and ICG-assisted 
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peeling. These phenomena included the (unintended) finding of adjacent 
retinal structures on the peeled ILM; decreased mitochondrial activity in 
cultured retinal pigment epithelial (RPE) cells; ERG-changes in rats with and 
without morphological damage; clinically observed RPE changes in patients 
in concurrence with an unexpected high rate of poor visual acuity outcomes 
after macular hole surgery; and postoperative peripheral visual field defects in 
patients. After these reports appeared, the use of ICG in macular hole surgery 
has been controversial.996-1001 The mechanisms of possible ICG-related toxicity 
are discussed in paragraph IV of this chapter. 
2.		 Trypan	Blue	for	epiretinal	and	internal	limiting	membrane	staining.
 In 2001 a study was published in which in a rabbit experiment trypan blue (TB) 
was injected into the vitreous cavity after gas-compression vitrectomy. TB in 
a concentration of 0.06 %, left in place for 4 weeks, was found not to result in 
any histopathological or functional (scotopic ERG) abnormalities. However, 4 
weeks exposure to TB 0.2 % resulted in significant morphological aberrations in 
the inferior retina. 1002 TB 0.06 % has since then been applied to stain epiretinal 
membranes (ERM) in proliferative vitreoretinopathy (PVR),  and to stain ILM and 
ERM in macular hole and macular pucker surgery.1003-1005 In spite of the findings 
in the study of Veckeneer et al.,1002 TB in a concentration of 0.2 % was also tried 
clinically in order to stain the ILM more intensely. This concentration provided 
adequate ILM and ERM staining in 50 patients with macular pucker, macular 
hole, a combination of both, PVR, or diabetic retinopathy. A commercial 
preparation of trypan blue 0.2% is now available (Membrane Blue, DORC 
International, Zuidland, The Netherlands).1006 A clinical study using 0.15 % 
trypan blue intraoperatively in macular pucker surgery showed good surgical 
and clinical (visual acuity, visual fields) results in 10 patients compared to 10 
matched controls. The same authors however reported in the same paper 
morphological retinal alterations in a study on post-mortem eyes with TB 0.15 
and 0.25 %, but not with 0.02%.1007 Studies on toxicity of trypan blue for retina 
and RPE cells will be discussed in more depth in paragraph  IV of this chapter. 
c.  TB and ICG in keratoplasty.
 After PK there sometimes may be inadvertently retained Descemets’ 
membranes, especially in bullous keratopathy or in CHED. Trypan blue may 
assist in removing these.1008
 During penetrating keratoplasty, deep anterior lamellar keratoplasty (deep 
LK) and posterior lamellar transplantation (PLK / DLEK), trypan blue and ICG 
have been applied. Descemet’s membrane or its remainders can be stained 
with TB. This may be advantageous when preparing a nearly full-thickness 
donor lamella in deep LK by rubbing Descemet’s membrane off,1009 or to better 
visualise the “Descemet’s roll” that is used in a variation of the posterior lamellar 
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transplantation technique.1010 TB has also been used to stain wound edges 
and gauge dissection depth during PK and deep LK.936 1011 The use of ICG has 
been reported to facilitate the visualisation of the posterior lamellar disk during 
PLK / DLEK, by staining its stromal side.1012 In part IV, Chapter 10 of this thesis, 
techniques for lamellar keratoplasty will be more extensively reviewed.
IV.  Toxicity & biocompatibility of intra-operative TB 
 and ICG.
a.  Systemic toxicity.
1.		 ICG.
 Sporadic, moderate pseudo-allergic  (i.e. non-specific release of histamine) 
to severe  allergic (anaphylactic) reactions, as well as vasovagal reactions, 
have been reported after intravenous injection of  ICG. No deaths have been 
reported. Risk factors for moderate to severe adverse reactions include liver 
disease and end-stage renal disease (uraemia), allergy to iodine (also: radio-
opaque contrast agents, shellfish), and a cross allergy to sulfonamides and 
penicilline.925 945 Experiments have shown that the dose for clinical intravenous 
applications is much lower than the lethal dose for 50 % of the mice (the LD50), 
which was 60/80 mg/kg.1013 Systemic toxicity resulting from the intra-operative 
use of ICG, be it in cataract or in vitreoretinal surgery, is therefore not to be 
expected. Although ICG is bound strongly to plasma albumin, it has been 
observed to leak choroidally and intraretinally after intravenous injection.1014
2.		 TB.
 As discussed in paragraph I of this chapter, trypan blue is known for its systemic 
toxicity, as it is a dye with mutagenic and carcinogenic capacities. A mechanism 
by which the mutagenesis and carcinogenesis of TB is brought about, has been 
postulated to be azo-reduction of trypan blue into the mutagenic product o-
tolidine, by chemicals or by intestinal anaerobe bacteria.937-940 1015 
 It is interesting to determine whether intra-ocularly used doses might cause 
a  possible hazard for teratogenicity or carcinogenicity. In the mentioned 
laboratory experiments, mice and rat strains were used which are inbred and 
therefore may be more susceptible to possible adverse effects. Assuming a 
mean weight of a laboratory mouse of 50 grams and of a rat of 200 grams, 
the intraperitoneally applied total dose of trypan blue to induce congenital 
malformations would be 50 – 100 mg/kg body weight.937-940 The applied total 
dose in the carcinogenicity study of Ford en Becker amounted to at least 300 
mg/kg body weight depending on the administration regimen, which required 
at least 6  subcutaneous administrations of trypan blue. 941 
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 In contrast, during cataract surgery maximally 0.5 ml of trypan blue 0.06 % 
is administered, i.e. a dose of ≤ 0.3mg (0.06 % = 0.6 mg/ml). Assuming for 
calculation purposes that the body weight of an adult patient is about 60 
kg, then the dose administered amounts to 0.005 mg/kg body weight. For 
a body weight of 60 kg the administered dose is about 10,000 times lower 
than lowest known teratogenic dose and 60,000 times lower than the total 
carcinogenic dose – which needed to be administered repeatedly in at least 
6 times. Moreover, the dose of 0.3 mg applied during cataract surgery does 
not remain completely in the eye. Excess dye is rinsed out immediately after 
application and a major part of the stained capsule is removed from the eye. All 
of the remaining dye is further diluted by irrigation during the operation and by 
aqueous circulation afterwards. Heavily diluted traces of dye could theoretically 
then reach the circulation via the aqueous drainage route. 
 
 In vitreoretinal surgery, 0.1 cc of 0.2 % is applied, resulting in a dose of  0.2 
mg (0.2 % = 2 mg/ml), or 0.5 cc of 0.06 % resulting in a dose of 0.3 mg, or 0.5 
cc of 0.15 % resulting in a dose of 0.75 mg. The latter dose is still 4,000 times 
lower than the lowest teratogenic dose.  Doses in vitreoretinal surgery may 
even be more completely rinsed out of the eye and removed with the stained 
membranes than in cataract surgery.
 In pregnant women and in young children it may however still be prudent not 
to use the entire provided dose of TB intraoperatively (or perhaps even not to 
use TB at all and switch to ICG if necessary), in order to minimize teratogenic or 
developmental side-effects.
b.  Toxicity in vitreoretinal surgical applications.
1.		 ICG
 As discussed in paragraph III of this chapter, clinical and experimental studies 
raised concerns that ICG applied directly onto the retina in macular hole 
surgery might be deleterious to RPE cells, and indirectly or directly, also to 
retinal receptor or nerve cells.996-1001 1016 After ICG-assisted ILM peeling, Müller cell 
footplates and other retinal cell debris were found more than usually attached 
to ILM specimens. This led to the hypothesis that ICG staining led to either a 
different “cleavage plane” in the ILM peeling, or to more forceful traction on the 
ILM during peeling by the surgeon.996 1000 ICG staining may also contribute to a 
higher susceptibility of RPE and retinal (ganglion- , Müller) cells to phototoxicity 
from endoillumination or (endo-)laser that is applied in vitrectomy surgery. 
However, this light-sensitization alone is not sufficient to explain all observed 
toxic effects.997 998 1017-1021 Regarding the used ICG solutions, the factors pH and 
especially osmolarity of the solutions have been shown to be very important 
factors influencing the occurrence of toxic effects.996 1021-1023 But again, effects of 
osmolarity (and pH) alone are not sufficient to explain all findings on toxicity 
caused by ICG. 1000 1001
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 The concentration of ICG in its solution has in many experimental studies 
been shown to have an effect on the amount of ICG-caused toxicity. 
Exposure time has also sometimes been implicated. The toxicity threshold, 
i.e. the concentration at or above which toxic effects were observed 
morphologically, varied between 5 mg/ml (0.5 %) and 0.01 mg/ml (0.001 %). 
It should be noted that toxic effects were observed with different cell types 
and cell lines, and after different exposure times (3 minutes – 3 days).1019-1021 
Functional (ERG) abnormalities were observed in animal experiments at lower 
concentrations: 0.025 mg/ml in rats and from 0.5 mg/ml upwards in rabbits. 
These concentrations were not observed to cause consistent and persisting 
morphological alterations in the retina. However when a concentration of 2.5 
mg/ml was used or when injected directly into the subretinal space structural 
damage was found. This experimental application may mimic subretinal 
diffusion of ICG when applied for macular hole surgery.999 1023-1026
 
 In conclusion, indications exist that there is concentration- and exposure-
time dependent toxicity of ICG to RPE and retinal cells. Possible mechanisms 
for additional toxicity may include light-sensitization. Part of the ICG-related 
toxicity however may stem from the toxic effects of hypo-osmolarity. The 
intraoperative application of ICG in concentrations that are currently used may 
have deleterious effects on the functional outcome of the patients. 
2.		 TB.	
 The study by Veckeneer et al. of 2001 in rabbits showed that there was dose-
related toxicity of  TB to the retina. No toxicity was observed after 4 weeks 
exposure to TB 0.06 %, whereas 4 weeks exposure to TB 0.2 % led to significant 
morphologic abnormalities.1002 These findings were more or less in line with 
study on post-mortem eyes, in which morphological alterations in the inner 
retina were observed after ILM staining with TB 0.15 % and 0.25 % (exposure: 
1 minute, after which the excess dye was rinsed out), whereas no alterations 
were found after staining with TB 0.02 %.1007 In this latter study however clinical 
ILM staining with TB 0.15 %  in 10 patients led to good surgical, anatomical, and 
functional results.1007 Studies on the effects of TB on RPE and Müller cell cultures 
did not find toxic effects, as measured with confocal microscopy and a live/
dead fluorescent,1027 or Mossmann’s MMT assay 1028-1030 in two later studies.1020 1021 
In the first of these three studies however, TB concentration calculations were 
incorrect, so it is not clear whether their conclusions are justified.1027 In the two 
MMT-assay studies, TB concentrations used varied from 0.0075 % to 0.2 %, with 
exposure times of  3, 5, 15, and 30 minutes, none of which led to any observed 
toxicity. Also, neither exposure of RPE cells to 0.0003% for 2, 24, or 72 hours, 
nor the use of direct illumination in addition to exposure to TB did lead to any 
observed toxicity.1020 1021 
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 In contrast, other studies found indications for cell viability reduction with an 
MMT-assay, as well as apoptosis, in cultured RPE cells after exposure to TB 0.06 
% and 0.4 % for 1 minute, 0.05 %, 0.1 %, and 0.5 % for 5 minutes, and more so 
after an exposure of 30 minutes. 1031 1032 
 In conclusion, there are indications that TB application does show a 
concentration-dependent toxicity for RPE cells, retinal cells, and Müller 
cells. Whether such an effect is truly observed probably depends on the 
experimental circumstances, the assay that is used to observe toxic effects, and 
importantly, the exposure time. The safety of the current clinical intraoperative 
application of both TB 0.06 % and of TB 0.15 % therefore asks for more thorough 
investigation. Clinical, prospective, functional testing with methods such as 
multifocal ERG and (micro-) perimetry seems indicated in patients who were 
operated with intraoperative application of TB. Ultrastructural analysis of 
harvested ERM and ILM specimens and more extensive studies on the toxicity 
of TB in cell cultures and animals are also warranted.
c.  Toxicity in lens capsule staining in cataract surgery.
1.		 ICG.
 In Horiguchi’s well thought-out, randomized prospective study of 1998 on ICG 
capsule staining in cataract surgery, no postoperative visual, or tonometric, 
or biomicroscopic differences were found. This study compared 10 eyes in 10 
patients in which ICG capsule staining was used to 10 eyes of 10 patients in 
which capsule staining was not used. Furthermore, there were also no significant 
differences in laser-flare photometry in the first postoperative week, nor in ECD-
loss or endothelial morphometry 1 month postoperatively.947 These safety results 
were confirmed recently in the randomized, clinical study by Dada et al. that 
compared ICG 0.5 %, TB 0.1 %, gentian violet 0.001 %, subcapsular fluorescein 
2 %, and hemocoloration (autologous blood) capsule staining, each in 10 
eyes of 10 patients with white cataracts who underwent phacoemulsification. 
No significant differences between the groups of differently stained eyes in 
tonometry,  pachymetry, or endothelial cell loss were observed at 1 day or 
1 month postoperatively.962 A comparative experimental study on viability, 
function, and ultrastructure of human and rabbit endothelia after perfusion 
with ICG 0.5 % for 3 minutes did not find any significant differences between 
ICG perfused corneas and controls.1033 In contrast to the observations on the RPE  
after ICG application in vitreoretinal surgery, ICG 0.5 % may be safe for the corneal 
endothelium in capsule staining during cataract surgery. However, clinical studies 
with more patients and longer follow-up, as well as more experimental studies are 
necessary to unequivocally demonstrate the safety for anterior segment toxicites 
structures. In addition, posterior segment may also be an issue, as recently a case 
was reported in which ICG 0.5 % that had entered the vitreous after attempted 
lens capsule staining, was the probable cause of  retinal cell damage.1034
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2.		 TB.
 When we started our clinical and experimental studies in 1998, which are 
described in the next two chapters, no comparative clinical trials existed on 
the effects of TB on the corneal endothelium. The information that was known 
on possible toxicity for the corneal endothelium, were the data gathered by 
Norn in the 1960s and 1970s with regards to the topical and intra-operative 
application of TB,931 933-935 and the experiments of Stocker in the 1960s and 
Sperling in the 1970s and 1980s regarding to the use of TB in donor corneal 
endothelial assessment.326-328 343 344 762 All of these studies indicated that 
those applications and concentrations of TB were not toxic to the corneal 
endothelium. This confirmed the experience in the Cornea Bank Amsterdam, 
where since their start in 1983 more than 20000 corneas have been examined 
with TB 0.3 % (later 0.12 %).323 In none of these endothelia an adverse effect 
caused by TB has been observed (E. Pels, personal communication, 1998). In 
the first study on TB capsule staining, no adverse effects were seen up to one 
year postoperatively.32 With the aim to investigate possible toxicity of trypan 
blue  for corneal endothelial cells more systematically, the studies described in 
chapters 9 and 10 were initiated.
 References
 See page 287.
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 In 1999, we described the use of a vital dye, trypan blue, for staining the 
anterior lens capsule, to facilitate the visualization of the capsulorhexis in 
cataract surgery.32 At one year, a first group of 30 patients showed no ocular or 
systemic side effects. (K.A. van Overdam, M.D. “One Year Follow-up After Trypan 
Blue Capsule Staining in Mature Cataract Surgery,” presented at the XVIIIth 
Congress of the European Society of Cataract and Refractive Surgeons, Brussels, 
Belgium, September 2000). To our knowledge, no adverse effects related to the 
use of the dye have been reported.
 Trypan blue 0.3% is widely used as an exclusion dye, to determine the viability 
of a donor endothelial cell layer, prior to corneal transplantation344 It may 
therefore seem unlikely that trypan blue 0.06% would have a toxic effect on the 
corneal endothelium in the living eye, when used during surgery. However, to 
our knowledge, a quantitative evaluation of the biocompatibility of trypan blue 
with the corneal endothelium has not been performed. 
 The purpose of our study was to quantitate the endothelial cell damage induced 
by trypan blue capsule staining by comparing endothelial cell densities between 
both eyes of patients after bilateral phacoemulsification with or without trypan 
blue capsule staining, by the same surgeon, using the same surgical technique.
 Patients and Methods
 
 Twenty-five patients with bilateral submature cataract in whom the use 
of capsule dye was relatively indicated were enrolled in the study after an 
institutional- review-board-approved informed consent was obtained. The 
mean age of the 8 men and 17 women was 72.7 ± 9.2 (S.D.) years. Exclusion 
criteria were uncontrolled glaucoma, uveitis, and diabetic retinopathy. Patients 
were scheduled for bilateral phacoemulsification by the same surgeon 
within four months. One eye of each patient was randomly selected for the 
intraoperative use of trypan blue.
 
 In each eye, a scleral tunnel incision was made and aqueous was exchanged 
with air. Trypan blue 0.06 % (Vision Blue®) was applied onto the anterior lens 
capsule. After a few seconds, the anterior chamber was thoroughly irrigated 
with balanced salt solution to wash out the excess dye. In the contralateral 
eye, the anterior chamber was filled with air and then irrigated with balanced 
salt solution, without application of the dye. After irrigation, the air in the 
anterior chamber was exchanged with viscoelastic material, and the procedure 
was continued as  routine phacoemulsification using a bimanual ‘divide-and-
conquer’ technique, with the implantation of an intraocular lens.1035
 Before and at twelve months after the second surgery, three images of the 
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endothelial cell layer were obtained from the central cornea in both eyes 
(Topcon SP2000p non-contact specular microscope) and analyzed (Imagenet 
2000 software, Topcon Corp.) Digital images were manually corrected in 
masked fashion, to better define the cell border configurations. Outcome 
parameters were endothelial cell density, coefficient of variation of cell size, cell 
hexagonality, and pachymetry.
 In each eye, the loss of endothelial cell density was calculated by subtracting 
the mean twelve months postoperative value from the mean preoperative 
value. The differences in the coefficient of variation, hexagonality, and 
pachymetry readings were calculated similarly. Statistical analysis was 
performed using the paired Student’s t-test, repeated-measures analysis of 
variance, and the Wilcoxon signed rank test.
 
 Results
 
 At twelve months after surgery, the postoperative endothelial cell loss averaged 
167 + 188 cells/mm2 (- 7.3%) in eyes operated on with the use of trypan blue, 
and 266 + 278 cells/mm2 (- 10.2%) in the control eyes (p ≥ 0 .1). The preoperative 
endothelial cell densities were 2561 + 376 cells/mm2 and 2593 + 377  cells/mm2  
respectively (p ≥ 0.1). The difference in coefficient of variation of cell size, cell 
hexagonality, and pachymetry did not differ between both groups (p ≥ 0.1).
 At 1 year, the best corrected visual acuity averaged 0.8 + 0.2  in experimental 
eyes, and 0.8 + 0.3  in control eyes (p ≥ 0.1). Three patients had mild atrophic 
age-related macular degeneration. All eyes were quiet, and the ocular pressure 
was normal.
 Discussion
 
 Our study showed that no mid-term endothelial cell damage is induced by 
the intraoperative use of trypan blue for staining the anterior lens capsule. 
This finding may agree with the clinical observation that no corneal edema is 
induced by the intraoperative use of the dye.32 The overall 7-11 % endothelial 
cell loss is similar to that reported previously after phacoemulsification.500 
 
 References
  See page 287.
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Abstract
Objective
To quantify the toxicity of trypan blue(TB) on human corneal cells according to  
exposure-time and concentration.
 Methods
Three in-vitro experiments were performed:
1. We exposed cultured human corneal fibroblasts to TB (0.0001% to 0.1 %) in Eagle   
 modified minimum essential medium (EMEM) or phosphate-buffered saline (PBS)  for  
 15 minutes to 24 hours. Cytotoxicity was evaluated by Mossman’s colorimetric 3-(4,5- 
 dimethylthiazol-2-yl)-2-5diphenyl tetrazolium bromide (MMT) assay. 
2. We exposed human corneas in EMEM for 24 hours to TB (0.001% to 0.1%). Fellow
  donor corneas served as controls. Endothelial survival was evaluated    
 morphologically and by cell density assessment. 
3. We morphologically compared the endothelial viability of human donor corneas   
 after exposure to 0.1% TB for 5 to 30 minutes with control corneas
 
 Results
In experiment 1, TB in EMEM was not significantly toxic at concentrations of 0.005% or 
lower. Higher concentrations were toxic only after exposure to TB for at least 6 hours. In 
PBS, significant toxicity was found after exposure to 0.1% TB for 30 minutes or longer. 
Lower concentrations were toxic after longer exposures. In experiment 2, exposure to 
0.01% and 0.1% TB resulted in significant loss in cell density. At lower concentrations, 
the endothelium was affected only morphologically. In experiment 3, endothelial 
morphology changed in control corneas and after exposure to 0.1% TB for as little as 5 
minutes. After 30-minute exposure, morphologic deterioration was more pronounced.
 Conclusions
Trypan blue was toxic in vitro to corneal endothelium and corneal fibroblasts at  higher
concentrations and at notably longer exposure-times. Toxicity was less in EMEM than in 
PBS.
 Clinical relevance
At commonly used concentrations, both during cataract surgery and in the cornea 
bank, trypan blue is safe for corneal cells. At higher concentrations or longer exposures, 
however, caution is warranted.
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 Introduction
 
 Trypan blue vital staining for the evaluation of the endothelium of donor 
corneas was first described by Stocker et al.326  Trypan blue stains the nuclei of 
severely damaged and dead endothelial cells of donor corneas, as well as areas 
of Descemet’s membrane denuded of endothelial cells. It does not stain viable 
endothelial cells with an intact cell membrane.326 344 921 922  Sperling introduced 
trypan blue vital staining in combination with induced dilation of intercellular 
spaces (with NaCl 0.45 % and 0.9 %, or with sucrose 1.8 %), for visualization of 
endothelial cell borders, thus allowing light-microscopic assessment of both 
endothelial damage and endothelial cell density on potentially transplantable 
donor corneas.343 762 822  Since 1982 this technique has been used by the 
Cornea Bank of the Netherlands Ophthalmic Research Institute (NORI) for the 
evaluation of the endothelium of human donor corneas after storage by organ 
culture preservation.332 849 Variations of this technique, all using trypan blue, are 
applied in many cornea banks in Europe.
 Norn933-935 was the first to use trypan blue intra-operatively, during intracapsular 
cataract surgery, to evaluate endothelial status. Recently, intra-operative 
application of the dye has gained new interest: trypan blue anterior lens capsule 
staining aims at improving the visualization of the capsulorrhexis during phaco-
emulsification in patients with absent red fundus reflex, eg., in mature cataracts.32 
 To expand the existing body of knowledge on the toxicity of trypan blue on 
human corneal cells, concentration- and exposure-time related effects of 
trypan blue were studied in 3 in vitro experiments on human donor corneas 
and human corneal fibroblasts. 
 Materials and Methods
1.  Cytotoxicity of trypan blue to human corneal fibroblasts.
	 Trypan	blue	solutions
 Trypan Blue was obtained from Gurr, BDH Chemicals Ltd., Poole, England. Unless 
stated otherwise, trypan blue was dissolved in sterile phosphate buffered 
saline (PBS, Azua Pharmacy, Amsterdam, The Netherlands). The Cornea Bank 
NORI uses a 1.2 %  solution from this stock for routine purposes since 1998. The 
photometric extinction value of this solution is 0.227 at 560 nanometer. This 
value is the same as for the 0.3 % trypan blue solution, obtained from another 
stock, and described and applied in previous years.323 324 332 
	 Human	corneal	fibroblast	cultures	and	their	experimental	incubation.
 Corneal fibroblasts were obtained from normal human donor eyes as described 
ch
ap
te
r 9
174
bart_part3DEF.indd   174 19-11-2006   13:56:00
previously.1036 1037 In short, corneal buttons were excised and fragmented. Three 
to 4 corneal pieces were implanted per well of a six well plate (Nunc, Roskilde, 
Denmark) and incubated with 1 ml of Eagle modified Minimum Essential 
Medium (EMEM) (ICN Biomedicals INC, Costa Mesa, Ca. , USA) supplemented 
with 10 % fetal bovine serum (FBS, Gibco Life Technologies Ltd, Paisley, 
Scotland), 100 units/ml penicillin (Gist Brocades, Leiderdorp, The Netherlands) 
and 50 µg/ml streptomycin (Biochemie GmbH, Vienna, Austria) at 37 °C. 
When the pieces adhered firmly to the bottom of the well by the outgrowing 
cells, 5 ml medium per well was added. Medium was renewed twice a week. 
Outgrowing fibroblasts were subcultured after 25-28 days and fibroblasts 
of the second passage were stored in liquid nitrogen. Cells were defrosted, 
subcultured for one passage, and used for experiments. At confluency the 
cells were removed form the culture flasks by incubation with a trypsin/EDTA 
solution, collected by centrifugation (200g), resuspended in medium, and 
plated out at 5 x 104 cells per well in 96-well flat- bottomed tissue culture plates 
(Nunc, Roskilde, Denmark). The cells were cultured at 37°C in a humidified 
atmosphere with 5 % carbon dioxide before exposure to freshly prepared 
sterile trypan blue solutions, varying in concentrations of 0.0001 % to 0.1 %, 
in a vehicle of  EMEM (half of the wells per tray) or sterile PBS. Wells were filled 
with 100 ml of study preparations, either with the trypan blue-solutions as 
described, or vehicle (EMEM or PBS) without added trypan blue as control. 
	 Quantitative	cytotoxicity	assessment	with	human	corneal	fibroblasts	
 Cytotoxicity was determined with Mosmann’s colorimetric 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay directly after 
exposure to trypan blue.1028 The MTT assay was performed as described earlier, 
1029 1038; it basically measures the capacity of mitochondrial enzymes to transform 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MMT) (Sigma 
Chemicals Co., St. Louis, Mo, USA) into a formazan product and thus reflects the 
mitochondrial activity of corneal fibroblasts. After exposure of the cells to the 
different concentrations of trypan blue during exposure times ranging from 15 
minutes to 24 hours, the cells were carefully washed three times with PBS and 
100 µl of a culture medium with 2 % FBS was added per well. Then 10 µl of a 
freshly prepared MMT solution (5 mg/ml MMT in PBS) was added to all wells 
and plates were incubated at 37 °C for 4 hours. The MMT-formazan reaction 
product was solubilized by the addition of 200 µl acid -isopropanol (0.04 N HCL 
in propanol-2) to the incubation medium without washing steps and overnight 
incubated at room temperature in the dark. The optical density of the solution 
was assessed at 560 nm in a spectrophotometer (IEMS Reader MF, Labsystems, 
Helsinki, Finland) taking medium with MTT and isopropanol as the blank. Each 
experiment was performed in 4-fold, and the experiments were repeated 3 
times. Irreversibility of the effect of exposure to trypan blue was confirmed by 
repeating the MMT-assay 2-3 days and 7-8 days after exposure to trypan blue. 
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 The cytotoxicity index CI of each culture was calculated using the formula:   
  CI = [(ODcontrol – ODtest)/ODcontrol] x 100% 
 
 where ODcontrol  is the optical density in the control wells (cell incubated with 
vehicle only, PBS or EMEM), and ODtest is the optical density in the wells with 
cells incubated with trypan blue in the vehicles PBS and EMEM.
 A CI of higher than 20 %, was considered to be significant, thus compensating 
for the standard deviation of mean CI from the three experiments.1029 1038 
2.  Endothelial cell survival after 24-hour exposure to trypan blue.
 Paired corneas from human donors judged unsuitable for transplantation for 
medical reasons or corneal scars were used. One randomly chosen cornea 
from each pair was used as a control and stored at 31 °C in EMEM with 2 % 
FBS and antibiotics, whereas the experimental cornea was preserved at the 
same temperature in the same medium, to which trypan blue was added. 
Concentrations of trypan blue that resulted were: 0.1 % (2 pairs), 0.01 % (2 
pairs), 0.005 % (5 pairs), and 0.001 % (5 pairs). After exposure for 24 hours 
all corneas were rinsed and preserved in fresh EMEM at 31ºC for another 21 
days. At 9 to10 and 20 to 21 days, corneal endothelium was evaluated by 
the technicians of the cornea bank. Storage of donor corneas in EMEM, as 
well as endothelial evaluation, was performed under sterile conditions using 
standard eye bank techniques, as described previously.323 324 332 Endothelia of 
experimental and control corneas were compared on ECD and morphological 
status. Endothelial morphology was graded normal (score of 3) when a normal, 
“string-of-pearls”-like swelling pattern of the intercellular space indicative of a 
well functioning cell membrane, was present; dubious (score of 2) was assigned 
to endothelia with irregular or locally poor swelling of the intercellular space, 
and with the presence of many vacuoles within the endothelial cells; and 
abnormal morphology (score of 1), was used for endothelia with rounding-up 
of the cells, indicative of loss of intercellular contacts, and with generally poor 
swelling of the intercellular space (endothelia were called dead with a score of 
0, when no recognizable endothelial cells could be discerned.323 324 
 Statistical evaluation of ECD was performed using a mixed model Analysis of 
Variance (ANOVA) with  ECD as dependent variable, adjusted for its baseline 
measurements and time of investigation as covariate in the model. There was 
a within-subject factor (trypan blue vs. control) and a between-subject factor 
(concentration) in the model. Interest was in the interaction between these 
latter two factors. No structure was assumed for the within-subject correlations. 
Endothelial morphology scores were evaluated using a non-parametric 
Wilcoxon signed rank test. Experimental corneas, all taken together, were tested 
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against all control corneas, for both time-points. Testing by concentration 
group was considered not to be meaningful because of small group size.
3.  Endothelial viability by morphologic assessment  after application of 
 trypan blue.
 Human donor corneas were used that were judged unsuitable for 
transplantation because of corneal scars, low ECD (between 1800 and 
2300 cells/mm2), or signs of abnormal morphology such as significant 
polymegathism323 324 These corneas were briefly (1-2 days) stored at the 
Cornea Bank under sterile conditions at 31 ° C in EMEM with  2 % FBS and 
supplemented with 5 % Dextran before shipment to the Rotterdam Eye 
Hospital for the experiment.
 Both at the beginning and the end of the experiment, the endothelium of all 
corneas was evaluated using 0.1 % trypan blue vital staining and provoked 
intercellular swelling with sucrose 1.8 % solution (hospital pharmacy of The 
Rotterdam Eye Hospital), and photographed with an inverted light-microscope. 
Corneas with endothelia that showed severe degenerative changes (i.e. trypan 
blue stained nuclei, vacuoles in the cells, poor swelling of the intercellular 
space) before the experiment, were excluded from the experiment. The 
remaining corneas were randomly allotted to one of the treatment groups or 
the control group. 
 The control corneas (n = 8) were merely incubated for two hours in EMEM with 
2 % FBS and 5 % dextran at room temperature. In three of the experimental 
groups, 0.1 %  trypan blue solution was applied to the endothelium of the 
corneas directly after the preexperimental evaluation, for 30 (n = 7), 10 (n = 9), 
and 5 (n = 7) minutes. A fourth experimental group (n = 6)  was exposed to 
0.01% trypan blue for 10 minutes. Then, after trypan blue was thoroughly rinsed 
off with balanced saline solution, all experimental corneas were incubated in 
EMEM for two hours with 2 % FBS and 5 % Dextran at room temperature.
 The pre- and post-experimental photomicrographs of the endothelium of 
control and experimental corneas were mixed and subjected to a masked 
assessment by five laboratory technicians of the Cornea Bank in Amsterdam. 
They used a four-tiered grading scale to estimate the percentage of dead 
endothelial cells (4, < 5 % dead cells; 3, < 5 % dead cells, but dead cells mainly 
over folds in Descemet's membrane; 2, 5-25 % dead cells, either diffusely or 
over folds, or both, and 1, > 25 % dead cells). The same morphology grading 
scale as in the second, “paired” experiment was used to assess morphology 
of areas without  dead cells (3 = normal, 2  = dubious, and 1 = abnormal 
morphology).  For each photomicrograph and for each of the observers, a 
product score ranging between 1 and 12 was calculated from the scores 
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on the two scales. Inter-observer correlation was evaluated by calculating 
Cronbach α. By averaging the product scores of the 5 observers an endothelial 
morphology assessment score was obtained for each cornea before and after 
the experiment. The product score was considered to be the best means to 
reflect the viability of the endothelium, irrespective of  cell density or variation 
in cell size. Figure 9.1 demonstrates this grading system by showing four 
microphotographs of donor cornea endothelia used in this experiment with 
their resulting mean endothelial assessment scores.
 The differences between pre- and postexperimental endothelial morphology 
assessment scores were calculated as change scores. Using these change 
scores, a linear regression model was constructed, and contributory effects of 
trypan blue exposure time were evaluated. The effects on the endothelium of 
the performance of the experiment per sé were also investigated.
 Results
1.  Cytotoxicity of trypan blue to human corneal fibroblasts.
 The relation between the mean cytotoxicity index CI, trypan blue 
concentration, and exposure time is shown in the three-dimensional graphs 
figure 9.2a and 9.2b, for EMEM and PBS respectively. Significant CIs (>20%) 
are represented by the gray bars in the graphs. Figure 9.2a shows that in 
EMEM, trypan blue concentrations of 0.01 % and higher resulted in significant 
toxicity after exposure for 6 hours or longer. At 24 hours’ exposure, a trypan 
blue concentration of 0.005 % showed a threshold significant CI. Lower 
concentrations did not cause significant toxicity with exposures up to 24 hours. 
The graph in figure 9.2b shows that in PBS significant toxicity was observed 
at exposures of 30 minutes or longer to 0.1 % trypan blue. The exposure 
times needed to reach significant CIs increased with decreasing trypan 
blue concentrations. With 0.0001 % trypan blue in PBS, no significant CI was 
observed, regardless of exposure times.  
 Dose-response relations for trypan blue in the 2 vehicles, EMEM and PBS, were 
plotted for each of the different exposure times. Response was expressed as 
the mean CI obtained in the 3 (repeated) experiments. Figure 9.3 shows a 
representative dose-response curve, in this example after 18 hours exposure 
to trypan blue in EMEM. Using a sigmoidal fit program (Origin version 4.0, 
Microcall Software Inc., Northampton, Mass), the maximal toxicity (CI) levels and 
LC50s (50 % lethal concentration, i.e. concentration resulting in half-maximal 
response) were calculated for all exposure times and for both of the vehicles. 
These data are summarized in Table 9.1. The LC50 appeared to be independent 
from exposure time and vehicle, and was found at a concentration of 0.02-
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0.04%. In contrast, the calculated maximal toxicity levels were strongly 
dependent on exposure time, and in PBS higher calculated maximal toxicities 
were found than in EMEM.
 At days 2-3 and days 7-8 after exposure, the results (not shown) are essentially 
the same as the results directly after exposure, indicating that the observed 
damage to the fibroblasts was irreversible. 
2.  Endothelial cell survival after 24-hour exposure to trypan blue. 
 The results after 9-10 days and 20-21 days of preservation of the donor cornea 
pairs were expressed as mean endothelial cell densities (ECDs), endothelial 
morphology scores, and percentages ECD-loss, and are summarized in table 9.2. 
All corneas exposed to trypan blue 0.1 or 0.01 % suffered total endothelial cell 
loss at 20-21 days of preservation; the endothelium of one cornea exposed to 
0.1% TB had already perished at day 9.
 Analysis of variance outcomes showed a significant interaction between 
the within-subject factor (TB vs. control) and the between-subject factor 
(concentration) (p < 0.001), as well as separate significant main effects of the 
factor “concentration” (p < 0.001),  and the factor “TB vs. control” (p < 0.001). 
These results indicate a significant concentration-dependent effect of trypan 
blue on ECD when experimental corneas were compared to their fellow 
controls. Estimated effects by this model of the interaction  (concentration – tb 
vs. control) on ECD-loss, with 95 % confidence limits, were 60 cells/mm2 for TB 
concentration 0.001% (p = 0.57), 93 cells/mm2 for  TB 0.005 % (p = 0.38), 2078 
cells/mm2  for TB 0.01 % (p < 0.001), and 1894 cells/mm2 for TB 0.1% (p < 0.001) 
(Table 9.2).
 On both observation points days 9-10 and days 20-21, the Wilcoxon signed 
ranks test showed a significant effect of trypan blue (all concentrations 
together) on endothelial cell morphology (p = 0.03 and p = 0.02, respectively) 
as compared to the endothelial cell morphology scores of all control corneas.
 
3.  Endothelial viability by morphologic scores after application of trypan blue. 
 Endothelial morphology assesment (EMA) and change scores are summarized 
in Table 9.3. Cronbach α, a coefficient for interobserver reliability was 0.942; this 
confirms strongly the validity of the grading scales. 
 Morphologic change scores were normally distributed. Unpaired, s-tailed t-
test revealed no significant difference (p= 0.33) between morphologic change 
scores in the corneas in the control group (n = 8) and the corneas in all the 
other groups together (n = 29), indicating an overall detrimental effect on the 
endothelium of manipulation of the donor corneas by merely performing this 
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experiment. A linear regression model was constructed of the morphologic 
change values for the 0.1 % trypan blue concentration. The overall contribution 
of exposure time was not significant (p = 0.18); however comparison of the 
different exposure times showed: controls vs. 5 minutes: p = 0.88, 5 minutes vs. 
10 minutes: p= 0.92; controls vs. 30 minutes: p = 0.08; 5 minutes vs. 30 minutes: 
p = 0.07; and 10 minutes vs. 30 minutes: p= 0.06. This is an indication that 
exposure to trypan blue 0.1% for 30 minutes may cause additional deterioration 
of endothelial morphology.
 The average morphologic change score of the group corneas exposed to 
trypan blue 0.01% appears to be lower than those of the groups exposed to 0.1 
% trypan blue (table 9.3).
 Discussion
 The results of our three experiments in which different methods were applied 
to assess toxic effects of trypan blue for corneal cells, endothelial cells in 
particular,  demonstrated the following effects: (1) a concentration-related 
effect of trypan blue on corneal cell viability; (2) an effect of exposure time 
to trypan blue on cell survival; (3) an effect of the vehicle on the degree of 
toxicity that is caused by trypan blue; (4) damaging effects of (experimental) 
manipulation of cells or endothelia.
 Each of the methods used in the 3 different experiments has its advantages 
and disadvantages. The first experiment assessing the cytotoxicity of trypan 
blue for corneal fibroblasts used an objective, quantitative evaluation method 
and  homogeneous material of good quality, and had closely controlled 
experimental circumstances. However, no endothelial cells but human 
fibroblast cell cultures were used and therefore this was not a true assessment 
of toxicity of trypan blue on human corneal endothelium in situ. The second, 
paired experiment met this latter objection. Furthermore, its design, using 
organ culture preservation as a controlled condition “stress”-test for endothelial 
cell survival on paired experimental vs. control endothelia, provided for a 
powerful quantitative assessment of long-term endothelial cell viability after 
exposure to trypan blue, obviating the need of large amounts of tissue. On 
the downside, relatively subjective assessment methods were needed to 
obtain quantitative parameters, a dose-response relationship was much more 
difficult to evaluate, and effects of exposure time were not examined. In the 
third experiment several short exposure times were studied, and the design, 
application of trypan blue on to donor cornea endothelium, reflected the 
actual situation in eye banks rather well. However, statistical evaluation suffered 
from lack of power due to relatively small numbers of corneas per treatment 
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group, because of restricted supply of suitable donor material. Second, the 
assessment of endothelial morphometrics was subjective; however, the 
use of five independent masked experienced observers and standardized 
grading scales that provided for a very high interobserver reproducibility both 
improved on the reproducibility of this semiquantitative assessment. Third, the 
surprising outcome with exposure for 10 minutes to 0.01% trypan blue (table 
9.3)  indicates a limitation of the use of morphometric measures on viable 
endothelium. When the osmolarity of the solutions tested differs, e.g. by the 
use of a different concentration of trypan blue in PBS as was the case in this 
experiment, the endothelium may become temporarily edematous and more 
vulnerable to a subsequent swelling of the intercellular space necessary to 
visualize living endothelial cell borders. Therefore, concentration-dependent 
effects were not further tested in this experiment. Finally, preexperimental 
status of the endothelia was rather heterogeneous because of the selection 
criteria and preexperimental conditions. This was compensated for by 
carefully evaluating preexperiment morphometric status and discarding 
morphologically clearly abnormal endothelia before the experiment started. 
This preexperiment evaluation appeared to have succeeded, for table 9.3 shows 
that the preexperimental endothelial assessment scores were quite good, and 
similar in all experimental and control groups.
 Although each of the experiments may have had its own flaws, each 
showed consistent results that furthermore were complementary to and in 
concordance with those from the other experiments. This study demonstrated 
a consistent relationship between concentration, exposure time, vehicle of 
trypan blue, and/or application circumstances. Under favourable conditions 
(the second experiment, and EMEM in first experiment) 24 hours of exposure 
to a trypan blue concentration of  0.005% was found to be a threshold at and 
below which there was no significant toxicity. Under unfavourable conditions 
(PBS in the first experiment, and the repeated manipulation in the third 
experiment) toxicity threshold was found at an exposure to trypan blue 0.1 
% for 30 minutes; this threshold shifted towards longer exposure times as 
concentrations decreased and vice versa. 
 A recent experimental study1002 confirms concentration-related toxicity and the 
existence of a threshold of toxicity related to trypan blue application. Interest 
had arisen in the application of the trypan blue as a surgical tool to facilitate 
visualization in epiretinal membrane surgery. Trypan blue application in a 
0.06 % concentration in the vitreous cavity of rabbit eyes for up to 4 weeks 
did not cause any recognizable damage to the rabbit retina. In contrast, the 
application of 0.2 % trypan blue caused considerable damage to retinal cells 
and architecture in areas that were more exposed to the dye. It is however 
not feasible to compare in more detail the results of this study with our own 
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findings on endothelial cells, due to the different nature of the cells of interest, 
the different circumstances under which the exposure took place: in vivo vs. 
in vitro,  and the far longer exposure times used, and with different techniques 
aplied for the determination of toxicity.
 The results in our study seem to be in line with the literature, and with 
experience with the dye in eye banks. Sperling344 and Stocker et al.328 stained 
the endothelium of human donor corneas briefly (1 and 1.5 minutes, 
respectively) with 0.3 %, and 0.25 - 0.5 % trypan blue solutions respectively. 
Both authors found no indications for endothelial cell loss caused by the 
staining.328 344 For many years the Cornea Bank NORI applied 0.3% trypan blue 
to the endothelium for 30-60 seconds for routine donor evaluation.323 324 In 
1998 colorimetric investigations of a new stock of trypan blue revealed higher 
extinction values of the 0.3 % solutions than before; the concentration of trypan 
blue solution for donor cornea evaluation was then changed to 0.12 % in order 
to use a trypan blue solution with the same extinction value as before. For 
almost 20 years and over 14,000 transplanted corneas, adverse effects to the 
endothelium have not been observed with application of  0.3 % or 0.12 % TB 
solutions. (E. Pels, unpublished results, 2000) Our present experimental findings 
may be considered to be congruous with our experience with trypan blue in 
the Cornea Bank NORI, and an extrapolation of the findings in the older studies. 
Although the reported concentrations of trypan blue were often higher than 
those used in our experiments, endothelia were exposed for shorter times, 
which most probably prevented possible toxic effects from taking place. 
 Observed toxicity limits in this study allow the intra-operative application 
of trypan blue. In trypan blue lens-capsule staining during cataract surgery, 
a concentration of 0.06 % is used to obtain adequate visualisation of the 
lens capsule in the absence of a red fundus reflex. The dye is applied on 
to the anterior lens capsule under an air bubble in the anterior chamber, 
which prevents dilution of the trypan blue by aqueous before staining the 
capsule and also impairs to some extent direct contact of the dye with the 
endothelium. Immediately after staining, the excess dye is washed out of the 
anterior chamber by copious irrigation, after which a viscoelastic substance 
is injected. The dye on the anterior lens capsule is partly removed with the 
anterior lens capsule after the capsulorrhexis is completed. The remaining 
dye is partly washed out with irrigation during the operative procedure, and 
remaining traces are thought to leave the anterior chamber by the aqueous 
route. The dye cannot be observed anymore on the first postoperative 
day.32 Thus, an initial concentration of 0.06 % trypan blue may partly contact 
the endothelium for a few seconds. Thereafter, only diluted and steadily 
decreasing concentrations of trypan blue are thought to be present within 
the anterior chamber due to a continuous wash-out effect through aqueous 
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flow and resorption. The results of our in-vitro study support the view that 
concentrations of trypan blue in the anterior chamber after trypan blue anterior 
lens capsule staining in cataract surgery do not reach a toxic level. Confirmation 
of safety for the corneal endothelium of trypan blue capsule staining was 
published recently in a prospective, randomized clinical trial on endothelial 
cell loss. At 1 year postoperatively, no deleterious effects could be observed, 
neither on corneal endothelial cell density nor on endothelial morphometric 
parameters.1039 
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Table 9.1 LC50 and maximum toxicity levels, as calculated from the sigmoidal fit program, for fibroblasts exposed to  
  trypan blue 
Exposure time LC50 Max. toxicity level
(in mass %) (CI, in %)
EMEM PBS EMEM PBS
15 minutes 0.04 0.02 8 30
30 minutes 0.03 0.03 1 48
60 minutes 0.02 0.04 13 60
3 hours 0.04 0.02 30 57
6 hours 0.03 0.02 60 125
12 hours 0.02 0.03 31 85
18 hours 0.03 0.02 55 103
24 hours 0.02 0.03 84 147
The LC50s are presented as concentrations of trypan blue, i.e. mass-percentages. The CIs are percentages (dimensionless).
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Fig. 9.1 Examples of endothelial morphometric assessment by grading scales. 
A: Mean product score of 11.2 : score 4 (<5% dead cells) x score 2.8 (completely normal morphology according to 4 of 5 
observers). B: Mean product score of 6.4: score 4 (<5% dead cells) x score 1.6 (abnormal to dubious morphology, poor swelling 
[star] and Descemet’s fold [arrowheads]). C: Mean product score of 6.2: score 2.6 (5-25 % dead cells [white arrowheads], over 
Descemet’s folds and diffusely) x score 2.4 (Descemet fold [black arrowheads], relatively normal  morphology in areas without dead 
cells). D: Mean product score of 2.6: score 1.6 (+ 25 % dead cells [ white arrowheads], diffusely and over Descemet’s fold) x score 
1.6   (abnormal morphology: poor swelling [stars] and Descemet’s fold [black arrowheads]).
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Fig. 9.2 Cytotoxicity Indices of human corneal fibroblast cultures after exposure to Trypan Blue. 
A:  EMEM. B:  PBS. The grey bars indicate significantly toxic CIs (Cut-off point: 20 %). Bars with black tops indicate CIs of less than 0 %.
A
B
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Fig. 9.3 Example of a sigmoid concentration-response curve of human corneal fibroblasts exposed to Trypan 
Blue. 
(In this case 18-hour-exposure, in EMEM vehicle [dashed curve] and PBS [solid curve]). The x-axis uses a logarithmical scale.
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I.  Introduction.
 
 From the earliest attempts in treatment of corneal opacification onwards, there 
has been a parallel development in full-thickness (i.e. penetrating) and par-
tial-thickness (i.e. lamellar) corneal transplant techniques. The next paragraph 
provides an overview of the history of corneal transplantation, a.k.a. keratoplasty. 
They may illustrate how technical developments and new insights in transplanta-
tion biology guided both concepts separately to their current status, and also 
how developments lamellar keratoplasty (LK) and penetrating keratoplasty (PK) 
influenced each other’s evolution. The development of the more recent concepts 
anterior lamellar keratoplasty and posterior lamellar keratoplasty are described. In 
paragraph III the background, rationale, and indications for anterior and posterior 
LK are described. In paragraph IV clinical results and effects on endothelial cell loss 
of anterior and posterior LK are described. 
II.  The development of penetrating and lamellar 
keratoplasty.
a.  History of keratoplasty.
 The first successful transplantation of living corneal tissue in a human patient was 
in fact a lamellar transplantation. A leucoma corneae was excised from a young 
girl’s eye with Descemet’s membrane and endothelium remaining, and a rabbit 
cornea was transplanted into the wound bed. This procedure was performed 
by von Hippel in 1886 and was described in 1888 as one of a series of 8 lamellar 
operations, of which in total 4 were succesful.1040 It was not until 1905 that the first 
successful penetrating keratoplasty was performed in a human patient, by Zirm. 
A man suffering from corneal scars caused by a chemical injury, was transplanted 
with a donor cornea obtained from an enucleated eye of a young boy.1041 
 Leading up to these first successful keratoplasties in humans, in ancient times 
cosmetic treatment of corneal scars had been performed by means of a tat-
too-like coloration of the scar. Lampblack or soot was used in Egyptian times  
(±1500 BC), and copper sulphate reduced with nutgall was applied to achieve 
reasonable cosmesis by Galenus (131-200 AD). In the England of 1761, an 
itinerant quack called Taylor was known to remove superficial corneal scars, 
by means of  rudimentary what now would be called “superficial keratectomy” 
and abrasion. This practice was also widely performed by surgeons in France 
and Germany around that time.1042 The idea of removing scars from the cornea 
using a trephine was first proposed by Erasmus Darwin (the grandfather of 
Charles Darwin) in 1796, but no one put this concept into practice.1043 In 1789 
Pellier De Quengsy introduced his ideas on treating corneal opacification with 
what now is called keratoprosthesis, i.e. to replace opaque corneal tissue by 
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man-made material. His concept entailed an artificial cornea made from glass 
framed in silver. No record exists if this idea was ever put into practice.1044 Attempts 
in the second half of the 19th century to treat humans with artificial corneas, 
among others by von Hippel and by Nussbaum, were not succesful.1040 1045 The 
artificial cornea concept was in fact not developed into a useful tech-nique until 
1963, when among others Strampelli published on successful clinical applications, 
in his case the osteo-odonto-keratoprosthesis.1042 In more recent times new kera-
toprostheses such as the Boston (Doane-Dohlman) and AlphaCor keratoprosthesis 
have been introduced. These new keratoprostheses and renewed attention for the 
OOKP have increased interest in the treatment of patients with corneal conditions 
that are very difficult to treat with keratoplasty. 1046-1048
 
 The first experiments with heterologous and homologous full-thickness 
corneal transplantations in animals are attributed to Reisinger in 1818, who 
also introduced the term “keratoplasty” for corneal transplantation.1049  Homolo-
gous transplantations are transplantations within the same species, whereas 
heterologous transplantations are transplantations with tissue from one species 
into another species. Bigger performed the first successful transplantation in 
animals, a homologous keratoplasty in a gazelle, in 1837.1050 Heterologous trans-
plantations of animal tissue to humans were then attempted. Already in 1838 
Kissam transplanted a pig’s cornea into a human patient, but this opacified 
very soon after the operation.1051 The experiments on corneal transplantation in 
humans and animals conducted by Power, described in 1872, suffered the same 
fate.1052 Success remained elusive until the successful (lamellar) heterograft by 
Von Hippel, described above. After the first successful homologous penetrat-
ing corneal transplantation by Zirm, also the concept of auto-keratoplasty or 
homograft was initiated. In this concept the donor cornea was harvested from 
the patient itself: from the fellow, blind eye, as described by Plange,1042 or a rota-
tion graft in the diseased eye with which a small corneal scar can be rotated out 
of the visual axis, as described by Kraupa.1045 This is in contrast to allografting, in 
which the donor cornea is harvested from another individual of the same spe-
cies.
 It took quite some time before reproducible results with corneal allograft-
ing were obtained, as the operative technique and donor tissue preservation 
and preparation had to be further developed and standardized. Much work 
in this respect was done and published in the 1930s and 1940s by Elschnig 
from Tsjechia, Filatov from Russia, Tudor Thomas in the UK, and Castroviejo in 
the U.S..1053-1059 Improvements in lamellar transplants, leading to a temporary 
renewed popularity of this treatment modality, were re-initiated by the French 
and Swiss ophthalmologists Paufique, Sourdille, and Franceschetti, from the 
1930s through the 1950s.1060 1061 Paufique also described the concept of “mala-
die du greffon”, i.e. opacification of a previously clear cornea, which he attribut-
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ed to sensitization of the donor by the recipient.1060 This seminal concept of im-
munological rejection of the donor graft was proven by Maumenee in 1951.1062 
Much important work in the field of corneal allograft rejection was done by 
Khodadoust and Silverstein.695 The use of corticosteroids realised a breakthrough 
in the treatment of rejection and in the prevention of corneal opacification. 
This concurred with the introduction of antibiotics, and  the introduction of the 
operation microscope and the development of microsurgical techniques and of 
newer suture materials that ensued. Other important developments included 
the better understanding of endothelial physiology and of donor preserva-
tion, as described in chapter 2. U.S.-based ophthalmologists and scientists such 
as Paton, Troutman, McCarey, and Kaufman played important roles in these 
developments.1042 1063-1066 All these developments led to a great improvement in 
the popularity of PK and in the number of cases operated with this technique. 
PK was performed for the first time in the Netherlands in 1939 by A. Deutman.1067 
Further pioneering work regarding technique, tissue, and transplant survival was 
among others done by Kok-Van Alphen.1045
b.  Anterior lamellar keratoplasty.
 The frequency with which lamellar keratoplasty (LK) was performed sank 
inversely with  PK’s increasing popularity. Until recently, only 3-8 % of all corneal 
grafts were LKs.1066 1068 Obviously, indications for LK are more restricted than for 
PK (see also paragraph II of this chapter). Endothelial disorders and full thick-
ness corneal opacifications cannot be treated by anterior LK.1069 But this alone 
cannot explain the unpopularity of LK. The fact that LK was technically more 
demanding and more time consuming than PK may explain better why it was 
so little used. And most importantly, LK’s visual results were dissapointing. Much 
of this last problem was caused by irregular scattering of light (diffraction) at 
the recipient-donor wound interface. The need for a very smooth recipient and 
host surface at the wound interface was recognized early on, but to attain this 
goal would require even more technical skills and time investment.1069 Yet, the 
advantages of LK over PK in suitable indications remained tempting. There were 
less complications to be expected, as LK was not truly intra-ocular surgery, and 
there was no risk for postoperative endothelial rejection, which would prolong 
graft survival. Lower postoperative astigmatism and hence shorter postopera-
tive rehabilitation time were other probable advantages.1065 1069 In the 1960s 
and 70s several attempts were made to improve on the visual results of LK and 
to simplify its technique. These include the use of a microkeratome by Barra-
quer,1070 the use of pre-prepared dried autologous donor material by Urrets-
Zavalía,1071 and the proposal of standardized dissection techniques as described 
by Malbran, Polack, and Anwar.1069 1072 However, studies from the late 1970s still 
show for keratoconus, one of the most suitable indications for LK, visual results 
were better after PK (Visual acuities (VA) ranging from 20/30-20/20) than after 
LK (VA ≤ 20/30), in spite of lower postoperative astigmatism after LK.1073-1075
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 Gasset (re-)emphasized the need for very deep lamellar dissection, at or just 
above the level of Descemet’s membrane, where he found a natural, smooth 
line of cleavage that provided an opportunity to obtain an optical interface as 
smooth as possible.1074 1075 During the 1980s and early 1990s several authors 
elaborated on the principle of deep lamellar dissection of the donor bed by 
injection of air into the corneal stroma just anterior to Descemet’s membrane. 
This was found to alleviate deep lamellar dissection substantially.1076-1079 After 
several years of relative quiet, renewed interest in deep lamellar dissection 
arose in the late 1990s. Manual deep dissection as described by Gasset and 
other authors remained a popular technique and some variations on this tech-
nique were developed. 1068 1075 1080-1083 But also variations on the air-assisted deep 
lamellar dissection technique were introduced, including “big bubble” (of  air)-, 
hydro- and visco-dissection or -delamination approaches, and even the use of 
trypan blue injected intrastromally. Visualisation of the endothelial surface with 
an endoscope in the anterior chamber may be of use when the air injection 
clouds the vision.1011 1065 1080 1084-1088 See figure 10.1.
 The technique introduced by Melles in 1998 and 1999 for deep anterior lamel-
lar keratoplasty (DALK) differed from the previously mentioned techniques, in 
that the deep lamellar dissection was not performed after an anterior corneal 
trephination had been made. Instead, a tunnelled corneoscleral incision was 
used through which a deep lamellar dissection was performed across the cor-
nea, using slightly curved, custom-made spatulas. Thus, a deep stromal pocket 
was created. Dissection depth was gauged with an air bubble in the anterior 
chamber that functioned as an optical interface. Consecutively, trephination 
was performed to the depth of the deep stromal pocket, and subsequently 
the recipient’s anterior corneal disc was removed “in toto”. In a later developed 
variation on this technique, the manual deep lamellar dissection was replaced 
by deep visco-elastic dissection. The excised disc was replaced with a near full-
thickness donor corneal button, from which the endothelium and Descemet’s 
membrane had been removed.34 1009 1089 1090 
 Besides deep lamellar dissection a different approach developed, concurrent 
with the emergence of new or renewed refractive surgical techniques. In this 
approach automated microkeratomes, developed from the types as originally 
proposed by Barraquer, were used for very smooth and regular cutting of both 
donor and recipient lamellar surfaces, at various depths. These LK techniques 
using an automated microkeratome, carry similarities with the refractive surgi-
cal procedure called “anterior lamellar keratoplasty”, in which however no donor 
corneal tissue is transplanted. Some authors even used the 193 nm excimer 
laser itself for lamellar dissection. 1070 1091-1098 The excimer laser can also be used 
for phototherapeutic keratectomy (PTK), in which a superficial layer of the cor-
nea is removed, in the case of superficial anterior corneal disorders that cause 
bart_part4DEF.indd   198 19-11-2006   14:04:51
ch
ap
te
r 1
0
199
superficial stromal opacities and/or recurrent corneal erosions.1099 1100
 With regards to the donor lamella that is transplanted into the deep lamellar 
dissection bed, it was recognized that retaining Descemet’s membrane and en-
dothelium on donor grafts predisposed to insufficient healing. A pseudo-anterior 
chamber was often formed. Furthermore, retaining Descemet’s and endothelium 
did not lead to an optically clearer recipient-donor interface.1101 From then on 
the donor endothelium was usually removed, when nearly full-thickness buttons 
were used in deep LK. Often, Descemet’s membrane is removed as well. Staining 
with trypan blue may be helpful in identifying remaining (damaged) endothe-
lial cells or rests of Descemet’s membrane, as this dye stains bare Descemet’s 
membrane and damaged endothelial cells, but not the corneal stroma.34 1009 1080 
1081 1084 1085 1087 1102 1103 Preparing the donor tissue before the operation by means of 
cutting lamellae or lenticules of desired dimensions from frozen tissue by means 
of a cryolathe is a different approach. This aimed at simplifying the procedure and 
saving operation time, as the need for the preparation of the donor lamella in the 
operating room was obviated.  Moreover, the preservation techniques for lamellar 
donor buttons could now be standardized. However, this technique is currently 
not widely used, although good visual results have been reported.1079 1104 1105
 Other, not yet mentioned lamellar keratoplasty techniques are currently used 
for tectonic purposes, i.e. to restore corneal integrity and/or contour. Some-
times this is an emergency measure to gain time before a PK can be performed. 
Also, lamellar keratoplasty techniques are often performed in ocular surface 
disease. Among these lamellar techniques are: 
 •   annular lamellar keratoplasty for peripheral corneal thinning disorders; 
 •   large-diameter corneoscleral grafts for global corneal thinning such as in
   keratoglobus, peripheral corneal thinning disorders, and ocular surface
   disease; 
 •  amnion membrane transplantation, with or without limbal stem cell 
  transplantation, for ulcerative and melting corneal defects and ocular surface  
 disease; 
 •  tectonic lamellar onlay procedures using donor tissue for corneal thinning
   disorders;
 •   use of combined penetrating and lamellar techniques, especially in the 
  peripheral wound configuration, for several indications; 
 •   and combinations of the above.1061 1066 1097 1098 1100 1106-1108
c.  Posterior lamellar keratoplasty.
 The visionary ophthalmic surgeon Dr José Barraquer is to be credited with the 
development of the concept of selective transplantation of an endothelium-con-
taining posterior corneal lamella, for the treatment of corneal edema.1109-1111 In 
1951 he reported for the first time on such a design, which involved the (manual) 
cutting of a hinged anterior lamellar corneal flap, followed by the excision and 
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replacement of a deep corneal stroma lamella including the endothelium.1109 In 
1964 he reported on the first results obtained with this technique in two human 
patients, who obtained clear grafts and good visual acuities. In 1983 he intro-
duced the electronically driven microkeratome for the cutting of the anterior flap 
in both donor and recipient, and reported a good result in one patient.1112
 Apparently unaware of Barraquer’s work, Tillet published a report in 1956 on 
the selective transplantation of a posterior donor corneal lamella with endothe-
lium, that he had  performed successfully in a patient with Fuchs’ endothelial 
dystrophy in 1954. The posterior recipient disc had been excised after a manual 
lamellar dissection through a 180˚ superior corneal incision. The half-thickness 
donor posterior disc was positioned onto the posterior surface of the recipient’s 
anterior cornea, and fixated with silk sutures. The graft remained clear for at 
least one year, however the visual results were dissapointing because of poorly 
controlled glaucoma.1113 
 In the late 1970s the concept of selective endothelial transplantation regained 
a lot of interest, when experimental models were developed for the transplan-
tation of cultured human and heterologous corneal endothelial cells. Experi-
ments were performed with seeding the endothelial cells on animal and hu-
man donor corneas, Descemet’s membranes, amnion membranes, and artificial 
carrier devices.1114-1120 Experiments on corneal constructs with cultured human 
corneal endothelial cells have continued into the present time and appear 
promising. However, none of these techniques has reached the clinical phase 
yet. 1121 1122 132 1123-1126 1126-1128 See also chapter 14.
 In 1993, a U.S. patent was obtained by White for a microkeratome-assisted 
posterior lamellar keratoplasty technique. Results of this procedure in eye bank 
eyes were presented in 1995 at the ASCRS meeting, with no patients treated at 
that time.1110 In 1998 Jones and Culbertson reported, unaware of White’s work, 
on the lamellar transplantation in eye bank eyes of a 250 μm thick posterior 
corneal lamella, after a 480 μm hinged flap had been made. Both the poste-
rior lamella and the hinged flap were sutured with 10.0 nylon. They called this 
procedure endothelial lamellar keratoplasty (ELK).1129 Their first clinical results, 
obtained in co-operation with Battle from the Dominican Republic, were pre-
sented in 1999.1110 In 2000 Ehlers et al.1130 and Busin et al.,1131 and in 2001 Azar et 
al. (on a case operated in 1996),1132 1133 reported clinical results with their own, 
similar techniques. Flap and button thickness and diameter varied among the 
techniques. Later, more cadaver eye studies were done by the group of Chuck 
and Behrens et al.,1134-1136 and other clinical case series were reported by Silk et 
al,1137 Guëll et al.1138 and Culbertson.1110 
 A quite different approach for posterior lamellar transplantation, more in line 
with the technique described by Tillet, was put forward by Ko et al. They used 
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a technique of posterior lamellar transplantation in rabbits though a superior 
limbal incision, after chemical destruction of the recipient endothelium. The pos-
terior lamella was sutured against the recipient corneal surface.1139 In 1997 and 
1998 Melles reported on an eye bank model for posterior corneal transplantation 
or posterior lamellar keratoplasty (PLK) based on Ko’s report: the transplantation 
of a posterior corneal lamella through a 9 mm corneoscleral tunnel incision. 
33 1140 Lamellar dissection across the cornea was performed (a stromal pocket 
was created) through this incision, using custom-made, curved spatulas. This 
was similar to Melles’technique for deep anterior lamellar keratoplasty (DALK) 
described earlier in this paragraph.34 1090 The posterior recipient disk was excised 
using an especially designed intrastromal posterior disc trephine and custom-
made curved scissors.33 1140 Remarkable in this technique is that posterior donor 
disc is not held in place by sutures. The mechanism that is supposed to maintain 
good donor disc apposition, is the mere pumping action of the endothelial cells. 
The pressure of an air bubble in the anterior chamber helped to keep the disc 
in place in the first postoperative hours during which period the endothelial 
pump is supposed to start functioning.33 However, the unsutured posterior disc 
was also observed to stay in place under non-physiological circumstances, e.g. 
in cadaver eye models. Therefore other explanations were also postulated. These 
include the inherent adhesive quality of bare stromal surfaces, assisted by the 
intraocular pressure.1066 1111 In 1999 the first, encouraging result in a patient with 
pseudophakic bullous keratopathy was reported with this technique.1141 In 2000 
the one-year postoperative results in the first 7 patients were presented. All 
transplants were clear and in situ.1142 Postoperative visual acuities, astigmatism 
and ECDs are discussed in paragraph in paragraph IV of this chapter. 
 
 In the next years, Melles introduced 2 variations on his first PLK technique. In his 
second technique, the recipient donor disc was completely excised with curved 
scissors after the deep lamellar cross-stromal dissection had been completed, 
obviating the intrastromal trephine. In this second technique there was no 
need for a 9 mm incision to allow entrance for the intrastromal trephine, so 
that the incision could be redesigned to a self-sealing 5 mm incision. This also 
obviated the need for suturing the tunnel incision, rendering a completely su-
tureless technique. The donor disc was now introduced folded like a taco, with 
the endothelial side inwards, through the 5 mm incision. In contrast, in the first, 
9 mm-incision technique the donor posterior disc had been introduced into 
the recipient eye unfolded on a spoon-shaped glide covered with visco-elastic, 
with the endothelium facing down. The visual results in the first patient oper-
ated with this “5-mm incision” method were good: at one year postoperatively, 
BCVA  was 0.8 and  astigmatism was 2.0 D.1143 
 
 The third technical variation entailed the use of a 5 mm tunnelled corneoscleral 
incision, through which from the posterior side a 9 mm diameter “descemeto-
bart_part4DEF.indd   201 19-11-2006   14:04:52
ch
ap
te
r 1
0
202
rhexis” was performed with a blunt cannula or a custom-made “scraper”. Acciden-
tally, the term descemetorhexis has also been used to describe an inadvertent 
removal of Descemet’s membrane during phacoemulsification,148 and for the 
secondary, trypan-blue-assisted, removal of inadvertently retained Descemets’ 
membranes after PK.1008 The descemetorhexis technique for PLK eliminated 
the need for the deep lamellar cross-corneal dissection. This technique further 
allowed for a larger diameter transplant, enabling the recipient cornea to be 
replenished with a larger number of donor endothelial cells. This may be ben-
eficial in disorders such as bullous keratopathy in which more graft failures are 
expected because of greater and more rapid chronic endothelial cell loss.1144 1145 
The donor Descemet’s membrane (DM) with endothelium was stripped from do-
nor corneoscleral buttons. The donor material spontaneously formed a roll with 
the endothelium on the outside (as identified by trypan blue staining of DM), 
although other authors debated that the endothelium may have been on the in-
side. The donor roll was introduced into the recipient eye using a custom-made 
inserter that carried some similarity to an injector that can be used to implant a 
foldable IOL in cataract surgery. The inner portion of the roll was manipulated, 
so that the endothelial side spread out over the recipient iris. Alternatively, the 
donor disc may also be folded into a “taco” and introduced into the eye, in the 
same way as in Melles’ second technique. After injecting an air bubble between 
the donor disc and the iris, the donor disc was positioned in the recipient wound 
bed. 1010 1097 1146-1149 In all Melles’ techniques, initial apposition of the posterior 
donor disc to the recipient posterior bed is aided by an air bubble in the anterior 
chamber. See fig. 12.1 for a schematic representation of  Melles’ first 2 techniques. 
 
 Price has reported on cataract surgery following PLK in 6 phakic patients out of a 
series of 47 patients. He used the 9-mm and 5-mm incision deep dissection PLK 
techniques as proposed by Melles.1150 Price later adopted Melles’ third technique, 
which involved making a Descemetorhexis. He named this technique Descemet’s 
stripping with endothelial keratoplasty (DSEK). He reported very promising results 
regarding visual acuity, astigmatism, and refraction, and, although there had been 
some initial problems, a high primary donor disc attachment rate.1151 1152 Melles’ 
first two techniques, that applied the 9 mm and 5 mm incisions, were adopted by 
Terry et al. and introduced in the US with slight modifications in the US under the 
name Deep lamellar endothelial keratoplasty (DLEK).1153 1154 The two different 
names have led to a disagreement between both authors.1155 Terry et al.’s results 
are similar to those by Melles et al. with excellent postoperative astigmatism 
and a rapid visual rehabilitation, although only one of Terry’s patients has 
reached 20/20 BCVA postoperatively. In some instances, Terry combined DLEK 
with cataract surgery in one operation session.1154 1156-1162 John has reported on 
two cases in which he used the DLEK procedure combined with ICG stain-
ing of the stromal side of the donor corneal disc. This increased visualization 
and helped donor disc alignment in the recipient lamellar bed. The ICG was 
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not observed anymore after 24 hours. He did not report on visual or refractive 
outcomes, but the grafts were reported to be clear and non-edematous.1012 
 For donor preparation in all techniques designed by Melles, fresh whole donor 
globes were used, in which a deep lamellar dissection was performed,  followed 
by the excision of a corneoscleral button and a punch-trephination of a poste-
rior disc from the endothelial side. However, using a donor posterior disc that is 
prepared from a donor corneoscleral button using an artificial anterior chamber 
is also a feasible concept in PLK, as has been proven by Terry and Price. It should 
be kept in mind however that Terry and Price use donor corneas preserved with 
cold storage in Optisol, whereas donor corneas in The Netherlands are stored 
in organ culture preservation at 31 º C. This difference in storage technique 
may have consequences for posterior donor disc preparation, if an artificial 
anterior chamber were to be used. Moreover, donor disc adherence may not be 
Fig. 10.1 Diagrammatic representation of the deep anterior lamellar keratoplasty technique.
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comparable between posterior discs obtained from cold stored donor corneas 
and from organ-cultured corneas.1150 1153 1154 An attempt of vitrification of pre-
prepared posterior corneal lamellae, i.e. cryopreservation of posterior discs, 
resulted in tremendous endothelial cell loss after thawing and is currently not 
an option.1163
III.  Background, rationale, and indications for anterior 
and posterior lamellar keratoplasty.
a.  General background and epidemiology.
 In  2004, 844 corneal transplants were performed in The Netherlands, of which 
between 24 and 73 (2.8 – 8.6 %) were anterior or posterior lamellar transplants. 
Between April 1 2004 and March 31 2005, 2378 corneal transplants were 
performed in the UK, of which between 42 and 76 cases (1.8 – 3.2 %) were 
lamellar keratoplasties. In 2004, more than 46000 transplants were performed 
in the US, of which an unknown number were anterior and posterior lamellar 
transplants.1164-1167 Lamellar keratoplasty techniques have increasingly become a 
focus of interest in the last few years, judging by the rapidly increasing number 
of studies that have been published on this subject. However, from the figures 
on performed number of keratoplasties it is obvious that at this point in times 
full-thickness PK still is the mainstay in the surgical treatment of corneal opacifi-
cation. 
 In the next sections of this paragraph it will be brought forward that in many, 
even up to 50% or more of PK cases, either anterior or posterior LK techniques 
could have been chosen as treatment modality. That is, as a treatment for opti-
cal improvement. Tectonic lamellar keratoplasties will be left out of consider-
ation. The choice for tectonic treatment modalities is often more determined by 
their ability to save the integrity of the globe, than by their direct postoperative 
visual outcome. Furthermore, they may provide just the first step in the treat-
ment plan. Additional treatment for improving optical results, including new 
keratoplasty, may be delayed until the primary disease process has quietened 
down.1066 1097 1098 1100 1106-1108
b.  Rationale.
1.  Anterior lamellar keratoplasty.
 Theoretical advantages of lamellar keratoplasty concepts over PK are manifold. 
In (anterior, deep) LK, the endothelium, which in Chapter 2, paragraph XVI of 
this thesis was shown to be crucial in graft survival after PK, is not transplanted. 
Rather, the recipient’s endothelium is retained. This implies that the possibility 
for endothelial graft rejection is absent.1065 1066 Furthermore, since LK is essen-
tially extraocular surgery, the chronic ongoing endothelial cell loss seen after PK 
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may be less. Therefore, performing LK and thus preserving the patients’s own 
endothelium are expected to diminish the risk for retransplantation important-
ly, as compared to performing a PK. 
 Suture and wound-healing related complications, such as suture-abscesses 
and (traumatic) wound dehiscence or wound dehiscence after suture removal, 
are important and relatively frequent complications occurring after PK. This is 
probably in part related to the relatively weak wound strength after PK wound 
healing.1168-1180 Because of frequently occurring suture-related problems, studies 
on different suture materials in PK were conducted. Alternatives to the com-
monly used nylon, such as mersilene (polyester) and stainless steel, have been 
proposed and investigated.1181-1184 However, a material such as polyester with 
experimental and theoretical advantages did not always result in less com-
plications in clinical series.716 1180 However in LK, by conserving the recipient’s 
Descemet’s membrane, a stronger wound configuration and a larger area for 
wound healing is ascertained. Also, less serious consequences may follow 
if nevertheless wound dehiscence occurs. Earlier suture removal is possible, 
which may be expected to result in a lesser risk for these suture- and wound-
healing related complications. 
 Perhaps the most important problem after PK is postoperative astigmatism, 
which is importantly related to both the presence and the removal of su-
tures.1177 1185-1190 Postoperative astigmatism is also expected to stabilize earlier 
in LK because of early suture removal. Early suture removal may also improve 
patient comfort, especially when for instance RGP contact lens wearing is 
necessary for optimization of postoperative visual acuity. Both factors will aid 
in faster and better visual rehabilitation.1065 1066 Moreover, transplantation of a 
normal-thickness and normally structured anterior lamella in LK, in a central 
corneal thinning disorder such as keratoconus, may reinforce the cornea and 
decrease ectasia, comparable to reported effects of epikeratoplasty. Hence, 
high preoperative spherical equivalent and astigmatism may be improved 
postoperatively. 1066 1191 1192 This may also provide for better postoperative visual 
acuity, both corrected and uncorrected. In case of a very steep conus however, 
the stretched Descemet’s membrane and posterior stroma that remain after la-
mellar dissection may also dimple and fold during the LK procedure. This would 
cause bad visual acuity postoperativily.
 As for disadvantages of LK, the higher demands regarding technical skills and 
time investment of the surgeon may especially still be present in the deep 
dissection approaches. In this aspect the microkeratome-assisted approaches 
may have an advantage, as probably more  ophthalmologists are experienced 
in using a microkeratome due to refractive surgery practice, than in perform-
ing deep lamellar dissection. The problem of poorer visual results after LK 
compared to PK is currently addressed by efforts to improve the optical quality 
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of the recipient-donor interface. The indication for LK should be evaluated 
carefully. Keratoconus that is very  steep, and stromal opacities that reach very 
deep, may better be treated with PK. Technically,  2 principles can be applied to 
obtain an optically good interface. These are either very deep dissection at or 
just above the level of Descemet’s membrane, where a natural smooth cleav-
age plain seems to exist, or using a microkeratome to make a very regular and 
smooth wound configuration.1065 1066 1096 1097 
 At this time it is appropriate to point out that virtually all of the advantages men-
tioned above for LK hold true for epikeratophakia or epikeratoplasty when ap-
plied for keratoconus. Epikeratophakia was one of the surgical fields pioneered 
by Barraquer. Early in the 1980s, the original purpose was to correct aphakia by 
suturing onto the anterior surface of the cornea (and in the periphery tucked 
into the stroma) a lyophilised and (cryo-)lathed lamellar piece of corneal tissue. 
As this lyophilised tissue can be lathed into desired optical properties, in this 
way spectacle or contact lens correction of aphakia could be lessened or even 
obviated. Lathed lamellar corneal tissue was commercially available in the 1980s. 
Soon this procedure was also applied to keratoconus where it was called epi-
keratoplasty, and where it had the additional advantage of flattening the cone 
and reducing myopia, and being reversible. Results on the short and long term 
were very encouraging, very much comparable to what has been found after la-
mellar keratoplasty. Among the disadvantages of this procedure was that central 
opacities (e.g. after hydrops) were not removed. Moreover, quality of vision after 
PK was in some studies reported to be superior. In the 1990s epikeratoplasty be-
came less popular as a treatment option of keratoconus, but may still be a very 
valid treatment alternative to PK (or LK), if lathed lamellae are still available.1191-1196
2.  Posterior lamellar keratoplasty.
 In anterior lamellar keratoplasty only opacified anterior layers of the cornea are 
replaced. Posterior lamellar keratoplasty is a treatment concept to replace only 
the diseased posterior layers, which have caused corneal opacification through 
edema. Disorders that may be treated with PLK involve endothelial dystrophies 
(mainly Fuchs’ Endothelial Dystrophy), and aphakic and pseudophakic bullous 
keratopathy, which are types of endothelial failure after cataract surgery (without 
or with IOL implantation).1066 1096 1097 1100 1110 1111 1157 Results of PK performed for 
bullous keratopathy are quite varying: at times they are quite satisfactory, but in 
some series they are outright discouraging, especially after longer follow-up.1144 
1145 1197-1200 PK for Fuchs endothelial dystrophy is usually rather succesfull.1197 1200 1201 
In Fuchs, there are still more good endothelial cells left in the periphery of the 
recipient’s cornea, so that less cells need to be replenished with a transplanta-
tion. (See also Chapter 2, paragraph XVI.d.) New surgical techniques for these 
indications need to have clear and substantial benefits before they will be widely 
accepted, more so for Fuchs than for bullous keratopathy.
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 This seems to be the case however, as with the posterior corneal transplanta-
tion concept some important problems may be addressed that occur fre-
quently after PK. High and/or irregular astigmatism may be prevented when 
the preoperative corneal contours are not altered as is the case after PK. Both 
the tunnel-incision concept and the flap concept for PLK aim at influencing 
the corneal contour only minimally, and if so, more predictably and regularly. 
Also, unaltered corneal contour will give better predictability to IOL power 
calculation, whether cataract surgery is performed before, simultaneously with, 
or consecutively to PLK. Better postoperative astigmatism after PLK will enable 
more rapid visual rehabilitation. After PLK, the need for selective suture removal 
is obviated, and the frequency of additional surgical procedures to address high 
astigmatism will diminish. All these factors together are thought to diminish the 
amount of necessary postoperative consultations which benefits both patients 
and clinic logistics. Additionally, the suture-related complications described 
before may be diminished in frequency or even completely prevented by 
performing posterior lamellar keratoplasty techniques. This may be all the more 
a benefit in patient’s with dry eyes.33 1066 1096 1097 1100 1110 1111 1142 1143 1153 1154 1156-1160 1202 
Especially of interest is that wound dehiscence was also observed to occcur 
relatively frequently after PK for bullous keratopathy and perhaps also after 
Fuchs’ Endothelial dystrophy, both important indications for posterior lamellar 
keratoplasty.1180 Tunnel-incision approaches probably have an advantage in 
avoiding suture-related complications over flap-approaches, in which sutures 
are still necessary.33 1066 1096 1097 1100 1110 1111 1142 1143 1153 1154 1156-1160 1202 
 
 Disadvantages of posterior lamellar keratoplasty techniques include the fact 
that these techniques may seem quite difficult to learn. Again, the micro-kera-
tome-based techniques might be learned more easily by ophthalmologists 
experienced in refractive surgery. Regarding the tunnel-incision techniques 
of PLK, pseudophakic status is much preferable to phakia from a technical 
standpoint. Furthermore, cataract has been found to rapidly develop after 
PLK. Phacoemulsification and PLK may be performed in one surgical session 
or following each other shortly, however. Interface opacities after PLK might 
compromise visual outcomes. After longstanding bullous keratopathy, only 
transplanting the endothelium may not suffice to clarify the cornea, due to sec-
ondary fibrotic changes. Also, the transplanted donor endothelium is a target 
for endothelial rejection. 1096 1097 1110 1150 1157 1158 1202 1111 And as it is not yet known 
whether the procedure itself is more traumatic to the endothelium than PK, 
scrutiny of pre- and postoperative endothelial cell density is advisable. Evalua-
tion of the rate of ongoing, accelerated postoperative cell loss is also warranted, 
since the evolution of endothelial cell density is crucial to transplant survival. 
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c.  Indications
1.  Anterior lamellar keratoplasty
 Indications for LK include many but not all cases of :  
  •  keratoconus, 
  • epithelial and (anterior) stromal corneal dystrophies, 
  • post-infectious (i.e. non-active) corneal scars, herpetic and non-herpetic.
  • non-infective corneal scars, which do not extend too deep into the cornea; 
  • as well as some of the active infectious and non-infectious ulcerative corneal 
   conditions.
 Over the last 25 years, PK for keratoconus has constituted 15 to 29 %  - depend-
ing on the series - of the total number of PKs.1203 679 729 1200 1204-1207 Keratoconus is ei-
ther the most frequent, second, or third indication for PK in most reported series, 
alternating with pseudophakic bullous keratopathy and regraft. The majority of 
cases with keratoconus may be treated with LK. However, in eyes with corneas 
that are too steep, have thinned too much, or in which Descemet membrane 
rupture and hydrops have occurred, LK is usually not a valid treatment option. 
Furthermore, PK for keratoconus has been reported to be very successful and 
the advantages of LK need to be pronounced in order to replace PK as treatment 
of choice for keratoconus.1074 1191 1192 1208 1209
 In some studies Fuchs endothelial dystrophy and other, more anterior dystrophies 
are grouped together into one category. In the studies in which the dystrophies 
are subdivided, non-Fuchs dystrophies appear to contribute 1.5 to 3 % to the total 
number of PKs. Some, but not all of these may be treated with LK.1200 1203 1210
 
 In some studies the share of PKs for infectious keratitis (herpetic and non-her-
petic) reported includes both quiescent and active disease, whereas in other 
studies these conditions are separately reported. Reported ulcerative corneal 
conditions may include non-infectious melting, infectious ulcers, or both. Cor-
neal scarring may in some studies have both traumatic and infectious origins, 
whereas in other studies these indications are counted separately, and in some 
instances this category includes other causes as well. This non-uniformity in 
categorization may explain the wide variation in reported proportion of PKs 
,  11 - 33 %  for  these indications. Certainly not all cases with these indications 
will be open for treatment with LK.679 729 1203 1210
 LK may therefore be an alternative treatment modality in roughly between 25  
and 65 % of all cases for which PK is considered. Other currently available alter-
native surgical treatment modalities for some of the indications for which either 
LK or PK are considered are discussed in chapter 14 (Summary and Perspective). 
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2.  Posterior lamellar keratoplasty.
 As mentioned before, the most import indications for PLK are Fuchs’ endothe-
lial dystrophy, pseudophakic, and aphakic bullous keratopathy. Reports from 
most studies indicate that between 20 and 35 % of all PKs were performed for 
(pseudo- and aphakic) bullous keratopathy; in one meta-analysis the range ex-
tended from 12 to 37 % of all PKs. This indication may be expected to decrease 
in importance, as cataract surgery and IOLs have become less deleterious to 
the endothelium. (See chapter 2,  paragraph XIII.) Fuchs’ endothelial dystrophy 
constituted between 4 and 16 % of all PKs. Estimatedly, in 25 - 50 % of  PK 
indications, posterior corneal transplantation techniques can be a therapeutic 
consideration.679 729 1200 1203-1207 1210
IV.  Results of anterior and posterior lamellar keratoplasty.
a.  Clinical results.
1.  Anterior LK.
 After LK, some studies reported poor to moderate visual acuity.1082 1102 Reasons 
for reduction of VA were interface opacification, blood-vessel ingrowth in 
the interface, and high astigmatism.1082 In most studies on LK however, mean 
astigmatism after LK is between 2.5 and 4.5 diopters, and certainly not higher 
than after PK.1105 1211 1081 1083 1102 1103 1212 1213 The visual results of the newer, deep LK 
techniques are encouraging in several studies. These include the comparative 
and prospective studies that could be retrieved. Equal or better results were 
found after LK compared to after PK. Results on the speed of visual rehabilita-
tion compared to after PK varied.1080 1083 1103 1212-1214 Sugita found no difference in 
visual acuity comparing cryolathed grafts to full-thickness grafts.1080 A number 
of studies report on the results of microkeratome assisted LK (also known as 
ALTK – anterior lamellar therapeutic keratoplasty, in contrast to an older refrac-
tive surgical procedure called ALK). These results were varying in success, but 
some satisfying results have been reported, including an older study from the 
Netherlands.1092 1215 1216
 Larger systematic comparative prospective studies are needed to establish 
whether the theoretical advantages of LK over PK as described in part III of this 
chapter are truly accomplished in practice, and whether the disadvantages of 
LK are diminished with the current technical developments. In The Netherlands, 
a multicentered randomized prospective clinical trial has started (the Dutch La-
mellar Corneal Transplant Study –DLCTS). Visual and other outcomes of several 
contemporary techniques of PLK and ALK are evaluated and  compared to the 
results of PK in the control group.
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2.  Posterior LK.
 At one year postoperatively, best corrected visual acuity in the 6 patients 
operated with Melles 9-mm incision technique was 20/80 – 20/20, and in the 
patients without pre-existent maculopathy or amblyopia 20/40 – 20/20. Post-
operative astigmatism was 1.5 D. At 3 years postoperatively, BCVA in 9 patients 
operated with the 9-mm or 5 –mm incision, deep dissection techniques, with-
out concomitant eye disease ranged from 0.7 - 1.0. Mean astigmatism was 2.1 
D.1142 1148 1217 Price reported on cataract development within one year after PLK in 
his only 4 phakic patients in his total series of 47 PLK patients. He had operated 
these patients with techniques similar to Melles’ 9-mm and 5-mm incision, deep 
dissection techniques. These 4 phakic PLK patients with cataract subsequently 
underwent phacoemulsification. One year post cataract-surgery, BCVAs ranged 
from 20/50 to 20/25, with manifest refraction astigmatism of  0- 1.5 D.1150 Price 
also reported on his results in 50 eyes in 47 patients in which he used Melles’ 
third PLK technique (with the ‘descemetorhexis’). Price called this technique 
Descemet’s Stripping with endothelial keratoplasty (DSEK). At 6 months follow-
up, 62 % of operated eyes saw ≥ 20/40 and 76 % saw ≥ 20/50, with significant 
improvement from preoperative BCVA, and with unchanged astigmatism or 
spherical equivalent.1151 Terry reported in his first series of DLEK patients BCVAs 
of  20/70 –20/30 in 8 patients at 6 months postoperatively, and 20/60-20/30 
in 4 patients at 12 months postoperatively, with induced astigmatisms of 1.1 
and 0.8 D at 6 and 12 months respectively.1154 In later, larger series (30 eyes) 
he reported mean BCVAs (from logMAR visual acuities) of 20/56 at 6 months, 
20/51 at 12 months, and 20/48 at 18 months postoperatively. In this series, at 
6 months postoperatively, 33 % of patients had BCVAs ≥ 20/40, 53 % ≥ 20/50, 
and 97 % ≥ 20/200. At 12 months all these figures had improved slightly. Mean 
topographic astigmatism was 2.1 D at 6 months, and 2.2 D at 12 months.1160 A 
later, larger series followed for 6 months postoperatively had similar results, with 
mean induced astigmatism of 0.28 D, and with a mean BSCVA of 20/46 and only 
one patient reaching 20/20.1162 Induced astigmatism and spherical equivalent 
changes in his clinical and cadaver eye series were similarly low.1153 1158
 With the microkeratome assisted posterior keratoplasty a.k.a. ELK a.k.a. endoker-
atoplasty, no postoperative BCVA’s higher than 20/30 were reported, except by 
Culbertson.1110 In most studies on the microkeratome assisted PLK techniques, 
including those on experimental cadaver eye models, postoperative keratomet-
ric astigmatism is more unpredictable than in the tunnel incision techniques.1110 
1130-1132 1134 1138 1157
 Reported complications during and after PLK (DLEK) include:
 • microperforation during lamellar dissection necessitating conversion of the
   technique to PK, 
 • early postoperative iridocorneal adhesions that required reintervention, 
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 • primary graft failure,
 •  sequestered viscoelastic material in the donor-recipient interface that 
  required secondary PK after 1 month, 
 •  visually impairing increasing donor-recipient interface haze that necessitated 
  secondary PK at one year post-operatively, 
 •  endothelial rejection episodes that were usually mild and reversible, and 
  sometimes caused by patient noncompliance,
 •  occasional development of glaucoma, early or later after PLK/DLEK, 
  sometimes induced by topical steroid medication, and occasionally requiring 
  trabeculectomy, 
 •  visually disturbing posterior graft folds,
 •  the rapid development of visually disturbing cataract in phakic PLK patients,
 • and probably the most often occurring complication: incomplete or no initial  
 graft adherence to the posterior stroma.1142 1148 1150 1152 1154 1157 1160 1218 1219 
 
 For ELK/endokeratoplasty/MAPK, reported complications include: 
 •  flap melt, requiring flap removal and resuturing the posterior disc, 
 •  epithelium downgrowth, requiring flap lift and aspiration, 
 •  extreme hyperopic shift (+ 16 D) due to unknown causes, 
 • necessary suture adjustments, 
 •  wound leaks, 
 • primary endothelial failure, requiring retransplantation, 
 • and Mycobacterium chelonae interface infection, requiring PK after failure of 
  conservative antibiotic therapy.1110 1130-1133 1137 1220
 Larger systematic comparative prospective studies are needed to establish 
whether the theoretical advantages of PLK over PK as described in part III of 
this chapter are truly accomplished in practice, and whether the disadvantages 
of PLK techniques do not outweigh their advantages. In The Netherlands, a 
multicentered randomized prospective clinical trial has started (the Dutch La-
mellar Corneal Transplant Study –DLCTS). Visual and other outcomes of several 
contemporary techniques of PLK and ALK are evaluated and compared to the 
results of PK in the control group.
b.  Endothelial cell loss.
1.  ECD after anterior LK.
 Only a few studies reported on endothelial cell loss after lamellar keratoplasty. 
In the study by Bodereau et al, the ECD after LK was twice that after PK, both 
performed in 11 eyes for herpetic keratitis. However, not clear was if there was a 
difference in post-operative time, and whether the study had been performed 
in a randomized fashion of that historic controls had been used.1221 Sugita 
reported in his series of 113 eyes that had undergone deep LK, ECDs of 2225 
cells/mm2 at 1 months postoperatively, and 1937 cells/mm2 at 24 months post-
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operatively, representing a loss of 13 %. In 74 eyes after deep LK for keratoco-
nus, the ECD almost stabilized after 6 months postoperatively, in contrast to the 
continuing drop in ECD observed in a nonrandomized control group of 48 eyes 
after PK for keratoconus.1080 In the study by Morris et al. no pre-operative ECDs 
had been obtained in 20 eyes that had undergone deep LK with lyophilized 
donor tissue. At one to eight years postoperatively (mean: 3 years) the mean 
ECD was 2417 cells/mm2. In 13 eyes with corneal disease thought to afflict the 
endothelium such as keratoconus and lattice dystrophy, the mean ECD was 
even 2837 cells/mm2; however, there was a substantial spread, with individual 
corneas having densities around 1000 cells/mm2. In 4 patients a comparison 
was made to the unoperated fellow eye; ECD was on average 10 %  (range 0.25-
20 %) lower in the LK eyes. In  4 patients LK eyes were compared to the fellow 
eye that had undergone PK; here the ECD was on average 50 % lower (32-71%) 
in the PK eyes. It should be noted however, the PKs had a longer follow-up 
time of  0.6 to 7,1 years compared to the LKs.1068 Trimarchi et al. retrospectively 
compared 150 patients after deep LK, to 150 age-, sex-, and indication-matched 
patients who had undergone PK. The general follow-up time for the LK patients 
was 5 months, whereas for PK patients it was 13 months. It is not clear from 
their paper whether in all 300 patients ECD measurements had been obtained. 
The mean ECD after LK was 2235 cells/mm2, whereas after PK is was 979 
cells/mm2.1213 Panda et al conducted a prospective clinical trial in which they 
compared results after LK to after PK, performed on 24 eyes each. Mean ECDs 
after LK were 2233 cells/mm2 at six months, and 2220 cells/mm2 at 12 months 
postoperatively; differences with ECD after PK were highly significant at both 
time points (p < 0.001; 1903 cells/mm2  at 6 months, and 1579 cells/mm2 at 12 
months, respectively).1083 Shimazaki et al. conducted a randomized prospective 
clinical trial comparing deep LK to PK. They investigated 26 eyes in 24 patients. 
They found ongoing endothelial cell loss until 6 to 12 months with stabilization 
at 24 months postoperatively, when also the difference with PK became statisti-
cally significant (2183 cells/mm2 vs. 1868 cells/mm2, p= 0.044).1103 
 In order to investigate the amount and pattern of endothelial cell loss after 
deep anterior lamellar keratoplasty (DALK) performed with the manual deep 
lamellar dissection technique described by Melles et al., 34 1100 the prospective 
clinical study described in chapter 11 of this thesis was initiated. The multi-
centered randomized prospective Dutch Lamellar Corneal Transplantation 
Study that has started will also look into endothelial cell loss after anterior 
lamellar keratoplasty techniques.
 
2.  ECD after posterior LK.
 Endothelial cell loss is essential in corneal transplantation follow-up, and all the 
more in posterior lamellar transplant survival. Therefore it is remarkable that 
only two authors reported on endothelial cell densities after ELK and similar 
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micro-keratome based procedures. In Culbertons’s series ECD was1693 cells/
mm2 at 6 months postoperatively (range 994 – 2168 cells/mm2), and in Ehlers’ 
series of 3 patients ECD ranged from 1200 to  2300 cells/mm2 at 12 months 
postoperatively.1110 1130 No figures on relative endothelial cell loss compared to 
preoperative donor ECDs were provided.
 In Melles’ initial report of his first 6 PLK patients (9 mm incision technique), 
mean ECD at 12 months postoperatively was 2520 cells/mm2.1142 In his report 
on 14 PLK patients with the 9-mm and 5-mm incision deep dissection tech-
niques which also included these first 6 patients, the ECDs were 2126 cells/mm2 
at 6 months, 1839 cells/mm2 at 12 months, 1418 cells/mm2 at 24 months, and 
1137 cells/mm2 at 36 months postoperatively. Price reported on 3 PLK eyes out 
of a much larger series of 47 PLK eyes. Postoperative ECDs were 1680 cells/mm2 
in one eye at 21 months after PLK followed by phacoemulsification 5 months 
later; 540 cells/mm2 in an eye 21 months after PLK followed by phacoemul-
sification 6 months later; both of these two eyes furthermore  experienced 
reversible rejection episodes; and 1810 cells/mm2 in a third, pseudophakic eye 
at 9 months after PLK. The second and third PLK eye were of the same pa-
tient. He did not report on ECDs of his entire PLK series nor in his DSEK series, 
however.1150 1151 Terry’s reports from 2003 are all on the same cohort of patients, 
with different numbers of patients and varying follow-up lengths reported. In 
his initial report, the mean 12-month post-operative ECD in 8 patients was 2409 
cells/mm2. In later reports with more patients, ECDs at 6, 12, and 24 months 
were all measured around 2200 cells/mm2 , which implied a loss of 17 – 25 
% from preoperatively. Remarkably, at 24 months postoperatively, only slight 
additional endothelial cell loss was observed compared to 12 and 6 months, 
respectively.1154 1156 1157 1159 1161 1162 
 The multicentered randomized prospective Dutch Lamellar Corneal Trans-
plantation Study that has started will also look into endothelial cell loss after 
posterior lamellar keratoplasty techniques. In order to investigate the amount 
and pattern of endothelial cell loss after PLK performed with the first two 
techniques described by Melles et al. (9- and 5- mm incision techniques), the 
prospective clinical study described in chapters 12 and 13 of this thesis was 
initiated.
 
 References
 See page 287.
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Abstract
 Purpose
To measure the recipient endothelial cell loss after the Melles technique for deep 
anterior lamellar keratoplasty. 
 
 Methods
 In 21 eyes of 21 patients a deep anterior lamellar keratoplasty procedure was 
performed. Before surgery, and at 6, 12 and 24 months after surgery, specular 
microscopy was performed to evaluate the endothelial cell density. For each 
postoperative time interval, the mean endothelial cell loss relative to the preoperative 
value was calculated. 
 
 Results
Mean postoperative endothelial cell loss averaged 283 cells/mm2 (± 293) at six months, 
335 cells/mm2 (± 309) at 12 months, and 421 cells/mm2 (± 316) at 24 months. Estimate 
relative endothelial cell density losses obtained by mixed model ANOVA were 11.1%, 
2.0%, and 1.2% respectively, each time compared to its previous measurement point. 
Second order comparisons showed that the loss within the first six months was 
significantly higher than after six months.
Conclusion 
In deep anterior lamellar keratoplasty, the recipient corneal endothelium showed a 
small initial drop in endothelial cell density followed by a physiological rate of cell loss. 
Cell survival after lamellar keratoplasty may be expected to be better when compared 
to that following penetrating keratoplasty.
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 Introduction
 
 Corneal endothelial cell loss after penetrating keratoplasty occurs at a higher 
than physiological rate (0.6% per year),310 to a cumulative cell loss of 50% or more 
within the first ten years. This suggests that after the initial surgical trauma, donor 
endothelial cell survival is compromised in the host ocular environment.310 779 
 
 In the past years, several techniques for deep anterior lamellar keratoplasty 
have been described, including deep stromal manual dissection,34 1080 as well as 
dissection by injecting air or visco elastic just anterior to Descemet’s membrane, 
to separate the Descemet’s membrane from the posterior stroma.1009 1084 1087 In 
contrast to penetrating keratoplasty, the recipient Descemet’s membrane and 
endothelium are left in-situ in deep anterior lamellar keratoplasty, i.e. only the 
anterior cornea is replaced by donor tissue. However, to our knowledge, no 
reports exist on the pattern of the recipient endothelial cell loss following deep 
anterior lamellar keratoplasty.
 Since the condition of the recipient endothelium is one of the major criteria to 
determine long-term transplant survival, we evaluated the pattern of corneal 
endothelial cell loss within the first two years after deep anterior lamellar 
keratoplasty. 
 Materials and methods
 
 From a larger group of patients who underwent deep anterior lamellar 
keratoplasty for various indications, 21 eyes of 21 patients were selected by the 
availability of pre- and postoperative specular microscopy examinations (Table 
11.1). The average patient age was 43.2 (± 15.2 ); ten patients were male and 
eleven female. Twelve patients were operated on for keratoconus, three for a 
quiescent Herpes Simplex stromal scar, three for a postinfectious quiescent 
stromal scar, and three for a hereditary stromal dystrophy. Each patient signed 
an informed consent as part of an Institutional Review Board approved study. 
 All patients had the same surgical procedure performed by the same surgeon 
(GM).The surgical technique has been previously described in detail.34  In short, a 
half-depth scleral incision, 5.0 mm in width, was made 1-2 mm from the limbus at 
the 12 o’clock surgical position. A sclero-corneal tunnel was dissected extending 
1.0 mm into the clear cornea. Through a side-port at 3 or 9 o’clock, the anterior 
chamber was completely filled with air, to create an air-to-endothelium interface, 
i.e. a reference plane to optically visualize the depth of the dissection within the 
cornea during surgery.1090 With dissection spatulas (DALK/PLK dissection spatulas, 
D.O.R.C. International, Zuidland, The Netherlands), a manual stromal dissection 
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was made at approximately 95% corneal depth,1090  using the air-to-endothelium 
reflex to monitor dissection depth through the operating microscope. The corneal 
pocket was extended up to the limbus over 360 degrees. 
 
 Then the pocket was filled with a visco elastic (hydroxypropylmethylcellulose, 
Ocucoat, Bausch & Lomb, Clearwater, USA) to displace the posterior corneal 
layers toward the iris to avoid damaging these layers during trephination. A 
Hessburg-Barron suction trephine was positioned onto the anterior corneal 
surface, and the blade was turned downward until visco elastic was seen to 
escape from the pocket. Remaining attachments of the anterior button were 
then cut with microscissors, and the recipient stromal bed was thoroughly 
irrigated to remove all visco elastic. 
 With a dry sponge, the endothelial side of the donor button was gently 
‘touched’ to damage or remove the endothelial cells. Trypan blue 0.06% 
(VisionBlue, D.O.R.C. International) was then applied onto the donor posterior 
corneal surface, to stain the dead cells or the denuded Descemet’s membrane. 
After removing all excess dye, the donor Descemet’s membrane with the 
endothelium was gently swapped from the button with a dry sponge.1009 The 
donor button was then positioned onto the recipient stromal bed, and fixated 
with two double-running 10-0 sutures. 
 Before the procedure, and 6, 12, and 24 months after surgery, the endothelium 
was photographed and evaluated using a Topcon SP2000p non-contact autofocus 
specular microscope (Topcon Corp, Tokyo, Japan). Images of the central corneal 
window were analyzed using Imagenet 2000 software (Topcon Corp) by the 
same observer (B.v.D.); manual correction of the cell borders was performed 
prior to final analysis of the endothelium. For each postoperative time interval, 
three measurements of endothelial cell density, coefficient of variation of cell size 
(polymegathism) and hexagonality (pleomorphism) were averaged. 
 Statistical analysis was performed using a mixed-model ANOVA (analysis of 
variance), with which (1) estimates of mean relative endothelial cell density 
losses per time point, (2) differences between time points, and (3) second 
order comparisons between the intervals were calculated. The within-subject 
correlation structure was assumed to be first order auto-regressive.310 
 Results
 
 The postoperative course was uneventful in fifteen patients. Two patients 
operated on for a quiescent Herpes Simplex scar had mild recurrent attacks 
under oral acyclovir treatment throughout the study period. Two patients de-
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veloped glaucoma that could be managed with topical medication. One of the 
latter patients also suffered from a temporary epithelial defect 14 months after 
surgery with secundary keratic precipitates that resolved after treatment with 
antibiotics and topical steroids. One patient underwent a phacoemulsification 
11 months after surgery that was complicated by a retinal detachment in the 
presence of high myopia (-18 diopters).
 The overall endothelial cell density averaged 2823 (± 549) cells/mm2 before 
surgery, and after surgery 2481 (± 506) cells/mm2 at six months, 2514 (± 506) 
cells/mm2 at 12 months, and 2476 (± 432) cells/mm2 at 24 months (Figure 
11.1). Mean postoperative endothelial cell loss averaged 283 (± 293) cells/mm2 
at six months, 335 (± 309) cells/mm2 at 12 months, and 421 (± 316) cells/mm2 
at 24 months (Table 11.1). Cell morphology as measured by endothelial cell 
polymorphism and hexagonality, did not change significantly over time. 
 Statistical analysis by mixed model ANOVA resulted in estimated endothelial 
cell density losses; at 6 months postoperatively 11.1% (p<0.0001), whereas 
the estimate cell loss at 12 months compared to 6 months decreased to 2.0% 
(p = 0.3) and the estimate cell loss at 24 months compared to 12 months was 
1.2% (p = 0.5) (Figure 11.2). Additional second order comparisons indicated 
that endothelial cell loss in the first postoperative period (0-6 months), was 
significantly higher than the cell loss in the subsequent time intervals (6-12 
months: p = 0.0019, and 12-24 months: p = 0.0008).
 Discussion
 
 Sufficient corneal endothelial cell density is required for long-term functional 
success of any type of keratoplasty. With penetrating keratoplasty, an overall 
endothelial cell loss has been reported of approximately 33% within the first 
two postoperative years, and the cell density continues to decrease at an 
accelerated rate up to 20 years after surgery.310 1068 1080 1083 1103 To our knowledge, 
it is unknown if the decrease in recipient endothelial cell density mimics that 
of the donor endothelium in penetrating keratoplasty, or whether it shows a 
physiological cell loss as in unoperated corneas. This is important in order to 
assess the risk of long-term lamellar transplant failure, and to determine if the 
risk varies between lamellar and penetrating grafts. 
 
 In the current study, corneal endothelial cell loss was measured at intervals of 
6, 12 and 24 months after deep anterior lamellar keratoplasty. Compared to the 
preoperative values, the transplanted corneas showed a drop in endothelial 
cell density of about 400 cells per sq. mm (~ 11%) at the first postoperative 
measurement at six months. Thereafter the rate of cell loss diminished to about 
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100 cells per sq. mm per year (~ 1-2%), thus approaching a physiological cell 
loss as found in virgin corneas.229 310 These findings suggest that an initial drop 
in cell density is induced by surgical trauma and/or topical treatment, but no 
continued elevated cell loss is present thereafter. This interpretation of the 
postoperative cell loss is supported by second order comparisons: in the first 
postoperative period (0-6 months) the cell loss was found to be significantly 
higher than in the two later periods (6-12 and 12-24 months).
 In contrast, endothelial cell loss occurs at continuous accelerated rate following 
penetrating keratoplasty.310 778 Although its exact cause is unknown, cell loss 
after penetrating keratoplasty may result from the surgical trauma, endothelial 
cell redistribution, and allograft rejection periods.310 777 Although we did 
observe stromal allograft rejections with formation of keratic precipitates 
onto the endothelium after deep anterior lamellar keratoplasty, the recipient 
endothelium in lamellar keratoplasty may not be compromised in the long-
term like the donor endothelium in penetrating keratoplasty.
 If the recipient endothelium underneath a lamellar graft shows a rate of cell loss 
similar to that in virgin corneas, deep anterior lamellar keratoplasty would have 
an important advantage over penetrating keratoplasty in the management 
of anterior corneal disorders. The majority of these disorders, like keratoconus 
and corneal scars, occur in young people in whom long-term endothelial cell 
survival is important. If the recipient endothelium following deep anterior 
lamellar keratoplasty is not subjected to significant surgical trauma and 
shows a physiological cell loss thereafter, the likelihood of a clear corneal graft 
throughout life may be higher than with a penetrating keratoplasty. Even more 
so when cataract surgery at old age may further compromise the condition of 
the corneal endothelium.310
   
   References
  See page 287.
Postoperative time interval
Measured endothelial cell loss
(cells/mm2)
Estimated endothelial cell loss
(%)
6 months 283 (± 293) 11.1
12 months 335 (± 309 ) 2.0
24 months 421 (± 316) 1.2
Table 11.1 Endothelial cell density and cell loss after deep anterior lamellar keratoplasty.
ch
ap
te
r 1
1
221
bart_part4DEF.indd   221 19-11-2006   14:05:07
Fig. 11.1 Measured ECD-loss after Deep Anterior Lamellar Keratoplasty
Fig. 11.2 Estimated percentual ECD-loss after Deep Anterior Lamellar Keratoplasty
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Abstract
 
 Purpose
To report the mid-term endothelial cell density measurements after posterior lamellar 
keratoplasty (Melles techniques).
 Design
Cohort study. 
Methods
Fifteen consecutive eyes of 15 patients in whom a posterior lamellar keratoplasty 
procedure was performed for pseudophakic bullous keratopathy or Fuchs’ endothelial 
dystrophy were evaluated. In eleven corneas the donor tissue was inserted through 
a 9.0 mm sclerocorneal pocket incision (Technique A); in four cases the donor was 
folded and inserted through a 5.0 mm incision (Technique B). Specular microscopy was 
performed at 6, 12, 24 and 36 months after surgery, to measure the endothelial cell 
density. 
 
 Results
Mean postoperative endothelial cell density averaged 2126 cells/mm2 (± 548) at six 
months, 1859 cells/mm2 (± 477) at 12 months, 1385 cells/mm2 (± 451) at 24 months, and 
1047 cells/mm2 (± 425) at 36 months. 
Conclusion
In posterior lamellar keratoplasty, the donor corneal endothelium showed a decrease 
in cell density similar to that following conventional full-thickness penetrating 
keratoplasty. 
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 Introduction
 
 In 1998, we described a new surgical technique, posterior lamellar keratoplasty, 
for the management of corneal endothelial disorders.33 Instead of excising a 
full-thickness corneal button, we evalutated the transplantation of a posterior 
lamellar disc, 7.0 to 8.0 mm in diameter, through a 9.0 mm scleral pocket 
incision. In 1999 and 2000 we reported on the preliminary results of this 
technique (Technique A; Figure 12.1).1141 1142
 In 2000, we also introduced a second technique, in which a larger 8.5 to 9.0 
mm diameter posterior lamellar disc was folded and transplanted through a 5.0 
mm scleral tunnel incision (Technique B; Figure 12.1).1100 1143 Both techniques 
eliminated the need of suture fixation of the donor tissue, so that the posterior 
cornea could be transplanted without the use of corneal surface incisions or 
-sutures. We expected that the advantages of either technique were (1) lower 
with the rule astigmatism, (2) elimination of suture related complications, and 
(3) a lower incidence of wound deshiscence, as compared with penetrating 
keratoplasty. 
 Because corneal endothelial disease is the main indication for performing these 
procedures, mid-term and long-term evaluation of the grafted endothelial cell 
density seems mandatory. The purpose of the current study was to determine 
the pattern of endothelial cell loss in the first 3 years after posterior lamellar 
keratoplasty. 
 Materials and methods 
 
 Fifteen consecutive patients who underwent posterior lamellar keratoplasty 
for pseudophakic bullous keratopathy and Fuchs’ endothelial dystrophy prior 
to August 2000, were enrolled in the study (Table 12.1). The average patient 
age was 74.3 (± 8.8) years; seven patients were male and eight were female. 
Each patient signed a informed consent as part of an institutional review board 
approved study.
 All patients were operated on by the same surgeon (GRJM); eleven patients 
underwent  9.0-mm incision surgical technique (Technique A; Figure 12.1),33 1141 
1142 and four with the 5.0 mm incision surgical technique (Technique B; Figure 
12.1) (Table 12.2).1100 1143 Postoperative endothelial cell density measurements 
were performed by the same observer (BTHvD) using the same specular 
microscope and software for processing of the digital images in each patient at 
each postoperative time interval.1222
 The surgical techniques have been previously described. )33 1100 1141-1143 In short, 
a deep stromal pocket was dissected across the recipient’s cornea through a 
scleral tunnel incision using an air bubble in the anterior chamber to monitor 
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dissection depth during surgery.1090 In patients operated on with Technique 
A, an intrastromal trephine was inserted into the stromal pocket to excise a 
recipient posterior lamellar disc. The remaining stromal strands were cut with 
microscissors. In patients operated on with Technique B, a 9.0 mm mark was 
made into the corneal epithelium, and only the microscissors were used to 
excise a (9.0 mm) posterior disc.
 After preparation of a donor posterior lamellar disc, implantation of the disc 
was performed via the scleral incision. In Technique A, the disc was placed 
endothelial side down on a spoon shaped glide covered with visco elastic to 
protect the donor endothelium.33 1141 1142 The scleral incision was then sutured 
with 10.0 nylon. In Technique B, an 8.5 mm posterior disc was folded prior to 
insertion into the anterior chamber, with visco elastic covering the endothelium 
for protection.1100 1143 The scleral incision was left unsutured. No corneal sutures 
were used in any case for fixation of the donor tissue. 
 At 6, 12, 24 and 36 months after surgery, the endothelium was photographed 
and evaluated using a Topcon SP2000p non-contact autofocus specular 
microscope (Topcon Corp, Tokyo, Japan). Images of the central corneal window 
were analyzed using Imagenet 2000 software (Topcon Corp); manual correction 
of the cell borders was performed prior to final analysis of the endothelium 
(Table 12.1).1222 For each postoperative time interval, three measurements of 
endothelial cell density were averaged. 
 
 A donor posterior lamellar disc was excised from a whole globe during surgery, 
so that preoperative endothelial cell counts could not be obtained. Since the 
endothelial cell density has been reported to be within 10% between mate 
eyes,267 for the surgeries whole globes were selected that had a contralateral 
cornea with a cell density of at least 2500 cells/mm2.1142  
 For statistical analysis of the relatively small number of patients, subdivided by 
two surgical techniques and with maximally five measurements per subject 
in time, a parsimonious exponential decay model for endothelial cell loss had 
to be constructed that was still flexible enough to fit to the data satisfactorily. 
This also had to be done in such a way that statistical inference could be 
made for both surgical techniques separately and that differences between 
both techniques could be easily tested (see Appendix). For estimating the 
coefficients of this model, analysis-of-variance for repeated measures was used 
(PROC MIXED of SAS, release 8.2 (2001), SAS Institute Inc, Cary, USA). The model 
was also used to make predictions, e.g., at which time point the endothelial cell 
loss in the two different techniques would be the same. 
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 Results
 
 At the three year postoperative time interval, all patients had a clear corneal 
graft without corneal or epithelial edema. For Technique A (Figure 12.1), the 
overall endothelial cell density averaged 2366 (± 387) cells/mm2 at 6 months (n 
= 10); 2062 (± 321) cells/mm2 at 12 months (n = 9); 1538 (± 484) cells/mm2 at 24 
months (n = 9); and 1126 (± 461) cells/mm2 at 36 months (n = 9) after surgery 
(Figure 12.2 a; Table 12.1). For Technique B (Figure 12.1), mean cell density 
averaged 1535 cells/mm2 (± 322) at 6 months (n =4); 1216 cells/mm2 (± 156) at 
12 months (n = 3); 1040 cells/mm2 (± 128) at 24 months (n = 4); and 869 cells/
mm2 (± 134) at 36 months (n = 4) after surgery (Figure 12.2a; Table 12.1). The 
overall endothelial cell density as measured in the contralateral donor cornea 
before the surgery averaged 2865 cells/mm2 (± 158) for Technique A (n = 10) 
and 2700 cells/mm2 (± 158) for Technique B (n = 4) (Figure 12.2b; Table 12.1). 
 For each of the surgical techniques, we first tried to apply the non-linear bi-
phasic exponential decay model proposed by Armitage and associates.231 
However, with our data-set covering only maximally five measurement 
points per subject during three years of follow-up, no good fit of this model 
containing four coefficients to be estimated could be achieved, for neither 
technique. After trying to fit several more parsimonious linear (one-phasic) 
exponential decay models, the models that showed the best fit to our data 
were:
Technique A: Predicted ECD = exp (7.9410 – 0.3034 t – 0.03876 t 1/3),
Technique B: Predicted ECD = exp (7.9410 – 0.02672 t – 0.7659 t 1/3);
 in which t = time after the operation measured in years. The Appendix provides 
more details on these decay models. 
 There was a highly significant difference between the two Techniques 
(p<0.0001) considering the coefficients simultaneously. With these models, the 
extrapolated, predicted time after which the endothelial cell density would 
reach 500 cells/mm2 was 5.5 years for Technique A and 7.8 years for Technique 
B; and it could be predicted that after 4.25 years ECDs would be the same for 
both operation techniques. (Figure 12.3)
 Discussion
 
 To manage corneal endothelial disorders like pseudophakic bullous 
keratopathy and Fuchs’ endothelial dystrophy, a posterior lamellar keratoplasty 
may be performed as an alternative procedure to penetrating keratoplasty.33 1100 
1141-1143 With penetrating keratoplasty, an overall endothelial cell loss has been 
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reported of approximately 33% after the first year after surgery (Table 12.2),764 
and the cell density has been found to continue to decrease at an accelerated 
rate up to 20 years after surgery.310 779 This suggests that after the initial surgical 
trauma, donor endothelial cell survival is compromised in the host ocular 
environment.755
 In the current study, the mid-term endothelial cell density was evaluated after 
posterior lamellar keratoplasty. Fourteen consecutive eyes with at least three 
years of follow-up were measured, to determine the rate and the pattern of cell 
loss after this new type of corneal surgery. The evaluation may be particularly 
important, because a posterior donor disc was implanted into the recipient 
eye using a spoon shaped glide covered with visco elastic (Technique A, Figure 
12.1), or by folding the donor for implantation through a small tunnel incision 
(Technique B, Figure 12.1). Both implantation techniques could potentially 
harm the donor endothelial cell layer. 
 In the first group of patients, in whom the donor tissue was implanted using 
a spoon shaped glide (Technique A, Figure 12.1), the endothelial cell counts 
averaged 2062 cells/mm2 (27.6% cell loss) at one year postoperative. Except 
two, all eyes had an endothelial cell density of 2000 cells/mm2 or more. A similar 
result was found by Terry et al. who performed our procedure with some minor 
modifications in eight patients.1154 1155 These findings suggests that the surgery 
itself, i.e. the preparation of the donor posterior lamellar disc, positioning of 
the corneal disc endothelial side down onto the spoon-shaped glide, and 
the implantation of the disc through the scleral incision, did not cause an 
unacceptable cell loss. 
 However, endothelial cell density measurements in the following years showed 
a rapid decline of the cell density, to 1126 cells/mm2 at three years (cumulative 
cell loss 61%). This rate of cell loss may still be similar to that after penetrating 
keratoplasty (Table 12.2).216 228 229 310 480 492 497 500 678 770
 
 The result may have been biased due to two additional factors. Initially patients 
were selected with a low visual potential due to a concomitant ocular disorder, 
that in some cases may have had an effect on postoperative endothelial cell 
survival, for example, the iris-fixated anterior chamber lens in case 1, or the 
uveitis glaucoma hyphema syndrome in case 2. Postoperative events may also 
have affected the endothelial cell counts: severe herpes keratitis 12 months 
after surgery, with poor compliance to topical treatment in case 8, and uveitis in 
the early postoperative period in Case 11. 
 In the second group of patients, in whom the donor tissue was implanted 
by folding the donor (Technique B, Figure 12.1), the endothelial cell counts 
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averaged 1215 cells/mm2 at one year postoperative. We are unaware of 
previous reports on the endothelial condition with this technique so far. 
Although no statistical difference in endothelial cell density was found between 
Techniques A and B at the three years postoperative time interval, there may be 
two possible explanations for the lower endothelial cell density in Technique 
B than Technique A (2062 cells/mm2 at one year). First the implantation 
of folded donor tissue may be more traumatic. Second, more endothelial 
cell redistribution may have occurred, because the recipient opening was 
intentionally made larger than the diameter of the donor disc to avoid 
inadvertent wrinkling of the donor tissue. As a result, a small stromal gap was 
present along the entire circumference of the donor disc. After surgery, some 
stromal edema was present over the area of the gap, disappearing within the 
first months probably because of donor endothelial cell migration covering the 
area of the stromal denuded of endothelial cells adjacent to the donor tissue. 
 It should be noted, that the models were fit on small groups with relatively 
short follow-up periods. This may have resulted in overfitting of the models 
and may explain that we could not fit a biphasic model (yet). According to 
extrapolated calculations, both Techniques would have the same endothelial 
cell densities after 4.25 years, with a slower decrease in cell density in Technique 
B. A possible explanation for the slower cell loss in Technique B may be that 
in Technique B an 8.5-9.0 mm donor was implanted, instead of a 7.0-7.5 mm 
donor in Technique A (Figure 12.1). As a result, the donor disc in Technique 
B is carrying more endothelial cells, and cell re-distribution toward the host 
peripheral rim may occur at a different rate or with a different pattern in each of 
the Techniques.777 
 
 In conclusion, the one year measurements in our study suggests that either 
an implantation technique using a spoon-shaped glide (unfolded donor) 
(Technique A) or a technique in which the donor is folded to allow implantation 
through a small incision (Technique B), does not cause unacceptable damage 
to the donor endothelial cell layer. The three year measurements suggest that 
the donor endothelial cell density after posterior lamellar keratoplasty may be 
similar to that following conventional full-thickness penetrating keratoplasty. 
 References
  See page 287.
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Table 12.1  Endothelial cell density (cells / mm2) after posterior lamellar keratoplasty
PPBK = Pseudophakic bullous keratopathy, FED = Fuchs’ endothelial dystrophy 
UGH = uveitis, glaucoma, hyphaema sydrome , PKP = penetrating keratoplasty
Case #
Age / 
sex
Indication 
surgery
Preoperative 
endothelial 
cell density 
(contralateral 
cornea) 
(cells / mm2)
Postoperative (months) 
endothelial cell density 
(cells / mm2) 
Remarks
6 12 24 36
Technique A – 9.0 mm incision technique (unfolded donor)
1 79F PPBK 2700 2120 2077 973 582
Anterior chamber 
lens in situ 
2 63M PPBK 3000 2842 n.a. 1566 842
Preoperative: 
UGH syndrome
3 86M FED + PPBK 2900 2255 2094 2033 2064
4 74F FED + PPBK 3100 2969 2102 1407 1088
5 74F FED 2900 2796 2508 1905 1141
6 72F FED + PPBK 3100 2332 2247 1932 1423
7 85M ABK 2700 n.a. n.a. n.a. n.a. 
Lost to follow up 
4 months 
postoperative
8 90F FED + PPBK 2800 1896 1738 1355 814
12 months 
postoperative 
severe HSV keratitis
9 77M FED 2750 2412 2287 1928 1574
10 61F FED + PPBK 2600 2325 2177 n.a. n.a.
13 months post-
operative PKP for
 interface scar
11 81M FED 2800 1681 1338 741 605
Postoperative 
uveitis
Average 9.0  mm incision  technique 2850 2366 2062 1538 1126
 SD 158 357 320 434 461
Technique B – 5.0 mm incision technique (folded donor)
12 77F FED 2600 1787 1465 1122 1077
13 64M FED 2500 1916 n.a. 1084 750
14 66F FED + PPBK 2800 1168 1053 821 751
15 65M FED 2900 1268 1227 1133 899
Average 5.0  mm incision technique 2700   1535 1216 1040 869
SD 183   322 156 128 134
Overall average 2818   2126 1859 1385 1047
SD 181   548 477 451 425
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Fig.12.1 Diagrammatic representation of the techniques for posterior lamellar keratoplasty.
 See colour figure on page 330.
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Fig. 12.2a  Measured decrease in endothelial cell density following posterior lamellar keratoplasty in (a) patients 
with the 9.0 mm incision technique and unfolded donor (Technique A) and (b) patients with the 5.0 
mm incision technique and folded donor (Technique B). 
Fig. 12.2b Measured overall decrease in endothelial cell density following posterior lamellar keratoplasty in all 
patients (Technique A + B). 
u = Technique A, l = Technique B
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Fig. 12.3  Estimated endothelial cell density following posterior lamellar keratoplasty for (a) 9.0 mm incision 
technique and unfolded donor (Technique A) and (b) the 5.0 mm incision technique and folded donor 
(Technique B). The horizontal line represents the 500 cells/mm2 level..Compare to Figure 12.2a.
Appendix: Exponential decay models of endothelial cell density after posterior lamellar keratoplasty
The specified model that showed a plausible fit to our data for ECD loss in time was an exponential decay model with a linear term and 
a cubic root term of time, of which the coefficients are assumed to be different between the two surgical techniques. Differences in the 
coefficients between the two techniques are represented in the model by interaction terms between time and technique. The intercept 
is assumed to be the same for both techniques. The residuals (differences between observed and predicted ECD) are assumed to have 
a spatial (i.e. distance in time) correlation structure, i.e. the correlation between repeated measurements decreases as the time interval 
between the measurements increases, apart from a separate component in the residual variance due to measurement error. 
The estimates are given below, with time t  measured in years. 
Technique A: 
 Predicted ECD = exp (7.9410  -  0.3034 t - 0.03876 t 1/3)
 SE’s:   (0.0672)  (0.0496)  (0.0793)
 p-values:      p < 0.001  p = 0.627
Technique B:
 Predicted ECD = exp (7.9410 -  0.02672 t  - 0.7659 t 1/3)
 SE’s: (0.0672)  (0.0753)  (0.1224)
 p-values:   p = 0.725    p < 0.001
There is a highly significant difference between the two techniques (p < 0.001) considering the two coefficients of the linear and 
the cubic root term of time simultaneously. The predicted time after which ECD will reach 500 cells/mm2 was calculated to be 5.5 
years for technique A and 7.8 years for technique B (figure 3, the horizontal line represents 500 cells/mm2.) The predicted time at 
which both techniques have the same ECD, that is the time where the two curves cross, is 4.25 years.
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Abstract
 
 Purpose
To report the 5-7 year endothelial cell density (ECD) measurements following posterior 
lamellar keratoplasty (PLK, Melles techniques).
Methods
Fifteen consecutive eyes of 15 patients in whom a PLK procedure was performed for 
pseudophakic bullous keratopathy or Fuchs’ endothelial dystrophy were evaluated. In 
eleven corneas the donor tissue was inserted through a 9.0 mm sclerocorneal pocket 
incision (Technique A); in four cases the donor was folded and inserted through a 5.0 
mm incision (Technique B). Specular microscopy for ECD measurements was performed 
longitudinally until 3 years post-operatively, and then cross-sectionally at 54 to 84 
months post-operatively. 
 
 Results
Three patients were not available or lost for follow-up. One graft had decompensated. 
In the remaining 11 PLK eyes, mean postoperative ECD was 741 cells/mm2 (± 305) cells/
mm2, ranging from 368 – 1576 cells/mm2. Mono- and bi-phasic regression models of 
ECD against time were fitted on the data, for each group separately.
 Conclusion
After PLK the ECD continued to decline in a rate higher than physiological, and 
probably also higher than after conventional full-thickness penetrating keratoplasty. 
Both early- and longer-term endothelial cell loss rates may be related to the surgical 
technique.
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 Since 1998, we have described various new surgical techniques for posterior           
lamellar keratoplasty (PLK). These techniques were popularized in the United States 
as deep lamellar endothelial keratoplasty (DLEK), small incision DLEK, and Descemet 
stripping endothelial keratoplasty (DSEK), respectively.1010 1096 1097 1100 1142 1143 1149 1151-1153 
From 1998 thru 2000, we operated on a series of patients using the two preliminary 
techniques. Fifteen patients were followed longitudinally, until the three year follow-
up interval. Our previous study on prospective central corneal endothelial cell 
density measurements (ECDs) in these patients involved monophasic regression 
models of ECD against time.1223 Using extrapolation of these models, predictions 
were made that ECD-loss would reach the 500-cells/mm2-level at 5.5 to 7.8 years 
postoperatively. 1223 In the current study, we report on the cross-sectional ECDs 
obtained in 2005 and 2006, at 54 to 80 months follow-up (mFU), for the same series 
of patients. This was the first group of PLK patients ever operated.
 Methods
 
 Eleven patients (Group A) were operated on with a PLK technique in which a 7.5 
mm diameter, unfolded donor posterior disk was transplanted through a 9.0 
mm scleral incision.1096 1100 1142 1153 1223 In four patients (Group B) a PLK technique 
was performed in which an 8.5 mm diameter, folded donor posterior disk was 
transplanted through a 5.0 mm scleral incision. 1010 1143 1223 (Surgery by GRJM) Central 
endothelial photographs were obtained with Topcon SP2000p non-contact 
specular microscopy. Semi-automated endothelial analysis was performed with 
Topcon IMAGEnet 2000 software, and involved manual correction (by BTHvD) of  
incorrect automatedly drawn cell borders (Topcon Corp, Tokyo, Japan).911 (Specular 
microscopy and analysis by BTHvD.) Donor ECDs were the ECDs of the contralateral 
donor cornea, obtained at the eye bank using light microscopy counting with a 
calibrated graticule after trypan blue 1.2 % and sucrose 1.8 % staining.332
 Results
 
 Table 13.1 shows the ECDs of the patients at the different FU points. In Group 
A, one patient (case 7) was altogether lost to FU 4 months postoperatively. One 
patient (case 10) was re-transplanted using penetrating keratoplasty (PK) at 
13 months postoperatively for interface scarring. One patient (case 8) was not 
available for FU for the present study. One graft in an eye with UGH syndrome 
(case 2) was found to have undergone late endothelial decompensation, and 
the patient was scheduled for penetrating keratoplasty (PK). In a fifth eye, the 
graft showed focal decompensation over one of the ‘claws’ of an aphakic anterior 
chamber IOL apparently due to ‘endothelial touch’. In this eye the central ECD 
measured 368 cells/mm2  (80 mFU). In the remaining six eyes in this group in the 
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present study, the central ECD ranged from 592 - 1576 cells/mm2 (60–84 mFU). 
In Group B, central ECDs ranged from 595 – 805 cells/mm2 (54 mFU). One patient 
in this group had experienced a mild, reversible endothelial allograft rejection. 
 With these additional data, the existing mono-phasic regression models of ECD 
loss over time for both groups from our previous study1223 were adjusted slightly, 
and extrapolations now predicted that both Groups would reach the 500-cells/
mm2-level almost simultaneously between 7 and 8 years postoperatively. See 
figure 13.1. ECD-loss was also evaluated using bi-exponential regression models 
as proposed by Armitage et al..231 The model that was fitted for Group A was: 
 
 ECD(time)= 353*exp[-0.5830*(time)] + 2498*exp[-0.2412*(time)] 
 
 which revealed fast-phase ECD loss with a half-time of 1.2 hours regarding a 
pre-operative proportion of 353 cells/mm2 of ECD , and a slow-phase half-time 
of 2.9 years regarding a proportion of 2498 cells/mm2. For Group B the bi-
exponential regression model was:
 
 ECD(time)= 1229*exp[-0.2280*(time)] + 1494*exp[-0.2054*(time)]
 with a fast-phase half-time of 3.0 hours which was related to a proportion of 
1229 cells/mm2 , and a slow-phase half-time of 3.4 years which was related to a 
proportion of 1494 cells/mm2. 
 Discussion
 
 The number of patients still available for follow-up and the number of follow-up 
time-points per patient were both small, which made the fitting of bi-exponential 
regression models difficult. Also, some over-interpretation of the data may occur. 
Nevertheless, our results suggest that the intra-operative endothelial cell loss is 
higher with the donor folding technique (Group B). In the late phase, grafts in 
Group B showed less cell loss. This may be related to the use of larger diameter 
grafts, as more endothelial cells were transplanted and less redistribution to 
the recipient is expected. In Group B the mean age was lower. Also, bullous 
keratopathy was less often the indication for transplantation. Both factors may 
diminish endothelial cell redistribution as well. Decline in ECD appears to be 
higher and faster than in historical PK groups, in all except one of these PLK 
patients.231 310 764 1223 However, because our patients constituted the first PLK cases 
performed worldwide, the ECD-loss may be skewed due to a learning curve, the 
use of prototype instruments, and selection of patients with pre-existing, possibly 
endothelial cell density influencing ocular diseases.
 
 References
  See page 287.
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Fig. 13.1 Predicted endothelial cell density (in cells/mm2) against time (in years) according to the mono-
  exponential regression models.
ECD (cells/mm2)
Years
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I.  Summary in perspective.
 In Chapter 1 a short overview is presented on how knowledge of and research 
on the corneal endothelium and endothelial specular microscopy evolved. It 
also briefly introduces the background and purpose of the studies in parts II, III, 
and IV of this thesis.
 Chapter 2 is a review of the literature on the corneal endothelium. Key points 
include the paramount importance of the endothelium, the innermost 
corneal layer, for hydration homeostasis. According to the Pump-Leak theory, 
the endothelium comprises a barrier that is permeable to water and smaller 
molecules in the anterior chamber (Leak), but not to larger molecules. 
Simultaneously, the endothelial cells actively pump water back into the 
anterior chamber (Pump). This hydration homeostasis is necessary to maintain 
corneal transparency. When in corneal edema the corneal water content 
becomes higher than normal, the cornea loses transparency. In humans, 
corneal endothelial cells possess very little mitotic capacity. This affects wound 
healing and it results in age-related loss of endothelial cells. This decay can 
be described using the endothelial cell density (ECD), the most important 
quantitative morphometric parameter of the endothelium. In vivo, endothelial 
morphology and ECD are often examined with specular microscopy. 
 Studies on cataract surgery and penetrating keratoplasty (PK) have raised 
concerns that there is prolonged endothelial cell loss at a higher-than-
physiological rate. After uncomplicated cataract surgery with modern 
techniques, peri-operative endothelial cell loss is relatively low and it may 
approach physiological rates within a few years. With older cataract extraction 
and lens implantation techniques, the loss was substantially higher and its 
rate stayed elevated for a long time. The amount and rate of endothelial cell 
loss may therefore be considered to be a safety standard for techniques and 
innovations in cataract surgery. 
 Increased endothelial cell loss has been observed for at least 10 and probably 
more years after PK. An important cause of endothelial cell loss is endothelial 
allograft rejection. But even in the absence of overt immunological rejection, 
endothelial cell loss occurs at a higher-than- physiological rate. Eventually this 
may lead to graft decompensation due to late endothelial failure (LEF). Too few 
endothelial cells are left to maintain the hydration homeostasis and hence to 
prevent graft opacification. Why the cell loss rate remains high after PK, and for 
how long, is still in debate. 
 As endothelial cell density is an important parameter, it is important that its 
measurements are reliable. Several aspects of reliability can be discerned. In 
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part II of this thesis we present studies on four of those aspects. We evaluated 
endothelial morphometric measurements with a Topcon SP2000P autofocus 
non-contact specular microscope, combined with Topcon IMAGEnet2000 
endothelial cell analysis software. 
 In chapter 3 we describe how the magnification of the SP2000P can be 
calibrated. We found incorrect calibrations in 4 different specular microscopes 
(unpublished data). Once again this proves the necessity of checking the 
calibration in any  biomedical measurement instrument. This is even more 
important when different types of instruments are used interchangeably.287,1224 
Furthermore, formulas were described for the calculation of correct ECD 
values, in case measurements had been obtained with an incorrectly calibrated 
instrument or software. 
 The validity of several ECD assessment methods was also investigated in this 
study, using the methods described by Bland and Altman.910 In our study there 
was a systematic difference between manual counts, and all ECD assessment 
methods in the SP2000P & IMAGEnet 2000 combination. However, almost 
all of these differences were relatively small, except in fully automated ECD 
assessment. The semi-automated assessment method, in which software-
defined cell borders had been manually corrected before ECD calculation, 
was the most valid method. It had the narrowest limits-of-agreement, which 
indicated less individual spread in measurements. In most instruments used for 
endothelial analysis, manual correction of automatedly recognized cell borders 
increases performance.1224,1225 
 The systematic difference between this assessment method and manual ECD 
counts implies that a correction factor must be used when semi-automated 
ECDs are compared to ECDs obtained with manual counting. Similarly, a 
correction factor should be applied when different assessment methods are 
used interchangeably. 
 As Bland and Altman  pointed out, calculating correlation coefficients for 
the comparison of measurement methods is not sufficient, as a systematic 
difference is not recognized. Nor should linear regression be used when two 
measurement methods are compared. Both measurement outcomes are 
independent parameters, and one method is not a function of the other. In 
literature sometimes the two mistakes can even be found in one study.313  
 A third aspect that affects the reliability of a measurement method is its 
reproducibility. In the study described in chapter 4 we found a reasonable to 
good overall reproducibility of endothelial morphometric parameters including 
ECD. Reproducibility was foremost affected by a relatively low repeatability, 
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i.e. a high sampling variability. High sampling variability can be decreased 
by obtaining more measurements and averaging their results. This way the 
variance of the measurements decreases with the inverse of the number of 
measurements. 
 Inter-observer reproducibility was good as well. ECDs obtained by different 
observers may be used interchangeably, provided that these observers have 
been trained well and use identical measurement and analysis techniques. 
Our results on reproducibility of ECD measurements with the SP2000P & 
IMAGEnet2000 were similar to those in other studies.294,1225
 In chapter 4 it was further demonstrated that ECDs from the nasal paracentral (i.e. 
3 mm off centre) area may be used to substitute for central ECD, if no clear images 
can be obtained of the corneal centre. The central ECD of the contralateral eye 
may substitute as well, provided the medical histories of both eyes were similar. It 
should be kept in mind that in individual cases a considerable difference between 
the substitution and substituted values may exist.
 The findings in chapters 3 and 4 show that it is possible to obtain reliable 
central ECD measurements with the SP2000P & IMAGEnet 2000 combination. 
Measurements can be reliably compared between individuals, and reliably 
followed over time within one individual, if the requirements described in these 
chapters are fulfilled.
 In the study described in chapter 5, a systematic, fixed difference of 140 cells/
mm2 was found between in-vivo SP2000P ECD and in-vitro, light microscopic 
eye bank ECD in the same corneal buttons. Specular microscopy measured 
higher ECDs than the in-vitro technique. This is relevant in follow-up studies 
on keratoplasty, such as those described in chapters 12 and 13 of this thesis, 
where donor ECDs are compared to specular microscopic ECDs. From now 
on, in similar studies either 140 cells/mm2 should be added to the donor 
ECDs or subtracted from the SP2000P ECD. When other specular or confocal 
microscopes are used, the existence of a systematic difference with donor 
ECDs obtained with a different method should be investigated using the same 
methods as in our study. 
 We did not expect to find a fixed, absolute difference, and it seems in 
contradiction with the most probable explanations for a possible difference. A 
relative difference, i.e. a difference that is proportional to the ECD value itself, 
was thought more probable. Therefore, one might assume that in reality there 
is a relative difference between in-vivo and in-vitro ECD measurements, but that 
this nature of the difference is masked by other effects. An explanation for such 
a masking effect is presented in chapter 5. The linear regression model that is 
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used in the cornea bank ECD counting method is more inaccurate in corneas 
with non-average ECDs. The model overestimates the in-vitro ECDs in the low 
regions, and underestimates them in the highest regions. 
 Chapters 5 and 6 discuss that there are several optical phenomena that could 
explain a proportional difference, i.e. a difference that increases with the ECD. 
Another possible explanation for a proportional difference may be found in 
chapter 3. In this study a similar systematic difference was described between a 
semi-automated and a manually obtained ECD. This difference may be inherent 
when fixed-frame and variable-frame counting methods are compared. 
Especially in small samples, a systematic underestimation of cell area resulting 
in overestimation of ECD may be introduced by variable-frame counting.279,280 
However, all these explanations remain speculative, since no proportional 
difference between in-vivo and in-vitro ECD was observed. There might be 
interaction between the effects of several simultaneously acting factors. 
 Indeed, the study on optical distortions in non-contact specular microscopy 
described in chapter 6 demonstrates that simultaneously several errors are 
introduced, whose effects oppose each other. We found that the total of optical 
distortions did not cause substantial errors in corneas with close to average 
thickness and curvature or in keratoconic eyes. However, this was only true 
when the error caused by the effect of an oblique angle of observation, the 
perspectivistic distortion, was eliminated. This appears to be the case in the 
SP2000P (Pierre Gelissen, Topcon Europe, personal communication, 2004). In 
instruments in which the oblique observation angle effect is not compensated for, 
the error increases with the co-sinus of the angle and may therefore be substantial.
 The studies in Part II of this thesis are not only valuable for users of the SP2000P 
and IMAGEnet2000, but also relevant to investigators using other instruments, 
assessment methods, and techniques for endothelial morphometry. Users of other 
specular or confocal microscopes may find our methodological considerations, 
investigative and statistical methods, and interpretations useful. The correction 
formulas presented in chapter 3 for incorrect magnification are more generally 
applicable. The physical formulas in chapter 6 are not specific to our specular 
microscope; they apply in other non-contact and contact types as well. 
 
 In part III of this thesis we focused on the effects of trypan blue on the corneal 
endothelium. The vital stains trypan blue (TB) and indocyanine green (ICG) 
have long been used in ophthalmology in several applications. From 1998 
onwards, both dyes have also been used for intra-operative staining, to 
enhance visualization of ocular membranous structures. Better viualization 
facilitates delicate surgical manoeuvres. The term dye-enhanced ocular surgery 
was coined to describe several surgical techniques in which these and other 
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dyes are valuable adjunctive tools. In chapter 7 early applications of both dyes 
are reviewed, and the development of the intra-operative application of each 
dye is described. From an increasing number of published studies it may be 
concluded that the two dyes have a concentration-related and exposure time-
related toxicity for ocular cells. In 1998 and 1999, the knowledge about toxic 
effects of TB on the corneal endothelium was based mostly on experience in 
cornea banks and a few rare studies. The studies described in chapters 8 and 
9 were initiated to investigate the toxicity of TB in depth, and to establish the 
safety of TB lens capsule staining in cataract surgery.
 The clinical study in chapter 8 demonstrates the safety of TB (0.06 %) lens 
capsule staining. One year after bilateral surgery, the endothelial cell loss in 
the eyes that had undergone phacoemulsification with intra-operative TB 
application was not higher than in the fellow, control eyes. 
 The results of the experimental study described in chapter 9 demonstrate that 
there is a concentration-related and exposure-time-related toxicity of TB to 
endothelial and other corneal cells. It was shown that under experimental 
circumstances especially the vehicle of  TB was essential for the degree of 
toxicity that was caused. We demonstrated that concentrations of and exposure 
times to TB such as currently applied in the Cornea Bank Amsterdam and 
during cataract surgery, remain below the toxicity threshold. However, caution 
is warranted whenever higher concentrations of TB are used or when the 
endothelium is exposed for a long time. 
 In animal experiments TB has been shown to have teratogenic effects. The 
dose used in ophthalmic surgery in humans is about 10,000 times lower than the 
systemic teratogenic dose in animals. Furthermore, most of the dye is removed from 
the eye immediately after the application, before it can even get into the systemic 
circulation. Nevertheless, it may also be advisable not to use TB in pregnant women 
or in infants. Operating theatre and eye bank staff should take protective measures 
(e.g. gloves) to prevent repeated exposure to small doses of TB. 
 The possible toxicity of ICG to retina and retinal pigment epithelium has also 
been the subject of much discussion. However, dye-enhanced surgery is 
probably here to stay. Therefore, the search continues for alternative dyes that 
are equally or even more effective, but less toxic. 
 
 In part IV of this thesis, in chapter 10, the development of new types of lamellar 
corneal transtplantation (lamellar keratoplasty, LK) is described in the context 
of the history of the overall development of corneal transplantation. In LK only 
diseased layers of the cornea are replaced, whereas in penetrating keratoplasty 
(PK) a full-thickness part of the cornea is transplanted.  Lamellar corneal surgery 
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has undeniably seen a revival of interest in the last 8 years.1226 The rationales 
for anterior and posterior lamellar keratoplasty (PLK) as reviewed in chapter 
10 illustrate that both types of surgery have important theoretical advantages 
on PK. These include more rapid visual rehabilitation, less astigmatism, and 
less wound-related and suture-related complications. Consequently, anterior 
and posterior lamellar keratoplasty might become the treatment of choice 
for many cases for which  PK used to be the mainstay treatment. For this to 
happen it is imperative that the theoretical advantages prove to be clinical 
assets. Furthermore, transplant survival should be similar or better than after PK. 
Transplant survival after PK depends on the occurrence of allograft rejection, 
and long-term non-rejection endothelial cell loss (late endothelial failure, LEF).
 In anterior lamellar keratoplasty the recipient endothelium remains in place. 
This eliminates the possibility of allograft rejection causing a graft failure. 
Furthermore, non-rejection LEF may be prevented, as anterior LK essentially 
is extra-ocular surgery.231,310 The results of the study on ECD-loss after deep 
anterior lamellar keratoplasty (DALK, Melles’ Technique), described in chapter 
11, indicate that after an initial drop in ECD, the cell loss soon approached a 
physiological, age-related rate. These findings are comparable to other studies 
on endothelial cell loss after (anterior) LK. 
 Our paper had been submitted just before Armitage’s important paper on 
bi-exponential endothelial cell decay models was published.231 Therefore, 
Armitage’s method was not applied in this study. Nevertheless, our results 
suggest that with longer follow-up and more measurement points such a 
decay pattern could be discerned. As in DALK surgery the endothelium is not 
directly manipulated, several indirect mechanisms for the initial drop in cell 
loss can be postulated. Mechanical attrition due to deep lamellar dissection 
just superior/anterior to Descemet’s membrane and the endothelium may 
cause shedding of endothelial cells. Noticed or unnoticed microperforations 
during deep lamellar dissection will directly damage the endothelium. Possibly, 
the presence of an air bubble in the anterior chamber during the procedure 
contributes to cell loss as well.535,536,899
 
 In contrast, after posterior lamellar transplantation (PLK), immunological 
allograft rejection may and does occur, and both peri-operative and late non-
immunologic endothelial cell loss are substantial. As has been discussed in 
chapter 2 paragraph XVI, all three factors affect graft survival. Therefore, the 
rate and pattern of endothelial cell loss after PLK needed clarification. In the 
prospective study described in chapter 12 we found that after 3 years the ECD-
loss was somewhat higher compared to that after PK reported in the literature. 
 Concerning these results, some observations need to be brought to attention. 
First, the donor ECDs were those of the contralateral donor eye. The posterior 
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lamellar discs were prepared in the operating room from whole globes. Thus, 
in the cornea bank no ECDs could be obtained from this donor eye itself (see 
chapter 2 paragraph VIII). As has been shown in the study described in chapter 
4, paired eyes usually do not have significantly different ECDs. However, in 
individual pairs differences in ECD between contralateral eyes may still have 
been substantial. Secondly, donor ECDs in the contralateral donor eyes were 
obtained with the usual cornea bank in-vitro light microscopic ECD counting 
methods, whereas follow-up in-vivo ECDs were obtained with non-contact 
specular microscopy. If the results of chapter 5 are taken into account, the 
cell loss after PLK is in fact even larger, on average 140 cells/mm2. Thirdly, in 
the study in chapter 12 we were not able to fit a bi-exponential decay model,             
probably because our follow-up was too short at that point (Armitage, personal 
communication, 2004). 
 For this last reason we gathered additional, cross-sectional data on ECD in this 
cohort of patients. With these data successful fitting of bi-exponential models 
could be performed, as chapter 13 proves. In the models in this study, the 
‘fast phase’ of endothelial cell loss applies to the first few hours after surgery. 
Again, because of our relatively short follow-up, this emphasis on the first 
post-operative hours in our models is probably a result of  “over-fitting” of a 
regression model (Armitage, personal communication, 2006). Still, the results 
are  interesting, because they indicate that in these first few post-operative 
hours a significantly larger proportion of donor ECD was lost in eyes in which 
the donor was folded before introduction into the recipient eye. Furthermore 
it is remarkable that after the use of a folded donor disc the late loss appeared 
to be slower. As an explanation, in this group a larger diameter donor disc was 
used, which provides in absolute numbers more donor endothelial cells, with 
a higher density towards the donor edge. Moreover, this larger donor disc was 
transplanted into a recipient cornea in which a smaller surface with a poor 
endothelium needing replenishment remained. For these reasons, substantially 
less redistribution of endothelial cells to the recipient cornea is to be expected. 
In the group in which folded donor discs were used, two additional factors 
may have diminished late redistribution of endothelial cells on to the recipient 
cornea. The mean recipient age was lower in this group, and the indication for 
PLK was less often aphakic or pseudophakic bullous keratopathy, and more 
often Fuchs’ endothelial dystrophy. Both these factors may also be associated 
with diminished redistribution to the recipient cornea.780
 In our study, endothelial cell loss appeared to be both higher peri-operatively 
and faster thereafter compared to historical PK groups. Using extrapolated 
predictions from the regression models an ECD level of 500 cells/mm2 was 
expected to be reached between 7 and 8 years postoperatively. This level of 
ECD is often regarded as a threshold below which graft decompensation is 
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imminent. However, these results may be skewed by small group size, relatively 
short follow-up, and the use of prototype instruments. As the groups in our 
studies were the first patients ever operated with PLK, a learning curve may 
have had substantial influence. 
 Eyes in the series operated by Terry with comparable techniques (which are 
called Deep Lamellar Endothelial Keratoplasty or DLEK, instead of PLK) also 
show an ongoing higher-than-physiologic endothelial cell loss. The level of cell 
loss however is lower than in our studies, and also lower than in historical PK 
groups.1161, 1162 Price, who has operated a large series of patients with a newer 
PLK-type operation called DSEK (see below), has until now not provided data 
on endothelial cell loss.1151,1152
 It is clear that there is an urgent need for more, well-planned, randomized 
clinical trials comparing the different treatment modalities in corneal 
transplantation. This does not only apply to the anterior and posterior 
lamellar keratoplasty techniques discussed above. Rather it should extend 
to all treatment modalities for corneal disease, including those new 
emerging techniques that are discussed below in paragraph II of this chapter 
(Perspectives on future developments). Only with such trials important 
outcome measures can be compared between any of these new techniques. 
These outcome measures should in any case include clinical results such 
as visual acuity, astigmatism, and spherical equivalent, and if possible also 
contrast sensitivity and/or stray light measurements. Other extremely important 
outcome measures are graft survival, endothelial cell loss, the occurrence of 
operative and post-operative complications, and patient satisfaction.
 Until recently only one such a comparative trial existed for anterior LK,1103 but 
recently the Dutch Lamellar Corneal Transplant Study started, which compares 
several techniques for both anterior and posterior lamellar keratoplasty to PK.
 The results of such trials will be very useful to better define or restrict 
indications for the  different treatment options. For instance, it may be clarified 
which subgroups of keratoconus eyes will do well with initial anterior LK (either 
ALTK or deep ALK, see below), which may be treated primarily with intrastromal 
rings (see below), and for which patients PK or a combined PK-LK variation (see 
below) should be the first treatment option.
  Obviously, especially for posterior lamellar techniques aiming at endothelial 
replacement, long-term follow-up results on endothelial cell loss are essential. 
However, even if such trials were to demonstrate that PLK techniques suffered 
from higher and more rapid ECD-loss and shorter graft survival, there still 
may be good indications for PLK. Advantages of PLK such as faster visual 
recovery, fewer follow-up visits to the clinic, and less suture- (removal-) related 
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complications may be preferable to graft longevity. In elderly or less mobile 
patients, PLK could still be the technique of choice for treating endothelial 
disease. In patients with severe dry eyes, where PK is virtually contra-indicated, 
PLK may even be the only available treatment for endothelial disease. Similar 
considerations may ensure anterior lamellar techniques a “niche” in the 
therapeutic armamentarium, even if some of their outcomes fall behind. 
 Ultimately, preferences of patients and perhaps also preferences and abilities of 
surgeons will influence the decision for one treatment or another.
II.  Perspective on future developments.
 In endothelial imaging, in-vivo confocal microscopy is rapidly gaining ground. 
Advantages of confocal microscopy over specular microscopy include its 
capability of imaging the endothelium in edematous corneas. Additionally, 
confocal microscopy can depict  cells in all corneal layers, and is able to 
quantify light reflectivity in different corneal layers – for instance as a measure 
for haze.303 Moreover, many of the optical distortions that affect specular 
microscopy are not relevant in confocal microscopy (see chapter 6). However, 
the other considerations regarding reliability, as discussed in part A of this 
summary, do apply to confocal microscopy as well. It usually is a contact-type 
examination, which is tolerated less well by patients and has inherent risks for 
microbial contamination. Therefore non-contact specular microscopy may 
remain a valuable tool for follow-up examinations on the endothelium, e.g. in 
patients after ocular surgery. 
 
 In dye-enhanced surgery, the search for suitable dyes continues. Dyes that both 
provide adequate staining and completely lack toxic effects are yet to be found. 
The dye Coomassie blue a.k.a. brilliant blue G may be a promising addition.1227
 In the last few years, many new treatment modalities and modifications of 
existing techniques have emerged for the treatment of corneal diseases. 
 In this thesis a shift of attention in the treatment of endothelial disease to 
the selective replacement of the endothelium has been described. The 
studies described earlier investigated the first clinically applied techniques 
of PLK. Currently, a newer technique is rapidly surpassing the older types of 
PLK/DLEK that were described before in popularity, judging by the size of the 
series in published reports. This new variation is most often called “Descemet 
stripping and endothelial keratoplasty” (DSEK), and is also known as PLK 
with Descemethorhexis. In DSEK, the removal of Descemet’s membrane 
with endothelium from the recipient’s eye is performed from behind, from 
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the anterior chamber. Descemet’s membrane is removed from within a 
circumscript area by a combined scraping and tearing off. The reason for the 
popularity of this specific technique is that it is faster and technically easier than 
the older PLK/DLEK techniques that used intrastromal dissection. Therefore, it 
may be more reproducible in the hands of more surgeons. Moreover, in DSEK 
a smoother wound surface may be expected in the recipient eye than with 
the older PLK/DLEK types. This, and the fact that the wound interface is at the 
deepest level possible, i.e. directly anterior to Descemet’s membrane, may 
provide better visual results because of better optical quality of the interface. 
Even the surgeons who pioneered PLK/DLEK, Melles, Terry, and Price, have 
generally switched to DSEK except in selected cases.1149,1151,1152,1228 Recent large 
DSEK series were promising with regards to visual results and complication 
rates. However, randomized comparative prospective clinical studies are 
needed to establish whether any of the posterior techniques has better clinical 
results, especially when compared to PK.1151,1152
 In this thesis also a revival of attention for anterior lamellar keratoplasty 
techniques in the treatment of anterior and ectatic corneal disease has been 
described. So far we have focused mainly on a deep dissection technique 
for anterior lamellar keratoplasty, but we did already mention the use of 
the automated microkeratome in LK. This is an instrument familiar to many 
refractive surgeons because of its application in the LASIK procedure. 
The microkeratome may be useful in both anterior and posterior lamellar 
keratoplasty.1229  This automated oscillating knife can be used to make lamellar 
dissections at several chosen depths, both in recipient’s and in donor corneas. 
Usually a very smooth wound surface is obtained which may provide an optical 
superior interface. Also, microkeratome cutting is faster than manual lamellar 
dissection. Several authors have applied it in anterior lamellar keratoplasty 
series.1092,1215,1216 This technique for anterior LK is also known as Automated 
Lamellar Therapeutic Keratoplasty. It has been shown to provide promising 
refractive and visual results, although it is not yet clear whether they compare 
favourably to other lamellar techniques or to PK. Baring Descemet’s membrane, 
as with the ‘big bubble technique’, may provide better post-operative visual 
acuity than ALTK.1216, 1230,1231 Furthermore, ALTK is not applicable in very steep or 
thin corneas, or in those with an irregular surface. 
 In posterior keratoplasty, the microkeratome may especially facilitate and speed 
up the preparation of the donor posterior disc. The combination of DSEK and 
the use of the automated microkeratome has been dubbed DSAEK.1232
 
 The last few years a new type of photodisruptive laser, the femtosecond ND:
Yag laser, has emerged as an alternative to the automated microkeratome. A 
great number of ultra-short pulses is used to create a dissection plane within a 
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cornea. Similar to the microkeratome, with this laser very fast and very precise 
lamellar dissections can be performed. An advantage over the microkeratome is 
that dissections and incisions can be performed not only horizontally, but also 
vertically, in a stepped fashion, or even obliquely. This instrument is not only 
suitable for  LASIK and anterior and posterior LK, but also for PK, and PK with 
stepped or lamellar wound configurations, and for the preparation of tunnels 
for intracorneal ring segments (see below).1098,1233-1235 In refractive surgery 
femtosecond lasers are rapidly gaining ground as they are used for LASIK flap 
dissection.1236-1240
 As an alternative to either posterior or anterior LK, new techniques of PK with 
lamellar wound configuration aspects have also been proposed in the last few 
years. These combine some of the advantages of both LK and PK. The concepts 
of these techniques are not new, as most of them have been developed 
in the middle of the last century.1061,1241 A combination of the availability of 
better instruments and microscopes, and an interest in resolving some of the 
disadvantages of conventional PK has led to their revival. Among the currently 
more often used techniques is the reversed mushroom PK, a.k.a. “nut-and-bolt 
PK, a.k.a. “top-hat” PK. Here, the vertical PK wound has a stepwise configuration 
with the posterior diameter of the graft being larger than the anterior diameter. 
This technique is foremost used in patients with endothelial disease, as it 
provides transplantation of  a large number of good donor endothelial cells 
into the recipient. The stepped incision provides a mechanically more stable 
wound configuration than after PK. Less and less deep sutures are needed, 
which furthermore may be removed earlier. This supposedly diminishes 
suture-(removal-)related complications such as wound dehiscence, infection, 
and high astigmatism. Moreover, in contrast to lamellar keratoplasty, there is 
no wound interface in the visual axis, which may improve visual acuity.1108,1242 
Similarly, an anterior mushroom PK with a larger anterior diameter and a smaller 
posterior diameter may be a valuable alternative treatment for keratoconus. 
This technique preserves more of the recipient’s healthy endothelium, and 
may provide low post-operative astigmatism, while it does not produce a 
wound interface in the visual axis.1061 Combinations of lamellar dissections with 
the microkeratome and deep penetrating buttons for the treatment of full 
thickness opacities have also been dubbed mushroom keratoplasty. They are 
akin to endothelial keratoplasty using a microkeratome that is an alternative 
technique for the selective replacement of endothelium.1243 The femtosecond 
laser may give several of these techniques an additional boost as the wound 
configurations can be made more easily.1242
 
 In some possible indications for posterior lamellar keratoplasty, caution is 
warranted to replace only the endothelium. Secondary stromal changes occur 
in corneas with persisting edema resulting from endothelial decompensation, 
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such as in longstanding bullous keratopathy. In long-term edematous corneas, 
stromal hydropic degeneration (necrosis) of keratocytes occurs. In a recent 
study confocal microscopy was able to quantify that this keratocyte necrosis 
itself caused significant stromal scatter, additional to the effects of the edema. 
Therefore, in these corneas the decrease in corneal transparency did not only 
result from a widened interfibrillary distance caused by edema, as stated in the 
classic theory. Unfortunately, this keratocyte degeneration is not reversible. 
Furthermore, decrease of proteoglycans has also been found in such corneas. 
Thus, in long-standing bullous keratopathy mere endothelial transplantation 
may not always suffice to obtain corneal transparency. To obtain significant 
visual improvement in these cases, PK or a variant of PK with a more complex 
wound configuration may still be necessary.874,1244 
 A recently emerging, non-keratoplasty surgical treatment in contact-lens 
intolerant patients for corneal ectatic disease, such as keratoconus or pellucid 
marginal degeneration, is the placement of intrastromal corneal ring segments. 
This treatment may provide an alternative or postponement for either PK or LK. 
Intrastromal rings were introduced as a refractive surgical technique to treat 
low to moderate myopia (see chapter 2, paragraph XIV), but are becoming less 
and less used for this purpose because of lack of predictability. Their advantages 
in ectatic disease include a mechanical “straightening” of ectatic corneas, and 
reversibility of refractive results. After this treatment refractive errors can persist, 
but these are often more accessible to correction with spectacles or soft 
instead of rigid contact lenses. Prerequisite for the placement of ring segments 
is that the corneas are not too steep or thin, and do not have central corneal 
opacities. Therefore, in selected cases of mild to moderate keratoconus and 
other corneal ectasias, ring segments (INTACS or Ferrara rings) may be a useful 
addition to the therapeutic arsenale.1192,1245-1256 The use of the femtosecond 
laser may facilitate the making of tunnels that are needed for the insertion of 
intrastromal corneal ring segments. 
 The most recently introduced treatment option  in corneal ectatic disease is 
stromal collagen cross-linking. This process involves topical riboflavin application 
followed by exposure to UV-A radiation.  Cross-links between corneal fibrils are 
formed by riboflavin radical molecules that are induced by the UV-A irradiation. 
This ensures biomechanical stiffening of the corneal stroma, and the treatment 
is predominantly aimed at halting progression of ectasia. As yet, only case series 
have been reported, which indicate good short- to midterm safety and suggest 
efficacy.1257-1259 However, whether this treatment is truly effective remains to be 
proven, by means of long-term, randomized, comparative, prospective studies.
 Finally, a few words need to be said about the induction of endothelial cell 
proliferation, as this may be the future approach for the treatment of all 
endothelial disease. Cultured endothelia may provide the solution to donor 
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cornea shortage, and either modification of antigen expression, or culturing or 
inducing proliferation of a patient’s own endothelial cells could provide for less 
immunogenic transplants. The concept of culturing human endothelial cells 
for the purpose of transplantation is not new.1114-1117 Later research investigated 
suitable carriers for the endothelial cells.1119,1126,1128,1260 Recently, corneal 
constructs have been manufactured from cultured endothelial cells combined 
with preserved human corneal stroma.1126 Even complete corneal constructs 
with all cellular layers derived from immortalized and cultured human cells 
(epithelial, stromal, and endothelial cells) have been reported.1124 Transfection, 
for instance with SV40 vectors, may be necessary to achieve sufficiently large 
ECDs in cultured human endothelial cell monolayers that are prepared for 
transplantation.132,1124 Some of these monolayers and corneal constructs have 
been shown to possess adequate endothelial pump and other physiological 
functions.132,1124  Current problems include the continuation of cell divisions 
in transfected cells even when this is not wanted. On the other hand, non-
transfected cultured endothelial cell monolayers provide inadequate ECDs and 
inadequate pump functions.132,1126 Currently, none of these endeavours have 
reached the stage of clinical application yet. 
 As an  alternative to transplanting cultured endothelial cells, a future solution 
to endothelial disease may be the the in-vivo induction into proliferation of 
the patients’ own endothelial stem cells. Although the endothelial stem cells’ 
suspected locus at the posterior limbus seems to be confirmed more and more, 
the exact identification of the stem cells themselves remains elusive. The stem 
cells need to be identified first, before the in-vivo induction of endothelial 
proliferation can be brought to the next level.132,874,1261,1262 Until these problems 
are solved, tranplantation of complete donor endothelia, by means of PK, PLK, 
or technical variations thereof, remains necessary.
 References
 See page 287.
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I.  Samenvatting in perspectief.
 Hoofdstuk 1 biedt een kort overzicht over hoe de kennis over en onderzoek naar 
het hoornvliesendotheel zich heeft ontwikkeld. Ook worden de achtergrond 
en het doel van de onderzoeken in de delen II tot en met IV van dit proefschrift 
ingeleid. 
 
 Hoofdstuk 2 is een bespreking van de literatuur over het hoornvlies- (cornea-) 
endotheel. Enkele essentiële punten hieruit worden hier nu samengevat. Het 
endotheel vormt de binnenste laag van het hoornvlies en is essentieel in het 
handhaven van een stabiele waterhuishouding in het hoornvlies. Volgens de 
“Pump-Leak theorie” vormt het endotheel een barrière die wel water en kleine 
moleculen vanuit de voorste oogkamer het hoornvlies in laat diffunderen, 
maar niet permeabel is voor grotere moleculen (Leak). Tegelijkertijd pompen 
de endotheelcellen actief water uit het hoornvlies terug naar de voorste 
oogkamer (Pump).  Deze hydratie-homeostasis is noodzakelijk om het hoornvlies 
transparant te houden. Als het watergehalte van het hoornvlies te hoog wordt 
(cornea-oedeem), verliest het zijn helderheid. Menselijke cornea-endotheelcellen 
hebben een zeer beperkt vermogen tot celdeling. Dit is niet alleen van belang 
bij de wondgenezing van het endotheel, maar het is ook verantwoordelijk voor 
het optreden van leeftijdsgebonden endotheelcelverlies. Dit verval in cellen 
kan worden beschreven met behulp van de endotheelceldichtheid (ECD), de 
belangrijkste maat in de morfometrie (kwantitatieve vormbeschrijving) van het 
endotheel. Kwalitatieve en kwantitatieve aspecten van het de vorm van het 
endotheel kunnen m.b.v. “spiegelmicroscopie” (specular microscopy) worden 
onderzocht bij levende patiënten (in vivo).
 
 Onderzoeken na staaroperaties (cataractchirurgie) met kunstlens implantatie, 
en na hoornvliestransplantaties (penetrerende keratoplastiek, PK) deden het 
vermoeden rijzen dat er na de operatie langdurig verhoogd endotheelcelverlies 
is. Bij ongecompliceerde cararact-operaties met moderne technieken is het 
endotheelcelverlies tijdens en vlak na de operatie beperkt, en bovendien 
lijkt het tempo van verval binnen enkele jaren al weer te normaliseren. Na 
staaroperaties met kunstlensimplantatie volgens oudere methoden was dit 
verlies echter veel hoger en bleef het verval ook langer verhoogd. Momenteel 
wordt daarom de mate van verlies aan endotheelcellen als veiligheids- en 
kwaliteitsmaatstaf gebruikt bij cataractchirurgie, zeker als het gaat om 
technische vernieuwingen.
 
 Tot ten minste tien jaar na PK en waarschijnlijk nog langer is er sprake van een 
verhoogd verlies aan endotheelcellen. Een belangrijke oorzaak voor dit verlies 
is immunologische afstoting van endotheelcellen. Maar zelfs als er nooit een 
duidelijke afstotingsreaktie is waargenomen, is het verval in ECD sterker dan 
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normaal. Op de lange termijn kan dit uiteindelijk leiden tot decompensatie van 
het transplantaat, waarbij het aanvankelijk heldere transplantaat vertroebelt. 
De vertroebeling onstaat door zwelling (oedeem) doordat er te weinig 
endotheelcellen over zijn om de hydratie-homeostase te kunnen handhaven. 
Dit proces wordt “laat endotheelfalen” (LEF) genoemd. Het is op dit moment 
nog steeds niet duidelijk wat de oorzaak van dit verhoogde endotheelcelverlies 
na PK is en hoe lang het verlies hoger dan normaal blijft.
 
 Omdat de ECD zo’n belangrijke maatstaf is, is het belangrijk dat de bepaling 
betrouwbaar gebeurt. In deel II van dit proefschrift beschrijven we onderzoeken 
naar vier aspecten van de betrouwbaarheid van een bepaalde techniek van 
ECD metingen. Alle morfometrische metingen aan het endotheel in deze 
onderzoeken werden verricht met een Topcon SP2000P non-contact autofocus 
spiegelmicroscoop (of specular microscope), gekoppeld aan IMAGEnet 2000 
endotheel-analyse software.
 
 In hoofdstuk 3 is aangegeven hoe de vergroting van de SP2000P geijkt 
(gecalibreerd) dient te worden. De noodzaak van het controleren van de ijking 
- van welk biomedisch meetinstrument dan ook- is opnieuw aangetoond, 
toen we bij controles in 4 verschillende opstellingen telkens calibratiefouten 
aantroffen (niet gepubliceerde gegevens). Deze noodzaak tot controle van de 
calibratie geldt des te meer als er voor dezelfde soort metingen afwisselend 
verschillende (typen) instrumenten gebruikt worden.287,1224 We hebben formules 
beschreven om de correcte ECDs te berekenen in de voorkomende gevallen 
waarin incorrecte waarden zijn verkregen met fout gecalibreerde instrumenten.
 Voorts is in dit onderzoek van verschillende ECD-meetmethoden de validiteit 
onderzocht met de methode volgens Bland en Altman.910 We vonden 
systematische verschillen tussen handmatige tellingen en al de verschillende 
ECD meetmethodes die in de SP2000P & IMAGEnet 2000 opstelling 
voorhanden zijn. Deze verschillen waren vrij klein, met uitzondering van bij 
de volledig geautomatiseerde ECD bepalingen. Bij de semi-automatische ECD 
meetmethode worden door software getrokken endotheelcelgrenzen eerst 
handmatig verbeterd voordat de ECD bepaald wordt. Deze semi-automatische 
ECD-bepaling was de meest valide meetmethode, aangezien hierbij individuele 
metingen de minste spreiding lieten zien binnen de zogenaamde “limits-of-
agreement”. Handmatige correctie van automatisch bepaalde celgrenzen blijkt 
meestal de nauwkeurigheid van ECD-meetinstrumenten te bevorderen.1224,1225
 Aangezien er een systematisch verschil was tussen deze semi-automatische ECD 
meetmethode en volledig handmatige tellingen, moet er een correctiefactor 
gebruikt worden om ECDs die verkregen zijn met beide methodes met elkaar 
te kunnen vergelijken. Een dergelijke correctiefactor is ook van toepassing als 
andere resultaten van andere meetmethodes onderling worden vergeleken.
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 Zoals reeds aangegeven door Bland en Altman volstaat het voor het vergelijken 
van 2 meetmethoden niet om een correlatie-coëfficiënt te berekenen, omdat 
hiermee een systematisch verschil niet herkend wordt. Lineaire regressie is 
voor de vergelijking van meetmethoden ook niet van toepassing, aangezien 
de uitkomsten van beide methoden onafhankelijke variabelen zijn, en de ene 
uitkomst niet een functie is van de andere. In sommige onderzoeken kan men 
echter beide foute methodes tegelijk aantreffen.313  
 
 Een derde aspect dat van belang is voor de betrouwbaarheid van een 
meetmethode, is de reproduceerbaarheid. In het onderzoek beschreven in 
hoofdstuk 4 werd er een redelijke tot goede reproduceerbaarheid gevonden 
voor alle morfometrische parameters, inclusief de ECD. De reproduceerbaarheid 
werd vooral beïnvloed door een relatief geringe herhaalbaarheid (repeatibility), 
d.w.z. een hoge variabiliteit tussen direct herhaalde steekproeven (sampling 
variability). Een hoge sampling variability kan worden verminderd door de 
uitkomsten van meer metingen te middelen. Hierdoor neemt de variantie in de 
metingen af met de inverse van het aantal metingen.
 
 De reproduceerbaarheid bij wisselende “beoordelaars” (inter-observer 
reproducibility) was eveneens goed. ECDs die door verschillende beoordelaars 
zijn verkregen kunnen dus onderling worden vergeleken, mits de beoordelaars 
dezelfde methodes gebruiken en goed getraind zijn. Onze resultaten t.a.v. de 
reproduceerbaarheid van ECD metingen met de SP2000P & IMAGEnet 2000 
kwamen overeen met die in andere studies. 294,1225
 
 Verder werd er in hoofdstuk 4 aangetoond dat ECDs in het nasale paracentrale 
gebied (dat is 3 mm van het centrum aan de nasale zijde) gebruikt kunnen 
worden in plaats van centrale ECDs, indien er van het centrum geen duidelijke 
afbeeldingen kunnen worden gemaakt. De centrale ECDs van het andere 
(contralaterale) oog van een paar kunnen hiervoor ook gebruikt worden, mits er 
geen verschillen in voorgeschiedenis tussen beide ogen zijn. Desalniettemin moet 
men hierbij er zich wel van bewust zijn dat er in individuele gevallen toch een 
aanzienlijk verschil kan bestaan tussen de vervangende en de vervangen waarde.
 
 De resultaten in de hoofdstukken 3 en 4 tonen aan dat met de SP2000P & 
IMAGEnet 2000 combinatie betrouwbare centrale ECD metingen verkregen 
kunnen worden. Als aan de voorwaarden zoals beschreven in deze twee 
hoofdstukken voldaan wordt, kunnen op betrouwbare wijze ECD-metingen 
betrouwbaar worden vervolgd bij herhaalde metingen bij dezelfde persoon, en 
ook betrouwbaar worden vergeleken tussen verschillende personen.
 
 In het onderzoek dat is beschreven in hoofdstuk 5 werden ECDs vergeleken 
die eerst in vivo waren gemeten met de SP2000P, en vervolgens in dezelfde 
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cornea’s (na excisie tijdens een transplantatie) opnieuw in vitro bepaald werden 
met de gebruikelijke lichtmicroscopische meetmethode van de hoornvliesbank. 
We vonden dat de specular microscopy metingen systematisch en constant 
140 cellen/mm2 hoger waren dan die van de corneabank. Dit verschil heeft 
consequenties voor vervolgonderzoeken na hoornvliestransplantatie, waarbij 
donor-ECDs vergeleken worden met specular microscopy ECD metingen. Dit is 
bijvoorbeeld het geval in de onderzoeken beschreven in hoofdstukken 12 en 
13 van dit proefschrift. In dergelijke onderzoeken zou van nu af aan ofwel 140 
cellen/mm2 bij de donor ECD moeten worden opgeteld, ofwel moeten worden 
afgetrokken van de SP2000P-ECD. Indien er een andere specular of confocal 
microscope wordt gebruikt, moet er opnieuw worden nagegaan of er een 
systematisch verschil bestaat met donor ECDs, op een vergelijkbare manier als 
in ons onderzoek. 
 
 Dat het systematisch verschil tussen de meetmethodes een constant 
en absoluut karakter had, was een onverwachte bevinding. De meest 
waarschijnlijke verklaringen voor een eventueel verschil zouden eigenlijk 
allemaal moeten leiden tot een relatief verschil, d.w.z. een verschil dat 
evenredig toeneemt met de ECD-waarde zelf. Men zou dus kunnen 
veronderstellen dat het verschil in werkelijkheid dan ook een relatief 
karakter had, maar dat dit gemaskeerd wordt door andere factoren. Een van 
deze maskerende factoren wordt beschreven in hoofdstuk 5. Het lineaire 
regressiemodel dat in de corneabank gebruikt wordt om de ECD te bepalen 
heeft de beste “fit” - en levert dus de meest betrouwbare waarden op - bij 
gemiddelde ECDs. Het model resulteert echter in overschatte ECDs in de lagere 
regionen en onderschat de ECDs als de waarden veel hoger zijn.
 
 In de “Discussion” paragrafen in de hoofdstukken 5 en 6 worden diverse optische 
factoren beschreven die een proportioneel verschil, dat dus evenredig toeneemt 
met de ECD, kunnen verklaren. Een andere mogelijke verklaring voor een 
dergelijk proportioneel verschil kan worden gevonden in hoofdstuk 3. In dat 
onderzoek werd een systematisch verschil van vergelijkbare grootte gevonden 
tussen een semi-automatische ECD meetmethode en handmatige tellingen 
op specular microscopy foto’s. Het verschil in ECDs zou gekoppeld kunnen 
zijn aan het inherente methodologische verschil tussen zgn. “fixed-frame” en 
“variable-frame” tellingen. Bij fixed-frame tellingen wordt het aantal cellen geteld 
dat binnen een opppervlak van vaste afmetingen ligt, terwijl bij variable-frame 
bepalingen de oppervlakte gemeten wordt van een bepaald aantal cellen (de 
ECD is dan de inverse van het gemiddelde oppervlak van die cellen). Bij variable-
frame tellingen kan m.n. in kleine steekproeven een onderschatting van het 
celoppervlak optreden, hetgeen resulteert in overschatting van de ECD.279,280 
Omdat er echter geen proportioneel verschil werd gevonden tussen in-vitro 
en in vivo ECDs, blijft het onduidelijk of en zo ja welke van al deze mogelijke 
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verklaringen van toepassing zijn..De interactie tussen diverse verklarende 
factoren zou van invloed kunnen zijn.
 
 In hoofdstuk 6 wordt inderdaad aangetoond dat de verscheidene optische 
vertekeningen die bij non-contact specular microscopy  een rol spelen, vaak 
een tegengesteld effect hebben. We vonden dat alle optische vertekeningen 
samen geen belangrijke meetfouten veroorzaakten, noch in met ogen met 
een normale hoornvliesdikte en –kromming noch in ogen met keratoconus. 
Dit was echter alleen het geval als de meetfout die veroorzaakt werd door 
perspectivistische vertekening als gevolg van een schuine observatiehoek, 
werd tenietgedaan. In de SP2000P is dit blijkbaar het geval (Pierre Gelissen, 
Topcon Europe, persoonlijke mededeling, 2004). Als de perspectivistische 
vertekening niet wordt gecompenseerd neemt de meetfout namelijk toe met 
de cosinus van de observatiehoek, en kan zodoende aanzienlijke waarden 
aannemen.
 
 De bevindingen in de onderzoeken in deel II van dit proefschrift zijn niet alleen 
van belang voor gebruikers van de SP2000P, maar ook voor onderzoekers die 
andere apparaten en analysemethoden en –technieken gebruiken voor de 
morfometrie van het cornea-endotheel. Onze methodologische overwegingen, 
onderzoeks- en statistische methoden, en interpretaties van gegevens kunnen 
ook nuttig zijn voor degenen die andere specular of confocal microscopen 
gebruiken. De correctieformules uit hoofdstuk 3 zijn vrij algemeen toepasbaar in 
geval van incorrect geijkte of ingestelde vergrotingswaarden. De natuurkundige 
formules in hoofdstuk 6 zijn eveneens op vele typen specular microscopes van 
toepassing.
 
 De onderzoeken in deel III van dit proefschrift gaan over de effecten van 
trypaan blauw op het cornea-endotheel. De vitaalkleurstoffen trypaan blauw 
(TB) en indocyanine groen (ICG) worden binnen de oogheelkunde al heel 
lang voor verscheidene doeleinden toegepast. Sinds 1998 worden beide 
kleurstoffen bovendien tijdens oogoperaties gebruikt voor het aankleuren, en 
daardoor beter visualiseren, van membraneuze strucuren. Voor deze nieuwere 
waardevolle toepassingen is in de literatuur inmiddels de term “dye-enhanced 
ocular surgery” in zwang. In hoofdstuk 7 wordt besproken hoe deze deze 
kleurstoffen van oudsher in de oogheelkunde en op andere terreinen werden 
toegepast. Voorts komt de ontwikkeling van de intra-operatieve toepassingen 
aan de orde. Verder wordt er een aantal onderzoeken besproken die steeds 
duidelijker maken dat beide kleurstoffen toxische eigenschappen kunnen 
hebben voor cellen in het oog. De mate van toxiciteit blijkt afhankelijk van 
de concentratie van en de duur van de blootstelling aan de kleurstof. In 1998 
en 1999 was de meeste kennis over toxische effecten van TB op het cornea-
endotheel gebaseerd op ervaringen met TB in hoornvliesbanken en op enkele 
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onderzoeken. De onderzoeken zoals beschreven in hoofdstuk 8 en 9 werden 
gestart om de toxiciteit van TB uitgebreider in kaart te brengen, en om de 
veiligheid van het gebruik van TB tijdens cataractchirurgie aan te tonen.
 
 Het klinische onderzoek in hoofdstuk 8 toont aan dat het gebruik van TB (0.06 % 
oplossing) tijdens cataractchirurgie veilig is voor het cornea-endotheel. Eén jaar 
na staaroperaties aan beide ogen bleek dat het endotheelcelverlies in ogen die 
geopereerd waren met gebruik van TB niet verhoogd was ten opzichte van de 
contralaterale ogen die zonder TB waren geopereerd (de controle-ogen).
 
 Het experimentele onderzoek uit hoofdstuk 9 bevestigt het bestaan van 
een concentratie- en blootstellingsduurafhankelijke toxiciteit van TB voor 
cellen in het hoornvlies. Uit de experimenten bleek dat het soort vehikel 
van de kleurstof van essentieel belang was voor de mate waarin toxische 
effecten werden veroorzaakt. We konden aantonen dat concentraties van en 
blootstellingsduur aan TB zoals die momenteel toegepast worden in de Cornea 
Bank Amsterdam en tijdens cataractoperaties, geen toxisch niveau bereikten. 
Maar tegelijkertijd werd wel duidelijk dat men zeer voorzichtig moet zijn met 
hogere concentraties van TB en/of een langere blootstellingsduur.
 
 Dierexperimenteel onderzoek heeft laten zien dat TB teratogeen kan zijn. De 
dosis die in mensen wordt gebruikt tijdens cataractchirurgie is ca. 10.000 keer 
lager dan de systemische teratogene dosis in proefdieren. Bovendien wordt 
tijdens de operatie direct na het aankleuren van het kapsel het overgrote deel 
van de kleurstof verwijderd. Zodoende zal het grootste deel van de toegepaste 
hoeveelheid TB nooit in de bloedsomloop komen. Desalniettemin dient 
men te overwegen om TB niet bij cataractoperaties bij zwangere vrouwen of 
heel jonge kinderen te gebruiken. Verder moet OK- en corneabankpersoneel 
beschermende maatregelen nemen (b.v. handschoenen) om herhaalde 
blootstelling aan kleine doses TB te voorkomen.
 
 De mogelijke toxiciteit van ICG voor het netvlies en retinale pigmentepitheel 
heeft ook tot veel discussie geleid. “Dye-enhanced surgery” lijkt echter bijna 
niet meer weg te denken uit de huidige chirurgische praktijk. Men blijft daarom 
zoeken naar alternatieve kleurstoffen met dezelfde of zelfs betere kleurende 
eigenschappen, maar met minder toxiciteit.
 In deel III, in hoofdstuk 10 is de geschiedenis van de ontwikkeling van 
hoornvliestrans-plantatie beschreven. In het bijzonder wordt er ingegaan op 
de ontwikkeling van nieuwe technieken van lamellaire hoornvliestransplantatie 
(lamellaire keratoplastiek, LK). Bij LK worden alleen de aangedane lagen van 
het hoornvlies vervangen, in tegenstelling tot de penetrerende keratoplastiek 
(PK) waarbij het hoorvlies over de volledige dikte wordt getransplanteerd. Er is 
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een duidelijke opleving in de belangstelling voor LK merkbaar in de laatste 8 
jaar.1226 In hoofdstuk 10 wordt uiteengezet dat er op theoretische gronden een 
duidelijke rationale is voor zowel de anterieure als de posterieure lamellaire 
keratoplastiek (PLK). De theoretische voordelen van beide technieken op PK 
omvatten een sneller herstel van de gezichtsscherpte, een lager postoperatief 
astigmatisme, en minder wond- of hechtinggerelateerde postoperatieve 
complicaties. In veel gevallen waarbij tot nu toe PK de algemeen gangbare 
behandeling was, zou daarom anterieure of posterieure lamellaire hoornvlies 
transplantatie wel eens de operatietechniek van eerste keus kunnen worden. 
Het is wel zo dat de genoemde theoretische voordelen dan ook daadwerkelijk 
in de praktijk van toepassing moeten blijken te zijn. Bovendien zou de 
overleving van het transplantaat minstens zo goed moeten zijn als na PK. 
Transplantaatoverleving na PK hangt vooral af van het al dan niet optreden 
van immunologische afstoting van de donor-endotheelcellen, en van het 
al eerder genoemde late endotheelfalen (LEF) dat niet door afstoting van 
endotheelcellen veroorzaakt wordt. 
 
 In anterieure lamellaire keratoplastiek worden alleen de voorste lagen van 
het hoornvlies vervangen en blijft het endotheel van de ontvanger op zijn 
plaats. Een afstotingsreaktie die leidt tot verlies van het transpantaat is hierdoor 
nagenoeg uitgesloten. Omdat er bij LK in feite alleen aan de buitenkant 
van het oog geopereerd wordt, zou ook het niet-afstotingsgerelateerde LEF 
op de lange termijn voorkomen kunnen worden.231,310  Ons onderzoek naar 
endotheelverlies na diepe anterieure lamellaire keratoplastiek (DALK, Melles 
Techniek) wordt beschreven in hoofdstuk 11. De resultaten van dit onderzoek 
laten zien dat het postoperatieve endotheelcelverlies aanvankelijk duidelijk 
verhoogd is, maar al vrij snel weer daalt en het fysiologische, leeftijdsafhankelijk 
niveau nadert.  
 Ons artikel was net voor publicatie aangeboden toen Armitages belangrijke 
artikel over bi-exponentiële modellen voor endotheelcelverval werd gepubli-
ceerd.231 Onze resultaten doen vermoeden dat een dergelijk vervalpatroon 
ook van toepassing is bij de ogen in ons onderzoek. Waarschijnlijk zou een 
dergelijk model dus ook wel aan de hand van ons onderzoek geconstureerd 
kunnen worden, mits er langer vervolgonderzoek met meer meetmomenten 
per oog zou worden uitgevooerd. Tijdens DALK-operaties vindt er in principe 
geen directe chirurgische manipulatie van het endotheel plaats. Andere 
factoren moeten dus  het aanvankelijke verhoogde endotheelcelverlies 
verklaren. Mechanische vervorming en wrijving bij de diepe lamellaire 
dissectie net boven/voor de membraan van Descemet en het endotheel kan 
waarschijnlijk endotheelcelverlies veroorzaken. Microperforaties naar de voorste 
oogkamer die soms tijdens de diepe lamellaire dissectie onbedoeld optreden, 
beschadigen het endotheel ter plaatse. Een luchtbel die om technische 
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redenen tijdens de operatie in de voorste oogkamer is kan mogelijk ook tot 
verlies aan endotheelcellen leiden.535,536,899
 
 In tegenstelling tot na anterieure lamellaire transplantatie kan er na posterieure 
lamellaire keratoplastiek (PLK) wel degelijk immunologische afstoting van 
endotheelcellen optreden. Verder is na PLK ook het niet-afstotingsgerelateerde 
endotheelcelverlies, zowel peroperatief als op de langere termijn, aanzienlijk. Elk 
van deze drie factoren heeft een negatief effect op de transplantaatoverleving 
– zie hoofdstuk 2 paragraaf XVI. Het is daarom van groot belang de mate en het 
patroon van endotheelcelverlies na PLK te onderzoeken. Uit het prospectieve 
onderzoek beschreven in hoofdstuk 12 bleek dat 3 jaar na de PLK-operatie het 
endotheelcelverlies licht verhoogd was ten opzichte van het verlies in ECD 
zoals dat vanuit de literatuur bekend is na PK.
 
 Ten aanzien van deze resultaten moeten er wel enkele kanttekeningen 
gemaakt worden. Ten eerste waren de donor-endotheelceldichtheden 
(ECDs) in dit onderzoek die van het andere, contralaterale oog. De achterste 
lamellaire transplantaten werden op de operatiekamer uit volledige, intacte 
bulbi geprepareerd. Daarom konden er in de hoornvliesbank geen ECDs van 
het donoroog zelf bepaald worden (zie hoofdstuk 2 paragraaf VIII). In het 
onderzoek van hoofdstuk 4 is aangetoond dat er meestal geen significante 
verschillen bestaan tussen de ECDs van beide ogen van een persoon. In 
individuele gevallen kunnen er desalniettemin aanzienlijke verschillen tussen 
beide ogen zijn. Ten tweede zijn de donor-ECDs met behulp van in-vitro licht-
microscopische methoden bepaald, zoals gebruikelijk in de hoornvliesbank, 
terwijl de vervolg ECDs gemeten zijn met behulp van non-contact specular 
microscopy. Eigenlijk dient men hierbij rekening te houden met de resultaten 
van hoofdstuk 5, en dat houdt in dat het verlies na PLK nog gemiddeld 140 
cellen/mm2 groter is dan gemeten. Ten derde waren we aan de hand van de 
data in het onderzoek van hoofdstuk 12 nog niet in staat een bi-exponentiëel 
ECD-verval model te construeren, waarschijnlijk omdat onze follow-up met 3 
jaar hiervoor nog te kort was. (Armitage, persoonlijke mededeling, 2004).
 
 Om deze reden hebben we nog aanvullende ECDs gemeten in dit 
patiëntencohort. Met aanvullende gegevens, die we op cross-sectionele 
wijze verkregen hebben, konden we zoals hoofdstuk 13 laat zien wel bi-
exponentiële modellen maken. In deze modellen blijkt de snelle fase van het 
endotheelcelverlies betrekking te hebben op de eerste uren na de operatie. 
Deze nadruk op de eerste postoperatieve uren is waarschijnlijk mede een 
gevolg van het “over-fitten” van een regressiemodel. Ook nu wordt dit 
weer veroorzaakt door een relatief korte follow-up (Armitage, persoonlijke 
mededeling, 2006). Toch zijn de resultaten wel interessant, omdat ze aangeven 
dat een grotere hoeveelheid endotheelcellen verloren gaat in de eerste 
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postoperatieve uren. Dit is zelfs significant meer wanneer de donorlamel 
gevouwen in het ontvangeroog wordt ingebracht, ten opzichte van het 
ongevouwen inbrengen. Verder is het opmerkelijk dat met een gevouwen 
donorlamel het late endotheelcelverlies langzamer bleek te zijn dan met 
een ongevouwen lamel. Als verklaring hiervoor kan aangevoerd worden dat 
de diameter van de gevouwen donorlamel groter was. Daarom droeg deze 
in absolute aantallen meer endotheelcellen en had een hogere ECD aan 
de rand. Het overgebleven oppervlakte op het ontvangerhoornvlies waar 
endotheelcellen vervangen moesten worden was daarentegen kleiner. Deze 
factoren maken het aannemelijk dat er op de langere termijn aanzienlijk 
minder redistributie van donorendotheelcellen naar het ontvangerhoornvlies 
plaatsvond. Twee andere factoren kunnen in deze groep waarin gevouwen 
lamellen werden gebruikt dienen als aanvullende verklaring voor verminderde 
endotheelcelredistributie. De gemiddelde leeftijd van deze ontvangers 
was lager, en ze hadden minder vaak een aphake of pseudophake bulleuze 
keratophatie. Waarschijnlijk is hierdoor de (perifere) ontvanger-ECD relatief 
hoger.780
 In onze onderzoeken bleek het endotheelcelverlies hoger te zijn rond de PLK-
operatie, en een hoger tempo aan te houden in de fasen daarna, in vergelijking 
tot gegevens die bekend zijn uit de literatuur over endotheelverlies rond en 
na PK. Door middel van extrapolatie van onze regressiemodellen konden we 
voorspellen dat gemiddeld 7 tot 8 jaar na PLK het niveau van 500 cellen/mm2 
bereikt zou gaan worden. Dit ECD-niveau wordt meestal aangehouden als de 
kritische grens voor decompensatie van het transplantaat. Het zou kunnen 
dat de resultaten in onze onderzoeken vertekend zijn doordat de groepen 
behandelde ogen klein zijn, de follow-up nog relatief kort is, en doordat er 
prototype instrumenten zijn gebruikt. Het betrof hier bovendien de eerste 
groep patiënten die ooit geopereerd is met een PLK techniek, en daarom kan 
het heel goed zijn dat er ook nog sprake is van een leercurve van de chirurg 
wat betreft de operatietechniek.
 
 In de groep ogen die door Terry met vergelijkbare technieken geopereerd 
is (hij noemt deze technieken Deep Lamellar Endothelial Keratoplasty, of 
DLEK, in plaats van PLK) is er ook sprake van een hoger dan fysiologisch 
endotheelcelverlies. Bij Terry is het verlies echter lager dan in onze studies en 
ook lager in vergelijking tot PK onderzoeken uit de literatuur.1161, 1142  Price heeft 
een grote groep patiënten geopereerd met een nieuwere PLK-achtige techniek, 
DSEK genaamd (zie hieronder). Hij heeft tot nu toe geen gegevens m.b.t. 
endotheelcelverlies gepubliceerd.1151,1152
 Het is duidelijk dat er een grote en dringende behoefte bestaat aan goed 
opgezette, gerandomiseerde klinische onderzoeken waarin de verschillende 
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behandelingsmodaliteiten voor hoornvliesaandoeningen met elkaar vergeleken 
worden. Dit geldt niet alleen voor de anterieure en posterieure LK technieken zoals 
hierboven besproken, maar ook voor alle andere recente nieuwe chirurgische 
behandelingen – zie paragraaf II van dit hoofdstuk (Toekomstperspectieven). 
Alleen met dit soort onderzoeken kunnen uitkomsten van deze operatietechnie-
ken echt goed vergeleken worden. Het gaat hierbij om klinisch relevante zaken 
zoals visus, astigmatisme, sferisch equivalent. Zo mogelijk moeten ook metingen 
van contrastgevoeligheid- en strooilicht-metingen vergeleken worden Verder 
zijn gegevens zoals transplantaatoverleving, endotheelcelverlies, het optreden 
van operatieve en postoperatieve complicaties, en patiënt-tevredenheid van het 
grootste belang.
 
 Tot dusverre bestond er slechts één dergelijk onderzoek en dat vergeleek 
anterieure LK met PK.1103 Onlangs is echter de Dutch Lamellar Corneal 
Transplant Study in ons land van start gegaan, en dit multi-center onderzoek 
vergelijkt prospectief en gerandomiseerd verschillende technieken voor zowel 
anterieure als posterieure LK met PK.
 
 Resultaten van dergelijke prospectieve vergelijkende onderzoeken zijn 
erg nuttig om indicatiegebieden voor de verschillende behandelopties 
te definiëren en aan te scherpen. Zo kan er bijvoorbeeld duidelijk worden 
welke subgroepen van ogen met keratoconus het beste behandeld moeten 
worden met anterieure LK (hetzij ALTK, hetzij DALK, zie beneden), welke ogen 
aanvankelijk behandeld kunnen worden met intracorneale ringsegmenten (zie 
beneden), en voor welke patiënten PK of een variant die aspecten van PK en LK 
combineert (zie beneden) de eerst aangewezen methode is.
 
 Het is duidelijk dat lange-termijn gegevens over endotheelcelverlies van 
zeer groot belang zijn in de evaluatie van technieken waarbij het endotheel 
selectief wordt vervangen, zoals in PLK. Gezien bovenstaande bevindingen 
zouden zulke prospectieve onderzoeken kunnen aantonen dat na PLK-achtige 
technieken het endotheelcelverlies groter en sneller is in vergelijking met 
andere technieken, resulterend in een kortere transplantaatoverleving. Toch 
zouden er nog steeds goede indicaties voor PLK kunnen zijn. Voordelen van 
PLK, zoals sneller herstel van de gezichtsscherpte, minder polikliniekbezoeken, 
en minder hechting-gerelateerde complicaties zouden kunnen opwegen 
tegen langere transplantaatoverleving. Dit zou voor oudere of minder mobiele 
patiënten PLK nog steeds tot de behandeling van eerste keus kunnen maken 
voor endotheelaandoeningen. In geval van ernstig droge ogen is PK relatief 
gecontra-indiceerd en zou PLK wel eens de enige keus voor het behandelen 
van endotheelaandoeningen kunnen zijn. Vergelijkbare overwegingen 
kunnen ook anterieure LK technieken verzekeren van een “niche” in het 
behandelingsrepertoire, zelfs als sommige uitkomsten wat achter zouden blijven. 
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 Uiteindelijk zal vooral de voorkeur van de individuele patiënt, in combinatie 
met  de mogelijke voorkeur, vaardigheden, of voorzieningen van de 
oogarts met wie de patiënt een behandelingsrelatie heeft bepalen welke 
behandelmethode er gebruikt wordt.
II.  Toekomstperspectief.
 Het  cornea-endotheel wordt de laatste tijd in toenemende mate onderzocht 
en afgebeeld met behulp van in-vivo confocale microscopie. Een van de 
belangrijkste voordelen ten opzichte van spiegelmicroscopie of specular 
microscopy is dat confocale microscopie het endotheel ook in beeld kan 
brengen in troebele, oedemateuze hoornvliezen. Daarnaast kan confocale 
microscopie ook gebruikt worden om cellen en structuren in alle andere 
lagen van het hoornvlies in beeld te brengen. Bovendien kan men met deze 
techniek de reflectiviteit van licht, en daarmee bijvoorbeeld een fenomeen als 
“haze”, in de verschillende hoornvlieslagen kwantificeren.303 De meeste van de 
optische vertekeningen die in specular microscopy een rol spelen zijn niet of 
van onderschikt belang in confocale microscopy (zie hoofdstuk 6). De andere 
aspecten van betrouwbaarheid zoals die in deel A van dit hoofdstuk zijn 
samengevat zijn dat wel. Confocale microscopie is meestal een contact-type 
onderzoek dat enige tijd vergt. Het is daarom minder prettig voor patiënten 
en draagt bovendien het risico van contaminatie met micro-organismen. 
Specular microscopy kan daarom wellicht een rol blijven spelen bijvoorbeeld 
bij vervolgonderzoeken aan het endotheel na oogoperaties.
 De zoektocht naar geschikte kleurstoffen voor het adjunctieve gebruik tijdens 
oogoperaties is nog niet voltooid. Tot dusverre zijn er nog geen kleurstoffen 
gevonden die wel een goede kleuring kunnen bewerkstelligen maar in het 
geheel geen toxische effecten veroorzaken. De kleurstof Coomassie blauw, ook 
bekend als Briljant Blauw G, vormt mogelijk een waardevolle aanwinst in dit 
opzicht. 1227
 
 De laatste jaren zijn er opmerkelijke ontwikkelingen geweest in de behandeling 
van hoornvliesaandoeningen: nieuwe behandelingsmodaliteiten zagen het 
licht, en bestaande technieken werden aangepast.
 In dit proefschift is eerder al beschreven hoe bij de behandeling van 
aandoeningen van het hoornvliesendotheel de aandacht is verschoven van 
PK naar de selectieve vervanging van dit endotheel. De in dit proefschrift 
weergegeven artikelen beschreven de eerste technieken voor PLK die klinisch 
zijn toegepast. Op dit moment lijken deze “oudere” varianten van de PLK/DLEK 
technieken al weer enigszins achterhaald en verschuift de aandacht naar een 
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nieuwere techniek, als men tenminste afgaat op de grootte van de series 
patiënten in de literatuur die hiermee worden behandeld. De nieuwe variant 
wordt “Descemet stripping and endothelial keratoplasty” (DSEK) genoemd, en 
staat ook wel bekend als PLK met Descemetorhexis. Deze techniek is zo snel 
zo populair geworden, omdat ze sneller en gemakkelijker uit te voeren is dan 
de oudere PLK/DLEK varianten die nog gebruik maakten van intrastromale 
dissectie. Hierdoor kan ze door meer chirurgen worden uitgevoerd en leidt 
ze waarschijnlijk ook tot meer reproduceerbare resultaten. Bovendien mag er 
aangenomen worden dat er in DSEK een egaler wondbed gecreëerd wordt. 
Dit, en het feit dat de wond “interface” zich op het diepst mogelijke niveau, 
namelijk direct boven Descemet bevindt, zouden wel eens een gunstig effect 
kunnen hebben op de optische kwaliteit en daardoor op de postoperatieve 
gezichtsscherpte. Ook de pioniers van de oudere varianten van PLK/DLEK 
(Melles, Terry en Price) zijn in het algemeen overgeschakeld op DSEK.1148, 
1150,1151,1227 Recente publicaties met grote series patiënten die behandeld zijn 
met DSEK lieten veelbelovende visuele resultaten zien, en bemoedigend 
lage complicatie-percentages. Er zijn echter vergelijkende, gerandomiseerde 
prospectieve onderzoeken nodig om vast te stellen of, en zo ja welke van 
de posterieure hoornvliestransplantaties de betere resultaten heeft, ook in 
vergelijking met PK.1150,1151
 De hernieuwde populariteit van anterieure lamellaire keratoplastiek voor 
de behandeling van cornea-ectasieën en anterieure cornea-afwijkingen is 
ook al eerder aan de orde gekomen. Tot dusverre hebben we ons met name 
gericht op een techniek voor diepe anterieure lamellaire keratoplastiek die 
met behulp van diepe instrastromale dissectie wordt uitgevoerd, maar het 
gebruik van de automatische microkeratoom bij LK is ook al eerder aangekaart. 
Dit is een instrument dat tot dusverre zijn belangrijkste toepassing had bij 
LASIK, en daarom vooral al bekend is bij refractiechirurgen. De automatische 
microkeratoom kan daarnaast ook in zowel  anterieure als posterieure lamellaire 
keratoplastiek zijn nut hebben.1228 Met behulp van het oscillerende mes kan 
men op diverse van tevoren gekozen dieptes lamellaire dissecties verrichten 
in het hoornvlies van de ontvanger en in de donorcornea. Het dissectievlak 
van een microkeratoom is meestal erg egaal, wat voordelig is voor de optische 
kwaliteit van de wond. Daarnaast kan een lamellaire dissectie sneller met de 
microkeratoom dan handmatig uitgevoerd worden. Verschillende onderzoekers 
hebben gepubliceerd over series patiënten bij wie ze anterieure LK met 
behulp van de microkeratoom hebben uitgevoerd. 1092,1215,1216 Deze techniek 
staat ook wel bekend als Automated Lamellar Therapeutic Keratoplasty (ALTK). 
Er zijn veelbelovende resultaten mee behaald wat betreft de postoperatieve 
gezichtsscherpte en refractie. Het is echter nog niet duidelijk of deze gunstig 
afsteken ten opzichte van de andere technieken voor lamellaire chirurgie 
of PK. Sommige auteurs rapporteren dat een lamellaire dissectie waarbij de 
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membraan van Descemet vrijgeprepareerd wordt, zoals met de ‘big bubble 
techniek’, een betere postoperatieve gezichtsscherpte oplevert dan ALTK. 
1216,1230,1231 De ALTK techniek kan bovendien niet toegepast worden op cornea’s 
die heel dun of steil zijn of een onregelmatig oppervlak hebben.
 
 Het nut van het gebruik van de microkeratoom bij posterieure lamellaire 
keratoplastiek ligt vooral in het vlugger prepareren van de posterieure 
donorlamel. Een dergelijke combinatie van DSEK waarbij de automatische 
microkeratoom gebruikt wordt voor de donorcornea is al wel DSAEK genoemd. 
1232
 In de laatste jaren is er een laser op de markt gekomen die een alternatief 
vormt voor de automatische microkeratoom: de femtosecond ND:Yag laser. 
Met deze fotodisruptieve laser kan door middel van een groot aantal ultrakorte 
laserpulsen een snijvlak in het hoornvlies gemaakt worden. Evenals met de 
automatische mikrokeratoom kan men dus zeer snel en precies een lamellaire 
dissectie uitvoeren. Een belangrijk voordeel van de femtosecond laser is dat 
dissecties en incisies in alle richtingen gemaakt kunnen worden; horizontaal, 
verticaal, trapvormig, en zelfs schuin. Daarom is deze laser geschikt voor 
LASIK en anterieure en posterieure LK, maar ook voor PK en PK-varianten 
met getrapte of lamellaire wondconfiguraties (zie hieronder). 1098,1233-1235 De 
femtosecond laser wordt al steeds meer toegepast in de refractiechirugie, voor 
het snijden van LASIK-flappen.1236-1240 
 Behalve voor posterieure of anterieure LK kan er de laatste tijd ook 
gekozen worden voor PK met diverse lamellaire wondconfiguraties. In deze 
varianten worden sommige voordelen van PK met andere voordelen van LK 
gecombineerd. De concepten hiervoor zijn niet nieuw maar al in het midden 
van de twintigste eeuw bedacht. 1061,1241 Ze zijn de laatste jaren echter in 
populariteit gestegen doordat er steeds meer interesse was ontstaan in het 
aanpakken van een aantal nadelen van ‘conventionele’ PK, in combinatie met 
het beschikbaar komen van betere instrumenten en operatiemicroscopen. 
Eén van de meest gebruikte technieken is op dit moment de omgekeerde 
mushroom PK,  in de literatuur ook wel benoemd als ‘nut-and-bolt’ PK, en ‘top-
hat’ PK. De normaal verticale PK-wond heeft hierbij een getrapte configuratie, 
waarbij de diameter van het achterste deel van het getransplanteerde 
hoornvlies groter is dan die van het voorste deel. Deze techniek wordt vooral 
gebruikt bij de behandeling van patiënten met een endotheliaal probleem, 
omdat hiermee een grote hoeveelheid goede donorendotheelcellen in het 
ontvangende oog kan worden ingebracht. De getrapte incisie levert een 
mechanisch stabielere wond op dan bij PK, waardoor er minder en ook minder 
diepe hechtingen nodig zijn. Die kunnen bovendien vroeger dan gebruikelijk 
worden verwijderd. In theorie zouden hierdoor er minder postoperatieve 
complicaties moeten zijn die te maken hebben met hechtingen of het 
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verwijderen daarvan, zoals wonddehiscentie, infectie, en hoog astigmatisme. 
Een belangrijk voordeel ten opzichte van LK is dat er geen wond-interface 
in de visuele as is, waardoor de postoperatieve gezichtscherpte mogelijk 
beter is.1108,1242 Op vergelijkbare wijze zou een voorste mushroom PK, met een 
grotere anterieure  en een kleinere achterste transplantaatdiameter voordelen 
kunnen hebben als chirurgische optie voor de behandeling van bijvoorbeeld 
keratoconus. Deze techniek zou een groter dan gebruikelijk deel van het 
normale, gezonde endotheel van het ontvangeroog kunnen sparen, terwijl 
tegelijkertijd het postoperatieve astigmatisme relatief laag is en er geen 
wond-interface in de visuele as gevormd wordt.1241 Een anterieure lamellaire 
dissectie met de automatische microkeratoom gecombineerd met een dieper 
penetrerend transplantaat is ook wel ‘mushroom’ keratoplastiek genoemd. Dit 
is toegepast voor troebelingen die zich over de gehele dikte van het hoornvlies 
uitstrekten, en lijkt qua techniek sterk op de endotheliale keratoplastiek 
met behulp van de microkeratoom, die gepropageerd is voor selectieve 
endotheeltransplantatie.1243 De komst van de femtosecond laser kan voor de 
populariteit van de meeste van deze technieken, waarbij PK met lamellaire 
dissectie of wondconstructie gecombineerd wordt, een stimulans vormen. 1242
 Het is belangrijk dat men op zijn hoede is met alleen het selectief vervangen 
van het endotheel in sommige gevallen. Langdurig cornea-oedeem ten 
gevolge van endotheeldecompensatie leidt tot secundaire veranderingen in 
het stroma. Dit kan men bijvoorbeeld aantreffen bij al geruime tijd bestaande 
bulleuze keratopathie. In dergelijke hoornvliezen treed er een hydropische 
degeneratie, een necrose van keratocyten op. Van deze keratocyten-necrose 
is recent aangetoond met behulp van confocal microscopy dat het op 
zichzelf al aanzienlijke verstrooiing van licht veroorzaakte. Dit stond los van de 
lichtverstrooiing die door het oedeem veroorzaakt werd. Hieruit kan worden 
opgemaakt dat het verlies aan helderheid in dergelijke hoornvliezen niet alleen 
voorkomt uit een vergrote afstand tussen de collageenfibrillen, wat volgens de 
klassieke theorie de oorzaak is van het transparantieverlies bij cornea-oedeem. 
Helaas is de degeneratie van keratocyten onomkeerbaar. Ook is er in dergelijke 
hoornvliezen een vermindering van het gehalte van proteoglycanen gevonden. 
Men dient zich er dus van bewust te zijn dat de selectieve vervanging van het 
endotheel bij bulleuze keratopathie wel eens niet in alle gevallen afdoende zou 
kunnen zijn om weer een helder hoornvlies te krijgen. In dergelijke gevallen 
zou men toch kunnen kiezen voor PK of een variant daarop met een lamellaire 
wondconfiguratie.874,1246
 Recent is er voor ectatische afwijkingen van het hoornvlies, zoals keratoconus en 
pellucide marginale degeneratie, nog een nieuwe chirurgische behandelingsoptie 
bijgekomen die niets te maken heeft met hoornvliestransplantatie. Deze 
behandeling, de intrastromale ringsegmenten, kan als alternatief voor PK 
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of LK toegepast worden, maar een transplantatie zou er ook enige tijd mee 
kunnen worden uitgesteld. De ringsegmenten werden reeds toegepast als 
een refractiechirurgische techniek ter behandeling van milde tot matige 
bijziendheid (ie ook hoofdstuk 2, paragraaf XIV). Voor dit doel worden ze echter 
steeds minder gebruikt, omdat de resultaten niet erg goed te voorspellen 
waren. Een voordeel van deze ringsegmenten bij de behandeling van cornea-
ectasieën is dat ze het uitgestulpte hoornvlies vlakker en strakker trekken. 
Ook zijn de gevolgen van deze behandeling voor de refractie (de brilsterkte) 
omkeerbaar. Na een behandeling met ringsegmenten kan er nog steeds wel 
een afwijkende refractie overblijven, maar vaak blijkt deze gemakkelijker dan 
voorheen te corrigeren te zijn met een bril of met een zachte contactlens 
(i.p.v. een harde contactlens). Cornea’s die te steil of te dun zijn, of waarin zich 
centraal een vertroebeling bevindt zijn  niet geschikt om met deze methode 
behandeld te worden. In een geselecteerde groep van ogen met niet al te ver 
voortgeschreden keratoconus kunnen ring segmenten (INTACS dan wel Ferrara 
ringen) een bruikbare aanvullende behandelmethode zijn1192,1245-1254 Met behulp 
van de femtosecond laser kan in een aantal gevallen op een makkelijkere 
manier de tunnels waarin de ringsegmenten moeten worden opgevoerd in het 
hoornvlies worden gemaakt.
 De meest recent beschreven nieuwe behandeloptie voor cornea-ectasieën is 
het cross-linken van het stromale collageen. Bij deze behandeling wordt het 
oog met bijvoorbeeld keratoconus blootgesteld aan een UV-A stralingsbron, 
nadat er riboflavine in is gedruppeld. De UV-A straling zorgt ervoor dat er 
riboflavine-radicalen ontstaan, en deze moleculen zijn in staat chemische 
cross-links tussen de collageenfibrillen in het hoornvliesstroma te maken. De 
cross-links zorgen voor een biomechanische verstijving van het stroma. Deze 
behandeling is met name bedoeld om het progressie van de ectasie, dus het 
verergeren van de uitbochting, tegen te gaan. Tot nu toe zijn er alleen nog 
maar ‘case series’ gepubliceerd. Hieruit blijkt dat de behandeling op de korte en 
middellange termijn veilig is, en er zijn aanwijzingen dat ze ook effectief is.1257-
1259 Om echter daadwerkelijk de effectiviteit te bewijzen zijn er lang lopende, 
gerandomiseerde, vergelijkende prospectieven onderzoeken nodig.
 Tot slot moet er nog kort worden ingegaan op het induceren van celdelingen 
in endotheelcellen. Als het gaat om endotheelaandoeningen zou dit wel 
eens de therapie van de toekomst kunnen worden. Een endotheel dat 
opgebouwd is uit gekweekte endotheelcellen is een antwoord op een tekort 
aan donorweefsel, en door modificatie van antigeenexpressie mogelijk ook op 
transplantaatafstoting. Dit laatste zou natuurlijk ook bereikt kunnen worden 
via het kweken of  induceren van proliferatie van eigen endotheelcellen van 
de patiënt. Het concept van het kweken van humane endotheelcellen voor 
transplantatiedoeleinden is in het verleden al beschreven.1114-1117 Nieuwer 
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onderzoek richtte zich op het vinden van geschikte dragers waarmee deze 
cellen getransplanteerd zouden kunnen worden.1119,1126,1128,1260 Recent onderzoek 
laat zien dat met gekweekte humane endotheelcellen en gepreserveerd 
humaan corneaweefsel hoornvliesconstructen kunnen worden vervaardigd.1126 
Er zijn zelfs publicaties over complete hoornvliesconstructen waarvan alle lagen 
opgebouwd zijn uit geïmmortaliseerde, gekweekte humane cellen (epitheliale, 
stromale en endotheliale cellen).1124 Transfectie met bijvoorbeeld SV40 virus 
vectoren is wellicht noodzakelijk om voor transplantatiedoeleinden een 
gekweekte endotheelcellaag te krijgen met een voldoende hoge ECD. 132,1124 
Van dergelijke getransfecteerde gekweekte endotheelcellagen is in sommige 
onderzoeken een adequate endotheelpompfunctie aangetoond.132,1124 
Deze getransfecteerde cellagen hebben echter vaak het probleem dat de 
celdelingen doorgaan ook als dat niet meer gewenst is. Maar cellagen die 
opgebouwd zijn uit niet-getransfecteerde cellen hebben vaak een te lage ECD 
of een onvoldoende endotheelpompfunctie. 132,1126 Tot nu toe heeft nog geen 
enkele van deze experimenten geresulteerd in een klinische toepassing.
 In plaats van het transplanteren van gekweekte endotheelcellen zou men 
endotheelaandoeningen ook kunnen proberen te verhelpen door in vivo de 
eigen endotheelcellen van de patiënt aan te zetten tot celdeling. Hiervoor is 
het exact identificeren van de endotheliale stamcellen noodzakelijk en dat is 
tot dusverre nog niet gelukt, hoewel wel steeds duidelijker wordt dat ze zich 
in de regio van de posterieure limbus bevinden. Dit probleem moet worden 
opgelost voordat deze benadering verder ontwikkeld kan worden. 132,874,1261,1262 
Tot het zover is, zal het transplanteren van complete donor-endothelia door 
middel van PK, PLK, of varianten daarop, nodig blijven.
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Abbreviations
ABK Aphakic bullous keratopathy
AC Anterior chamber
ACAID Anterior chamber associated immune deviation
AJC Apical junctional complex (of endothelial cells) 
a.k.a. Also known as
ALTK Automated lamellar therapeutic keratoplasty, a.k.a. 
 Lamellar keratoplasty with an automated microkeratome
ANOVA Analysis of variance
B(S)CVA Best (spectacle) corrected visual acuity
BSS Balanced salt solution
CCC Continuous circular/curvilinear capsulorhexis
CE (+ I) Cataract extraction (plus implantation of an IOL)
CHED Congenital hereditary endothelial dystrophy
CI Cytotoxicity index
CRT Corneal refractive therapy (= Orthokeratology, OK) 
CT Corneal thickness 
CV Coefficient of variation (= standard deviation divided by mean),   
 of endothelial cell size
D Diopter(s)
DALK Deep anterior lamellar keratoplasty
DLCTS Dutch lamellar corneal transplant study
DLEK Deep lamellar endothelial keratoplasty ( = PLK)
DM Descemet’s membrane
DSAEK Descemet’s stripping with automated endothelial keratoplasty
 (= DSEK/PLK with Descemetorhexis, with donor preparation
 using an automated microkeratome)
DSEK Descemet’s stripping with endothelial keratoplasty (= PLK with 
 Descemetorhexis)
ECCE Extracapsular cataract extraction
ECD Endothelial cell density
ELK Endothelial lamellar keratoplasty ( = MAPK)
EMEM Eagle’s minimal essential medium, for organ culture tissue 
 preservation.
ERM Epiretinal membrane
FBS (= FCS) Fetal bovine/calf serum
FED Fuchs’ endothelial dystrophy
HLA Human leukocyte antigen
HSV Herpes simplex virus
ICC Intraclass correlation coefficient
ICCE Intracapsular cataract extraction
ICE syndrome Iridocorneal endothelial syndrome
ab
br
ev
ia
ti
o
n
s
324
bart_part5DEF.indd   324 19-11-2006   14:06:54
ICG Indocyanine green, also: infracyanine green 
ICL Implantable contact lens (= posterior chamber phakic IOL)
ICRS Intrastromal corneal ring segments
i.e. Id est (= that is)
ILM Internal limiting membrane (of the retina)
INTACS Type of ICRS
IOI Interuniversitair oogheelkundig instituut (=NORI), now NIN
IOL Intra-ocular lens (artificial)
IOP Intra-ocular pressure
IP Imbibition pressure
KC Keratoconus
KP Keratoprosthesis
L Imaged length of corneal endothelium (in specular microscopy)
LASIK Laser in-situ keratomileusis
LASEK Laser-assisted subepithelial keratomileusis
LC50, LD50 Concentration/dose at which 50 % of maximum toxic effect is 
 reached
LEF Late endothelial failure
LK (= LKP) Lamellar keratoplasty
M Magnification
MAPK Microkeratome assisted posterior keratoplasty  
MHC Major histocompatibility complex
MK-medium McCarey-Kaufman medium, for cold donor cornea preservation
MMC Mitomycin-C
MMT assay (Mossman’s) Mossman’s 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
 bromide assay
MS Morphology score
n Refractive index, or number of patients/eyes in study group
Na+/K+ ATPase Sodium-potassium ion exchanger = endothelial metabolic pump
NIIOC Netherlands institute for innovative ocular surgery in Rotterdam
NIN Netherlands institute for neurosciences
NM Normalized magnification
NORI Netherlands ophthalmic research institute in Amsterdam,
 (=IOI in Dutch), now NIN 
OK Orthokeratology (= corneal refractive therapy (CRT) = corneal
 reshaping with contact lenses)
OOKP Osteo-odonto-keratoprosthesis
P Corneal power
PBS Phosphate buffered solution (laboratory)
PCL Posterior collagenous layer
PIOL Phakic intraocular lens
PK (= PKP = PKPl) Penetrating keratoplasty (a.k.a. perforating keratoplasty)
PLK Posterior lamellar keratoplasty
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PMMA Polymethyl-methacrylate
PPBK Pseudophakic bullous keratopathy
PPD (= PPMD) Posterior polymorphous dystrophy
PRK Photo-refractive keratectomy
PTK Photo-therapeutic keratectomy
PVR Proliferative vitreoretinopathy
r Corneal radius
RGP Rigid gas-permeable (= hard) contact lens
RK Radial keratotomy
RPE Retinal pigment epithelium
SD Standard deviation
SEM Scanning electron microscope
SP Swelling pressure
TASS Toxic anterior segment syndrome
TB Trypan blue
TECD syndrome Toxic endothelial cell destruction syndrome
UCVA Uncorrected visual acuity
UGH syndrome Uveitis glaucoma hyphaema syndrome
UV-A, -B Ultraviolet radiation of type A, B
VA Visual acuity
5-FU 5-Fluorouracil
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Colour figures
Fig. 2.VII.1  Example of a specular microscopic image, analysed with the “borders” variable frame endothelial as-
sessment method. In this example, automatedly drawn cell borders were corrected manually.
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Fig. 6.1 Diagrammatic representation of the optic distortions in non-contact specular microscopy. 
Notice the dominant epithelial reflex (heavy green line). The maximal endothelial width that can be observed Lmax is determined by 
the corneal thickness CT and the incident angle after anterior corneal deflection α, according to 
Lmax = 2 * CT * tan α. In the SP2000P, α  = 16.1˚.
a. An oblique observation-angle introduces underestimation of the observed dimension. β is the incident angle (without anterior  
 corneal deflection). Lassumed (PR ) = cos β * Lmax (PQ) (assuming that PQ were not curved). In the SP2000P β = 22.5˚, and hence:  
 Lassumed (PR ) = 0.924 * Lmax (PQ).
b.  Observation of a cuved surface (PQ) instead of a straight surface introduces slight underestimation of the observed dimension.  
 See text for details. 
c.  Magnification by the anterior corneal surface introduces overestimation of the observed area. See text for details.
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Fig. 7.1 Trypan blue capsule staining to aid visualisation of the anterior lens capsule in
  mature cataract phacoemulsification.
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Fig.12.1 Diagrammatic representation of the techniques for posterior lamellar keratoplasty. 
In Technique A, a 9.0 mm sclerocorneal pocket incision was made, and a recipient posterior lamellar disc was excised with an instra-
stromal trephine and microscissors. The donor posterior lamellar disc was inserted endothelium side down on a spoon-shaped glide 
covered with visco elastic to protect the endothelium. The scleral incision was sutured, but no sutures were used to fixate the donor 
tissue. In Technique B, a 5.0 mm sclerocorneal tunnel  incision was made, and the recipient posterior corneal tissue was excised with 
microscissors only. The donor  disc was folded prior to insertion with the endothelium on the inside, and the tissue was unfolded inside 
the anterior chamber and positioned against the posterior recipient cornea. Because the scleral incision was self-sealing, no sutures were 
used in the procedure.
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Dankwoord
Het avontuur van het promotieonderzoek dat nu zijn neerslag in dit proefschrift heeft 
gekregen, is voor mij in augustus 1998 begonnen. Het werk aan dit proefschrift is nauw 
verweven met mijn tijd in het Oogziekenhuis Rotterdam, eerst als arts-onderzoeker, later als 
AGNIO, vervolgens als AGIO/AIOS, en tenslotte nu als cornea-fellow. De promotie is in mijn 
ogen dan ook een toepasselijke afsluiting van mijn werkzaamheden in het OZR. 
Dit proefschrift had nooit tot stand kunnen komen als niet vele mensen mij daarbij hadden 
gesteund en geholpen. Al deze mensen wil ik daarvoor hartelijk danken. Allereerst alle 
patiënten en vrijwilligers die de afgelopen jaren, soms herhaalde malen, belangeloos en 
welwillend hebben meegewerkt aan het promotieonderzoek. 
Mijn promotor, professor Van Rij. Dank voor uw begeleiding en geduld. Door uw stimulans 
en acties heeft de eindsprint die ik dit voorjaar heb ingezet, erin geresulteerd dat steeds meer 
“bijna af” nog in 2006 ook echt “helemaal af” is. Ook in de periode daarvoor, vanaf het moment 
dat u de directe begeleiding van het project hebt overgenomen, wist u in de stimulerende 
voortgangsbesprekingen altijd weer overzicht aan te brengen. Ik vermoed dat u zich niet 
heeft gerealiseerd dat uw opmerking in één van de eerste van onze besprekingen “dat het 
proefschrift wat meer ‘body’ moest krijgen”, zulke gevolgen zou hebben voor de omvang van 
dit proefschrift en de lengte van het traject. U heeft inmiddels gemerkt waar dat in combinatie 
met mijn onverbeterlijk optimistische manier van ‘plannen’ toe geleid heeft.
Mijn co-promotor: Gerrit Melles. Ik heb veel bewondering voor je innovatieve geest, je drive 
om jouw ideeën te verwezenlijken en je heldere formuleringen bij het schrijven van artikelen. 
Dank dat ik een tijdje in jouw keuken heb mogen kijken; jouw ideeën en technieken 
vormden de aanzet tot deze promotie en zijn het onderwerp van een belangrijk deel van dit 
proefschrift. Onze samenwerking was heel wisselend in intensiteit, zo zagen we elkaar tijden 
lang nauwelijks om dan vrij plotseling samen weer veel werk te verzetten. Blijkbaar was dat 
wel de goede formule om tot succesvolle afronding van een aantal projecten te komen. Ik 
heb in meerdere opzichten veel van de samenwerking met jou geleerd.
Mijn co-promotor: Liesbeth Pels. Jij was niet alleen mijn wetenschappelijke steun en 
toeverlaat, maar stond me op moeilijke momenten ook bij met je vriendschap en 
belangstelling. En dat terwijl je zelf ook roerige tijden doormaakte. Ik dank je daarvoor 
hartelijk! Je wist altijd weer tijd vrij te maken om mijn schrijfsels door te lezen en van 
nuttige opmerkingen te voorzien. Door jouw opbouwende input wisten we het niveau van 
een aantal artikelen aanzienlijk te verhogen. Dank voor je gastvrijheid van het begin af aan.
De leden van de Kleine en Grote Promotiecommissies wil ik danken voor het doornemen 
van het manuscript en het toelaten tot de promotie daarvan; respectievelijk voor hun 
bijdrage aan de verdediging van het proefschrift. In particular I would like to thank Prof.
W.J.Armitage, Ph.D. for his willingness to come over from Bristol in order to participate in 
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the defence of this thesis. Dear John, I was very impressed by your hospitality at my visit 
in March 2004, and by your openness in our discussions on the bi-exponential endothelial 
decay models. Your additional comments in e-mails and during our recent encounter at last 
ARVO-meeting were very helpful in firming my grasp on these concepts. I feel honoured 
that you are a member of my Thesis Defence Committee.
Houdijn Beekhuis, ik kan jou eigenlijk niet genoeg bedanken. Heel bijzonder en waardevol 
vond en vind ik onze vriendschap. Je was mede-initiator van dit promotie-onderzoek. Je 
hebt een essentiële rol gespeeld in de begeleiding, en er op een cruciaal moment voor zorg-
gedragen dat ik kon doorgaan met dit project. Ook is het bijzonder nuttig en inspirerend voor 
mij geweest dat ik met jouw hulp contacten kon leggen en inhoudelijke discussies kon voeren 
met autoriteiten als Armitage en Hartmann. Hierdoor, en door de inspirerende manier waarop 
je vormgaf aan je patiëntenzorg, heb je grote invloed gehad op de keuzes die ik ten aanzien van 
mijn carrière heb gemaakt. Je bent daarom in veel opzichten mijn leermeester geweest. Altijd 
was je er voor een gesprek, en met jouw humor, en je kennis, inzicht en ervaring wist je altijd 
weer dingen in perspectief te plaatsen. En dat bleef zelfs zo toen je al met pensioen was en een 
groot deel van het jaar genoot van je verblijf als “God in Frankrijk”. Gertrude en ik komen met de 
kinderen jullie daar graag opzoeken, als het straks eindelijk wat rustiger lijkt te gaan worden.
Prof.dr.H.J.M. Völker-Dieben, veel dank voor uw vriendelijke belangstelling en enthousiaste 
aanmoedigingen tijdens het hele promotietraject. Uw belangstelling heeft er in belangrijke 
mate aan bijgedragen dat ik bepaalde vraagstellingen in dit proefschrift verder heb willen 
uitdiepen. Uw professionele en wetenschappelijke attitude en carrière zijn voor mij een 
voorbeeld. Ik ben vereerd dat u mede-auteur bent van een aantal artikelen en dat u zitting 
wilde nemen in de promotiecommissies van dit proefschrift. 
Paul Mulder, grote dank ben ik jou verschuldigd voor de bereidwillige, vriendschappelijke 
en geduldige wijze waarop je je hebt ingespannen om dit proefschrift van een statistische 
ruggengraat te voorzien. Bijzonder vind ik je vermogen om zeer diverse klinische en 
biologische vraagstellingen om te zetten in een statistisch probleem, en om uit de ruwe 
data via soms complexe bewerkingen altijd weer een bruikbaar onderzoeksresultaat 
te destilleren. Dank ook dat je altijd opnieuw bereid was om nog weer eens naar reeds 
verricht werk te kijken, als voor ons mede-auteurs of voor de reviewers de implicaties niet 
duidelijk waren, of ik de klinische relevantie van één en ander beter moest verwoorden.
Ook dank aan mijn andere mede-auteurs: Tom van de Berg, voor de vriendschappelijke 
en daadkrachtige manier waarop je geholpen hebt een gedachtewisseling over de optica 
van non-contact specular microscopy om te zetten in een manuscript voor een artikel. 
Wim van Schaick, dank voor je vriendschap en belangstelling, en voor de gezelligheid bij 
de (uiteindelijk succesvolle!) noeste arbeid aan ons eerste gezamenlijke artikel. Angela Lie, 
dank voor de grote hoeveelheid werk die je in het uitwerken van de endotheelfoto’s hebt 
gestopt, voor je kameraadschap, en voor een prettige dosis relativering. Peter de Waard 
en Hesther van Nouhuijs, dank voor jullie bijdragen aan en input bij het klinische trypaan-
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blauw artikel. Carla Nieuwendaal, dank voor je interesse en hulp. Hans Lemij, dank voor je 
hulp bij het schrijven van een lastig abstract.
Mijn opleiders, Seerp Baarsma en Prof.dr. Jan van Meurs; ik wil jullie hartelijk danken voor jullie 
vertrouwen. Daarmee hebben jullie me de mogelijkheid gegeven om in het Oogziekenhuis 
de opleiding tot oogarts te volgen en later mijn subspecialisatie te starten. Ook dank voor 
de ruimte die jullie mij boden om het promotie-onderzoek voort te zetten en af te ronden, 
en voor de uiterst prettige opleidingstijd die ik onder jullie hoede heb gehad. Jan, ik ben 
vereerd dat je zitting wilde nemen in de promotiecommissies van dit proefschrift.
De oogartsen van het cornea-team, Lies Remeijer, Annette Geerards, Jeroen van Rooij, en 
Hugo van Cleynenbreugel: dank voor jullie grote inzet en bereidheid om me op te leiden 
tot cornea- en refractiechirurg. Dank ook voor jullie begrip wanneer ik weer eens iets moest 
laten wijken om dingen voor het proefschrift af te handelen, en voor jullie belangstelling 
door de jaren heen. Jullie vriendschap en alles wat jullie me leerden maken dit laatste jaar 
in het oogziekenhuis, dat door het afronden van dit proefschrift soms best zwaar was, er 
één waar ik straks met heel veel voldoening en plezier aan zal terugdenken.
 
Alle andere stafleden van het OZR; dank voor alles wat jullie me geleerd hebben en voor de 
hele bijzondere, collegiale en vriendschappelijke manier waarop jullie mijn tijd hier mede 
hebben vormgegeven.
 
Alle huidige en oud-assistenten in het Oogziekenhuis; dank voor jullie belangstelling en 
steun. De assistentengroep was weer altijd een bron van energie en gezelligheid! Sorry als 
ik weer eens gepreoccupeerd was met het proefschrift en me daardoor misschien van mijn 
minder sociale kant liet zien. 
Trees, Dick, Bert, Kees, Sandra, Hans, Wendy en andere (voormalige) medewerkers van de 
afdeling Fotografie van het Oogziekenhuis Rotterdam: ik wil jullie hartelijk danken voor 
jullie vriendschap. Super dat jullie me een aantal jaren met mijn endotheelcamera hebben 
willen tolereren als kraker op jullie afdeling. Dank ook voor de vele vermakelijke en soms 
hilarische verhalen uit de oude doos over het Oogziekenhuis, en voor het doen opvlammen 
van mijn voorliefde voor oude-mannen-rock. Dat alles maakte het monnikenwerk aan de 
endotheelfoto’s nog enigszins te verdragen. Bert Smit, speciale dank voor je hulp met de 
grafische software en bij het maken van figuren.
Yvonne, Hanneke, Teja, Jikke, Wessel, Lidwien, Mercedé, Lidwien, Paul en andere (voormalige) 
medewerkers van de Cornea Bank Amsterdam wil ik danken voor hun gastvrijheid, gezellig-
heid, belangstelling, soep, en voor onmisbare hulp bij diverse projecten.
Medewerkers van het OK-complex, en de afdeling screening/intake van het OZR, 
verpleegkundigen en spreekuur-/balie-assistentes, en niet te vergeten Jan Voets, die 
hebben meegeholpen bij het opsporen en doorsturen van geschikte patiënten en bij het 
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verzamelen en versturen van cornea-buttons: hiervoor mijn dank.
George, Ans, Natascha, Paula, Dorry, Marianne en collega’s, dank voor jullie grote hulp 
bij het organiseren en regelen van onderzoeksspreekuren, verzamelen van lijsten, steun 
tijdens de spreekuren (koffie,thee, soep,gezelligheid!) en voor jullie belangstelling.
Hellen Scholten: heel veel dank voor je hulp bij het opvragen van al die artikelen en voor je 
interesse.
Alle andere (oud-)medewerkers van het OZR die ik heb leren kennen, met wie ik heb 
mogen samenwerken en die ik (nog) niet met name genoemd heb: jullie maakten met z’n 
allen dat het OZR zo’n bijzondere plek was om te werken. Mijn hartelijke dank daarvoor.
Esther de Bruijn, dank voor je voortreffelijke lay-out en vormgeving, en je geduld met deze 
eigenwijze perfectionist. Het ziet er subliem uit en ik ben heel blij dat je het met zo weinig 
tijd tot je beschikking wilde doen!
Mede-promovendi tijdens dit lange traject: Martha, Luc, Rob, Fred, Anna, An, Lies, Caroline, 
Jacqueline, Antoinette, Nicole, Redmer, Emine, Olga, Thomas, Tanja, Markus, Jelle, Kiki, 
Andrea, Ruurd, Nic, Marjolijn, Esther, Suzanne, Hanneke, Kris, Leonieke en Ellen. Jullie weten 
welke pieken je bestijgt en in welke dalen je terechtkomt tijdens het afleggen van de weg 
naar de promotie-bul. (En als je het nog niet weet: maak je borst maar nat!) Het werkt erg 
relativerend om af en toe eens flink je frustraties weg te kunnen mopperen met lotgenoten. 
Markus en Jeroen, dank voor vele jaren van vriendschap. Ik ben er trots op dat jullie bij de 
verdediging naast en ‘bij’ me willen staan.
Alle nog niet genoemde familie en vrienden: dank voor jullie belangstelling, vriendschap 
en geduld.
Lieve pap en mam, heel erg veel dank voor al die jaren van onvoorwaardelijke steun. Pap, 
je hebt de voltooiing van mijn opleiding en dit proefschrift niet meer mogen meemaken. 
Maar je voorzag dat het goed zou komen, en wij weten dat je nu ziet dat dat ook zo is. 
Mam, als altijd heb je ook bij dit traject het begrip ‘meeleven’ van een extra dimensie 
voorzien. Hartstikke bedankt dat je altijd in me bleef geloven en me altijd bleef steunen.
Lieve Gertrude, jij hebt deze weg zelf al eerder afgelegd. Maar ook los van die ervaring weet 
je wel hoe blij ik ben dat het nu echt af is. En ik weet dat jij daar minstens zo blij mee bent. 
Onnoemelijk veel dank voor je steun en voor alles wat je me uit handen hebt genomen zodat 
het doel bereikt kon worden. We kunnen ons nu eindelijk weer meer samen gaan richten op 
Jonathan en ?...  en de toekomst. Ik kijk heel erg uit naar de komende jaren samen met jullie!
Bart van Dooren
Rotterdam, 1 november 2006
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Curriculum Vitae
Bart T.H. van Dooren werd op 5 juni 1968 geboren te Geleen. In 1986 haalde hij zijn 
gymnasium-β diploma (magna cum laude) aan de RKSG Sint Michiel te Geleen en begon 
hij met de studie geneeskunde aan de Rijksuniversiteit Groningen. Het doctoraalexamen 
werd cum laude behaald in 1991, en het artsexamen in 1994. 
Zijn aanvankelijke carriéreplannen waren gericht op specialisatie in de neurochirurgie, en 
in dit kader doorliep hij in 1993 en 1994 gedurende een half jaar keuzeco-schappen in de 
Verenigde Staten. Deze vonden plaats op de afdelingen Neurosurgery van het Presbyterian 
University Hospital te Pittsburgh, en de Mayo Clinics te Rochester, Minnesota. Na zijn 
artsexamen vervulde hij eerst in 1994 en 1995 zijn militaire dienstplicht als eerste-luitenant-
arts bij de geneeskundige compagnie van de 11. Luchtmobiele Brigade van de Koninklijke 
Landmacht. Vanaf april 1995 werkte hij daarna gedurende 3 jaar als AGNIO neurochirurgie, 
in achtereenvolgens het Academisch Ziekenhuis Groningen, het Academisch Ziekenhuis 
Utrecht, en het Academisch Ziekenhuis St.Radboud in combinatie met het Canisius-
Wilhelminaziekenhuis, beide te Nijmegen. 
Gedurende deze laatste betrekking werd het hem steeds meer duidelijk dat een specialisatie 
als neurochirurg niet zijn ideale carrière-invulling zou zijn en daarom besloot hij zich 
in andere richtingen te oriënteren. Dit omvatte in 1998 het opstarten van een studie 
bouwkunde aan de Technische Universiteit Eindhoven, en daarnaast het beginnen met het 
onderhavige promotieonderzoek, in het Oogziekenhuis Rotterdam. 
In de loop van 1999 besloot hij zich volledig op een loopbaan in de oogheelkunde te 
richten. Vanaf 2000 werkte hij 23 maanden als AGNIO in het OZR, waarbij hij deels werkzaam 
was in de patiëntenzorg en deels verder werkte aan het promotieonderzoek. Vanaf 1 maart 
2002 doorliep hij in het OZR voltijds de opleiding tot oogarts, en rondde deze onlangs (per 
31 augustus 2006) af. Momenteel voltooit hij in dezelfde kliniek zijn fellowship cornea- en 
refractiechirurgie. Per 1 januari 2007 zal hij toetreden tot de  oogartsenmaatschap van het 
Amphia Ziekenhuis, te Breda en Oosterhout.
De auteur is getrouwd met Gertrude Smit, en ze hebben samen een zoon: Jonathan. In 
februari 2007 verwachten zij hun tweede kindje.
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